57th ASH Annual Meeting and Exposition (December 5-8, 2015): Author Index L

La Cava, P.

2767 - Monocytic Myeloid Derived Suppressor CELLS (M-MDSC) As Prognostic Factor in Chronic Myeloid Leukemia Patients Treated with Dasatinib
4018 - Mesenchymal STEM CELLS Favor Tumor Growth By Generating Granulocyte-like Myeloid Derived Suppressor CELLS in CML Patients

La Clair, J. J.

567 - RNA Splicing Modulation Impairs Acute Myeloid Leukemia Stem Cell Maintenance

La, L.

3051 - Recapturing Disease Response: A Phase II Study of High Dose Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma Who Have Progressed on Standard Dose Carfilzomib
4226 - A Phase II Study of Panobinostat with Lenalidomide and Weekly Dexamethasone in Myeloma

La Nasa, G.

2122 - Health-Related Quality of Life in Patients with Primary Immune Thrombocytopenia (pITP): Investigating Differences Amongst Newly Diagnosed, Persistent and Chronic Pitp Patients

La Rocca, F.

3254 - A Pyrazolo[3,4-d]Pyrimidine Compound Reduces Fyn Phosphorylation and Induces Apoptosis in Large Granular Lymphocyte Leukemia Cells

La Rosa, C.

3108 - Safety, Maximum Tolerated Dose and Immunogenicity of CMV-MVA-Triplex in Healthy Volunteers with or without Prior Immunity to CMV and Vaccinia

La Rosée, P.

3880 - Immunoglobulin M Heavy/Light Chain Pair Measurement Independently Predicts Clinical Outcome and Refines Prognostic Information Provided By Interim PET in Patients with Aggressive Lymphomas
- Treatment of Hemophagocytic Lymphohistiocytosis in Adults

La Scaleia, R.

1529 - Phenotypically and Functionally Altered T Cell Compartment in DLBCL Patients at Diagnosis and Its Long-Term Modification upon Chemoimmunotherapy Regimen

Laadem, A.

92 - Luspatercept Treatment Leads to Long Term Increases in Hemoglobin and Reductions in Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from the Phase 2 PACE-MDS Extension Study
752 - Luspatercept (ACE-536) Reduces Disease Burden, Including Anemia, Iron Overload, and Leg Ulcers, in Adults with Beta-Thalassemia: Results from a Phase 2 Study
2862 - Biomarkers of Ineffective Erythropoiesis Predict Response to Luspatercept in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Final Results from the Phase 2 PACE-MDS Study
4241 - Phase 1 Dose-Escalation Study of Sotatercept (ACE-011) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma

Laane, E.

1218 - XRCC5 Plays an Important Role in Homologous Recombination, Genome Stability and Survival of Myeloma Cells
3034 - Analysis of Final Data from the Multinational, Non-Interventional, Observational Emmos Study (NCT01241396) in Patients (Pts) with Multiple Myeloma (MM) in Real-World Clinical Practice

Labar, B.

4022 - Single-Cell Immune Signatures in Patients with Chronic Phase Chronic Myeloid Leukemia (CML) Treated with Nilotinib: An ENEST1st Sub Study

Labeit, A. M.

4024 - Assessment of Quality of Life in the NCRI Spirit 2 Study Comparing Imatinib with Dasatinib in Patients with Newly-Diagnosed Chronic Phase Chronic Myeloid Leukaemia

LaBelle, J.

4438 - Cathepsin-Cleavable BIM BH3 Peptide Amphiphiles Are Potent Inducers of Cellular Apoptosis

Laberko, L.

1132 - Blood Hypercoagulation Assessed with Thrombodynamics Test Predicts Postoperative Venous Thrombosis in Patients at High Risk

Labianca, R.

654 - Measurement of Thrombin Generation Is a Positive Predictive Biomarker of Venous Thromboembolism (VTE) in Metastatic Cancer Patients Enrolled in the Hypercan Study

Labopin, M.

Labotka, R.

26 - Randomized Phase 2 Study of the All-Oral Combination of Investigational Proteasome Inhibitor (PI) Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible (NCT02046070)
3032 - A Phase 1 Study to Assess Pharmacokinetics (PK) and Safety of Ixazomib, an Oral Proteasome Inhibitor, in Patients with Moderate or Severe Hepatic Impairment
3309 - Predictors of Second-Line Treatment Choice with Triplet Therapy in Routine Care Among Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
4515 - Treatment Patterns and Outcomes Among Patients Who Initiate Therapy for Relapsed/Refractory Multiple Myeloma (RRMM) in Routine Care
4516 - Healthcare Resource Use and Costs Among Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Laboure, G.

3872 - Number of Circulating t(14;18) Tumor Cells at Diagnosis Is Related to, but Add to the Prognostic Value of Metabolic Tumor Burden in Follicular Lymphoma

Labouré, G.

3920 - Cell-of-Origin (COO) Classification, BCL2 and MYC Expression Associated-Outcome in Younger Patients Treated By RCHOP Front-Line Therapy Versus Intensive Regimen Followed By Autologous Transplant for De Novo Advanced Diffuse Large B Cell Lymphoma (DLBCL) : Results of the French Prospective Multicenter Randomized Trial Goelams-075

Labrador, J.

4356 - Immunoparesis Recovery As Predictor Marker of Progression after Autologous Stem Cell Transplantation in Multiple Myeloma

Labuhn, M.

165 - Crispr-Cas9 Induced MLL-Rearrangements Cause Clonal Outgrowth in CD34+ Hematopoietic Stem Cells

Labussière-wallet, H.

2577 - Mixed Chimerism at Three Months after Allogeneic Hematopoietic Stem Cell Transplantation Is a Significant Predictor of Disease Relapse in High-Risk Acute Myeloid Leukemia Patients in First Complete Remission
2774 - Very Long-Term Follow-up (> 80 months) of Imatinib (IM) First-Line for Chronic Phase (CP) CML Patients
3213 - Allogeneic Hematopoietic Stem Cell Transplantation from Unrelated Peripheral Blood or Bone Marrow Donors: The Impact of HLA Matching Including HLA-DPB1 Allele in a Multivariable Risk Model
4324 - Optimizing the Outcomes of Allogeneic Hematopoietic Stem Cell (HSC) Transplantation for Hematological Malignancies: The Perfect Combination of Conditioning Regimen, Disease Stage and Type of HSC Donor
4477 - First Results of a Prospective Study on Erythropoietin Biosimilar (Epoetin zeta) Use in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies

Labussière-Wallet, H.

1922 - Impact of Early Post-Transplant Complications on Survival of Patients with Myelodysplastic Syndrome Undergoing Allo-SCT Following Reduced Intensity Conditioning: An SFGM-TC Study
3428 - Survey of Serum Aspergillus Antigen in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia or Allogeneic Hematopoietic Stem Cell Transplantation: Role in Predicting Invasive Aspergillosis and in Modifying the Therapeutic Strategy
4377 - Brentuximab Vedotin Followed By Allogeneic Stem-Cell Transplantation for Patients with CD30 Anaplastic or T Cell Non Hodgkin Lymphomas: A Study on Behalf of the SFGM-TC.

LaCasce, A. S.

4159 - A Phase II Study of Ofatumumab-High Dose Methylprednisolone Followed By Ofatumumab-Alemtuzumab in 17p Deleted or TP53 Mutated CLL

LaCasce, A. S.

337 - Bortezomib Maintenance (BM) Versus Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): CALGB (Alliance)50403
342 - Risk-Adapted Therapy in Adults with Burkitt Lymphoma: Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R
522 - Double Expressing (MYC/BCL2) and Double-Hit Diffuse Large B-Cell Lymphomas Have Inferior Survival Following Autologous Stem Cell Transplantation
3156 - Sequencing-Based Detection of Circulating Tumor DNA in the Autologous Stem Cell Grafts of Patients with Diffuse Large B-Cell Lymphoma Undergoing Hematopoietic Stem Cell Transplantation
3961 - Long-Term Outcomes, Secondary Malignancies, and Stem Cell Collection Following Bendamustine in Patients with Previously Treated Indolent Non-Hodgkin Lymphoma
3982 - Brentuximab Vedotin Plus Bendamustine: A Highly Active Salvage Treatment Regimen for Patients with Relapsed or Refractory Hodgkin Lymphoma
4001 - B and T-Cell Lymphoma Patient-Derived Xenografts Recapitulate Aspects of Disease Biology and Progression and Represent Novel Tools for Preclinical Drug Development

Lacey, S. F.

1334 - Biomarkers Accurately Predict Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Acute Lymphoblastic Leukemia (ALL)

Lacey, S. F.

183 - Sustained Remissions Following Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas
681 - Durable Remissions in Children with Relapsed/Refractory ALL Treated with T Cells Engineered with a CD19-Targeted Chimeric Antigen Receptor (CTL019)
683 - Efficacy and Safety of Humanized Chimeric Antigen Receptor (CAR)-Modified T Cells Targeting CD19 in Children with Relapsed/ Refractory ALL
704 - The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Engraftment and Antitumor Responses Against Mantle Cell Lymphoma
2523 - Combination of Anti-CD123 and Anti-CD19 Chimeric Antigen Receptor T Cells for the Treatment and Prevention of Antigen-Loss Relapses Occurring after CD19-Targeted Immunotherapies
3769 - Efficient Trafficking of Chimeric Antigen Receptor (CAR)-Modified T Cells to CSF and Induction of Durable CNS Remissions in Children with CNS/Combined Relapsed/Refractory ALL

Lachance, S.

2562 - Phase I Study of Non-Engrafting Allogeneic, Mismatched, Unmanipulated Peripheral Blood Mononuclear Cell Infusions to Treat Poor-Prognosis Acute Myeloid Leukemia
3171 - Safety and Efficacy of Autologous Hematopoietic Cell Transplantation for Elderly Patients with Lymphoma: Chemosensitive Disease Rather Than Age or Co-Morbidity Index Predicts Outcome

Lachance, S.

4319 - Influence of Prophylactic Antibiotics Aiming at Gut Decontamination on Gastrointestinal Graft-Versus-Host Disease and Overall Survival Following Allogeneic Haematopoietic Stem Cell Transplantation
4391 - Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Reduce Transplant Related Mortality and Improve Overall Survival in Haploidentical HSCT for Patients with AML and ALL, Using an Immunosuppressant-Free Transplant Regimen

Lachmann, H.

732 - Oral Doxycycline Improves Outcomes of Stage III AL Amyloidosis - a Matched Case Control Study

Lachmann, N.

4417 - Innovative Hematopoietic Gene-Therapy Concepts for Hereditary Pulmonary Alveolar Proteinosis Utilizing Hematopoietic Stem Cell Derived Macrophages

Lackey, J.

3976 - A Phase 1 Study of the Anti-CD37 Antibody-Drug Conjugate AGS67E in Advanced Lymphoid Malignancies. Interim Results

Lackner, K.

2192 - Platelet-Localized FXI Promotes a Glycoprotein Ib Alpha Dependent Feedback Loop in Arterial Hypertension and Vascular Inflammation

Lacombe, C.

938 - Deep Proteomic Analysis of Human Erythropoiesis
3736 - Addition of Lomustine (CCNU) to Induction and Post-Remission Chemotherapy for Fit Elderly AML Patients without Unfavorable Cytogenetics: Results of the Lamsa-2007 Goelams Trial

Lacout, C.

3959 - R-DHA-Oxaliplatin Versus R-DHA-Cisplatin Regimen in B-Cell Nhl's Treatment: A Eight Years Retrospective Study

Lacouture, M.

481 - Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms

Lacroix, R.

3812 - Biological Description of 109 Cases of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) from the French Network of BPDCN

Lacroix-desmazes, S.

106 - Identification of T Cell Epitope of ADAMTS13 in Thrombotic Thrombocytopenic Purpura Patients

Lacronique-Penard, V.

3833 - Serum 2-Hydroxyglutarate Allows Early Prediction of Response during Induction Chemotherapy in Acute Myeloid Leukemia with IDH Mutation
3835 - Serum 2-Hydroxyglutarate Level Can Predict IDH2 Mutation in Myeloid Sarcoma

Lacut, K.

2326 - Association Between Hospitalization for Acute Medical Illness and VTE Risk: A Lower Efficacy of Thromboprophylaxis in Elderly Patients? Results from the Edith Case-Control Study

Lacy, M. Q.

1774 - In Patients with Light-Chain (AL) Amyloidosis Myocardial Contraction Fraction (MCF) Is a Simple, but Powerful Prognostic Measure That Can be Calculated from a Standard Echocardiogram (ECHO)
1830 - Necrobiotic Xanthogranuloma (NXG) Associated with Monoclonal Gammopathies (MG): Clinical Features and Treatment Outcomes
1839 - Appropriate Dose Adjustment of Dexamethasone Does Not Compromise Outcomes in Relapsed Refractory Multiple Myeloma
3039 - Anti-Tumor Phagocytic Cell Activation in Multiple Myeloma By the IAP Antagonist LCL161: Results of a Phase II Clinical Trial
3044 - The Impact of Induction Regimen Choice on Transplant Outcome and Survival in Newly Diagnosed Multiple Myeloma in the Era of Novel Agents
3050 - Randomized Phase 2 Trial of Two Different Doses of Ixazomib in Patients with Relapsed Multiple Myeloma Not Refractory to Bortezomib
3177 - Impact of Bone Marrow Plasmacytosis on Outcome in Patients with AL Amyloidosis Following Autologous Stem Cell Transplant
3292 - N-Terminal Fragment of the Type-B Natriuretic Peptide (NT-proBNP) Is a Prognostic Factor for Overall Survival in Newly Diagnosed Patients with Multiple Myeloma (MM)
3317 - AL Amyloidosis and Patient Reported Quality of Life
4176 - Occurrence and Prognostic Significance of Cytogenetic Evolution in Patients with Multiple Myeloma
4197 - Presentation and Outcomes of Localized Amyloidosis: The Mayo Clinic Experience

Ladanyi, M.

2447 - Next-Generation Sequencing of Matched Normal Blood Identifies Clonal Hematopoiesis in a Significant Subset of Solid Tumor Patients without Hematologic Malignancies

Ladd, A.

3243 - Characterization of Lentiviral Vector Derived Anti-Bcma CAR T Cells Reveals Key Parameters for Robust Manufacturing of Cell-Based Gene Therapies for Multiple Myeloma

Ladetto, M.

336 - A Molecular Model for the Prediction of Progression Free Survival in Young Mantle Cell Lymphoma Patients Treated with Cytarabine-Based High Dose Sequential Chemotherapy and Autologous Stem Cell Transplantation: Results from the MCL0208 Phase III Trial from Fondazione Italiana Linfomi (FIL)
701 - Identification of a Novel Gene Expression Signature in Mantle Cell Lymphoma from the Fondazione Italiana Linfomi (FIL)-MCL-0208 Trial: A Focus on the B Cell Receptor Pathway
1411 - Library Preparation Is the Major Factor Affecting Differences in Results of Immunoglobulin Gene Rearrangements Detection on Two Major Next-Generation Sequencing Platforms
3934 - Khorana Score and Histotype Predict the Incidence of Early Venous Thromboembolism (VTE) in Non Hodgkin Lymphoma (NHL). a Pooled Data Analysis of Twelve Clinical Trials of Fondazione Italiana Linfomi (FIL)
3937 - Phase II Study of the Fondazione Italiana Linfomi on Gemcitabine Plus Romidepsin (GEMRO Regimen) in Relapsed and Refractory Peripheral T-Cell Lymphoma Patients

Ladetto, M.

2645 - Highly Sensitive Droplet Digital PCR for MYD88^L265P Mutation Detection and Minimal Residual Disease Monitoring in Waldenström Macroglobulinemia
3985 - LONG-TERM Outcome of a Fondazione Italiana Linfomi Study Comparing Short Rituximab Maintenance Vs Observation after Brief First-LINE R-FND Chemoimmunotherapy Followed By Rituximab Consolidation in Elderly Patients with Advanced Follicular Lymphoma (FL)

Ladogana, S.

2788 - Early Response Does Not Impact on the Long-Term Outcome of Children and Adolescents with Chronic Myeloid Leukemia Treated with High-Dose Imatinib. the Italian Experience

Lafanechere, L.

1257 - Role of LIM Kinase in Oncogenic Signaling from FLT3 and KIT Receptors and Its Targeting in Myeloid Leukemia

LaFave, L. M.

713 - BAP1 Loss Results in EZH2-Dependent Transformation in Myelodysplastic Syndromes

Laffan, M.

1043 - The N-Linked Glycans of ADAMTS13 Are Critical Determinants of Conformation and Proteolytic Activity
2421 - A Double Strand Break during Telophase Is Repaired with Homologous Recombination Despite the Absence of an Available Sister Chromatid
4481 - Patient Age Predicts the Delay before Survivors of Cancer Utilise Their Cryopreserved Sperm for Assisted Reproductive Technology

Laffin, J.

4209 - Cytogenetic Progression in Patients with Multiple Myeloma As Assessed By Serial Bone Marrow Biopsy Is Associated with Worse Outcome

LaFollette, T. D.

318 - A Novel Inhibitor of BET Family Bromodomains Demonstrates In Vivo and In Vitro Potency in B-Cell Malignancies
2471 - In Vitro and In Vivo Anti-Leukemic Effects of KPT-9274, a Reported PAK4 Allosteric Modulator, in Acute Myeloid Leukemia: Promising Results Justifying Further Development in This Disease

LaFramboise, T.

608 - The Complete Mutatome and Clonal Architecture of Del(5q)
709 - Serial Sequencing in Myelodysplastic Syndromes Reveals Dynamic Changes in Clonal Architecture and Allows for a New Prognostic Assessment of Mutations Detected in Cross-Sectional Testing
2848 - Determinants of Phenotypic Commitment and Clonal Progression-- Conclusions from the Study of Clonal Architecture in CMML

Lagana, A.

840 - Towards a Network-Based Molecular Taxonomy of Newly Diagnosed Multiple Myeloma
4226 - A Phase II Study of Panobinostat with Lenalidomide and Weekly Dexamethasone in Myeloma

Lagana', A.

1851 - Patient-Specific Mutation-Derived Tumor Antigens As Targets for Cancer Immunotherapy in Multiple Myeloma

Lagana', A.

1253 - SOX11 Cooperates with CCND1 in Mantle Cell Lymphoma Pathogenesis

Lagomarsino, E.

2494 - Predictive Value of Minimal Residual Disease: Analysis By Flow-Cytometry in Children with Relapsed Acute Lymphoblastic Leukemia

Lagrange, J.

2192 - Platelet-Localized FXI Promotes a Glycoprotein Ib Alpha Dependent Feedback Loop in Arterial Hypertension and Vascular Inflammation

Laguna, P.

3506 - Clinical Use of Ultrasound Superb Micro-Vascular Imaging Technique in Patients with Hemophilia Treated with Standard Radiosynovectomy. Initial Report

Lahary, A.

2151 - Assessment of Cardiac Iron Overload in Chonically Transfused Patients with Thalassemia, Sickle Cell Anemia, and Myelodysplastic Syndromes

Lahn, M.

1669 - Phase 2 Study of Monotherapy Galunisertib (LY2157299 Monohydrate) in Very Low-, Low-, and Intermediate-Risk Patients with Myelodysplastic Syndromes

Lähteenmäki, H.

343 - Mature, Adaptive-like CD56^DIM NK Cells in Chronic Myeloid Leukemia Patients in Treatment Free Remission

Lahuerta, J. J.

19 - Prognostic Value of Antigen Expression in Multiple Myeloma (MM): A Large GEM/Pethema Study Based in Four Consecutive Clinical Trials
23 - Mutational Profile and Prognostic Relevance of Circulating Tumor Cells in Multiple Myeloma
721 - Prognostic Value of Immune Profiling Multiple Myeloma Patients during Minimal Residual Disease Monitoring in the Pethema/GEM2010MAS65 Study
725 - What Is the Frequency of Transplant-Eligible Multiple Myeloma Patients Being Cured? the Impact of an MGUS-like Signature at Diagnosis and MRD-Negativity
2955 - Low-Dose Dexamethasone Does Not Abrogate the Immunomodulatory Effects of Lenalidomide and Both Reactivate the Impaired Immune System of High-Risk Smoldering Multiple Myeloma Patients
2963 - Comparison Between First-Generation 4-Color Vs. Second-Generation 8-Color Multiparameter Flow Cytometry (MFC) to Monitor Minimal Residual Disease (MRD) in Multiple Myeloma (MM)
4181 - The Relevance of Minimal Residual Disease (MRD) Monitoring in Elderly Multiple Myeloma (MM) Patients
4231 - Assessment of Clinical Differences Between Starting Antimyeloma Treatment at Biological Relapse or at Clinical Relapse: Preliminary Results of an Observational Prospective Registry
SCI-52 - Characterization of Minimal Residual Disease

Lahuerta, J. J.

521 - Progression-Free Survival at 24 Months (PFS24) and Complete Response at 30 Months (CR30) from Autologous Stem Cell Transplantation (ASCT) Should be Used As Surrogates for OS in Follicular Lymphoma (FL) Patients
1848 - Bortezomib, Melphalan, Prednisone (VMP) and Lenalidomide Plus Dexamethasone (Rd) Is the Optimal Combination for Patients with Newly Diagnosed Multiple Myeloma (MM) Patients Between 65 and 80 Years
1856 - Autologous Activated and Expanded Natural Killer Cells Are Safe and Clinically Actives in Multiple Myeloma
2962 - Usefulness of Serum-Free-Light-Chains-Ratio (SFLCR) and Serum Heavy-Light-Chains-Ratio (SHLCR) in Multiple Myeloma in the Context of Three GEM/Pethema Clinical Trials
2972 - Simplified in-House Deep Sequencing Method of Inmunoglobulin Genes for Minimal Residual Dissease Quantification and Risk Stratification in Multiple Myeloma
4201 - Outcomes after Initial Relapse of Multiple Myeloma: An International Myeloma Working Group Study
4243 - Bortezomib Plus Melphalan and Prednisone (VMP) Followed By Lenalidomide and Dexamethasone (Rd) in Newly Diagnosed Elderly Myeloma Patients Overcome the Poor Prognosis of High-Risk Cytogenetic Abnormalities (CA) Detected By Fluorescence in Situ Hibridization (FISH)

Lahvic, J.

1176 - A GATA-2-GPR65 Regulatory Module Controls Hematopoietic Stem Cell Generation

Lai, C. E.

472 - Phase I Study of Dose-Adjusted-Teddi-R with Ibrutinib in Untreated and Relapsed/Refractory Primary CNS Lymphoma
3212 - Comparison of Donor KIR Genotype, Recipient CMV Reactivation and Pretransplant MRD in Predicting Relapse after Ex Vivo T-Deplete Allohsct
3616 - Development of Somatic NRAS Mutation Associated with Rapid Transition from Germline GATA2 Mutation Associated Myelodysplastic Syndrome to Acute Myeloid Leukemia
4350 - Multigene MRD Assessment Improves AML Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation

Lai, C. Y.

1867 - Protection of Transplanted Hematopoietic Stem Cells from Inflammatory Recipient Marrow Environment through Specific TNF-α Signal Blockade
3071 - Proof of Benefit in Multiple-Cord Blood Transplantation Evidenced By Early Hematopoietic Reconstitution

Lai, D.

4012 - Identification of a New AHI-1-Mediated-PP2A-Beta-Catenin-BCR-ABL-JAK2 Complex Modulating Resistance of CML Stem/Progenitor Cells to Tyrosine Kinase Inhibitors

Lai, E.

2141 - Survival Comparability Between Thalassemia Major Versus Thalassemia Intermedia

Lai, E.

4256 - Final Results of the Phase I/II Study of Chemosensitization Using the CXCR4 Inhibitor Plerixafor in Combination with Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

Lai, H. Y.

1632 - A Blunted Response to the Anti-Inflammatory Cytokine IL-10 Contributes to Excessive TNF Production in Myeloproliferative Neoplasm

Lai, M.

3566 - Granulocyte Transfusions at Appropriate Doses Improve Survival in Hematological Patients with Febrile Neutropenia

Lai, P.

2118 - Comparison of the 5 Year Medical Outcome and Quality of Life of Patients with Chronic Myeloid Leukemia Treated with Imatinib or Allogeneic Transplant

Lai, T. H.

1222 - Histone Deacetylase Inhibitors Induce microRNAs Targeting BTK in Acute Myeloid Leukemia
3639 - HDAC Inhibition Induces microRNA-182 Which Targets Rad51 Protein and Impairs Homologous Recombination Repair to Sensitize Cells to the Double Strand Break Inducing Nucleoside Analog, Sapacitabine in AML

Lai, X.

3130 - Excellent Therapeutic Results Achieved in Salvage Therapy for Steroid-Refractory Grades III-IV Acute Gvhd with Basiliximab and Etanercept : A Multicenter Prospective Study

Lai, X.

3774 - Chimeric Antigen Receptor 4SCAR19-Modified T Cells in Acute Lymphoid Leukemia: a Phase II Multi-Center Clinical Trial in China

Lai, Y. S.

SCI-17 - Modified IPS Cells for Hemoglobinopathies

Lai, Y.

220 - Tamibarotene Compared to All-Trans Retinoic Acid (ATRA) As Add-on to Arsenic Trioxide (ATO) in Subjects with Relapsed Acute Promyelocytic Leukemia (APL)
2153 - Optimizing Iron Chelation Therapy with Deferasirox for Non-Transfusion-Dependent Thalassemia Patients: 1-Year Results from the Phase IV, Open-Label Thetis Study
3366 - Efficacy and Safety of Deferasirox Across Underlying Non-Transfusion-Dependent Thalassemia Syndromes: 1-Year Results from the Thetis Study

Laird, A. D.

3698 - Exploring Relationships of Exposure, Pharmacodynamic Changes and Gene Expression to Clinical Outcome in Adults with Acute Lymphoblastic Leukemia Receiving Inotuzumab Ozogamicin

Laja, O.

2171 - Plasma FGF23 Is a Biomarker for Left Ventricular Hypertrophy and Mortality in Adults with Sickle Cell Anemia Chronic Kidney Disease

Lake, J. A.

1052 - Evaluation of a Standardized Approach to the Diagnosis of Mild Platelet Function Defects: Recommendation for a Targeted Approach to the Diagnosis of Mild Platelet Function Defects and Identification of a Subset of Children with a "Developmental" Form

Lakhani, J.

3478 - Second Line ITP Therapy in the UK: Results from the UK Paediatric ITP Registry

Lakshmanan, V.

4386 - Improved Outcomes with Allogeneic Stem Cell Transplantation for Aplastic Anaemia Using HLA Identical Sibling Donors: The Indian Stem Cell Transplant Registry (ISCTR) Experience

Lakshmi, K.

1064 - Efficacy of Second Line Agents Dapsone & Azathioprine in Children & Adults with Immune Thrombocytopenia: Single Centre Experience from India
2620 - Prognostic Significance of Immunophenotypic Composition of B Cell Acute Lymphoblastic Leukemia at Diagnosis: A Novel Immunophenotype Based Risk Score
3120 - Population Pharmacokinetics of Fludarabine and Treosulfan in Patients with Thalassemia Undergoing Hematopoietic Stem Cell Transplantation
3219 - Outcome of Allogeneic Stem Cell Transplantation for Thalassemia Major in India
3732 - Adult Acute Lymphoblastic Leukemia: A Cost Effective Strategy and Limitations of Intensification of Therapy in India
3758 - Coagulopathy in Acute Promyelocytic Leukemia: Strategies to Improve Assessment of Hemostatic Risk
4386 - Improved Outcomes with Allogeneic Stem Cell Transplantation for Aplastic Anaemia Using HLA Identical Sibling Donors: The Indian Stem Cell Transplant Registry (ISCTR) Experience

Lakshminarashimhan, R.

778 - Interleukin-1 Drives Precocious Myeloid Differentiation of Hematopoietic Stem Cells at the Expense of Self-Renewal

Lal, A.

441 - Balancing Proliferation, Differentiation, and Survival: Powerful Genetic and RNAi Technologies Reveal Essential microRNA Signaling for Leukemic Progenitor Cell Fitness

Lal, A.

950 - Iron Level and Monocyte Morphology Predict TLR4 Expression and Reactive Oxygen Species Production Which Influences Chronic Inflammation in β-Thalassemia

Lal, L. S.

4509 - Predictors of Increase in Emergency Room (ER) Visits and Hospitalizations in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Chemotherapy
4526 - Predictors of Emergency Room (ER) Visits and Hospitalizations in Patients with Mantle Cell Lymphoma (MCL) Treated with Chemotherapy

Lalaoui, N.

SCI-29 - The Role of Receptor Interacting Protein Kinase in Myelopoiesis in Health and Disease

Laliberté, F.

626 - Current Practice Patterns and Patient Persistence on Anticoagulant Treatments for Cancer-Associated Thrombosis

Lalli, A.

4326 - Reiterated Therapeutic Drug Monitoring (TDM) Dosing to Significantly Improve the Control of Exposure to IV Busulfan in Infants and Older Children Undergoing Hematopoietic Stem-Cell Transplantation (HSCT)

Lam, A.

875 - Economic Burden of Relapsed or Refractory Multiple Myeloma: Results from an International Trial
4498 - Analyses of Real World Data on Overall Survival in Multiple Myeloma Patients with at Least 3 Prior Lines of Therapy Including a PI and an IMiD, or Double Refractory to a PI and an IMiD

Lam, C. J.

562 - Emerging Risks of AML/MDS and Other Myeloid Neoplasms Following Chemotherapy for First Primary Malignancy, 2000-2012

Lam, H. S.

2408 - Disrupted Lymphocyte Homeostasis in Hepatitis-Associated Acquired Aplastic Anemia Is Associated with Very Low Telomere Lengths

Lam, S.

2169 - Acupuncture Led Attenuation of Inflammatory and Nociceptive Peripheral and Central Microenvironment in Sickle Mice

Lam, S.

2720 - Safety and Efficacy of Mini-CHOP-R Chemotherapy for Treatment of Diffuse Large B Cell Lymphoma in Very Elderly Patients: A Quality Assurance Study

Lam, S. H.

3637 - NOTCH1 Induces Differential Epigenomic Patterning and Genomic Organization in Fetal Liver- and Adult Bone Marrow-Derived Hematopoietic Progentiors

Lam, S. S. Y.

1400 - Whole Exome Sequencing of FLT3-ITD Sorafenib-Resistant Acute Myeloid Leukaemia

Lam, T.

4456 - Fatigue, Quality of Life and Related Symptoms: Patient Reported Outcomes in Myelodysplastic Syndrome, Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria

Lam, W. A.

215 - Clot Contraction-Mediated Erythrocyte Packing Is Significantly Altered in Sickle Cell Disease
240 - Engineering a "Self-Healing" Hydrogel-Based Microvasculature-on-a-Chip for Investigating the Effects of Cellular and Biomolecular Interactions on Endothelial Permeability in Sickle Cell Disease
965 - Vessel Geometry Interacts with Red Blood Cell Stiffness to Promote Endothelial Dysfunction in Sickle Cell Disease
2164 - Commonly Used Clinical Intravenous Fluid Formulations Differentially Affect Sickle Red Blood Cell Stiffness and Transit Time
3381 - Characterizing Cellular Interactions Contributing to Vaso-Occlusion in Patients with Sickle Cell Disease Utilizing a Novel Endothelialized Microfluidic Device
3485 - Engineering a Valve-Regulated Endothelialized Microfluidic Device As an "in Vitro" Bleeding Time for Assessing Global Hemostasis
4415 - Improving Lentiviral Transduction Efficiency with Microfluidic Systems

Lama-Sherpa, T. D.

1797 - The Role of Adipocyte Lineage Cells in Myeloma Growth and Dissemination in Bone

Lamanna, N.

3284 - Reasons for Initiation of First-Line Therapy and Early Outcomes for Patients (Pts) with Rai 0/1 Chronic Lymphocytic Leukemia (CLL): An Analysis of the Connect CLL® Cohort Study
4483 - Treatment Selection and Practice Patterns for the Management of High-Risk Chronic Lymphocytic Leukemia (CLL) in the US: An Analysis of the Impact of Risk Stratification on Treatment Selection from the Connect CLL® Registry

Lamanna, N.

715 - Preliminary Results of a Phase 2, Open-Label Study of Venetoclax (ABT-199 / GDC-0199) Monotherapy in Patients with Chronic Lymphocytic Leukemia Relapsed after or Refractory to Ibrutinib or Idelalisib Therapy
719 - Favorable Outcomes in CLL Pts with Alternate Kinase Inhibitors Following Ibrutinib or Idelalisib Discontinuation: Results from a Large Multi-Center Study

Lamar, Z. S.

1201 - A Human Bone Marrow-Derived Stromal Cell Population with Hemogenic Potential

Lamarque, M.

2368 - XPO1 (Exportin-1) Is a Major Regulator of Human Erythroid Differentiation. Potential Clinical Applications to Decrease Ineffective Erythropoiesis of Beta-Thalassemia

Lamarre, Y. Y.

2169 - Acupuncture Led Attenuation of Inflammatory and Nociceptive Peripheral and Central Microenvironment in Sickle Mice

Lamas, C. H.

400 - Impact of CTLA4 Genotype and Other Immune Response Gene Polymorphisms on Outcomes after Umbilical Cord Blood Transplantation - a Eurocord, CBC-Ctiwb-EBMT, Netcord and FMRP-USP Study

Lamb, A.

1418 - Early T-Cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) Is a High-Risk Subtype in Adults

Lamb, T.

1838 - First Interim Results of a Phase I/II Study of Lenalidomide in Combination with Anti-PD-1 Monoclonal Antibody MDV9300 (CT-011) in Patients with Relapsed/Refractory Multiple Myeloma

Lamba, J. K.

1260 - Genetic Variations in Calicheamicin Pathway Genes Are Predictors of Gemtuzumab Ozogamicin Response in AML Patients: Results from COG-AAML0531 Study
2056 - Cflar Splicing SNP As Predictor of Chemo-Sensitivity to Anticancer Drugs
2434 - Methylation of DNMT3B Strongly Associates with the Methylome, Cytogenetic Risk Groups, and Prognosis of Pediatric Acute Myeloid Leukemia

Lambe, M.

1586 - Increased Prevalence of Prior Malignancies and Autoimmune Diseases in Patients Diagnosed with Chronic Myeloid Leukemia

Lambert, D.

2768 - GATA2 Expression Level in Chronic Myeloid Leukemia (CML) Patients Correlates with Their Prognostic Scores and Is Associated with Disease Stage at Diagnosis

Lambert, G.

276 - Long-Term Follow up of the Beneficial Effects and of Issues in Subtotal Splenectomy for Hereditary Spherocytosis

Lambert, J. F.

451 - Is Arsenic Trioxide (ATO) Required in the Treatment of Standard Risk Newly Diagnosed APL? Analysis of a Randomized Trial (APL 2006) By the French Belgian Swiss APL Group

Lambert, J.

492 - The Gain of the Short Arm of Chromosome 2 (2p+) Induces XPO1 Overexpression and Drug Resistance in Chronic Lymphocytic Leukemia

Lambert, M. P.

73 - Genes Influencing the Development and Severity of Chronic ITP Identified through Whole Exome Sequencing
3474 - Can Immature Platelet Fraction (IPF) be Used to Assess Bleeding Risk in Pediatric Immune Thrombocytopenia (ITP) and to Differentiate ITP from Bone Marrow Failure/Aplastic Anemia? A Retrospective Analysis
4450 - Honing in on the Range: Using the Electronic Medical Record to Establish Normal Reference Ranges for Pediatric Coagulation Testing

Lambert, P. C.

2779 - Temporal Trends in Chronic Myeloid Leukemia Outcome Using the Loss in Expectation of Life: A Swedish Population-Based Study

Lambert, Q. T.

2826 - Single Molecule Dual JAK2-BET Inhibition As an MPN Therapeutic

Lambert, T.

3535 - Hemophilia Prophylaxis No Longer Just for Children without Inhibitors - Increasing Use of Prophylaxis in Other Groups (children with inhibitors and adults with and without inhibitors)

Lambert-Fliszar, F.

1863 - Tracking Normal and Chronic Myeloid Leukemia Progenitor Cell Cycle Kinetics in a Defined Niche Using Live Time Lapse Confocal Imaging with Fucci2BL a Novel Lentiviral Bicistronic Reporter

Lambiase, A.

263 - Tracking Genetically Engineered Lymphocytes Long-Term Reveals the Dynamics of T-Cell Immunological Memory

Lambie, A.

2020 - Extramedullary Disease at Diagnosis of Acute Myeloid Leukemia Does Not Influence Outcome of Patients Undergoing Allogeneic Hematopoietic Cell Transplant in First Complete Remission
3201 - Analysis of Impact of Comorbidities Constituting the HCT-CI Score on the Outcome of Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia
3289 - Predictors of the Trajectory of Neurocognitive Functioning in the First Six Months after Allogeneic Hematopoietic Stem Cell Transplantation

Lamble, A.

1374 - Defining the Immune Microenvironment in Patients with Acute Myeloid Leukemia

Lambotte, O.

3460 - A Multicenter, Case-Control Study Evaluating the Characteristics and Outcome of ITP Patients Refractory to, Rituximab, Splenectomy and Both TPO Receptor Agonists

Lameh, J.

2659 - Quantitative Multiplexed Immunohistochemistry Assays for Exploring CAR Modified T Cells and Checkpoint Inhibitors in Lymphoma Trials

LaMere, M. W.

358 - Restoration of the Bone Marrow Microenvironment Improves Hematopoietic Function in a Murine Model of Myelodysplastic Syndrome
685 - Distinct Properties of Leukemia Stem Cells in Primary Refractory Acute Myeloid Leukemia
4266 - A Role for IL1RAP in Acute Myelogenous Leukemia Stem Cells Following Treatment and Progression

Lameris, R.

2914 - Chronic Lymphocytic Leukemia (CLL) Cells Are Susceptible to γδ-T Cell Mediated Killing, Provided CLL-Derived γδ-T Cell Dysfunction Can be Reversed

Lamers, C.

387 - Early CD4+ T-Cell Effector Alloreactivity Towards Multiple Mismatched HLA Class II Alleles Is Associated with Graft Predominance after Double Umbilical Cord Blood Transplantation (dUCBT)

Lammens, T.

1409 - Identification of Candidate Oncogenes and Chromosomal Breakpoint Sequencing By Targeted Locus Amplification in T-Cell Acute Lymphoblastic Leukemia
2506 - Excellent Outcome in Pediatric AML with Response Guided Chemotherapy without Allogeneic HSCT in First Complete Remission: Results from Protocol DB-AML01

Lammert, F.

940 - Persisting Hyperbilirubinemia in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Chronically Treated with Eculizumab: The Role of Hepatocanalicular Transport Variants

Lamparelli, T.

1866 - Allogeneic Transplanst for ACUTE Myeloid Leukemia: Cut Off Levels of WT1 Expression in 207 Patients and Pre-Emptive Therapy of Relapse
4336 - Allogeneic STEM CELL Transplants for Patients with Myelofibrosis: Changes in the Transplant Platform and Improved the Outcome

Lampson, B. L.

497 - Idelalisib Given Front-Line for the Treatment of Chronic Lymphocytic Leukemia Results in Frequent and Severe Immune-Mediated Toxicities
1735 - Altered Expression of Functional Proteins in CD4 Regulatory T Cells during Therapy with Idelalisib

Lamy, T.

191 - Evaluation of Minimal Residual Disease (MRD) By Next Generation Sequencing (NGS) Is Highly Predictive of Progression Free Survival in the IFM/DFCI 2009 Trial
335 - Predictive Power of FDG-PET Parameters at Diagnosis and after Induction in Patients with Mantle Cell Lymphoma, Interim Results from the LyMa-PET Project, Conducted on Behalf of the Lysa Group
451 - Is Arsenic Trioxide (ATO) Required in the Treatment of Standard Risk Newly Diagnosed APL? Analysis of a Randomized Trial (APL 2006) By the French Belgian Swiss APL Group
1472 - Integrative Analysis of Diffuse Large B Cell Lymphoma Mutational Landscape: A Lysa Study
2250 - French Observatory of Adult' Chronic Immune Thrombocytopenia (ITP) Treated By Thrombopoietin Receptor Agonists (TPO-RAs)
2948 - Central Nervous System Involvement in Chronic Lymphocytic Leukemia: Diagnosis and Treatment in a Retrospective Cohort of Thirty Patients
3111 - Impact of HLA of Winning Cord Blood Unit on Outcomes after Double Umbilical Cord Blood Transplantation in Adults with Acute Leukemia: A Retrospective Study on Behalf of Eurocord, the Cord Blood Committee Cellular Therapy and Immunobiology Working Party and the Acute Leukemia Working Party of the EBMT
3920 - Cell-of-Origin (COO) Classification, BCL2 and MYC Expression Associated-Outcome in Younger Patients Treated By RCHOP Front-Line Therapy Versus Intensive Regimen Followed By Autologous Transplant for De Novo Advanced Diffuse Large B Cell Lymphoma (DLBCL) : Results of the French Prospective Multicenter Randomized Trial Goelams-075
3970 - Inhibition of Hedgehog Signaling for the Treatment of Lymphoma and CLL: A Phase II Study from the Lysa

Lamy, T.

1478 - T-Cell Defect in Diffuse Large B-Cell Lymphomas Involves Expansion of Myeloid Derived Suppressor Cells Expressing IL-10, PD-L1, and S100A12
2726 - Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib Dose-Escalation
3932 - PET Adapted Salvage Therapy for Advanced Hodgkin Lymphomas: Towards the Suppression of Positive Interim PET Unfavorable Prognosis? a Report of the Goelams Multicentric Phase 2 Trial LH2007

Lan, D.

1186 - Thrombopoietin (TPO) Induces Hematopoietic Differentiation of Mouse ES Cells Via HIF-1 Alpha-Dependent Activation of a BMP4 Autoregulatory Loop

Lan, F.

515 - A Phase II, Open-Label Pilot Study to Evaluate the Hematopoietic Stem Cell Mobilization of TG-0054 Combined with G-CSF in 12 Patients with Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Lymphoma - an Interim Analysis

Lan, J.

3130 - Excellent Therapeutic Results Achieved in Salvage Therapy for Steroid-Refractory Grades III-IV Acute Gvhd with Basiliximab and Etanercept : A Multicenter Prospective Study

Lan, W.

3237 - Human Induced Pluripotent Stem Cells Incorporating Safe Harbor Loci Integrated Inducible Suicide Systems for Use in the Application of Cellular Therapeutics

Lanasa, M.

361 - Exome-Wide Sequencing Reveals Oncogenic Mutations in Both Progressive and Non-Progressive MBL
2125 - Real-World Treatment Patterns and Outcomes Among Patients with Hairy Cell Leukemia
4161 - High Response Rate of Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia Includes Eradication of Minimal Residual Disease: Potential Importance for Outcome
4520 - Healthcare Utilization and Costs Among Patients with Hairy Cell Leukemia: Analysis of a Large US Administrative Claims Database

Lanc, I.

4207 - A Second Generation, Multiple Myeloma-Specific, Targeted Sequencing Platform for Detecting Translocations, Copy Number Alterations, and Single Nucleotide Variants

Lance, A.

1623 - Congenital Neutrophilia Arising from a T618I Germline Mutation in the CSF3R Gene

Lancé, M. D.

3549 - Hypobaric Hypoxia Induces Hypercoagulability Due to an Increase in Microparticles

Lancesseur, C.

4245 - Time to Spare Newly Diagnosed Non Transplant Eligible Myeloma (eNDMM) from Thalidomide

Lancet, J. E.

324 - A Phase 1 Trial of SGN-CD33A As Monotherapy in Patients with CD33-Positive Acute Myeloid Leukemia (AML)
454 - SGN-CD33A Plus Hypomethylating Agents: A Novel, Well-Tolerated Regimen with High Remission Rate in Frontline Unfit AML
1664 - Somatic Gene Mutations Serve As Molecular Biomarkers Predictive for Response to Immunosuppressive Therapy (IST) in Myelodysplastic Syndromes (MDS)
1673 - Prognostic Impact of ASXL1 Mutations in MDS and CMML
1698 - Prognosis and Outcomes in MDS-MPN Unclassifiable: Single Institution Experience of a Rare Disorder
1705 - Impact of Hypomethylating Agent Therapy in Myelodysplastic Syndromes with Chromosome 3 Abnormalities
2112 - What Is the Impact on Quality of Life of Various Treatments in Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome? Rethinking the Goals
2505 - Survival Comparison Amongst Commonly Used Frontline Regimens in Patients Age 70 Years and Older with Acute Myeloid Leukemia (AML): A Single-Institution Study of over 600 Patients
2560 - Baseline Predictors of Mortality in Patients with Relapsed or Refractory Acute Myeloid Leukemia Treated with Vosaroxin Plus Cytarabine or Placebo Plus Cytarabine in the Phase 3 VALOR Study
2897 - Eltrombopag Use in Chronic Myelomonocytic Leukemia (CMML) Patients: A Cautionary Tale
2898 - Myelodysplastic Syndromes in Adolescent Young Adults (AYA)
3750 - Inferior Outcomes with Intensive AML Induction Therapy in Patients Age 70 or Greater Compared to Age 60-69
4076 - Refining Triage to Polycythaemia Vera or Primary Myelofibrosis Based on Targeted Molecular Profiling By Clinical Next Generation Sequencing
4121 - P53 Protein Overexpression By Immunohistochemical Staining Is Correlated with TP53 Mutation Burden and Adverse Clinical Outcome in Myelodysplastic Syndromes
4382 - TP53 and IDH2 Somatic Mutations Are Associated with Poor Outcomes Following Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome
4388 - Allogeneic Hematopoietic Stem Cell Transplantation (HCT) for Acute Myeloid Leukemia (AML) Not in First Remission
4507 - CPX-351 Enables Administration of Consolidation Treatment in the Outpatient Setting and Increases the Time Spent out of the Hospital after Completion of AML Treatment Compared with 7+3

Lancia, F.

2483 - Role of Genetic Polymorphisms on Response to R-Chopregimen in Diffuse Large B-Cell Lymphoma Patients: An Interim Analysis of a Multicenter Prospective Pharmacogenetic Study

Land, J.

4265 - Incidence and Management of Proteasome Inhibitor-Related Cardiotoxicity in Multiple Myeloma Patients at Memorial Sloan Kettering Cancer Center

Landau, D. A.

362 - Quantitative Clonal Dynamics Define Mechanisms of CLL Evolution in Response to Combination Chemotherapy

Landau, D. A.

3277 - The Appropriateness of Heparin Antibody Testing. A Single Institution Retrospective Analysis

Landau, H.

4263 - Vemurafenib (VEM) in Relapsed Refractory Multiple Myeloma Harboring BRAF^V600 Mutations (V600m): A Cohort of the Histology-Independent VE-Basket Study

Landau, H. J.

1785 - Presence of PD-1 Expressing T Cells Predicts for Inferior Overall Survival in Newly Diagnosed Multiple Myeloma
1786 - The Majority of Patients with Relapsing Light Chain (AL) Amyloidosis Are Not Eligible for Enrollment Onto Clinical Trials: Using Screen Failures to Define Major Unmet Medical Needs
1975 - Continuous Treatment with Lenalidomide Plus Low-Dose Dexamethasone (Ld) Versus Ld Induction Followed By Autologous Stem Cell Transplant (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Pooled Analysis of Two Randomized Clinical Trials
1996 - Autologous Hematopoietic Stem Cell Transplantation Overcomes Primary Refractory Disease in Multiple Myeloma Patients Treated with Novel Agents
3041 - Updated Results of a Phase 2 Study of Bendamustine in Combination with Dexamethasone (Ben/Dex) in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis
3049 - The Finding of Del 17p in Marrow Plasma Cells from Patients with Light-Chain Amyloidosis (AL) May Confer a Worse Prognosis
3178 - Induction with Bortezomib and Dexamethasone (BD) Followed By Risk Adapted High Dose Melphalan and Autologous Stem Cell Transplantation and BD Consolidation in Patients with AL Amyloidosis: A Phase II Feasibility Study
4257 - Biomarkers of Cardiotoxicity Among Multiple Myeloma Patients Subsequently Treated with Proteasome Inhibitor Therapy
4332 - Low Dose Unfractionated Heparin (UFH) Prophylaxis Is a Safe Strategy for the Prevention of Hepatic Sinusoidal Obstruction Syndrome (SOS) in Adult Allogeneic Stem Cell Transplant (HSCT) Recipients

Lander, E.

362 - Quantitative Clonal Dynamics Define Mechanisms of CLL Evolution in Response to Combination Chemotherapy

Landesman, Y.

129 - Recurrent Mutations of the Exportin 1 Gene (XPO1) in Primary Mediastinal B-Cell Lymphoma: A Lysa Study
326 - Nuclear Export Inhibitor KPT-8602 Is Highly Active Against Leukemic Blasts and Leukemia-Initiating Cells in Patient-Derived Xenograft Models of AML
1345 - Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination with Fludarabine and Cytarabine in Pediatric Patients with Relapsed or Refractory AML
2487 - Development of a Pharmacodynamic Assay for XPO1 Occupancy Using Fluorescence Cross Correlation Spectroscopy (FCCS)
2751 - Selective Inhibitors of Nuclear Export (SINE) Compounds Suppress Both HIV Replication and AIDS Related Lymphoma
3017 - Selinexor Is an Effective Cancer Treatment in Hypoxic Conditions and Synergizes with Proteasome Inhibitors to Treat Drug Resistant Multiple Myeloma
3048 - Combination Therapy of Selinexor with Bortezomib or Carfilzomib Overcomes Drug Resistance to Proteasome Inhibitors (PI) in Human Multiple Myeloma
3683 - Selinexor, a Selective Inhibitor of Nuclear Export (SINE) Compound, Shows Synergistic Anti-Tumor Activity in Combination with Dexamethasone Characterized By Specific Pattern of Gene Expression in Multiple Myeloma (MM)
3686 - Dissecting Signaling Network Responses to PAK4 Allosteric Modulators (PAMs) in Cell Subsets within Primary Human Acute Myeloid Leukemia Samples

Landgren, O.

1605 - A Population-Based Study of Incidence of Myeloproliferative Neoplasms in Sweden Between 2000 and 2012
1785 - Presence of PD-1 Expressing T Cells Predicts for Inferior Overall Survival in Newly Diagnosed Multiple Myeloma
1786 - The Majority of Patients with Relapsing Light Chain (AL) Amyloidosis Are Not Eligible for Enrollment Onto Clinical Trials: Using Screen Failures to Define Major Unmet Medical Needs
1975 - Continuous Treatment with Lenalidomide Plus Low-Dose Dexamethasone (Ld) Versus Ld Induction Followed By Autologous Stem Cell Transplant (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Pooled Analysis of Two Randomized Clinical Trials
1996 - Autologous Hematopoietic Stem Cell Transplantation Overcomes Primary Refractory Disease in Multiple Myeloma Patients Treated with Novel Agents
3057 - The Long PD-1 Receptor Binding Kinetics of Nivolumab May Increase Efficacy of Subsequent Therapy in Relapsed and Refractory Multiple Myeloma Patients
3178 - Induction with Bortezomib and Dexamethasone (BD) Followed By Risk Adapted High Dose Melphalan and Autologous Stem Cell Transplantation and BD Consolidation in Patients with AL Amyloidosis: A Phase II Feasibility Study
3320 - Success of Online Curriculum-Based Education in the Management of Multiple Myeloma and Continuing Gaps Among Hematologists/Oncologists
4252 - No Risk of Arterial or Venous Thrombosis in Monoclonal Gammopathy of Undetermined Significance: Results from a Population-Based Study
4257 - Biomarkers of Cardiotoxicity Among Multiple Myeloma Patients Subsequently Treated with Proteasome Inhibitor Therapy
4265 - Incidence and Management of Proteasome Inhibitor-Related Cardiotoxicity in Multiple Myeloma Patients at Memorial Sloan Kettering Cancer Center

Landier, W.

82 - 6-Mercaptopurine (6MP) Intake during Maintenance for Childhood Acute Lymphoblastic Leukemia (ALL) - a Comparison of Self-Report and Electronic Monitoring: A Report from the Children's Oncology Group (COG) Study AALL03N1

Landini, I.

2483 - Role of Genetic Polymorphisms on Response to R-Chopregimen in Diffuse Large B-Cell Lymphoma Patients: An Interim Analysis of a Multicenter Prospective Pharmacogenetic Study

Landry, A.

187 - Phase I/II Trial of the Efficacy and Safety of Combination Therapy with Lenalidomide/Bortezomib/Dexamethasone (RVD) and Panobinostat in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma
3155 - Phase II Study of the Combination of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma

Landry, D.

4435 - Targeting NF-κB with First in Class N-Quinoline Benzenesulfonamides (NQBS) Reveals Potent Activity in Models of Diffuse Large B-Cell Lymphoma (DLBCL)

Landsburg, D. J.

183 - Sustained Remissions Following Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas
719 - Favorable Outcomes in CLL Pts with Alternate Kinase Inhibitors Following Ibrutinib or Idelalisib Discontinuation: Results from a Large Multi-Center Study
2694 - Brentuximab Vedotin in Combination with Multi-Agent Chemotherapy Is Well Tolerated and Shows Promising Activity As Frontline Treatment for Primary Mediastinal B-Cell Lymphoma
2696 - Patients with "Single-Hit" but Not MYC-Amplified Non-Burkitt High-Grade B Cell Non-Hodgkin Lymphomas Experience Poor Survival Outcomes and May Benefit from Intensive Induction Therapy
2701 - Long Term Outcomes of Rituximab, Temozolamide, and High-Dose Methotrexate for Lymphoma Involving the Central Nervous System
2929 - Utilization of Next Generation Sequencing Identifies Potentially Actionable Mutations with Prognostic Significance in Chronic Lymphocytic Leukemia
3183 - Autologous Stem Cell Transplantation in First Complete Remission May Not Extend Progression Free Survival in Patients with ALK-Negative Peripheral T Cell Lymphoma

Landsman-Blumberg, P.

4478 - Evaluation of Cardiovascular Disease Risk in Chronic Myelogenous Leukemia Patients Using Electronic Medical Records from Community-Based Oncology Practices in the United States

Lane, A.

3518 - Assessing Bleeding Risk in Pediatric Patients Undergoing Major Spinal Surgery

Lane, A. A.

3252 - Proxe: A Public Repository of Xenografts to Facilitate Studies of Biology and Expedite Preclinical Drug Development in Leukemia and Lymphoma
3665 - Escape from X-Inactivation Tumor Suppressor (EXITS) Genes Are Associated with Excess Incidence of Cancer in Men
3795 - Lead-in Stage Results of a Pivotal Trial of SL-401, an Interleukin-3 Receptor (IL-3R) Targeting Biologic, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or Acute Myeloid Leukemia (AML)
3797 - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Patient-Derived Xenografts Are Faithful Genomic and Phenotypic Models of Primary Leukemia and Respond to the IL3 Receptor Targeting Agent SL-401 In Vivo

Lane, H.

2289 - Non-Factor VIII Coagulation Proteins Fail to Predict Joint Outcome in Severe Hemophilia a

Lane, J. M.

500 - Inhibition of CDK4/CDK6 Sensitizes Myeloma to IMiD By Reducing the MEIS2 to Cereblon Ratio That Accelerates IKZF1 and IKZF3 Degradation

Lane, P. A.

987 - Estimation of Glomerular Filtration Rate (GFR) Using Serum Cystatin C and Creatinine Has Poor Precision and Accuracy in Adults with HbSS Sickle Cell Disease
2179 - Hydroxyurea Effectiveness in Children and Adolescents with Sickle Cell Anemia: A Large Retrospective, Population-Based Cohort Study
2183 - Angiotensin Blockage with Losartan Is Associated with Decreased Albuminuria and Stable Renal Function in Adults and Children with HbSS on Hydroxyurea
3262 - Inpatient Utilization Among Children and Adolescents with Sickle Cell Disease: Analysis of a Large Populated-Based Retrospective Cohort

Lane, R. M.

416 - Extended Platelet In Vivo Survival Results in Exhausted Platelets

Lane, S.

4446 - A Qualitative Research Study to Understand Post-Transfusion Well-Being in Patients with Myelodysplastic Syndromes

Lane, S. W.

557 - Cdx2 Cooperates with Flt3-ITD to Induce Acute Myeloid Leukaemia in Mice
2405 - SSB1/NABP2 and SSB2/NABP1 Have Essential and Overlapping Roles in Maintaining Hematopoietic Stem and Progenitor Cells
4279 - Recipient CD8⁺ DC Delete Alloreactive Donor CTL and Promote Leukemic Relapse after Allogeneic BMT

Lane, T.

1836 - Dose-Dependent Progressive Immunotherapeutic Clearance of Systemic Amyloid Deposits By Repeated Doses of Antibody to Serum Amyloid P Component (SAP)

Laneuville, P.

2778 - Comparative Effectiveness of Generic Imatinib and Brand-Name Imatinib for the Treatment of Chronic Myeloid Leukemia

Lanford, L.

3508 - Liver Tropism and Factor VIII Transgene Expression after Intrauterine Chorionic Villus Stem Cell Transplantation

Lang, A.

2515 - Azacitidine in Acute Myeloid Leukemia with >30% Bone Marrow Blasts and <15 G/L White Blood Cell Count: Results from the Austrian Azacitidine Registry of the AGMT Study Group Versus Randomized Controlled Phase III Clinical Trial Data
3742 - Is It Time to Redefine Response in Elderly Patients with WHO-Acute Myeloid Leukemia (AML) Unfit for Intensive Chemotherapy?
4022 - Single-Cell Immune Signatures in Patients with Chronic Phase Chronic Myeloid Leukemia (CML) Treated with Nilotinib: An ENEST1st Sub Study

Lang, K. J.

2334 - Rivaroxaban-Mediated Vascular Relaxation As a Potential Cause of Headaches and Dizziness
3550 - Screening for Occult Malignancy Following First Unprovoked VTE: A Single Centre Experience

Lang, P. J.

3764 - Leukemia Related Co-Stimulation / Co-Inhibition Predict T-Cell Attack of Acute Lymphoblastic Leukemia Mediated By Blinatumomab
4338 - Pharmacokinetic Analysis during Antifungal Prophylaxis with Posaconazole Suspension in Pediatric and Adolescent Patients after Allogeneic Hematopoietic Stem Cell Transplantation

Lang, T.

2366 - The Common Genomic Locus of Evl and MiR-342 Regulates Both Lymphopoiesis and Myelopoiesis

Lange, E.

2773 - Health-Related Quality of Life Impairment in Patients with Chronic Myeloid Leukemia: Results of a German Cross-Sectional Study of Patients Registered in Prospective, Controlled Clinical Trials

Lange, T.

135 - Quantification of BCR-ABL with Digital PCR Results in a Significantly Lower Rate of Deep Molecular Responses When Compared to RT-qPCR in CML Patients Treated in the ENEST1st Trial
599 - Frequency of CTLA-4 Receptor Ligand (CD86, B7.2) -Positive Plasmacytoid Dendritic Cells Predicts Risk of Disease Recurrence after Tyrosine-Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia: Results from a Prospective Substudy of the Euroski Trial

Lange, T.

2032 - High Expression of the Hedgehog Transcription Factor GLI1 Is Associated with Improved Outcomes in Patients with Acute Myeloid Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Non-Myeloablative Conditioning

Langella, M.

4071 - Clinical and Biological Features in Patients with Ph-Negative Chronic Myeloproliferative Neoplasm Showing Different Molecular Pattern. Comparative Study in 596 Patients of the Registro Italiano Trombocitemie (RIT)

Langellotto, F.

164 - PI3Kdelta Inhibitors Increase Genomic Instability By Upregulating Aid Expression
3673 - FBXO11, a Regulator of BCL6 Stability, Is Recurrently Mutated in Burkitt Lymphoma

Langemeijer, S.

1209 - C5 Polymorphism in a Dutch Patient with Paroxysmal Nocturnal Hemoglobinuria (PNH) and No Asian Ancestry, Resistant to Eculizumab, but in Vitro Sensitive to Coversin

Langenheim, J. F.

1819 - Targeting Redox Overcomes Proteasome Inhibitor Resistance in Multiple Myeloma

Langer, A. L.

188 - Results of Phase I Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients with AL Amyloidosis

Langer, C.

1795 - Targeted Genomic Mutation Panel (M³P) Results from 504 Multiple Myeloma (MM) Patients

Langer, E.

2885 - Association Between Mitochondrial DNA Haplogroup and Myelodysplastic Syndromes

Langer, F.

1085 - Expression and Release of Platelet Protein Disulfide (PDI) Isomerase Is Increased in Patients with Hemophilia a

Langer, M.

765 - Complement C5 Inhibition Blocks the Cytokine Storm and Consumptive Coagulopathy By Decreasing Lipopolysaccharide (LPS) Release in E. coli Sepsis

Langerak, A. W.

720 - A Model for Predicting Effect of Treatment on Progression-Free Survival Using Minimal Residual Disease As a Surrogate Endpoint in Chronic Lymphocytic Leukemia
1411 - Library Preparation Is the Major Factor Affecting Differences in Results of Immunoglobulin Gene Rearrangements Detection on Two Major Next-Generation Sequencing Platforms
1657 - The Integrated Immunological Signature of Refractory Cytopenia of Childhood (RCC)
1712 - ATM Mutations in Major Stereotyped CLL Subsets: Enrichment in Subset #2 is Associated with Unfavourable Outcome
2750 - Identification and Characterization of HLA Class I-Restricted MYD88 L265P-Derived Peptides As Tumor-Specific Targets for Immunotherapy
2924 - Analytical Validation of Patient-Specific PCR-Based MRD Assessment for Use As a Primary Endpoint in CLL Clinical Trials
4126 - EGR2 Mutations in Chronic Lymphocytic Leukemia: A New Bad Player

Langerbeins, P.

2934 - Ibrutinib in Early Stage CLL: Preliminary Safety Results of a Placebo-Controlled Phase III Study
4151 - CLL2-BIG - a Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed By Ibrutinib and GA101 Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL): Interim Results of a Phase II-Trial
4156 - Prognostic Impact and Risk Factors of Reducing Prescribed Doses of Fludarabine, Cyclophosphamide and Rituximab (FCR) during Frontline Treatment of Chronic Lymphocytic Leukemia (CLL)

Langes, M.

4287 - Evidence for CD19+ (B) CD8+ (T)-Cell Interactions in Blood and Tissues from Patients with Graft-Versus-Host Disease

Langguth, P.

2224 - Transcutaneous Immunization with a Solid Nanoscopic Imiquimod Suspension Enhances Tumor Rejection

Langhi, C.

948 - Peroxisome Proliferator-Activated Receptor Alpha Contributes to Hepcidin up-Regulation in Mice during Fasting

Langlois, N.

890 - Low Molecular Weight Heparin for Prevention of Placenta-Mediated Pregnancy Complications: An Individual Patient Data Meta-Analysis

Langridge, T.

4011 - ONC201 Induces Apoptosis in Cutaneous T-Cell Lymphoma Cells through a Mechanism That Involves the Integrated Stress Response and Inactivation of Jak/Stat Signaling

Langridge, T.

3981 - Blood Transcriptional Profiling in Patients with Leukemic Cutaneous T-Cell Lymphoma on Extracorporeal Photopheresis Reveals the Integrin Signaling As the Top Pathway Associated with Clinical Response

Langsjoen, J.

1016 - Ferumoxytol-Contrasted MRI for Macrophage Imaging of Inflammation in Human Osteomyelitis, a Feasibility Study

Langston, A.

1938 - Ruxolitinib As Sparing Agent for Steroid-Dependent Chronic Graft-Versus-Host Disease (cGVHD)
3779 - Decreasing Early Deaths in Acute Promyelocytic Leukemia (APL) By Using a Simplified Treatment Algorithm and Establishing a Network with Academic and Community Centers in USA

Langston, A.

1496 - A Phase I Study of Gemcitabine and Bendamustine in Relapsed/Refractory Hodgkin Lymphoma

Languille, L.

3483 - Portal or Splenic Vein Thrombosis after Splenectomy for Immune Cytopenia: A Retrospective Cohort Study

Laniado, M.

386 - The Extent of Labile Plasma Iron (LPI) Predicts for Non-Relapse-Mortality (NRM) in AML and MDS Patients with Systemic Iron Overload Undergoing Allogenic Stem Cell Transplantation Results of the Prospective, German-Austrian Allive Trial

Lanic, H.

1452 - Molecular Profile and FDG-PET/CT Metabolic Tumor Volume Improve Risk Classification at Diagnosis for Patients with Diffuse Large B Cell Lymphoma

Lanieri, L.

1548 - IMGN529, a Novel Antibody-Drug Conjugate (ADC) Targeting CD37 Shows Synergistic Activity with Rituximab in Non-Hodgkin Lymphoma (NHL) Models

Lanino, E.

621 - Hematopoietic Stem Cell Transplantation for Hemophagocytic Lymphohistiocitosis : A National Retrospective Analysis of Data from the Italian Association of Pediatric Hematology Oncology (AIEOP)

Lankester, A. C.

645 - A Common Progenitor for Macrophages, Osteoclasts and Dendritic Cells Newly Discovered in Human Bone Marrow and Cord Blood Yields Dendritic Cells with T-Cell Priming Ability
1018 - CD69andCXCR6 Identify a Distinct Population of Human Bone Marrow and Spleen Resident NK Cells
2015 - Risk Factors Affecting Outcome of Transplantation in Pediatric Acute Lymphoblastic Leukemia: Results of the International BFM ALL SCT Study

Lankiewicz, M.

- Clinical Careers in Hematology

Lannert, K. W.

2242 - Complex Relationship of Blood Group H, ABO Glycans, and Von Willebrand Factor Levels

Lannutti, B. J.

2908 - ACP-196 Is a Second Generation Inhibitor of Bruton Tyrosine Kinase (BTK) with Enhanced Target Specificity
2920 - The Bruton Tyrosine Kinase (BTK) Inhibitor ACP-196 Demonstrates Clinical Activity in Two Mouse Models of Chronic Lymphocytic Leukemia

Lansigan, F.

1284 - Lipid Addiction of Diffuse Large B-Cell Lymphoma (DLBCL): Fatty Acid Synthase (FASN) and PI3K Dependent Cell Death Identifies a Novel Therapeutic Paradigm
1314 - The Epidemiology and Clinical Associations of Stroke in Patients with Acute Myeloid Leukemia: A Review of 10,972 Admissions from the 2012 National Inpatient Sample
1533 - Remission Induction in a Phase I/II Study of an Anti-CD20-Interleukin-2 Immunocytokine DI-Leu16-IL2 in Patients with Relapsed B-Cell Lymphoma
2737 - Retrospective Analysis of Lymphomas in the Setting of Autoimmune Disease and the Impact of Immunosuppression

Lantz, K.

4222 - Target-Mediated Drug Disposition of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma after Prior Proteasome Inhibitors and Immunomodulatory Drugs: A Population Pharmacokinetic Analysis

Lanuti, P.

4134 - MiR-181b in Chronic Lymphocytic Leukemia B Cells Is Regulated By Cellular Interaction with CD4+ T Cells and Increases the CTL Toxicity Versus the Leukemic Clone

Lanza, F.

3645 - GEP Analyses of Bone Marrow CD34+/Lin- Cells of Chronic Phase CML Patients at Diagnosis Identified Different Sets of Genes Associated to the Molecular Response after 3 and 6 Months of First-Line Nilotinib Treatment

Lanza, F.

1597 - REL-Protocol PhilosoPhi34: An Open Label, Single Arm, Phase II Study of Nilotinib 300 Mg BID in Newly Diagnosed Chronic Phase Chronic Myeloid Leukaemia Patients, to Study the Disappearance of CD34+/Lin-Ph+ Cells from Bone Marrow during Treatment. Preliminary Data

Lanzel, E. A.

1803 - Predicting Non-Responders to Immunotherapy Treatments through Simulation of NGS Information

Lanzi, M. R.

979 - Initial Clinical Validation of a Rapid, Low-Cost, Paper-Based Diagnostic Test for Sickle Cell Anemia As a Tool to Facilitate Newborn Screening in Resource-Limited Settings

Lanzkron, S.

3263 - Contraceptive in Women with Sickle Cell Disease: A Survey Study
3405 - Metabolic Syndrome Risk Among Adults Living with Sickle Cell Disease
- The Five Key Things You Need to Know to Manage Adult Patients with Sickle Cell Disease

Lao, F. S.

4150 - Pharmacologic Modulation of STAT1 and Wnt Signaling in Chronic Lymphocytic Leukemia

Lao, Z.

3184 - Impact of Post-Remission Consolidation Modalities in the Clinical Outcomes of Acute Myeloid Leukemia Patients in First Remission - Is There a Role for Autologous Hematopoietic Stem Cell Transplant?

Laouedj, M.

3858 - Myeloid-Related Protein S100A9 Induces Cellular Differentiation in Acute Myeloid Leukemia through TLR2 and TLR4 Receptors

Lapalombella, R.

317 - Next Generation XPO1 Inhibitor Shows Improved Efficacy and In Vivo Tolerability in Hematologic Malignancies
318 - A Novel Inhibitor of BET Family Bromodomains Demonstrates In Vivo and In Vitro Potency in B-Cell Malignancies
1232 - Targeting BTK By a microRNA Mechanism in Chronic Lymphocytic Leukemia
2471 - In Vitro and In Vivo Anti-Leukemic Effects of KPT-9274, a Reported PAK4 Allosteric Modulator, in Acute Myeloid Leukemia: Promising Results Justifying Further Development in This Disease
2752 - The Eµ-Myc/TCL1 Transgenic Mouse As a New Aggressive B-Cell Malignancy Model Suitable for Preclinical Therapeutics Testing

Lapeyre-Mestre, M.

9 - Serious and Non-Serious Infections in Non-Splenectomized Adults Treated for Persistent or Chronic Primary Immune Thrombocytopenia: Effect of Treatments and Protection of Vaccines. Results of the French Nationwide Faith Study
1056 - Incidence of Adverse Drug Reactions Related to Immune Thrombocytopenia Drugs. A Prospective Cohort Study
3473 - Clinical Epidemiology and First-Line Treatment in Immune Thrombocytopenia Adults. Results of the Carmen Prospective Cohort

Lapidot, T.

33 - EPCR/PAR1 Signaling Navigates Long-Term Repopulating Hematopoietic Stem Cell Bone Marrow Homing to Thrombomodulin-Enriched Blood Vessels
664 - Distinct Bone Marrow Blood Vessels Differentially Regulate Normal and Malignant Hematopoietic Stem and Progenitor Cells

Lapin, V. A.

2497 - Absence of High-Dose Consolidation Courses and Low Numbers of Allogeneic HSCTs Did Not Affect Overall Optimistic Results in B-Cell Precursor Ph-Negative Adult ALL Patients Treated By Non-Intensive but Non-Interruptive ALL-2009 Protocol: Data of the Russian ALL Study Group
2708 - Addition of R-HMA to R-DA-EPOCH Favourably Changes the Outcome in Patients with Untreated High-Grade Diffuse Large B-Cell Lymphoma: The First Results of Russian Prospective Multicenter Trial

Laplant, B. R.

813 - Everolimus Plus RCHOP-21 Is Safe and Highly Effective for New Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results of the Phase I Trial NCCTG1085 (Alliance)
834 - PD-1 Blockade with Pembrolizumab (MK-3475) in Relapsed/Refractory CLL Including Richter Transformation: An Early Efficacy Report from a Phase 2 Trial (MC1485)
3050 - Randomized Phase 2 Trial of Two Different Doses of Ixazomib in Patients with Relapsed Multiple Myeloma Not Refractory to Bortezomib

Laport, G.

1536 - Phase I/II Clinical Trial of CpG-Activated Whole Cell Vaccine in Mantle Cell Lymphoma (MCL): Results in Safety and Efficacy from Planned Interim Analysis
3232 - Donor-Derived CIK Cell Infusion As Consolidative Therapy after Non-Myeloablative Allogeneic Transplant in Patients with Myeloid Neoplasms

Lapoumeroulie, C.

2174 - Effects of Poloxamer 188 on Red Blood Cells Membrane Properties in Sickle Cell Disease

Lappin, T. R. J.

3630 - Conditional Deletion of the Hoxa Cluster in MLL-AF9 Is Incompatible with Leukemia Maintenance

Laquerriere, A.

332 - Somatic Mutations Detected in Plasma Cell-Free DNA By Targeted Sequencing: Assessment of Liquid Biopsy in Primary Central Nervous System Lymphoma

Lara, R.

1232 - Targeting BTK By a microRNA Mechanism in Chronic Lymphocytic Leukemia

Larfars, G.

2309 - Post-Thrombotic Syndrome and Quality-of-Life after Venous Thromboembolism in Young and Middle-Aged Women

Largaespada, D. A.

3060 - Single-Cell Analysis Reveals Molecular Mechanisms of NRAS-Mediated Leukemia Stem Cell Self-Renewal in a Murine Model of AML

Laribi, K.

393 - Bortezomib, Thalidomide and Dexamethasone (VTD) Is Superior to Bortezomib, Cyclophosphamide and Dexamethasone (VCD) Prior to Autologous Stem Cell Transplantation for Patients with De Novo Multiple Myeloma. Results of the Prospective IFM 2013-04 Trial
395 - Prospective Evaluation of MRI and PET-CT at Diagnosis and before Maintenance Therapy in Symptomatic Patients with Multiple Myeloma Included in the IFM/DFCI 2009 Trial
510 - Elotuzumab Plus Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: 2-Year Follow-up
952 - Treatment of Chemotherapy-Induced Anemia Using Epoetin Alfa Biosimilar for Patients with Lymphoma and Myeloma: The Synergy Study
3363 - Epoetin Alfa Biosimilar Treatment for Chemotherapy-Induced Anemia in Current Oncology and Hematology Practice: An Iron Supplementation Subanalysis of the Synergy Study

Larkins, G.

4229 - Clinical Outcomes of Patients with Newly Diagnosed Multiple Myeloma Receiving Triplet Therapy in the Connect MM^® Disease Registry

Larocca, A.

927 - Impact of Complete Response on Survival with Either Autologous Stem Cell Transplantation or Conventional Chemotherapy: Results of a Pooled Analysis of 5 Phase III Trials in Newly Diagnosed Multiple Myeloma Patients
1760 - Minimal Residual Disease Detection By Multiparametric Flow Cytometry in Newly Diagnosed Multiple Myeloma Patients: A Preliminary Analysis of the EMN02/HO95 MM Study
1828 - Weekly Carfilzomib, Cyclophosphamide and Dexamethasone (wCCyd) in Elderly Newly Diagnosed Multiple Myeloma Patients: Results of a Phase 2 Study

Larochelle, A.

2407 - The Thrombopoietin Receptor Agonist Eltrombopag Has DNA Repair Activity in Human Hematopoietic Stem and Progenitor Cells

LaRosee, P.

3930 - Temsirolimus in Combination with Bendamustine and Rituximab for the Treatment of Relapsed Mantle Cell and Follicular Lymphoma: Report on an Ongoing Phase I/II Trial

Larrayoz, M.

365 - Genomic Disruption of the Histone Methyltransferase SETD2 in Chronic Lymphocytic Leukemia
1716 - The Syk\Jak Inhibitor Cerdulatinib (PRT062070) Shows Promising Preclinical Activity in Chronic Lymphocytic Leukemia By Antagonising B Cell Receptor and Microenvironmental Signalling

Larripa, I.

4275 - TGFB1 Functional Polymorphisms in Sibling HSCT. "Tto be or Not Tto be"

Larrue, C.

2542 - The Combination of ATRA and Dasatinib for Differentiation Therapy in Acute Myeloid Leukemias with IDH Mutations

Lars, K.

3333 - Gardos Channel Mutation Is Associated with Hereditary Dehydrate Stomatocytosis: a Complex Channelopathy

Larsen, A.

1074 - Newly Diagnosed Multiple Myeloma Is Associated with Enhanced TF Pathway Activation, Thrombin Generation and Increased Concentration of Procoagulant Microparticles
1113 - Acquision of Resistance to Doxorubicin By Breast Cancer Cells MCF7 Enhances Their Procoagulant Properties and Alters the Efficacy of Antithrombotic Agents to Inhibit Thrombin Generation

Larsen, E. K.

2736 - Five-Year Survival Data Demonstrating Durable Responses from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma
3172 - Updated Efficacy and Safety Data from the AETHERA Trial of Consolidation with Brentuximab Vedotin after Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse

Larsen, E. C.

250 - Genetic Risk Factors for the Development of Osteonecrosis in Children Under Age 10 Treated for Acute Lymphoblastic Leukemia
695 - Germline Genetic Variation in ETV6 and Predisposition to Childhood Acute Lymphoblastic Leukemia
807 - Genetic and Response-Based Risk Classification Identifies a Subgroup of NCI High Risk Childhood B-Lymphoblastic Leukemia (HR B-ALL) with Outstanding Outcomes: A Report from the Children's Oncology Group (COG)
1303 - Incidence of Allergic Reactions to Pegaspargase (PEG) Administered Intramuscularly Versus Intravenously (IM vs. IV) in Children and Young Adults with High Risk B- Lymphoblastic Leukemia (HR B-ALL): Results of Children's Oncology Group (COG) Studies AALL0232/AALL1131

Larsen, R. H.

3245 - Treatment with ¹⁷⁷lu-HH1 Increases CD20 Expression in Non-Hodgkin Lymphoma Cells in Vitro and In Vivo

Larsen, S. R.

815 - Early Treatment Intensification with R-ICE Chemotherapy Followed By Autologous Stem Cell Transplantation (ASCT) Using Zevalin-BEAM for Patients with Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) As Identified By Interim PET/CT Scan Performed after Four Cycles of R-CHOP-14: A Multicenter Phase II Study of the Australasian Leukaemia Lymphoma Study Group (ALLG)
3081 - Characterisation of Human CD83 Expression on Immune Cells and Their Targeting with CD83 Antibodies to Prevent Graft Versus Host Disease in Allogeneic Haematopoietic Cell Transplantation
4314 - Evaluation of Pharmacokinetic-Based Dose Predictions of High Dose Melphalan in Patients with Myeloma

Larsen, T. S.

824 - Safety and Efficacy of Combination Therapy of Interferon-Alpha2 + JAK1-2 Inhibitor in the Philadelphia-Negative Chronic Myeloproliferative Neoplasms. Preliminary Results from the Danish Combi-Trial - an Open Label, Single Arm, Non-Randomized Multicenter Phase II Study
3905 - The Absolute Number of Extranodal Sites Detected By PET-CT Is a Powerful Predictor of Secondary Central Nervous System Involvement in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP
4097 - The Impact of Interferon-alpha2 on HLA-Genes in Patients with Polycythemia Vera and Related Neoplasms

Larson, R. A.

6 - The Multi-Kinase Inhibitor Midostaurin (M) Prolongs Survival Compared with Placebo (P) in Combination with Daunorubicin (D)/Cytarabine (C) Induction (ind), High-Dose C Consolidation (consol), and As Maintenance (maint) Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients (pts) Age 18-60 with FLT3 Mutations (muts): An International Prospective Randomized (rand) P-Controlled Double-Blind Trial (CALGB 10603/RATIFY [Alliance])
319 - Addition of Sorafenib to Chemotherapy Improves the Overall Survival of Older Adults with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) (Alliance C11001)
321 - Antileukemic Activity and Tolerability of ASP2215 80mg and Greater in FLT3 Mutation-Positive Subjects with Relapsed or Refractory Acute Myeloid Leukemia: Results from a Phase 1/2, Open-Label, Dose-Escalation/Dose-Response Study
1308 - Tipifarnib As Maintenance Therapy in Acute Myeloid Leukemia (AML) Improves Survival in a Subgroup of Patients with High Risk Disease. Results of the Phase III Intergroup Trial E2902
2518 - Efficacy of Single-Agent Decitabine in Relapsed and Primary Refractory (rel/ref) Acute Myeloid Leukemia (AML)
2781 - Impact of Treatment with Frontline Nilotinib (NIL) vs Imatinib (IM) on Sustained Deep Molecular Response (MR) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
3667 - Overexpression and Knockout of Mir-126 Both Promote Leukemogenesis through Targeting Distinct Gene Signaling
3777 - Dose-Escalation Study of Azacitidine Followed By High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in High-Risk Acute Myeloid Leukemia (AML)
3784 - Targeted Treatment of FLT3-Overexpressing Acute Myeloid Leukemia with MiR-150 Nanoparticles Guided By Conjugated FLT3 Ligand Peptides
3853 - Epigenetic Modifying Drugs Inhibit MDS/AML Cell Growth through Selective Disruption of the Interactions Between Lineage-Determining Transcription Factors and DNA/Histone Modifiers
- Is There a Best Tyrosine Kinase Inhibitor for Chronic-Phase Chronic Myeloid Leukemia?

Larson, R. S.

694 - Mixed Lineage Leukemia Rearrangements (MLL-R) Are Determinants of High Risk Disease in Homeobox A (HOXA)-deregulated T-Lineage Acute Lymphoblastic Leukemia: A Children's Oncology Group Study

Larson, R. P.

1901 - Functional Characterization of a T Cell Stimulation Reagent for the Production of Therapeutic Chimeric Antigen Receptor T Cells

Larson, S.

377 - Combination Treatment of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib and Carfilzomib in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Initial Results from a Multicenter Phase 1/2b Study
3702 - Efficacy and Mechanism of Action of the Novel Bromodomain Inhibitor, PLX51107, in B Cell Malignancies
4430 - Pre-Clinical Development of Gene Modification of Hematopoietic Stem Cells with Chimeric Antigen Receptors for Cancer Immunotherapy

Larsson, J.

36 - Ciclopirox Ethanolamine Is a Novel Modifier of Human Hematopoietic Stem Cell Ex Vivo Expansion

Larsson, K.

2921 - Personalized Modeling of Disease Evolution in CLL: Does Statistical Significance Translate into Predictive Accuracy?

Larue, R. S.

3060 - Single-Cell Analysis Reveals Molecular Mechanisms of NRAS-Mediated Leukemia Stem Cell Self-Renewal in a Murine Model of AML

Lashkari, A.

2904 - A Phase 2 Study of Birinapant in Combination with 5-Azacitadine in Patients with Myelodysplastic Syndrome Who Are Naïve to 5-Azacitadine: A Preliminary Analysis of Phase 2a

Lasho, T. L.

55 - Telomerase Inhibitor Imetelstat Therapy in Refractory Anemia with Ring Sideroblasts with or without Thrombocytosis
350 - A 27-Gene NGS Panel in Primary Myelofibrosis Identifies ASXL1, CBL, RUNX1 and SRSF2 Mutations As Being Unfavorable and Absence of Any Non-Driver Mutation As Being Favorable to Survival
354 - Targeted Next-Generation Sequencing in Polycythemia Vera and Essential Thrombocythemia
828 - ASXL1 and CBL Mutations Are Independently Predictive of Inferior Survival in Advanced Systemic Mastocytosis
1599 - Driver Mutations and Prognosis in 502 Patients with Essential Thrombocythemia
2801 - Driver Mutations and Prognosis in 1118 Patients with Primary Myelofibrosis
2864 - Prognostic Interaction Between ASXL1 and TET2 Mutations in Chronic Myelomonocytic Leukemia
2882 - ASXL1 Mutations in Myelodysplastic Syndromes with 1% or More Ring Sideroblasts: Prevalence, Clinical Correlates and Prognostic Relevance
4062 - Momelotinib Therapy for Myelofibrosis: Impact on Long-Term Survival and Genotype Correlations
4067 - Vascular Events and Risk Factors for Thrombosis in Refractory Anemia with Ring Sideroblasts and Thrombocytosis (RARS-T)
4068 - Molecular Correlates of Anemia in Primary Myelofibrosis

Lassaletta, A.

172 - Predictors of Early Death in Childhood Acute Promyelocytic Leukemia: Results of an International Retrospective Study

Lassalle, F.

2273 - High-Throughput Genotyping of Haemophilia A and B Using Next-Generation Sequencing Technology in Lille University Hospital

Lassen, U.

507 - Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results of a Phase 1/2 Study (GEN503)

Lasserre, S. F.

4263 - Vemurafenib (VEM) in Relapsed Refractory Multiple Myeloma Harboring BRAF^V600 Mutations (V600m): A Cohort of the Histology-Independent VE-Basket Study

Laszlo, G. S.

2570 - High Expression of Myocyte Enhancer Factor 2C (MEF2C) Is Associated with Adverse Risk Features and Poor Outcome in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Laszlo, S.

1261 - Effective Treatment of Human CML By RNAi In Vivo in a Xenotransplantation Mouse Model

Latagliata, R.

91 - Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Results on Efficacy, Safety and Quality of Life of an International, Multicenter Prospective, Randomized, Trial
1582 - Very Elderly Patients with Chronic Phase-Chronic Myeloid Leukemia on Imatinib: No Impact of Concomitant Drugs on Complete Cytogenetic Response
1598 - Long-Term Follow-up in Very Elderly Patients with Chronic Myeloid Leukemia Treated with Imatinib Frontline
1606 - Risk Factors for Infections in Myelofibrosis: Role of Disease Status and Treatment. A Study on 507 Patients
1614 - JAK2V617F-Positive Patients with Essential Thrombocythemia or Early Primary Myelofibrosis: The Impact of Histological Diagnosis on Outcome
2811 - Are ET and PV Patients Two Similar Populations As Concern Thrombotic Risk Factors?
2815 - The Platelet COUNT at Diagnosis of Essential Thrombocythemia Is a Prognostic Factor for Thrombosis-Free Survival: Retrospective Analysis on 1201 Patients
2821 - Application of the International Prognostic Score of Thrombosis for Essential Thrombocytemia(ET) (IPSET-Thrombosis) in a Cohort of ET Patients: Experience from Gruppo Laziale for Myeloproliferative Ph Negative Neoplasms
4038 - Event-Free Survival According to Age in Patients with Chronic Myeloid Leukemia Receiving Imatinib Frontline: The Younger, the Later, the Worse?

Latargia, M. L.

3645 - GEP Analyses of Bone Marrow CD34+/Lin- Cells of Chronic Phase CML Patients at Diagnosis Identified Different Sets of Genes Associated to the Molecular Response after 3 and 6 Months of First-Line Nilotinib Treatment

Latargia, M. L.

1597 - REL-Protocol PhilosoPhi34: An Open Label, Single Arm, Phase II Study of Nilotinib 300 Mg BID in Newly Diagnosed Chronic Phase Chronic Myeloid Leukaemia Patients, to Study the Disappearance of CD34+/Lin-Ph+ Cells from Bone Marrow during Treatment. Preliminary Data

Latchman, Y.

1144 - Immunomodulatory Effects of Transfusion

Latger Cannard, V.

3812 - Biological Description of 109 Cases of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) from the French Network of BPDCN

Latger-Cannard, V.

2662 - Multicentric Analyses of the CD148, CD180, and CD200 Combination for the Diagnosis of Mature B-Cell Neoplasm Using Flow Cytometry

Latif, A. L.

674 - Dual Inhibition of MDM2 and BET Cooperate to Eradicate Acute Myeloid Leukemia

Latif, E. S.

2619 - A Whole Genome In Vivo Crispr Screen in Primary ALL Predicts Leukaemic Relapse

Latifoltojar, A.

1850 - Whole Body (WB) MRI in Newly Diagnosed Multiple Myeloma (MM): Fat Fraction Changes at 8 Weeks Predict Response to Induction with Bortezomib Regimens

Latimer, IV, H. J.

1893 - Manufacturing an Enhanced CAR T Cell Product By Inhibition of the PI3K/Akt Pathway During T Cell Expansion Results in Improved In Vivo Efficacy of Anti-BCMA CAR T Cells
3094 - A Novel and Highly Potent CAR T Cell Drug Product for Treatment of BCMA-Expressing Hematological Malignances
3243 - Characterization of Lentiviral Vector Derived Anti-Bcma CAR T Cells Reveals Key Parameters for Robust Manufacturing of Cell-Based Gene Therapies for Multiple Myeloma

Latouche, J. B.

106 - Identification of T Cell Epitope of ADAMTS13 in Thrombotic Thrombocytopenic Purpura Patients

Latremouille-Viau, D.

1596 - Treatment Patterns and Healthcare Costs in Newly Diagnosed Patients with Chronic Myeloid Leukemia Receiving Dasatinib or Nilotinib As First-Line Therapy in the United States: A Retrospective Claims Database Analysis

Latzko, M.

2998 - A New Class of T-Cell Bispecific Antibodies for the Treatment of Multiple Myeloma, Binding to B Cell Maturation Antigen and CD3 and Showing Potent, Specific Antitumor Activity in Myeloma Cells and Long Duration of Action in Cynomolgus Monkeys

Lau, A.

1742 - A Phase 2 Study of Ofatumumab in Combination with a Pan-AKT Inhibitor (Afuresertib) in Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL)
4163 - An Phase 2 Study of Lenalidomide in Combination with Oral Dexamethasone in Previously Untreated, Symptomatic Patients with Chronic Lymphocytic Leukemia (CLL)

Lau, J. T.

2374 - Systemic Glycosyltransferase Attenuates Granulocyte Progenitor Differentiation

Lau, K. K.

955 - Serum Ferritin Is Not Sensitive or Specific for the Diagnosis of Iron Deficiency in Patients with Normocytic Anemia

Lau, K.

3571 - Outcomes and Management of Red Blood Cell Transfusions in Multiple Myeloma Patients Treated with Daratumumab

Lau, Y. K. (.

537 - Phase 1 Study of a Hepcidin Antagonist, LY2787106, in Cancer-Associated Anemia

Laubach, J.

4256 - Final Results of the Phase I/II Study of Chemosensitization Using the CXCR4 Inhibitor Plerixafor in Combination with Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

Laubach, J. P.

3036 - A Phase 1, Multicenter Study of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Patients with Proteasome Inhibitor Exposed and Lenalidomide-Refractory Myeloma (Trial MM-005)

Laubach, J. P.

23 - Mutational Profile and Prognostic Relevance of Circulating Tumor Cells in Multiple Myeloma
507 - Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results of a Phase 1/2 Study (GEN503)
510 - Elotuzumab Plus Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: 2-Year Follow-up
727 - Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study (NCT01564537)
3306 - Feasibility of Routine Frailty Screening Assessment for Patients in a Hematologic Oncology Clinic: Results from a Pilot Study
4217 - A Phase II Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVD-lite) for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
4218 - Blockade of PD-1 in Combination with Dendritic Cell/Myeloma Fusion Cell Vaccination Following Autologous Stem Cell Transplantation Is Well Tolerated, Induces Anti-Tumor Immunity and May Lead to Eradication of Measureable Disease
4220 - Phase 1, Multicenter, Open-Label, Combination Study (NPI-0052-107; NCT02103335) of Pomalidomide (POM), Marizomib (MRZ, NPI-0052), and Low-Dose Dexamethasone (LD-DEX) in Patients with Relapsed and Refractory Multiple Myeloma
4241 - Phase 1 Dose-Escalation Study of Sotatercept (ACE-011) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma

Lauber, K.

1204 - A Human Bone Marrow Failure Syndrome Caused By a Homozygous Mutation in MYSM1

Lauer, E.

2027 - Prospective Evaluation of Cord Blood (CB) & Haplo-Identical Donor Availability Reveals Compromised Donor Access for Both Graft Types in Minorities and High Rates of Failure to Clear Haplo Donors in Adult Patients
3231 - Age-Adjusted Co-Morbidity Score - but Not Revised Disease Risk Index - Is Associated with Progression-Free Survival after Intermediate Intensity Double Unit CBT in Adults with Hematologic Malignancies

Laughlin, M.

1870 - Impact of Erythropoietin Modulation Using Hyperbaric Oxygen on Umbilical Cord Blood CD34+ Cell Homing

Laukkanen, S.

3646 - Identification of Novel Drug Targets in T-Cell Acute Lymphoblastic Leukemia

Laumann, K.

319 - Addition of Sorafenib to Chemotherapy Improves the Overall Survival of Older Adults with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) (Alliance C11001)
1839 - Appropriate Dose Adjustment of Dexamethasone Does Not Compromise Outcomes in Relapsed Refractory Multiple Myeloma
3050 - Randomized Phase 2 Trial of Two Different Doses of Ixazomib in Patients with Relapsed Multiple Myeloma Not Refractory to Bortezomib

Launer, L.

4252 - No Risk of Arterial or Venous Thrombosis in Monoclonal Gammopathy of Undetermined Significance: Results from a Population-Based Study

Launonen, K.

1977 - A Prospective Phase 2 Study to Assess Immunophenotypic Remission after Lenalidomide-Based Induction Followed By ASCT and Lenalidomide Maintenance in Patients with Newly Diagnosed Multiple Myeloma

Laurence, D. A.

4459 - Current Practice of Hospital Acquired Thrombosis (HAT) Prevention in an Acute Hospital (a single centre cross sectional study)

Laurent, C.

3970 - Inhibition of Hedgehog Signaling for the Treatment of Lymphoma and CLL: A Phase II Study from the Lysa

Laurent, G.

9 - Serious and Non-Serious Infections in Non-Splenectomized Adults Treated for Persistent or Chronic Primary Immune Thrombocytopenia: Effect of Treatments and Protection of Vaccines. Results of the French Nationwide Faith Study
1051 - Thrombosis in Immune Thrombocytopenia Patients with Antiphospholipid Antibodies: A Meta-Analysis
1056 - Incidence of Adverse Drug Reactions Related to Immune Thrombocytopenia Drugs. A Prospective Cohort Study
3473 - Clinical Epidemiology and First-Line Treatment in Immune Thrombocytopenia Adults. Results of the Carmen Prospective Cohort

Laurenti, E.

2360 - The Human Blood Hierarchy Is Shaped By Distinct Progenitor Lineages Across Development

Laurenti, L.

489 - Inhibition of SYK More Effectively Overcomes MCL-1 Mediated ABT-199 Resistance of BCR-Stimulated CLL Cells Than Inhibition of BTK or PI3Kdelta
2925 - The Hypoxia-Inducible Factor-1alpha Is Constitutively Upregulated in TP53 Disrupted CLL Cells: A Potential Target to Overcome Fludarabine Resistance
4131 - Serum IgM Activates BCR Signaling Pathways and Increases Survival of Chronic Lymphocytic Leukemia B Cells
4134 - MiR-181b in Chronic Lymphocytic Leukemia B Cells Is Regulated By Cellular Interaction with CD4+ T Cells and Increases the CTL Toxicity Versus the Leukemic Clone

Laurenzana, I.

3254 - A Pyrazolo[3,4-d]Pyrimidine Compound Reduces Fyn Phosphorylation and Induces Apoptosis in Large Granular Lymphocyte Leukemia Cells

Lauri, B.

1745 - Real-World Results on Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Data from 97 Swedish Patients Treated in a Compassionate Use Program
3047 - The Rev II Trial: Lenalidomide and Dexamethasone As Second Line Treatment in Myeloma Followed By Extended Lenalidomid Vs Len/Dex

Lauriente, V.

4147 - Mechanisms of the BCR-Mediated CXCR4 Down-Regulation and Its Clinical Relevance in Chronic Lymphocytic Leukemia Progression

Lauris, G.

1317 - Acute Myeloid Leukemia in Elderly Patients: Experience of the Antoine Lacassagne Center and a New Score to Define Fit Patients

Laursen, L. G.

2358 - Bloodspot: A Web Resource Facilitating the Analysis of Transcriptional Programs in Normal and Malignant Hematopoiesis

Laursen, M. B.

1455 - High Expression of CXCR4 Impairs Anti-CD20 Monoclonal Antibody (Rituximab)-Dependent Cytotoxicity in Diffuse Large B-Cell Lymphoma

Lauseker, M.

1581 - Major Route Additional Chromosomal Aberrations (ACA) Precede Increase of Blasts in CML: An Analysis of the German CML-Studies III and IIIA
2773 - Health-Related Quality of Life Impairment in Patients with Chronic Myeloid Leukemia: Results of a German Cross-Sectional Study of Patients Registered in Prospective, Controlled Clinical Trials
4047 - Smoking Is a Prognostic Factor for Survival in Chronic Myeloid Leukemia

Lausen, B.

1576 - Switch to Subsequent Line of Treatment in Children and Adolescents with Chronic Myeloid Leukemia (CML) Treated with Imatinib: Experience of the International Registry for Chronic Myeloid Leukemia in Children and Adolescents (I-CML-Ped Study)
2789 - Description and Management of Accelerated Phase and Blast Crisis in 21 CML Pediatric Patients

Lausen, B.

3745 - Effect of Age and Weight on Toxicity and Survival in Pediatric Acute Myeloid Leukemia

Lausen, B.

3749 - qPCR MRD Monitoring in Peripheral Blood May Predict Hematological Relapse in Pediatric Acute Myeloid Leukemia

Lauterbach, R.

3484 - High Incidence of Alloimmunization to Platelets and Platelet Transfusion Refractoriness during Induction Therapy in Patients Diagnosed with Acute Myeloid Leukemia

Lauwers-Cances, V.

191 - Evaluation of Minimal Residual Disease (MRD) By Next Generation Sequencing (NGS) Is Highly Predictive of Progression Free Survival in the IFM/DFCI 2009 Trial
391 - Autologous Transplantation for Multiple Myeloma in the Era of New Drugs: A Phase III Study of the Intergroupe Francophone Du Myelome (IFM/DFCI 2009 Trial)

Laux, V.

3500 - Acute Efficacy of a Novel Anti-Tissue Factor Pathway Inhibitor Antibody BAY 1093884 in Hemophilia A Mouse Severe Tail Bleeding

Lavabre-Bertrand, T.

1207 - In Vitro Functional Rescue of a Double MPL K39N/W272R Mutant Associated with Congenital Amegakaryocytic Thrombocytopenia (CAMT) Using Crispr/Cas9

Lavallee, V. P.

3370 - Prospective Evaluation of Fetal Haemoglobin Induction in Maternal Erythrocytes: A Preliminary Analysis of a Cohort of 345 Parturients

Lavallée, V. P.

802 - Mutational and Transcriptomic Landscape of AML with Core-Binding Factor Rearrangements
1859 - The Novel Leukemia Stem Cell Marker GPR56 Discriminates Leukemic Subclones with Divergent Stem Cell Properties in Human Acute Myeloid Leukemia
3855 - Transcriptome Analysis Reveals That G Protein-Coupled Receptors Are Potential Diagnostic Markers or Therapeutic Targets in Acute Myeloid Leukemia

LaVasseur, C.

933 - Loss of FoxM1 Promotes Erythroid Differentiation through Increased Proliferation of Erythroid Progenitors

Lavela, J.

3414 - A Pilot Study of Sleep Disordered Breathing (SDB) and Nocturnal Hypoxemia in Young Adults with Sickle Cell Disease

Lavelle, D.

642 - The LSD1 Inhibitor RN-1 Recapitulates the Fetal Pattern of Hemoglobin Synthesis in Anemic and Normal, Non-Anemic Baboons
3386 - Investigation of Two Combination HbF Induction Regimens, RN-1 and Hydroxyurea Versus RN-1 and Decitabine, in a Humanized Sickle Cell Mouse Model

Laverdiere, C.

248 - Higher Incidence of Treatment-Related Toxicities in Non-Hispanic Patients Undergoing Therapy for Newly Diagnosed Pediatric Acute Lymphoblastic Leukemia on Dana-Farber Cancer Institute ALL Consortium Protocol 05-001
249 - Effectiveness of Antibacterial Prophylaxis during Induction Chemotherapy in Children with Acute Lymphoblastic Leukemia
2613 - Ikaros Gene Deletion Significantly Predicts Relapse in Pediatric B-ALL Patients with Low End-Induction Minimal Residual Disease

Laverdiere, I.

3681 - Identification of Existing Bioactive Compounds That Target Acute Myeloid Leukemia Stem Cells
4267 - G Protein-Coupled Receptor 56 As a Potential Regulator of Normal and Leukemic Stem Cells

Lavi, N.

3810 - Astarabine, a Pro-Drug of Cytarabine, Is Safe for Patients with Advanced Acute Leukemia. A Phase I/IIa Single Center Study in Relapsed/Refractory or Medically Unfit Patients
4081 - Anticoagulation Therapy for Venous Thrombotic Events in Patients with Myeloproliferative Neoplasms

Lavie, D.

827 - An Open-Label, Multicenter, 2-Arm, Dose-Finding, Phase 1b Study of the Combination of Ruxolitinib and Buparlisib (BKM120) in Patients with Myelofibrosis: Results from HARMONY Study
3954 - Favorable Outcome of Primary Mediastinal Large B-Cell Lymphoma Patients Treated with Sequential R-CHOP/R- ICE Regimen Omitting Radiation

Lavilla, E.

2723 - Incidence, Treatment and Prognosis of Patients with Relapsed Burkitt Lymphoma/Leukemia Treated with Specific Chemotherapy or Immunochemotherapy in Spain

Lavon, O.

4524 - Integrative Approach Successfully Improves Safety of in-Patient Chemotherapy and Reduces Health Care Costs

Lavrisha, L.

3412 - The Effects of Glutamine Supplementation on Markers of Autophagy and Apoptosis in Peripheral Blood Mononuclear Cells from Patients with Sickle Cell Disease

Law, A.

2904 - A Phase 2 Study of Birinapant in Combination with 5-Azacitadine in Patients with Myelodysplastic Syndrome Who Are Naïve to 5-Azacitadine: A Preliminary Analysis of Phase 2a

Law, C. L.

594 - SGN-CD19B, a Pyrrolobenzodiazepine (PBD)-Based Anti-CD19 Drug Conjugate, Demonstrates Potent Preclinical Activity Against B-Cell Malignancies

Law, F.

140 - Sf3b1 K700E Mutation Impairs Pre-mRNA Splicing and Definitive Hematopoiesis in a Conditional Knock-in Mouse Model

Law, P.

624 - Reduction in CMV and Adenovirus Viremia after Haploidentical Donor Transplantation Utilizing CD45RA Depletion and NK Cell Infusion

Law, T.

1419 - High Prevalence of Relapse in Australian Children with Ph-like Acute Lymphoblastic Leukemia Despite Risk Adapted Treatment
2614 - Improved Concordance of Minimal Residual Disease Measurements By Quantitative PCR and 10-Color Flow Cytometry in Pediatric Acute Lymphoblastic Leukemia

Lawerenz, C.

3875 - Identification of Blut, a Novel Long-Noncoding RNA Differentially Expressed in Burkitt Lymphoma

Lawes, M. J.

3064 - Protein Kinase C-ß Dependent IL-8 Release Promotes Acute Myeloid Leukemia Blast Cell Survival in Co-Cultures with Bone Marrow Stromal Cells

Lawlor, M.

838 - Discovery and Characterization of Promoter and Super-Enhancer-Associated Dependencies through E2F and BET Bromodomains in Multiple Myeloma

Lawrence, H. R.

2826 - Single Molecule Dual JAK2-BET Inhibition As an MPN Therapeutic

Lawrence, M. S.

3665 - Escape from X-Inactivation Tumor Suppressor (EXITS) Genes Are Associated with Excess Incidence of Cancer in Men

Lawrence, M.

3922 - Comprehensive Analyses of Genetic Features Identify Coordinate Signatures in Diffuse Large B-Cell Lymphoma

Lawrence, N. J.

2826 - Single Molecule Dual JAK2-BET Inhibition As an MPN Therapeutic

Lawrie, A.

1516 - Outcome of Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: Subgroup Analysis from the UK NCRI R-CHOP 14 Vs 21 Trial
2689 - R-CHOP in Primary Mediastinal B-Cell Lymphoma (PMBL): Results from the UK NCRI R-CHOP 14 v 21 Trial

Lawrie, E.

733 - Fludarabine, Melphalan and Alemtuzumab Conditioned Reduced Intensity (RIC) Allogeneic Hematopoietic Cell Transplantation for Adults Aged >40 Years with De Novo Acute Lymphoblastic Leukemia: A Prospective Study from the UKALL14 Trial (ISRCTN 66541317)

Lawson, A. K.

2111 - Average Time to Treatment in Lymphoma Patients Undergoing Ovarian Preservation: Experience from a Single Institution

Lawson, M.

2117 - Glucose Levels Prior to Stem Cell Transplant Affect Length of Stay and 90-Day Readmission Rates

Lawson, S.

153 - Outcomes of Cord Blood Transplantation from an HLA-Identical Sibling for Patients with Inherited or Acquired Bone Marrow Failure Disorders: A Report from Eurocord, Cord Blood Committee (CBC-CTIWP) and Severe Aplastic Anemia Working Party (SAAWP) of the European Group of Blood and Bone Marrow Transplantation (EBMT)
1414 - Validation of MRD Quantification By Flow Cytometry for Pediatric BCP ALL Relapsed Patients Treated on the Intreall Protocol
4404 - Allogeneic Stem Cell Transplantation for Refractory Acute Myeloid Leukemia in Pediatric Patients: The UK Experience

Layer, J. H.

3663 - Lmo2's Oncogenic Function in T-Cell Leukemia Requires Ldb1

Layton, J. E.

1180 - Zbtb11, an Evolutionarily Conserved Pu.1-Regulated Transcriptional Repressor of TP53, Is Required for Neutrophil Development

Layton, M.

542 - GBT440, a Potent Anti-Sickling Hemoglobin Modifier Reduces Hemolysis, Improves Anemia and Nearly Eliminates Sickle Cells in Peripheral Blood of Patients with Sickle Cell Disease

Lazar, Y.

2135 - Glucocorticoid Regulation of Erythropoiesis in Humans: A Study of Patients with Cushing's Disease

Lazarchick, J.

4467 - Analyzing the Impact of Implementing a Systems-Based Hematologist into the Healthcare Delivery System at an Academic Medical Center

Lazarevic, V.

3137 - Targeting Integrin a4b7-Expressing T-Cells in Steroid Refractory Intestinal GvHD

Lazarevic, V.

3748 - Reasons for Decreasing Early Mortality in Acute Myeloid Leukemia: An Epidemiological Study from the Swedish Acute Leukemia Registry
3830 - Comprehensive Prospective Next Generation Sequencing of Acute Myeloid Leukemia

Lazaro, J. B.

4187 - Dysregulated Nucleotide Excision Repair (NER) Is a New Target in Multiple Myeloma

Lazarus, A. H.

3570 - Anti-RhD Mediates Loss of RhD Antigen Following Anti-RhD Infusion

Lazarus, H. M.

217 - North American Leukemia‚ Intergroup Phase III Randomized Trial of Single Agent Clofarabine As Induction and Post-Remission Therapy‚ and Decitabine As Maintenance Therapy in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age ≥60 Years): A Trial of the ECOG-ACRIN Cancer Research Group (E2906)
795 - in Philadelphia-Chromosome-Negative Acute Lymphoblastic Leukemia, Late Relapses Are Not Uncommon, Occur Mostly in Patients at Standard Risk and Have a Relatively Favorable Outcome. Results of the International ALL Trial: MRC Ukallxii/ECOG E2993
1308 - Tipifarnib As Maintenance Therapy in Acute Myeloid Leukemia (AML) Improves Survival in a Subgroup of Patients with High Risk Disease. Results of the Phase III Intergroup Trial E2902
1315 - Very Poor Long-Term Survival, Also in Contemporary Studies, of Patients with AML Who Relapse after Achieving a First Complete Remission: The ECOG-ACRIN Cancer Research Group Experience
1360 - Glycogen Synthase Kinase-3 (GSK3) Inhibition with Lithium in Combination with Tretinoin Induces Differentiation in Non-Promyelocytic Acute Myeloid Leukemia (AML)
3968 - Venous Thromboembolic Events in Diffuse Large B Cell Lymphoma. Incidence, Risk Factors and Outcomes

Lazarus, S. G.

2185 - Poor Sensitivity of Physician Assessment to Predict Acute Chest Syndrome in Children with Sickle Cell Disease and Fever

Lazaryan, A.

Lazo-Langner, A.

625 - Risk Factors Predictive of Occult Cancer Detection in Patients with Unprovoked Venous Thromboembolism
893 - A Prospective Cohort Study of Upper Extremity Deep Vein Thrombosis
1116 - Updates on the Risk of Dalteparin Thromboprophylaxis Failure in Hospitalized Acutely Ill Medical Patients with Cancer (ARTIC STUDY)
2320 - Evaluating the Need for Anticoagulation Beyond 6 Months for Patients with Cancer-Associated Venous Thromboembolism (VTE): A Retrospect of Real Life (EXTEND study - updated results)
2903 - Systematic Review of the Efficacy and Safety of Alternative Azacitidine Regimens in Myelodysplastic Syndrome
3346 - Erythropoietin in Elderly Patients with Anemia of Unknown Etiology

Lazorko, N.

4051 - Efficacy of Tyrosine Kinase Inhibitors in Third Line Therapy in Chronic Phase Chronic Myeloid Leukemia

Le, A.

2231 - Wdr1-Mediated Actin Reorganization Is Essential for Integrin αIIbβ3 Activation in Platelets

Le Beau, M. M.

295 - Brca1 Deficiency Causes Bone Marrow Failure and Spontaneous Hematologic Malignancies in Mice
2879 - Prognostic Impact of Rare Single Abnormalities in Myelodysplastic Syndromes

Le Beau, M. M.

357 - Cytotoxic Exposure to Both Hematopoietic Stem and Progenitor Cells and the Bone Marrow Niche Cooperate to Promote Leukemogenesis in a Mouse Model of Therapy-Related Myeloid Neoplasms with a Del(5q)
3784 - Targeted Treatment of FLT3-Overexpressing Acute Myeloid Leukemia with MiR-150 Nanoparticles Guided By Conjugated FLT3 Ligand Peptides

Le Blanc, K.

2398 - Phenotypic and Functional Alterations of Bone Marrow Mesenchymal Stem and Progenitor Cells in Chronic Myeloid Leukemia
3138 - Treatment of Chronic GvHD with Mesenchymal Stromal Cells Induces Durable Responses; A Phase II Study

Le Bourgeois, A.

3122 - Impact of Pre-Transplant Diffusion Lung Capacity for Nitric Oxide (DLNO) and of Dlno/Pre-Transplant Diffusion Lung Capacity for Carbon Monoxide (DLNO/DLCO) Ratio on Pulmonary Outcomes in Adults Receiving Allogeneic Stem Cell Transplantation for Haematological Diseases

Le Bousse-Kerdiles, M. C.

1193 - Roles of Exosomes in the Hematopoietic Stem Cell-Supporting Capacity of Stromal Cells
2823 - Assessment of Sites of Marrow and Extramedullary Hematopoieis By Hybrid Imaging in Patients with Primary Myelofibrosis

Le Bras, F.

1505 - Bendamustine Treatment in Refractory or Relapsed T Cell Lymphomas: A Retrospective Multicenter Study

Le Bris, Y.

1947 - Expansion of T or B Lymphocytes after Unrelated Cord Blood (UCB) Allogeneic Stem Cell Transplantation in Adults Correlates with CMV Reactivation and Is Associated with a Better Outcome
3218 - Allogeneic Stem Cell Transplantation for Primary or Secondary Myelofibrosis: A Retrospective Intent-to-Treat Analysis and Impact of Mutational Status and JAK1/2 Inhibitor Ruxolitinib Prescription in Patients Who Cannot Proceed to Transplantation
4339 - Post-Transplant Cyclophosphamide (PTCY) Versus Anti-Thymoglobulin (ATG) As Part of the Gvhd Prophylaxis for Fludarabine/Clofarabine/Busulfan Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT): Influence on Early Outcomes

Le Coquil, S.

4147 - Mechanisms of the BCR-Mediated CXCR4 Down-Regulation and Its Clinical Relevance in Chronic Lymphocytic Leukemia Progression

le Coutre, P.

2012 - Grouping of Genetic Risk By the European Leukemia Net Classification Predicts Overall Survival and Relapse Incidence in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation
2775 - Imatinib Suspension and Validation (ISAV) Study: Results at 24 Months
4025 - Efficacy and Safety of Ponatinib in CP-CML Patients By Number of Prior Tyrosine Kinase Inhibitors: 4-Year Follow-up of the Phase 2 PACE Trial

Le Coutre, P.

2784 - Droplet Digital PCR Reliably Detects a Single Copy of BCR-ABL1
2799 - Safety and Efficacy of Ruxolitinib in an 1869-Patient Cohort of JUMP: An Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis

le Coutre, P.

827 - An Open-Label, Multicenter, 2-Arm, Dose-Finding, Phase 1b Study of the Combination of Ruxolitinib and Buparlisib (BKM120) in Patients with Myelofibrosis: Results from HARMONY Study

Le Du, K.

4245 - Time to Spare Newly Diagnosed Non Transplant Eligible Myeloma (eNDMM) from Thalidomide

Le Gal, G.

1098 - Delayed Major Bleeding in Critically Ill Trauma Patients
2326 - Association Between Hospitalization for Acute Medical Illness and VTE Risk: A Lower Efficacy of Thromboprophylaxis in Elderly Patients? Results from the Edith Case-Control Study

Le Garff Tavernier, M.

1464 - Auto-Immune Origin of B Cells from HCV-Associated Lymphoma

LE Garff Tavernier, M.

3812 - Biological Description of 109 Cases of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) from the French Network of BPDCN

Le Garff-Tavernier, M.

3222 - RIC Allogeneic Stem Cell Transplantation for High Risk CLL Followed By Preemptive MRD-Based Immunointervention - Intermediate Results from the Phase II ICLL03 Ricac-Pmm Trial (FILO & SFGM-TC French intergroup)
3878 - To Dose or Not to Dose: Are IL-10 and IL-6 Accurate Biomarkers to Detect Leptomeningeal Involvement in Small B-Cell Lymphoproliferation?

Le, G. N.

1761 - N-Glycan Analysis of Polyclonal IgG from Patients with Multiple Myeloma Enables Classification of Stage Specific Pathologies
1775 - Characterisation of Myeloma Paraprotein Glycosylation Reveals Functional Insights and Increased Sialylation of Residual Polyclonal Antibodies

Le Gouill, S.

335 - Predictive Power of FDG-PET Parameters at Diagnosis and after Induction in Patients with Mantle Cell Lymphoma, Interim Results from the LyMa-PET Project, Conducted on Behalf of the Lysa Group
338 - Predictive Power of Early, Sequential MRD Monitoring in Peripheral Blood and Bone Marrow in Patients with Mantle Cell Lymphoma Following Autologous Stem Cell Transplantation with or without Rituximab Maintenance ; Interim Results from the LyMa-MRD Project, Conducted on Behalf of the Lysa Group
1478 - T-Cell Defect in Diffuse Large B-Cell Lymphomas Involves Expansion of Myeloid Derived Suppressor Cells Expressing IL-10, PD-L1, and S100A12
2520 - No Advantages of Fractionated Versus Single Dose(s) of Gemtuzumab Ozogamicin (GO) As Part of the Midam Salvage Regimen in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients
3218 - Allogeneic Stem Cell Transplantation for Primary or Secondary Myelofibrosis: A Retrospective Intent-to-Treat Analysis and Impact of Mutational Status and JAK1/2 Inhibitor Ruxolitinib Prescription in Patients Who Cannot Proceed to Transplantation
3920 - Cell-of-Origin (COO) Classification, BCL2 and MYC Expression Associated-Outcome in Younger Patients Treated By RCHOP Front-Line Therapy Versus Intensive Regimen Followed By Autologous Transplant for De Novo Advanced Diffuse Large B Cell Lymphoma (DLBCL) : Results of the French Prospective Multicenter Randomized Trial Goelams-075
3970 - Inhibition of Hedgehog Signaling for the Treatment of Lymphoma and CLL: A Phase II Study from the Lysa
4339 - Post-Transplant Cyclophosphamide (PTCY) Versus Anti-Thymoglobulin (ATG) As Part of the Gvhd Prophylaxis for Fludarabine/Clofarabine/Busulfan Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT): Influence on Early Outcomes

Le guenno, G.

3338 - A Multi-Centre Randomized and Double-Blind Controlled Trial of Rituximab for Warm Autoimune Hemolytic Anemia in Adults
3460 - A Multicenter, Case-Control Study Evaluating the Characteristics and Outcome of ITP Patients Refractory to, Rituximab, Splenectomy and Both TPO Receptor Agonists

Le, J.

239 - N-Acetylcysteine Treatment in Two Patients with Relapsed Thrombotic Thrombocytopenic Purpura Increased ADAMTS13 Activity, Free Thiol Concentration in Plasma, and Inhibited Platelet Activation

Le, K.

1310 - Longitudinal Pharmacokinetic/Pharmacodynamic Profile of AG-120, a Potent Inhibitor of the IDH1 Mutant Protein, in a Phase 1 Study of IDH1-Mutant Advanced Hematologic Malignancies
2509 - Evaluation of the Pharmacokinetics of AG-221, a Potent Mutant IDH2 Inhibitor, in Patients with IDH2-Mutation Positive Advanced Hematologic Malignancies in a Phase 1/2 Trial
3336 - Population Pharmacokinetics and Pharmacodynamics of AG-348 in Healthy Human Volunteers Guide Dose Selection for the Treatment of Pyruvate Kinase Deficiency

Le, L.

119 - Anti-Sclerostin Treatment Prevents Multiple Myeloma Induced Bone Loss and Reduces Tumor Burden

Le, L. W.

1742 - A Phase 2 Study of Ofatumumab in Combination with a Pan-AKT Inhibitor (Afuresertib) in Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL)
4163 - An Phase 2 Study of Lenalidomide in Combination with Oral Dexamethasone in Previously Untreated, Symptomatic Patients with Chronic Lymphocytic Leukemia (CLL)
4234 - Insulin Growth Factor 1 Receptor (IGF-1R) Inhibitor, Linsitinib (OSI-906) in Combination with Bortezomib and Dexamethasone Demonstrates Favorable Safety Prolife and Clinical Activity in Patients with Relapsed/Refractory Multiple Myeloma

Le Marechal, C.

2808 - Sequential Analysis By Next Generation Sequencing of 18 Genes in Polycythemia Vera and Essential Thrombocythemia Reveals a Association Between Mutational Status and Clinical Outcome after 3-Year Follow-up

LE Moigne, R.

1350 - Activation of the Unfolded Protein Response with the First-in-Class P97 Inhibitor CB-5083 Induces Stable Disease Regression and Overcomes Ara-C Resistance in AML

Le, P. M.

2403 - Acute Myeloid Leukemia (AML) Cells Alter the Bone Marrow Microenvironment By Inducing Osteogenic and Suppressing Adipogenic Differentiation of MSCs through BMP-RUNX2-CTGF Mediated Mechanisms

Le Pioufle, B.

2174 - Effects of Poloxamer 188 on Red Blood Cells Membrane Properties in Sickle Cell Disease

Le Priol, J.

1478 - T-Cell Defect in Diffuse Large B-Cell Lymphomas Involves Expansion of Myeloid Derived Suppressor Cells Expressing IL-10, PD-L1, and S100A12

Le Quellec, S.

2287 - Effect of Five Therapeutic Strategies on the Coagulation Defect Induced By the Thrombomodulin C.1611C>a Mutation

Le, R. Q.

3212 - Comparison of Donor KIR Genotype, Recipient CMV Reactivation and Pretransplant MRD in Predicting Relapse after Ex Vivo T-Deplete Allohsct

Le Roy, C.

4147 - Mechanisms of the BCR-Mediated CXCR4 Down-Regulation and Its Clinical Relevance in Chronic Lymphocytic Leukemia Progression

Le Texier, L.

34 - Hematopoeitic Stem Cells and Their Progenitors Critically Require Autophagy to Promote Early Engraftment Following Allogeneic Stem Cell Transplantation

Le, T. T. T.

974 - Sustained Elevation of Adenosine-ADORA2B Signaling Promotes Chronic Pain through Neuro-Immune Interaction in Sickle Cell Disease

Le, T.

1884 - Ex Vivo Modulation of Donor Cells Results in Enhanced Survival and Reduced Gvhd Mortality

Le Van Kim, C.

162 - Staphylococcus Aureus Targets the Duffy Antigen Receptor for Chemokines (DARC) to Lyse Erythrocytes
2174 - Effects of Poloxamer 188 on Red Blood Cells Membrane Properties in Sickle Cell Disease
2343 - Contribution of Imaging Flow Cytometry to Storage Lesion Assessment: Identification of a Sub-Population of Morphologically Altered Erythrocytes
3334 - The Human Kell Blood Group Binds the Erythroid 4.1R Protein: New Insights into the 4.1R-Dependent Red Cell Membrane Complex

Le-Rademacher, J.

389 - A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients with Hematological Malignancies
1979 - Autologous Hematopoietic Cell Transplantation in Patients with High Risk Multiple Myeloma: Post- Transplant Responses Do Not Translate to Longer Survival

Lea, N.

347 - Impact of Finding of Low Level Kinase Domain Mutations Using Ultra Deep Next Generation Sequencing in Patients with Chronic Phase CML
3129 - Immunological Profile of Patients after HSCT Using the FCC Conditioning Regimen for Treatment of Severe Aplastic Anemia Shows Sustained Mixed T-Cell Chimerism Is Due to Persistence of Recipient CD8 T Cells and Indicates Potential Basis for Tolerance and Extremely Low Incidence of Graft Versus Host Disease

Leach, J. W.

342 - Risk-Adapted Therapy in Adults with Burkitt Lymphoma: Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R

Leader, A.

1124 - Clopidogrel Treatment Is Associated with a Decrease in Cancer Incidence
2798 - Pathogenesis of Ponatinib Associated Vascular Disease in Chronic Myeloid Leukemia: An in Vitro Study
4034 - The Effect of Adherence-Encouraging Interventions on Adherence to Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia (TAKE-IT): A Pre-Post Intervention Pilot Study
4081 - Anticoagulation Therapy for Venous Thrombotic Events in Patients with Myeloproliferative Neoplasms

Leads, J.

3706 - Predicting Cerdulatinib Therapeutic Concentrations in Patients with Relapsed/Refractory B Cell Malignancies Using Preclinical Models and Clinical PK/PD and Tumor Response Correlates

Leal, C. T.

1637 - Decreased Activity of NK Cells in Myeloproliferative Neoplasms

Leal da Costa, F.

2955 - Low-Dose Dexamethasone Does Not Abrogate the Immunomodulatory Effects of Lenalidomide and Both Reactivate the Impaired Immune System of High-Risk Smoldering Multiple Myeloma Patients

Leamy, D.

4459 - Current Practice of Hospital Acquired Thrombosis (HAT) Prevention in an Acute Hospital (a single centre cross sectional study)

Lear, M.

692 - Genomic Landscape of Relapsed Acute Lymphoblastic Leukemia

Leather, H.

3221 - Minimal Residual Disease (MRD) By Either Flow Cytometry or Cytogenetics Prior to an Allogeneic Hematopoietic Cell Transplant (allo-HCT) Predicts Poor Acute Myeloid Leukemia (AML) Outcomes
3852 - A New Model to Predict Remission Status in Acute Myeloid Leukemia (AML) Patients Based on Day 14 Bone Marrow (D14 BM) Biopsy

Leavitt, M.

3806 - AGS62P1, a Novel Anti-FLT3 Antibody Drug Conjugate, Employing Site Specific Conjugation, Demonstrates Preclinical Anti-Tumor Efficacy in AML Tumor and Patient Derived Xenografts

Lebensburger, J. D.

41 - Outcomes of Referrals for Mild and Moderate Thrombocytopenia
3403 - Acute Kidney Injury Is Prevalent Among Pediatric Admissions for Acute Chest Syndrome

Leber, B.

1701 - Iron Chelation Is Associated with Improved Survival Adjusting for Disease and Patient Related Characteristics in Low/Int-1 Risk MDS at the Time of First Transfusion Dependence: A MDS-CAN Study
4029 - Treatment-Free Remission (TFR) Eligibility in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Residual Disease on Long-Term Imatinib (IM) Who Switched to Second-Line Nilotinib (NIL)
4446 - A Qualitative Research Study to Understand Post-Transfusion Well-Being in Patients with Myelodysplastic Syndromes

Leberecht, K.

2910 - SYK Is Involved in the CD38 Signal Transduction Pathway in Chronic Lymphocytic Leukemia

Lebert-Ghali, C. E.

3630 - Conditional Deletion of the Hoxa Cluster in MLL-AF9 Is Incompatible with Leukemia Maintenance

LeBlanc, F. R.

1288 - FTY720 (Fingolimod) Targets the Sphingolipid Pathway and Induces Autophagy-Related Apoptosis in Human Natural Killer Large Granular Lymphocyte Leukemia

Leblanc, M.

518 - Pre-Transplant R-Bendamustine Induces High Rates of Minimial Residual Disease in MCL Patients: Updated Results of S1106: US Intergroup Study of a Randomized Phase II Trial of R-HCVAD Vs. R-Bendamustine Followed By Autologous Stem Cell Transplants for Patients with Mantle Cell Lymphoma
2678 - Genomic Alterations Important for the Prognosis in Patients with Follicular Lymphoma Treated on SWOG Study S0016
3931 - A Phase I/II Trial of Vorinostat (SAHA) in Combination with Rituximab-CHOP in Patients with Newly Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL): SWOG S0806

LeBlanc, R.

730 - Impact of Cytogenetics on Outcomes of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone in the First (MM-020) Trial
4234 - Insulin Growth Factor 1 Receptor (IGF-1R) Inhibitor, Linsitinib (OSI-906) in Combination with Bortezomib and Dexamethasone Demonstrates Favorable Safety Prolife and Clinical Activity in Patients with Relapsed/Refractory Multiple Myeloma

Leblanc, T.

671 - HSP70, the Key to Account for Erythroid Tropism of Diamond-Blackfan Anemia?

LeBlanc, T. W.

874 - Multiple Myeloma Patient Experience with Financial Toxicity: Findings from the Cancer Experience Registry
2104 - Outcomes for Older Patients with Acute Myeloid Leukemia Admitted to the Intensive Care Unit
2119 - Patient Experiences of Acute Myeloid Leukemia (AML): A Qualitative Study about Diagnosis, Illness Understanding, and Treatment Decision-Making
2126 - Health Care Utilization and End of Life Care for Older Patients with Acute Myeloid Leukemia Receiving Supportive Care Alone
3310 - Potentially Avoidable Hospitalizations in Older Patients with Acute Myeloid Leukemia (AML)
4496 - Symptom Burden, Quality of Life, and Distress in Acute Myeloid Leukemia Patients Receiving Induction Chemotherapy: Results of a Prospective Electronic Patient-Reported Outcomes Study
- When and Why Should Patients with Hematological Malignancies See a Palliative Care Specialist?

Leblond, V.

492 - The Gain of the Short Arm of Chromosome 2 (2p+) Induces XPO1 Overexpression and Drug Resistance in Chronic Lymphocytic Leukemia
816 - Response to Rituximab Induction Is a Predictive Biomarker in Post-Transplant Lymphoproliferative Disorder (PTLD) and Allows Successful Treatment Stratification in an International Phase II Trial Including 152 Patients
1524 - Very High Efficiency of ICE (Ifosfamide-Carboplatin-Etoposide) in Relapse/Refractory (R/R) Primary Central Nervous System (PCNSL) and Vitreo-Retinal (VRL) Non Hodgkin Lymphoma. a LOC Network Multicenter Retrospective Study on 58 Cases
1985 - Autologous Hematopoietic Stem Cell Transplantation (AHSCT) in Severe Auto-Immune Disease Adult Patients: Analysis of Outcomes from the French Society for Bone Marrow Transplantation and Cellular Therapy (SFGMT-TC) in Light of the European Society for Blood and Marrow Transplantation (EBMT) Activity
2745 - Ibrutinib Therapy in Rituximab-Refractory Patients with Waldenström's Macroglobulinemia: Initial Results from an International, Multicenter, Open-Label Phase 3 Substudy (iNNOVATE^TM)
2948 - Central Nervous System Involvement in Chronic Lymphocytic Leukemia: Diagnosis and Treatment in a Retrospective Cohort of Thirty Patients
3042 - Can Assessment of Patient Monoclonal Immunoglobulins By Heavy/Light Analysis be Used to Assign Patient Responses Analogous to IMWG Response Criteria?
3878 - To Dose or Not to Dose: Are IL-10 and IL-6 Accurate Biomarkers to Detect Leptomeningeal Involvement in Small B-Cell Lymphoproliferation?
4170 - First Line Chronic Lymphocytic Leukemia Immunochemotherapy for the Elderly Patients over 79 Years Is Feasible, and Achieves Good Results : A Filo Retrospective Study

Leblonde, V.

493 - Safety and Efficacy of Obinutuzumab Plus Bendamustine in Previously Untreated Patients with Chronic Lymphocytic Leukemia: Subgroup Analysis of the Green Study

Leboeuf, C.

406 - Peroxiredoxin-2: A Novel Factor Involved in Iron Homeostasis

LeBoeuf, N.

860 - A Multicenter Phase I/Ib Study of Ipilimumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation

Lebois, M.

11 - Regulation of Platelet Lifespan in the Presence and Absence of TPO Signaling
416 - Extended Platelet In Vivo Survival Results in Exhausted Platelets

Leboulch, P.

201 - Update of Results from the Northstar Study (HGB-204): A Phase 1/2 Study of Gene Therapy for Beta-Thalassemia Major Via Transplantation of Autologous Hematopoietic Stem Cells Transduced Ex-Vivo with a Lentiviral Beta AT87Q-Globin Vector (LentiGlobin BB305 Drug Product)
202 - Outcomes of Gene Therapy for Severe Sickle Disease and Beta-Thalassemia Major Via Transplantation of Autologous Hematopoietic Stem Cells Transduced Ex Vivo with a Lentiviral Beta AT87Q-Globin Vector
3233 - Initial Results from Study Hgb-206: A Phase 1 Study Evaluating Gene Therapy By Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo with the Lentiglobin BB305 Lentiviral Vector in Subjects with Severe Sickle Cell Disease
SCI-18 - Bench to Bedside-Gene Therapy for Thalassemia and Sickle Cell Disease

Lebow, M. E.

2258 - Relative and Absolute Platelet Count Drops As a Risk Factor for Mortality, Bleeding, and Venous Thrombosis in Hospitalized Medical Patients

Lebreton, A.

1080 - Soluble Endothelial Protein C Receptor (sEPCR) Is Increased in Cirrhotic Patients. A Possible Role in Procoagulant Imbalance?

Lebrun, A.

3350 - Hemin: A Salvage Treatment for a Patient with Severe Auto-Immune Hemolytic Anemia and Reticulocytopenia

Lebuhotel, C.

2555 - TCRab Deficient CAR T-Cells Targeting CD123: An Allogeneic Approach of Adoptive Immunotherapy for the Treatment of Acute Myeloid Leukemia (AML)

Lecciso, M.

1019 - The Induction of Inhibitory Pathways in Dendritic Cells May Hamper the Efficient Activation of Anti-Leukemia T Cells within Chemotherapy-Induced Immunogenic Cell Death

Lech Maranda, E.

1321 - Clinical Features and Outcome of Patients with Acute Myeloid Leukaemia (AML) and Central Nervous System Involvement at the Time of Diagnosis and during the Course of AML - Retrospective, Multicentre Study of the Polish Adult Leukemia Group (PALG)

Lech-Maranda, E.

314 - FOXO1 Activation Is an Effector of SYK and AKT Inhibition in Tonic BCR Signal-Dependent Diffuse Large B-Cell Lymphomas
1436 - HIF1-Alpha and MYC Transcription Factor Signatures in B-Cell Acute Lymphoblastic Leukemia Are Associated with Positive Minimal Residual Disease Status: Therapeutic Implications
1549 - Activity of PIM Kinases in Chronic Lymphocytic Leukemia Modulates Tumor Cell Survival and Stromal Interactions through a Pleiotropic Mechanism Involving Modulation of CXCR4 - mTOR Pathway

Lechel, A.

1724 - Eµ-TCL1mTerc^-/- Mouse Model for Telomere Dysfunction in Chronic Lymphocytic Leukemia

Lechman, E. R.

900 - Mir-125a Confers Multi-Lineage Long-Term Repopulating Stem Cell Activity to Human Hematopoietic Committed Progenitors

Leclerc, G. M.

1327 - The NEDD8 Activating Enzyme Inhibitor Pevonedistat Induces ER Stress/UPR-Mediated Cell Death and Rebalances Homeostasis of Pro- and Anti-Apoptotic Proteins in Favor of Cell Death in Acute Lymphoblastic Leukemia Cells

Leclerc, G. J.

1327 - The NEDD8 Activating Enzyme Inhibitor Pevonedistat Induces ER Stress/UPR-Mediated Cell Death and Rebalances Homeostasis of Pro- and Anti-Apoptotic Proteins in Favor of Cell Death in Acute Lymphoblastic Leukemia Cells

Leclerc, J. M.

249 - Effectiveness of Antibacterial Prophylaxis during Induction Chemotherapy in Children with Acute Lymphoblastic Leukemia
2613 - Ikaros Gene Deletion Significantly Predicts Relapse in Pediatric B-ALL Patients with Low End-Induction Minimal Residual Disease

Leclerc, M.

3208 - Reduced Intensity Versus Myelo-Ablative Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm: A Retrospective Study of the French Society of Bone Marrow Transplantation and Cell Therapy (SFGM-TC)

Leclerc-Teffahi, S.

2250 - French Observatory of Adult' Chronic Immune Thrombocytopenia (ITP) Treated By Thrombopoietin Receptor Agonists (TPO-RAs)

Leclercq, G.

3087 - Chimeric Antigen Receptor Transgenic, T Cell Receptor/CD3 Negative Monospecific T Cells Generated from Cord Blood CD34 Positive Cells

Leclercq, T. M.

596 - A 20 Gene Expression Signature That Predicts Early Molecular Response Failure in Chronic Phase CML Patients Treated with Frontline Imatinib
2770 - High Peroxisome Proliferator-Activated Receptor-Gamma (PPARγ) Transcriptional Activity Reduces Active Influx of Imatinib and Kinase Inhibition in CML Cells

Lecoq Lafon, C.

3812 - Biological Description of 109 Cases of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) from the French Network of BPDCN

Lecras, T.

977 - Placenta Growth Factor Links the IL-13 Response and the Leukotriene Pathway to Augment Airway Hyper-Responsiveness

Ledderose, G.

4318 - Feasibility and Outcome of Sequential Therapy in the Setting of HLA-Haploidentical Transplantation Utilizing Reduced-Intensity Conditioning, T-Cell-Replete Grafts and Post-Transplantation High-Dose Cyclophosphamide in the Treatment of High-Risk AML and MDS

Lederer, E.

506 - A Phase II Study of Anti PD-1 Antibody Pembrolizumab, Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Ledergor, G.

664 - Distinct Bone Marrow Blood Vessels Differentially Regulate Normal and Malignant Hematopoietic Stem and Progenitor Cells

Ledesma, C.

2011 - Bfr (bendamustine, fludarabine, rituximab) Nonmyeloablative Allogeneic Conditioning Improves Survival in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).
3191 - Multi-Center Study of Outcomes of Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Extra-Nodal Natural Killer/T-Cell Lymphoma, Nasal Type (ENKL)
4321 - Fluid Overload As New Toxicity Category Has a Strong Impact on Non Relapse Mortality and Survival in Allogeneic Hematopoietic Stem Cell Transplantation
4345 - Ibrutinib in Patients (Pts) with Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL) with Relapsed Disease Post Allogeneic Stem Cell Transplantation (alloSCT)
4376 - Clofarabine (Clo) Plus Busulfan (Bu) Is an Effective Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients (pts) with Acute Lymphoblastic Leukemia (ALL): Long-Term Study Results
4408 - Multi-Center Analysis of the Effect of Disease Subtype and Minimal Residual Disease on Allogeneic Stem Cell Transplantation Outcomes in T-Cell Acute Lymphoblastic Leukemia (T-ALL)

Ledoux, D.

4147 - Mechanisms of the BCR-Mediated CXCR4 Down-Regulation and Its Clinical Relevance in Chronic Lymphocytic Leukemia Progression

Leduc, I.

3962 - Ruxolitinib in Combination with Orally Etoposide and Corticosteroids (REC) Is Safe and Effective in Heavily Pretreated Hodgkin and Non-Hodgkin Lymphomas

Leduc, M.

938 - Deep Proteomic Analysis of Human Erythropoiesis

Lee, A. Y.

2324 - Role of Extended Thromboprophylaxis after Abdominal and Pelvic Surgery in Cancer Patients: A Systematic Review and Meta-Analysis

Lee, A. I.

1138 - North American Cooperative Group Members' Patterns of Blood Products Transfusion for Patients with Acute Leukemia
2107 - Predictive Value of Rothman Index in Patients That Develop Febrile Neutropenia
3275 - Clinical Practice Patterns of Anti-Xa Monitoring During Low Molecular Weight Heparin Therapy
3529 - Whole Exome Sequencing in Evaluation of Thrombophilia: A Novel 33-Gene Panel
4455 - Patterns of Venous Thromboembolism Prophylaxis during Inpatient Treatment of Acute Leukemia: Results of a North American Web-Based Survey

Lee, A. E.

3070 - Prenatal Allospecific Tolerance Is Characterized By Early T_reg Expansion and a Surprisingly Slow Pace for T_eff Clonal Deletion
4274 - Asymmetric Allospecific Signals Shape iNKT Cell Lineage Fate Decisions

Lee, B. J.

17 - Identification of TKI-Sensitive Point Mutations That Activate c-ABL Kinase Activity and Transformation Potential and Confer in Vitro Resistance to the Allosteric ABL Inhibitor GNF-5

Lee, C.

2907 - Comprehensive Genetic Characterization of 17p Deleted CLL Identifies Predictors of Overall Survival

Lee, C. S.

1059 - Standard Dose Rituximab and 3 4-Day Cycles of Dexamethasone (R+3D) Appears Curative in Females with ITP < 12 Months Duration

Lee Chuy, K.

Lee, C.

3376 - Gene Editing with Crispr-Cas9 for Treating Beta-Hemoglobinopathies

Lee, III, D. W.

100 - CD4 CAR T Cells Mediate CD8-like Cytotoxic Anti-Leukemic Effects Resulting in Leukemic Clearance and Are Less Susceptible to Attenuation By Endogenous TCR Activation Than CD8 CAR T Cells
383 - Myeloid Cells in Peripheral Blood Mononuclear Cell (PMBC) Concentrates Inhibit the Expansion of Chimeric Antigen Receptor (CAR) T Cells
684 - Safety and Response of Incorporating CD19 Chimeric Antigen Receptor T Cell Therapy in Typical Salvage Regimens for Children and Young Adults with Acute Lymphoblastic Leukemia
1324 - Clinical Activity and Persistence of Anti-CD22 Chimeric Antigen Receptor in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)

Lee, D.

3469 - Testing for Heparin Induced Thrombocytopenia: Comparison of Practice at an Academic Center with Choosing Wisely Guidelines

Lee, D. A.

3085 - Therapeutic Effects of ALT-803, an IL-15 Superagonist, in Combination with Anti-CD20 Chimeric Antigen Receptor Modified Expanded Natural Killer CELLS Against Pediatric Burkitt Lymphoma (BL)

Lee, D. A.

102 - Phase I Trial of IL-21 Ex Vivo Expanded NK Cells Administration to Prevent Disease Relapse after Haploidentical Stem-Cell Transplantation for Myeloid Leukemias
152 - Results of a Two-Arm Phase II Clinical Trial Using Post-Transplantation Cyclophosphamide for Prevention of Graft-Versus-Host Disease in Haploidentical and Mismatched Unrelated Donors Hematopoietic Stem-Cell Transplantation
862 - Pre-Emptive Donor Lymphocyte Infusion with CD19-Directed, CAR-Modified T Cells Infused after Allogeneic Hematopoietic Cell Transplantation for Patients with Advanced CD19⁺ Malignancies
929 - Infusion of Ex Vivo Expanded Allogeneic Cord Blood-Derived Natural Killer Cells in Combination with Autologous Stem Cell Transplantation for Multiple Myeloma: Results of a Phase I Study

Lee, D. H.

2749 - Targeting CD99 in T-Cell Neoplasms with Monoclonal Antibodies

Lee, D. H.

3860 - Frequency, Characteristics and Prognostic Significance of RUNX1 mutations in Patients with Acute Myeloid Leukemia, Not Otherwise Specified

Lee, D. S.

1233 - Clonal Changes Detected By Target Capture Sequencing and Molecular Cytogenetic Study in Patients with Aplastic Anemia
1726 - Ethnic Difference in Genomic Profiles of Chronic Lymphocytic Leukemia in Korea: Targeted Exome Sequencing and Molecular Cytogenetics
3347 - Molecular Diagnosis of Hereditary Spherocytosis By Multi-Gene Target Sequencing in Korea

Lee, D. H.

1220 - Identification of Novel Fusion Genes and Differentially Expressed Genes in Acute Leukemia through Transcriptome Analysis
4205 - Increased Circulating Plasma Cells Predicts Poor Overall Survival in Symptomatic Plasma Cell Myeloma Patients

Lee, D.

3502 - A Quantitative Systems Pharmacology Model for the Coagulation Network Describes Biomarker Changes Observed in a Clinical Study with FXa Variant and Predicts Age-Associated Biomarker Variations

Lee, E. S.

2488 - Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-Cell Acute Lymphoblastic Leukemia

Lee, E. H.

1461 - Expression of Programmed Cell Death 1 and Programmed Cell Death Ligand 1 in Extranodal NK/T-Cell Lymphoma, Nasal Type

Lee, E. J.

1138 - North American Cooperative Group Members' Patterns of Blood Products Transfusion for Patients with Acute Leukemia
3529 - Whole Exome Sequencing in Evaluation of Thrombophilia: A Novel 33-Gene Panel
4455 - Patterns of Venous Thromboembolism Prophylaxis during Inpatient Treatment of Acute Leukemia: Results of a North American Web-Based Survey

Lee, F.

3085 - Therapeutic Effects of ALT-803, an IL-15 Superagonist, in Combination with Anti-CD20 Chimeric Antigen Receptor Modified Expanded Natural Killer CELLS Against Pediatric Burkitt Lymphoma (BL)

Lee, G.

4289 - Mechanisms of B Cell Tolerance after in Utero Hematopoietic Cell Transplantation

Lee, G. M.

3461 - Characterization of Human and Murine Anti-Protamine/Heparin Antibodies

Lee, G. W.

2535 - A Prospective Randomized Comparison of Idarubicin and High-Dose Daunorubicin in the Induction Chemotherapy for Acute Myeloid Leukemia

Lee, H. R.

2212 - Neutrophil Infiltration Is Partially Inhibited By EC-18 in the LPS-Induced Acute Lung Injury

Lee, H.

3010 - RNA Polymerase I Inhibition with CX-5461 As a Novel Strategy to Target MYC in Multiple Myeloma

Lee, H.

2051 - ONC201 Induces p53-Independent Apoptosis and Abrogates Stem Cell Function in Hematological Malignancies By Induction of ATF4 through Integrated Stress Response

Lee, H. S.

1687 - Lenalidomide As a Second-Line Therapy after Failure of Hypomethylating Agents in Patients with Myelodysplastic Syndrome

Lee, H. Y.

3590 - Thyroid Hormone Receptor Beta and NCOA4 Regulate Terminal Erythrocyte Differentiation

Lee, H. J.

439 - hnRNP K Is a Novel Haploinsufficient Tumor Suppressor at the 9q21.32 Locus That Defines a Subset of AML
1502 - Management Strategies and Outcomes for Very Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL)
2476 - Developing Therapeutic Strategies for CLL with Mutant p53
2738 - The Survival Outcome of the Patients with Relapsed/Refractory Anaplastic Large-Cell Lymphoma
3969 - Lenalidomide Plus Rituximab for Relapsed or Refractory Diffuse Large B-Cell, Follicular and Transformed Lymphoma: Final Data Analysis of a Phase 2 Trial
3984 - The Survival Outcome of the Patients with Relapsed/Refractory PTCL-NOS and AITL

Lee, H. W.

3942 - Final Report on Phase II Trial of L-Asparaginase Plus Concurrent Chemoradiotherapy Followed By Midle (Methotrexate, Ifosfamide, Etoposide, Dexamethasone, and L-asparaginase) Chemotherapy for Patients with Newly Diagnosed Stage I/II Extranodal NK/T-Cell Lymphoma, Nasal Type

Lee, H. J.

2595 - Genetic Profile and Novel Thrombospondin-1(THBS1) Mutation of Familial AML Syndrome: A Genomic Analysis By Whole Genome Sequencing and Whole Transcriptome Sequencing

Lee, I.

1767 - Racial Differences in Molecular Cytogenetic Abnormalities in Black and White Patients with Multiple Myeloma (MM): A Single-Center Experience

Lee, I.

3396 - Hemolysis Controls Pro-Inflammatory Monocyte Priming Via Induction of and Interaction with Circadian Clock Protein Rev-Erbα in Sickle Cell Disease

Lee, J. H.

3026 - Final Analysis of Overall Survival from the Phase 3 Panorama 1 Trial of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma
3942 - Final Report on Phase II Trial of L-Asparaginase Plus Concurrent Chemoradiotherapy Followed By Midle (Methotrexate, Ifosfamide, Etoposide, Dexamethasone, and L-asparaginase) Chemotherapy for Patients with Newly Diagnosed Stage I/II Extranodal NK/T-Cell Lymphoma, Nasal Type
4185 - A New Prognostic Model for Multiple Myeloma Patients in the Era of Novel Agents
4201 - Outcomes after Initial Relapse of Multiple Myeloma: An International Myeloma Working Group Study
4230 - Analysis of Outcomes Based on Response in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma Treated with Panobinostat or Placebo in Combination with Bortezomib and Dexamethasone in the Panorama 1 Trial: Updated Analysis Based on Prior Treatment
4240 - Continuous Treatment with Lenalidomide and Low-Dose Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma in Asia: Subanalysis of the First Trial

Lee, J. W.

1325 - IFITM3 (CD225) Links the B Cell Antigen CD19 to PI3K-AKT Signaling in Human ALL Cells
1434 - CD25 (IL2RA) Orchestrates Negative Feedback Control and Stabilizes Oncogenic Signaling Strength in Acute Lymphoblastic Leukemia

Lee, J.

2559 - Role of Glutamine in Metabolic and Epigenetic Reprogramming in AML

Lee, J. S.

261 - Lentiviral Hematopoietic Stem Cell Gene Therapy for Older Patients with X-Linked Severe Combined Immunodeficiency

Lee, J. H.

1220 - Identification of Novel Fusion Genes and Differentially Expressed Genes in Acute Leukemia through Transcriptome Analysis
1687 - Lenalidomide As a Second-Line Therapy after Failure of Hypomethylating Agents in Patients with Myelodysplastic Syndrome
1726 - Ethnic Difference in Genomic Profiles of Chronic Lymphocytic Leukemia in Korea: Targeted Exome Sequencing and Molecular Cytogenetics
2535 - A Prospective Randomized Comparison of Idarubicin and High-Dose Daunorubicin in the Induction Chemotherapy for Acute Myeloid Leukemia
2580 - Clinical Response to Idasanutlin (RG7388) in Acute Myeloid Leukemia Patients Is Associated with Pre-Treatment MDM2 Protein Expression in Leukemic Blasts and Leukemic Stem Cells
2861 - Panobinostat Plus Azacitidine in Adult Patients with MDS, CMML, or AML: Results of a Phase 2b Study
3826 - Expression of JL1 Antigen in Acute Leukemia and Myelodysplastic Syndrome
3860 - Frequency, Characteristics and Prognostic Significance of RUNX1 mutations in Patients with Acute Myeloid Leukemia, Not Otherwise Specified
4379 - Allogeneic Hematopoietic Cell Transplantation for Acute Myelogenous Leukemia in Remission - a Prospective Comparison of Three Different Donor Groups; Matched Sibling, Matched Unrelated, and Haploidentical Family Donors

Lee, J. J.

1446 - Discrepancy of Interim PET/CT Responses Based on Visual and Quantitative SUV-Based Assessments in the Patients with Diffuse Large B-Cell Lymphoma and Extranodal Involvements
3832 - 5-Hydroxymethylcytosine Is Correlated with TET2 or IDH1/2 Mutations However, May Not be a Prognostic Value to Predict the Survivals in Normal Karyotype AML
4185 - A New Prognostic Model for Multiple Myeloma Patients in the Era of Novel Agents
4240 - Continuous Treatment with Lenalidomide and Low-Dose Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma in Asia: Subanalysis of the First Trial

Lee, J.

4518 - Acute Leukemia of Ambiguous Lineage - Analysis of Survival Using SEER-Medicare Database

Lee, J. O.

4240 - Continuous Treatment with Lenalidomide and Low-Dose Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma in Asia: Subanalysis of the First Trial

Lee, J. Y.

2539 - Anti-Leukemic Activation of Immune Cells in a Leukemic-Induced Microenvironment By CXCR4 Inhibition

Lee, J.

3286 - Relationship Between Lenalidomide Dose Modification and Outcomes in Patients with Myelodysplastic Syndromes
3294 - Patterns of Total Costs of Care over Time for Patients with Multiple Myeloma (MM)

Lee, J. M.

69 - Elevations in MR Measurements of Whole Brain and Regional Cerebral Blood Flow and Oxygen Extraction Fraction Suggest Cerebral Metabolic Stress in Children with Sickle Cell Disease Unaffected By Overt Stroke

Lee, J. B.

1355 - Efficacy and Safety of Allogeneic Double Negative T Cell As a Cellular Therapy for AML and Its Underlying Mechanism

Lee, J. W.

1338 - Improved Outcomes of Low-Dose Cytarabine Regimen By Increased Dose and Duration of Cytarabine in Combination with Oral Etoposide for Elderly Acute Myeloid Leukemia
1522 - Clinical Manifestations and Treatment Results in Accordance with Frontline Treatment Modalities for Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma (OAML)
1769 - Impact of Lenalidomide Plus Low-Dose Dexamethasone Treatment on Immune Cell Populations of the Patients with Refractory/Relapsed Multiple Myeloma
1941 - Granulocytic and Monocytic Myeloid-Derived Suppressor Cells May Have Different Role on Allogeneic Stem Cell Transplant Outcomes
2152 - Prospective, Multinational/Regional, Non-Interventional Study to Assess Treatment Practices in Anemia Patients Prone to Iron Overload: Results from the 3-Year Transfusional Hemosiderosis Registry (TORS)
3842 - High Post-Remission WT1 Expression Is a Predictive Marker for Subsequent Molecular Relapse and Poor Survival Outcome in Adult Patients with Acute Promyelocytic Leukemia (APL)
4366 - Long Term Clinical Outcome of Hematopoietic Cell Transplantation for Intermediate to High-Risk Adult AML in Complete Remission; Can We Enhance the Survival Outcome Using Alternative Donor Types?

Lee, J. H.

1235 - Lateral Gene Transfer Contributing to Leukemogenesis

Lee, J. H.

4190 - No Mutations of SF3B1, U2AF1, and SRSF2 spliceosomal Gene but Polymorphisms Associated with the Worse Prognosis in Multiple Myeloma

Lee, J. Y.

1457 - The Prognostic Role of CD68 and FoxP3 Expression in Primary Central Nervous System Lymphoma
1489 - Risk Factors for Cancer- and Catheter-Associated Thrombosis in Asian Patients with Diffuse Large B-Cell Lymphoma Receiving R-CHOP Chemotherapy

Lee, J. H.

1220 - Identification of Novel Fusion Genes and Differentially Expressed Genes in Acute Leukemia through Transcriptome Analysis
2535 - A Prospective Randomized Comparison of Idarubicin and High-Dose Daunorubicin in the Induction Chemotherapy for Acute Myeloid Leukemia
3826 - Expression of JL1 Antigen in Acute Leukemia and Myelodysplastic Syndrome
3860 - Frequency, Characteristics and Prognostic Significance of RUNX1 mutations in Patients with Acute Myeloid Leukemia, Not Otherwise Specified
4205 - Increased Circulating Plasma Cells Predicts Poor Overall Survival in Symptomatic Plasma Cell Myeloma Patients
4379 - Allogeneic Hematopoietic Cell Transplantation for Acute Myelogenous Leukemia in Remission - a Prospective Comparison of Three Different Donor Groups; Matched Sibling, Matched Unrelated, and Haploidentical Family Donors

Lee, J. M.

245 - Long-Lasting Dysregulation of the Hematopoietic Stem Cell Compartment in Obesity

Lee, J.

2535 - A Prospective Randomized Comparison of Idarubicin and High-Dose Daunorubicin in the Induction Chemotherapy for Acute Myeloid Leukemia

Lee, J.

2539 - Anti-Leukemic Activation of Immune Cells in a Leukemic-Induced Microenvironment By CXCR4 Inhibition
2595 - Genetic Profile and Novel Thrombospondin-1(THBS1) Mutation of Familial AML Syndrome: A Genomic Analysis By Whole Genome Sequencing and Whole Transcriptome Sequencing
3102 - Defining Parameters That Can Guide Public Cord Blood Units (CBUs) in Korea

Lee, K. P.

288 - CD28 Induces Mitochondrial Respiration through Slp-76 in Long-Lived Plasma Cells for Reactive Oxygen Species-Dependent Survival
3975 - Augmenting Neutrophil Function By Administration of Peg-Filgrastim Potentiates Rituximab and Is Safe in Patients with Indolent B-Cell Non-Hodgkin Lymphomas: Results of a Phase II Study
4184 - In Situ CD28-CD86 Interactions on Myeloma - Targeting the Achilles Heel

Lee, K. H.

1220 - Identification of Novel Fusion Genes and Differentially Expressed Genes in Acute Leukemia through Transcriptome Analysis
2535 - A Prospective Randomized Comparison of Idarubicin and High-Dose Daunorubicin in the Induction Chemotherapy for Acute Myeloid Leukemia
3826 - Expression of JL1 Antigen in Acute Leukemia and Myelodysplastic Syndrome
3860 - Frequency, Characteristics and Prognostic Significance of RUNX1 mutations in Patients with Acute Myeloid Leukemia, Not Otherwise Specified
4379 - Allogeneic Hematopoietic Cell Transplantation for Acute Myelogenous Leukemia in Remission - a Prospective Comparison of Three Different Donor Groups; Matched Sibling, Matched Unrelated, and Haploidentical Family Donors

Lee, L. J.

1743 - Immunoliposomal Delivery of Mir-29b By Targeting Tumor Antigen ROR1 Induces Epigenetic Reprograming in Human-ROR1-Expressed Mouse Model of Chronic Lymphocytic Leukemia

Lee, L. H.

2323 - A Randomized, Double Blind, Placebo-Controlled, Cross-over Study to Evaluate the Haemostatic Effects of Three Commonly Used Traditional Herbal Medicines, (Curcuma Longa, Angelicae Sinensis and Panax Ginseng) and Their Interactions with Aspirin

Lee, L.

1643 - Heterozygous Hotspot SF3B1 Mutations Found in Myelodysplastic Syndromes Downregulate Genes Involved in Differentiation of Erythroid Cells

Lee, M. S.

2487 - Development of a Pharmacodynamic Assay for XPO1 Occupancy Using Fluorescence Cross Correlation Spectroscopy (FCCS)
3683 - Selinexor, a Selective Inhibitor of Nuclear Export (SINE) Compound, Shows Synergistic Anti-Tumor Activity in Combination with Dexamethasone Characterized By Specific Pattern of Gene Expression in Multiple Myeloma (MM)

Lee, M. T.

981 - Enhanced MRI Evaluation of Children with Sickle Cell Following Hematopoietic Stem Cell Transplantation

Lee, M. T.

3 - TCD with Transfusions Changing to Hydroxyurea (TWiTCH): Hydroxyurea Therapy As an Alternative to Transfusions for Primary Stroke Prevention in Children with Sickle Cell Anemia

Lee, M. C.

1874 - Targeting JAK2 By Gene Knockout or Pacritinib Treatment Reduces Gvhd and Xenograft Rejection By Promoting Induced Treg Differentiation

Lee, M.

1344 - A Phase I Study of Idarubicin Dose Escalation for Remission Induction Therapy in Acute Myeloid Leukemia
3942 - Final Report on Phase II Trial of L-Asparaginase Plus Concurrent Chemoradiotherapy Followed By Midle (Methotrexate, Ifosfamide, Etoposide, Dexamethasone, and L-asparaginase) Chemotherapy for Patients with Newly Diagnosed Stage I/II Extranodal NK/T-Cell Lymphoma, Nasal Type

Lee, M.

3498 - Pharmacokinetics of Intravenous Infusion of Glu-Plasminogen Concentrate in Patients with Hypoplasminogenemia

Lee, M. Y.

1595 - Outcome of Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients Treated with Various Frontline Second-Generation Tyrosine Kinase Inhibitors: A Single-Center Experience

Lee, M. K.

3163 - Identifying Inherited and Acquired Genetic Factors Involved in Poor Stem Cell Mobilization and Donor-Derived Malignancy

Lee, M.

2596 - Whole Exome Sequencing Reveals the Landscape of Clonal Evolution from MDS to AML Progression

Lee, O. L.

3562 - RBC Alloimmunization Burden Is High in Regularly RBC-Transfused Myelodysplastic Syndrome (MDS) Patients: A Report from South Australian-MDS Registry

Lee, P.

3824 - CSF1R Inhibition Targets AML Cells By Depleting Supportive Microenvironmental Signal from CD14+ Monocytes
4439 - Colony Stimulating Factor 1 Receptor (CSF1R) As a Potential Novel Therapeutic Target in CLL

Lee, P. L.

2574 - Characterization of AML Patients with CEBPA Mutations in a South-East Asian Population

Lee, R.

1499 - Improved Survival in Peripheral T-Cell Lymphoma (PTCL) Following Complete Response to First-Line Chemotherapy: 10 Year Experience at the Royal Marsden and the Christie Hospitals 2002-2012

Lee, R. H.

2235 - Ibrutinib-Treated Platelets Secure Vascular Integrity in Inflammation

Lee, S. A.

2254 - Natural Killer Cells Contribute to Pathophysiology of Placenta Leading to Miscarriage in Fetal and Neonatal Alloimmune Thrombocytopenia

Lee, S.

2114 - Evaluation of Institutional Non-Core Chemotherapy Regimens Approved for the Treatment of Leukemia and Multiple Myeloma

Lee, S. Y.

4428 - Preservation of CD20-Specific Chimeric Antigen Receptor T Cell Function in the Presence of Residual Rituximab

Lee, S. M.

2535 - A Prospective Randomized Comparison of Idarubicin and High-Dose Daunorubicin in the Induction Chemotherapy for Acute Myeloid Leukemia

Lee, S. W.

3953 - Efficacy and Safety of Dose Attenuated CHOP Chemotherapy for Peripheral T-Cell Lymphoma in Elderly Patients

Lee, S. Y.

3669 - Novel Role for Rpl22 in Controlling Lymphoma Progression and Dissemination

Lee, S.

3656 - Downregulation of DLEU1 Significantly Shortened Survival in a Rituximab-Treated DLEU1 Knockout Human Burkitt Lymphoma (BL) Xenograft NSG Mouse Model: DLEU1 May Act As a Tumor Suppressor Gene in Pediatric BL

Lee, S.

2732 - Ruxolitinib Significantly Prolongs Survival in Both a Primary Mediastinal B-Cell Lymphoma (PMBL) and Hodgkin Lymphoma (HL) Xenograft NSG Mouse Model: Ruxolitinib May be a Potential Adjuvant Agent in the Treatment of PMBL and of HL

Lee, S.

1338 - Improved Outcomes of Low-Dose Cytarabine Regimen By Increased Dose and Duration of Cytarabine in Combination with Oral Etoposide for Elderly Acute Myeloid Leukemia
1522 - Clinical Manifestations and Treatment Results in Accordance with Frontline Treatment Modalities for Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma (OAML)
1769 - Impact of Lenalidomide Plus Low-Dose Dexamethasone Treatment on Immune Cell Populations of the Patients with Refractory/Relapsed Multiple Myeloma
1941 - Granulocytic and Monocytic Myeloid-Derived Suppressor Cells May Have Different Role on Allogeneic Stem Cell Transplant Outcomes
3842 - High Post-Remission WT1 Expression Is a Predictive Marker for Subsequent Molecular Relapse and Poor Survival Outcome in Adult Patients with Acute Promyelocytic Leukemia (APL)
4366 - Long Term Clinical Outcome of Hematopoietic Cell Transplantation for Intermediate to High-Risk Adult AML in Complete Remission; Can We Enhance the Survival Outcome Using Alternative Donor Types?

Lee, S. S.

1446 - Discrepancy of Interim PET/CT Responses Based on Visual and Quantitative SUV-Based Assessments in the Patients with Diffuse Large B-Cell Lymphoma and Extranodal Involvements
3832 - 5-Hydroxymethylcytosine Is Correlated with TET2 or IDH1/2 Mutations However, May Not be a Prognostic Value to Predict the Survivals in Normal Karyotype AML

Lee, S. S.

2659 - Quantitative Multiplexed Immunohistochemistry Assays for Exploring CAR Modified T Cells and Checkpoint Inhibitors in Lymphoma Trials

Lee, S.

2450 - Myc-Directed Suppression of Autophagy Provides Therapeutic Vulnerabilities Targeting Amino Acid Homeostasis

Lee, S.

3472 - M281: A Therapeutic Anti-FcRn Blocking Antibody for Rapid Clearance of IgG and IgG Autoantibodies in Immune Cytopenias and Other Auto/Allo-Immune Disease

Lee, S.

4 - Therapeutic Targeting of Spliceosomal Mutant Myeloid Leukemias through Modulation of Splicing Catalysis
302 - ASXL2 Is a Novel Mediator of RUNX1-ETO Transcriptional Function and Collaborates with RUNX1-ETO to Promote Leukemogenesis
481 - Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms

Lee, S. J.

265 - The Impact of Pre-Transplant Depression on Outcomes of Allogeneic and Autologous Hematopoietic Stem Cell Transplantation
270 - 5 Year Results of BMT CTN 0201: Unrelated Donor Bone Marrow Is Associated with Better Psychological Well-Being and Less Burdensome Chronic Gvhd Symptoms Than Peripheral Blood
398 - A Predictive Model Using Telomere Length to Select Optimal Donors for Hematopoietic Stem Cell Transplant (HCT) for Acute Leukemia
532 - Impact of Comorbidities at Diagnosis of Acute Myeloid Leukemia on One-Year Mortality
3151 - Development and Preliminary Usability and Accuracy Testing of the EBMT Gvhd App to Support Graft Versus Host Disease Diagnosis and Scoring According to NIH Criteria, By the EBMT Complications and Quality of Life Working Party
3226 - Evaluation of the Impact of Non-Inherited Maternal Antigens on the Outcome of HLA Mismatched Unrelated Donor Hematopoietic Stem Cell Transplantation for Hematological Malignancies on Behalf of the ALWP of the EBMT and the CIBMTR
3229 - Investigating Effect of Genetic Admixture and Donor/Recipient Genetic Disparity on Transplant Outcomes
- Strategies for Success for Junior Faculty

Lee, S. I.

3629 - Mini-Chromosome Maintenance (MCM) DNA Helicase Genes Influence Acute Myeloid Leukemia (AML) Replication and Response to Chemotherapy-Induced DNA Damage

Lee, S. E.

1338 - Improved Outcomes of Low-Dose Cytarabine Regimen By Increased Dose and Duration of Cytarabine in Combination with Oral Etoposide for Elderly Acute Myeloid Leukemia
1522 - Clinical Manifestations and Treatment Results in Accordance with Frontline Treatment Modalities for Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma (OAML)
1595 - Outcome of Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients Treated with Various Frontline Second-Generation Tyrosine Kinase Inhibitors: A Single-Center Experience
1769 - Impact of Lenalidomide Plus Low-Dose Dexamethasone Treatment on Immune Cell Populations of the Patients with Refractory/Relapsed Multiple Myeloma
1941 - Granulocytic and Monocytic Myeloid-Derived Suppressor Cells May Have Different Role on Allogeneic Stem Cell Transplant Outcomes
3842 - High Post-Remission WT1 Expression Is a Predictive Marker for Subsequent Molecular Relapse and Poor Survival Outcome in Adult Patients with Acute Promyelocytic Leukemia (APL)
4053 - Predictive Value of 3-Month Early Molecular Response in New Chronic Phase Chronic Myeloid Leukemia Patients Treated with Radotinib
4366 - Long Term Clinical Outcome of Hematopoietic Cell Transplantation for Intermediate to High-Risk Adult AML in Complete Remission; Can We Enhance the Survival Outcome Using Alternative Donor Types?

Lee, S. H.

1798 - Tuning T Cell Affinity Improves Efficacy and Safety of Anti-CD38 × Anti-CD3 Bispecific Antibodies in Monkeys - a Potential Therapy for Multiple Myeloma

Lee, T. J.

2359 - ER71/ETV2 Is Essential for Hematopoietic Regeneration after Injury

Lee, T.

1011 - Increased Alternative Macrophage-2 (M2) Polarization with Trib1 Gene over Expression in Myeloma Patients with Progressive Disease and Jak2 Inhibitors Reduce M2 Polarization
2995 - Crosslinking of Fc Gamma-Rllb and Fc Epsilon-RI Binding Peptides Inhibits Osteoclast Formation in Multiple Myeloma through Inactivation of the ITAM Signaling Pathway

Lee, T. A.

2653 - Risk of Non-Hodgkin Lymphoma Following Treatment of Inflammatory Conditions with Tumor Necrosis Factor-Alpha Inhibitors
2954 - Tumor Necrosis Factor-Alpha Inhibitor Medications for Inflammatory Conditions and Incidence of Multiple Myeloma

Lee, T. T.

3237 - Human Induced Pluripotent Stem Cells Incorporating Safe Harbor Loci Integrated Inducible Suicide Systems for Use in the Application of Cellular Therapeutics

Lee, V.

2191 - SIRPαFc, a CD47-Blocking Cancer Immunotherapeutic, Sensitizes Malignant B Cells to Macrophage-Mediated Destruction

Lee, W. H.

2764 - Functional Analysis of the CML Blast Crisis Transcriptome and Epigenome Using Crispr-CAS9 and Pharmacologic Approaches
3737 - The Genomic and Epigenomic Landscapes of Blast Crisis Transformation in Chronic Myeloid Leukemia

Lee, W. J.

2653 - Risk of Non-Hodgkin Lymphoma Following Treatment of Inflammatory Conditions with Tumor Necrosis Factor-Alpha Inhibitors
2954 - Tumor Necrosis Factor-Alpha Inhibitor Medications for Inflammatory Conditions and Incidence of Multiple Myeloma

Lee, W.

728 - Phase 2 Study of Carfilzomib (CFZ) with or without Filanesib (FIL) in Patients with Advanced Multiple Myeloma (MM)

Lee, W. S.

476 - Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients: 12 Months Result of Phase 3 Clinical Trial
2535 - A Prospective Randomized Comparison of Idarubicin and High-Dose Daunorubicin in the Induction Chemotherapy for Acute Myeloid Leukemia

Lee, W. S.

1687 - Lenalidomide As a Second-Line Therapy after Failure of Hypomethylating Agents in Patients with Myelodysplastic Syndrome
4053 - Predictive Value of 3-Month Early Molecular Response in New Chronic Phase Chronic Myeloid Leukemia Patients Treated with Radotinib

Lee, Y. T.

639 - IGF2BP1 Reverses Hemoglobin Switching in Adult Erythroblasts
2161 - Erythroid-Expression of HMGA2 Increases Fetal Hemoglobin in Human Adult Erythroblasts

Lee, Y. T.

2181 - Early Pathogenesis of Sickle Cell Anemia: Absolute Reticulocyte Counts Are Correlated with Increased Detection of CD36+ Reticulocytes during the First Two Years of Postnatal Life

Lee, Y. S.

273 - ALK2 Inhibition Via TP-0184 Abrogates Inflammation-Induced Hepcidin Expression and Is a Potential Therapeutic for Anemia of Chronic Disease
1343 - Alvocidib Potentiates the Activity of Azacytidine in an MCL-1-Dependent Fashion
3799 - Alvocidib Potentiates the Activity of Cytarabine and Mitoxantrone through the Targeting of MCL-1 When Administered in a Time Sequential Regimen in AML

Lee, Y. J.

2123 - Brincidofovir (BCV) Prophylaxis for Herpes Simplex Virus (HSV) and Varicella Zoster Virus (VZV) after Hematopoietic Cell Transplantation (HCT): Clinical Experience at Memorial Sloan-Kettering Cancer Center
3303 - Burden of Pneumococcal Disease in Cancer Patients: A 20 Year Single Center Study at Memorial Sloan-Kettering Cancer Center
4320 - Infection Burden of Double Stranded DNA (dsDNA) Viruses after CD34⁺ Selected, T-Cell Depleted (TCD) Hematopoietic Cell Transplantation (HCT) for Myeloid Malignancies at Memorial Sloan Kettering Cancer Center (MSK)

Lee, Y. C.

3296 - Double-Stranded DNA (dsDNA) Viral Infections Among Allogeneic Hematopoietic Cell Transplant (HCT) Recipients in the First Year after Transplant

Lee, Y. J.

1446 - Discrepancy of Interim PET/CT Responses Based on Visual and Quantitative SUV-Based Assessments in the Patients with Diffuse Large B-Cell Lymphoma and Extranodal Involvements

Lee, Y. S.

4379 - Allogeneic Hematopoietic Cell Transplantation for Acute Myelogenous Leukemia in Remission - a Prospective Comparison of Three Different Donor Groups; Matched Sibling, Matched Unrelated, and Haploidentical Family Donors

Lee, Y. S.

1750 - Risk-Adapted Induction and Maintenance with Ofatumumab in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)

Lee-Kim, Y. J.

2330 - Association of Outcomes and Anti-Xa Monitoring in Treatment of Pediatric Venous Thromboembolism
2333 - Evaluating Frequency of Anti-Xa Monitoring in Treatment of Pediatric Venous Thromboembolism

Lee-Sherick, A. B.

76 - A Dominant Negative Mutation (p.P214L) in ETV6 is Associated with Megakaryocyte and Erythroid Transcript Misregulation

Lee-Sundlov, M. M.

420 - Recognition of Megakaryocyte-Specific T-Antigen By Macrophages Negatively Regulates Platelet Production in Bone Marrow

Leeb-Lundberg, L. M. F.

897 - Bile Acids Protect Expanding Hematopoietic Stem Cells from Unfolded Protein Stress in Fetal Liver

Leebeek, F. W. G.

3510 - Perioperative FVIII Concentrate Treatment in Mild Hemophilia a Patients Shows a High Rate of Overdosing - David/Opti-Clot Studies

Leeder, J. S.

2486 - Effect of Intrathecal Methotrexate on CSF and RBC Folate Levels in Children Receiving Treatment for Acute Lymphoblastic Leukemia

Leeds, J. M.

3929 - Clinical and Correlative Results of a Phase 1 Study of Cerdulatinib (PRT062070) a Dual SYK/JAK Inhibitor in Patients with Relapsed/Refractory B Cell Malignancies

Leeksma, A.

2918 - Assessment of p53 and ATM Functionality in Chronic Lymphocytic Leukemia By Multiplex Ligation-Dependent Probe Amplification

Leen, A. M.

186 - Immunotherapy for Lymphoma Using T Cells Targeting Multiple Tumor Associated Antigens
622 - Administration of Most Closely HLA-Matched Multivirus-Specific T Cells for the Treatment of EBV, CMV, AdV, HHV6, and BKV Post Allogeneic Hematopoietic Stem Cell Transplant
1926 - Adoptively-Transferred EBV-Specific T Cells to Prevent or Treat EBV-Related Lymphoproliferative Disease in Allogeneic HSCT Recipients - a Single Center Experience Spanning 22 Years

Leenders, M.

1357 - A Phase I Study of Allogeneic Natural Killer Cell Therapy Generated from Cord Blood Hematopoietic Stem and Progenitor Cells in Elderly Acute Myeloid Leukemia Patients

LeFave, C.

1837 - Serum Proteomic Analysis of Multiple Myeloma Subjects Treated with Daratumumab Monotherapy

Lefebvre, P.

626 - Current Practice Patterns and Patient Persistence on Anticoagulant Treatments for Cancer-Associated Thrombosis

Lefebvre, T.

2151 - Assessment of Cardiac Iron Overload in Chonically Transfused Patients with Thalassemia, Sickle Cell Anemia, and Myelodysplastic Syndromes

Lefebvre, V.

2927 - Splicing Factor 3B Subunit 1 (SF3B1) Mutations Impact FOXP1 Splicing in Chronic Lymphocytic Leukemia (CLL) Cells but Conserve the Balance Between Newly Described and Classical Splicing Variants of ZAP-70

Lefevre, S.

2174 - Effects of Poloxamer 188 on Red Blood Cells Membrane Properties in Sickle Cell Disease

Leffell, M. S.

2002 - Nonmyeloablative (NMA), HLA-Mismatched Unrelated Donor (mMUD) BMT with High-Dose Posttransplantation Cyclophosphamide (PTCy) Has Outcomes Similar to Matched BMT

Lefkowitz, R. J.

486 - β-arrestin2 Is Necessary for Development of MPLW515L Mutant Primary Myelofibrosis

Lefranc, M. P.

1479 - Unique Versus Common: Disease-Biased Immunoglobulin Gene Repertoires Along with Public Antigen Receptor Stereotypes in Marginal Zone B-Cell Lymphoproliferations

Lefrere, F.

202 - Outcomes of Gene Therapy for Severe Sickle Disease and Beta-Thalassemia Major Via Transplantation of Autologous Hematopoietic Stem Cells Transduced Ex Vivo with a Lentiviral Beta AT87Q-Globin Vector

Legendre, C.

2973 - In-Depth Molecular Profiling of Multiple Myeloma in African Americans

Legendre, M.

779 - Recombinant DEK Enhances Ex Vivo expansion of Human Cord Blood and Mouse Bone Marrow Hematopoietic Stem Cells in a CXCR2- and Hspg-Dependent Manner

Legiec, W.

3034 - Analysis of Final Data from the Multinational, Non-Interventional, Observational Emmos Study (NCT01241396) in Patients (Pts) with Multiple Myeloma (MM) in Real-World Clinical Practice

Legrand, F.

1908 - CloB2A2 Reduced-Intensity Conditioning (RIC) Regimen Prior to Allogeneic Stem Cell Transplantation Provides Significant Better Survival Compared to FB2A2 RIC Regimen in Adults with Acute Myeloid Leukemia (AML): A Study on Behalf of the SFGM-TC
4393 - Impact of NK Cell Reconstitution and Recipient HLA-C Typing on Clinical Outcome after Reduced Intensity Cord Blood Transplant: Results of a Prospective Phase II Multicentric Trial on Behalf of Societe Francaise De Greffe De Moelle Osseuse Et Therapie Cellulaire (SFGM-TC) and Eurocord

Legrand, O.

1362 - Targeting Acute Myeloid Leukemia with a New CXCR4 Antagonist IgG1 Antibody (PF-06747143)in NOD/SCID Mice

Legrand-Izadifar, F.

3222 - RIC Allogeneic Stem Cell Transplantation for High Risk CLL Followed By Preemptive MRD-Based Immunointervention - Intermediate Results from the Phase II ICLL03 Ricac-Pmm Trial (FILO & SFGM-TC French intergroup)

Legros, L.

133 - Personalized Daily Doses of Imatinib By Therapeutic Drug Monitoring Increase the Rates of Molecular Responses in Patients with Chronic Myeloid Leukemia. Final Results of the Randomized OPTIM Imatinib Study
134 - Combination of Dasatinib and Peg-Interferon Alpha 2b in Chronic Phase Chronic Myeloid Leukemia (CP-CML) First Line: Preliminary Results of a Phase II Trial, from the French Intergroup of CML (Fi-LMC)
137 - Osteoarticular Pain after Discontinuation of Tyrosine Kinase Inhibitors (TKI): A French Cohort
345 - Long-Term Follow-up of the French 1 Stop Imatinib Study (STIM1) in Chronic Myeloid Leukemia Patients
1578 - Pegylated Interferon-Alpha 2a in Combination with Nilotinib As First-Line Therapy in Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (Nilopeg trial). Four-Year Follow-up Results
1831 - Salvage Therapy Post Pomalidomide-Based Regimen in Relapsed/Refractory Myeloma
2869 - A Phase II Study of the Efficacy and Safety of an Intensified Schedule of Azacitidine (AZA) in Intermediate-2 and High Risk MDS Patients: A Study By the Groupe Francophone Des Myelodysplasies (GFM)
4039 - Ponatinib for Chronic Phase (CP) CML Failing Two or More Tyrosine Kinase Inhibitors (TKI) or Harboring a T315I Mutation in the Real Life: Pearl Observational Study
4245 - Time to Spare Newly Diagnosed Non Transplant Eligible Myeloma (eNDMM) from Thalidomide

Leguay, T.

1 - Addition of Rituximab Improves the Outcome of Adult Patients with CD20-Positive, Ph-Negative, B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL): Results of the Randomized Graall-R 2005 Study
2492 - Pharmacokinetic and Pharmacodynamic Characterization of Graspa Versus Native L-Asparaginase in Combination with Cooprall Chemotherapy in a Phase 3 Randomized Trial for the Treatment of Patients with Relapsed Acute Lymphoblastic Leukemia (NCT01518517)
3723 - Updated Clinical Activity of Graspa Versus Native l-Asparaginase in Combination with Cooprall Regimen in Phase 3 Randomized Trial in Patients with Relapsed Acute Lymphoblastic Leukemia (NCT01518517)
3734 - Evaluation of the Impact of the Presence of Neutralizing L-Asparaginase Antibodies on the Efficacy and Safety of Graspa in Phase 3 Randomized Trial Versus Native L-Asparaginase in Patients with Relapsed Acute Lymphoblastic Leukemia (NCT01518517)
3736 - Addition of Lomustine (CCNU) to Induction and Post-Remission Chemotherapy for Fit Elderly AML Patients without Unfavorable Cytogenetics: Results of the Lamsa-2007 Goelams Trial

Leguit, R.

1662 - Clonal Mutational Landscape of Childhood Myelodysplastic Syndromes

Lehman, A. M.

317 - Next Generation XPO1 Inhibitor Shows Improved Efficacy and In Vivo Tolerability in Hematologic Malignancies
318 - A Novel Inhibitor of BET Family Bromodomains Demonstrates In Vivo and In Vitro Potency in B-Cell Malignancies
1248 - NFkB p50 (Nfkb1) Contributes to Disease in the Eu-TCL1 Mouse Model of Chronic Lymphocytic Leukemia
2477 - BRAF^V600E Induces ABCB1/P-Glycoprotein Expression and Drug Resistance in B-Cells Via AP-1 Activation
2911 - The Aberrantly Expressed Long Noncoding RNA, TRERNA1, Predicts for Aggressive Disease in Chronic Lymphocytic Leukemia

Lehman, M.

3527 - A Novel Microfluidic Assay to Determine Von Willebrand Factor Levels and Bleeding Phenotypes in Patients with Von Willebrand Disease and Mucocutaneous Bleeding

Lehmann, C.

3432 - Human CD21^low CD86^pos B Cells Are Potent Antigen Presenting Cells, Which Are Expanded in Inflammatory Conditions

Lehmann, L. E.

737 - Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome with Multi-Organ Dysfunction: Final Results from a Pivotal, Historically Controlled, Phase 3 Trial

Lehmann, L. E.

3121 - Defibrotide for the Treatment of Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome with/without Multi-Organ Dysfunction Following Chemotherapy: Results from an Ongoing Expanded Access Program
4311 - Early Initiation of Defibrotide in Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome Following Hematopoietic Stem Cell Transplantation Improves Day +100 Survival

Lehmann, S.

2398 - Phenotypic and Functional Alterations of Bone Marrow Mesenchymal Stem and Progenitor Cells in Chronic Myeloid Leukemia
2606 - Bone Marrow Fibroblasts Derived from Vitally Frozen Mononuclear Cells As a Source for Germ Line DNA in Acute Myeloid Leukemia (AML)

Lehmann, S.

343 - Mature, Adaptive-like CD56^DIM NK Cells in Chronic Myeloid Leukemia Patients in Treatment Free Remission

Lehmann, S.

3748 - Reasons for Decreasing Early Mortality in Acute Myeloid Leukemia: An Epidemiological Study from the Swedish Acute Leukemia Registry

Lehmann, T.

4073 - Impact of Disease Duration upon Symptom Burden Amongst Patients with Myeloproliferative Neoplasms (MPNs)
4080 - Symptom Burden Profile in Myelofibrosis Patients with Thrombocytopenia: Lessons and Unmet Needs

Lehmann, U.

352 - Impact of Molecular Genetics on Disease-Free Survival in Myelofibrosis Patients Following Allogeneic Stem Cell Transplantation

Lehners, N.

856 - ATG and Statins Reduce Incidence of Severe Chronic Gvhd By Distinct Mechanisms Involving CXCL9 and Kynurenine Catabolism
3964 - Analysis of Prognostic Factors and Outcome of Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma of the Gastrointestinal Tract

Lehrer-Graiwer, J.

542 - GBT440, a Potent Anti-Sickling Hemoglobin Modifier Reduces Hemolysis, Improves Anemia and Nearly Eliminates Sickle Cells in Peripheral Blood of Patients with Sickle Cell Disease

Lehrke, M.

782 - Adipogenic Chemokine Inhibition of Hematopoietic Cell Adherence and Transmigration, a Hurdle to Homing

Lei, B.

1393 - Acute Monocytic Leukemia Associated Antigen MLAA-34 up-Regulates JAK2/STAT3 Expression and JAK2/STAT3 Enhances MLAA-34 Activation in a Positive Feedback Loop

Lei, F.

2705 - Gene Expression Profiling for Molecular Features of Response in a Phase I Trial of Alisertib Plus Romidepsin for Relapsed/Refractory Aggressive B- and T-Cell Lymphomas

Lei, G.

3971 - Prevalence and Prognostic Value of BCL2 and MYC Protein Expression within ABC and GCB Subtypes in Patients with Previously Untreated, Diffuse Large B-Cell Lymphoma: Analysis from the Phase III MAIN Study

Lei, H.

1572 - USP47 Is a New Target in Chronic Myelogenous Leukemia

Lei, J.

278 - Pharmacological Inhibition of TLR4 Reduces Mast Cell Activation, Neuroinflammation and Hyperalgesia in Sickle Mice
2169 - Acupuncture Led Attenuation of Inflammatory and Nociceptive Peripheral and Central Microenvironment in Sickle Mice
3385 - Hemin-Induced Mast Cell-Extracellular Traps Impart Resistance to Therapy in a Sickle Microenvironment

Lei, X.

1766 - Alterations in a Panel of Serum Peptides Correlate with the Disease States of Multiple Myeloma
2968 - Serum Peptidome Based Multiple Myeloma Renal Impairment Biomarker Screening

Leiba, M.

4218 - Blockade of PD-1 in Combination with Dendritic Cell/Myeloma Fusion Cell Vaccination Following Autologous Stem Cell Transplantation Is Well Tolerated, Induces Anti-Tumor Immunity and May Lead to Eradication of Measureable Disease

Leiblein, S.

2573 - Unsupervised Cluster Analysis of Antigen Expression Patterns Identifies Subgroups with Distinct Biological and Clinical Features in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation

Leibold, J.

3793 - Induction of NK Cell Reactivity Against Myeloid Leukemia By a Novel Fc-Optimized CD133 Antibody

Leibundgut, K.

926 - Autologous Stem Cell Transplantation for Adult Acute Myelocytic Leukemia in First Remission : Better Outcome Following Busulfan and Melphalan Compared to Busulfan and Cyclophosphamide : A Retrospective Study from the Acute Leukemia Working Party of the EBMT

Leiby, B.

2023 - Moderate Reduction in LVEF Is Associated with an Increased Risk of Post-HSCT Symptomatic Cardiomyopathy
3220 - Creatinine > 1.5 Mg/Dl and MDS Diagnosis Predicts Poor Outcome Following HSCT
3892 - Metabolic Patterns in Cancer Cells and Tumor Microenvironment in Diffuse Large B-Cell Lymphoma: Tumor-Stromal Metabolic Coupling
4394 - Smoking History and Pre-Transplant Pulmonary Function Predict Post-Transplant Respiratory Failure, Acute Renal Failure Requiring Dialysis and 100-Day Mortality in Allogeneic Bone Marrow Transplantation

Leighton, Jr., J. C.

1092 - Qbleed Score in an African American Cohort

Leip, E.

4041 - Predictors of Response Duration and Survival with Second-Line Bosutinib Therapy in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML) Resistant or Intolerant to Prior Imatinib

Leis, J. F.

834 - PD-1 Blockade with Pembrolizumab (MK-3475) in Relapsed/Refractory CLL Including Richter Transformation: An Early Efficacy Report from a Phase 2 Trial (MC1485)
2926 - Correlation Between Peripheral Blood Counts and Extent of Bone Marrow Infiltration in Chronic Lymphocytic Leukemia
2935 - Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL): An Analysis of a Large Cohort of Patients Treated in Routine Clinical Practice
2950 - Atrial Fibrillation in Patients with Chronic Lymphocytic Leukemia (CLL)
4169 - Pure Red Cell Aplasia (PRCA) in Chronic Lymphocytic Leukemia (CLL): Etiology, Therapy, and Outcomes

Leischner, I.

362 - Quantitative Clonal Dynamics Define Mechanisms of CLL Evolution in Response to Combination Chemotherapy

Leisenring, W. M.

1927 - Biomarkers for Idiopathic Pneumonia Syndrome after Hematopoietic Cell Transplantation: Comparison with Viral Infectious Pneumonia
3104 - Detection of Multiple Double-Stranded DNA Viruses after Cord Blood Transplantation Is Frequent and Persistent

Leissinger, C. A.

761 - A Cross-Sectional Analysis of Cardiovascular Disease in the Hemophilia Population
2289 - Non-Factor VIII Coagulation Proteins Fail to Predict Joint Outcome in Severe Hemophilia a
3525 - Rviii-Singlechain in Surgical Prophylaxis: Efficacy and Safety of Continuous and Bolus Infusion
3535 - Hemophilia Prophylaxis No Longer Just for Children without Inhibitors - Increasing Use of Prophylaxis in Other Groups (children with inhibitors and adults with and without inhibitors)

Leitch, H. A.

1701 - Iron Chelation Is Associated with Improved Survival Adjusting for Disease and Patient Related Characteristics in Low/Int-1 Risk MDS at the Time of First Transfusion Dependence: A MDS-CAN Study

Leith, C. P.

3323 - Bone Marrow Biopsy Quality: A Quality Improvement Project to Identify Factors Affecting Bone Marrow Biopsy Length and Find Strategies to Improve Overall Biopsy Quality
4209 - Cytogenetic Progression in Patients with Multiple Myeloma As Assessed By Serial Bone Marrow Biopsy Is Associated with Worse Outcome

Leivas, A.

1856 - Autologous Activated and Expanded Natural Killer Cells Are Safe and Clinically Actives in Multiple Myeloma

Lejeune, C.

2577 - Mixed Chimerism at Three Months after Allogeneic Hematopoietic Stem Cell Transplantation Is a Significant Predictor of Disease Relapse in High-Risk Acute Myeloid Leukemia Patients in First Complete Remission
3213 - Allogeneic Hematopoietic Stem Cell Transplantation from Unrelated Peripheral Blood or Bone Marrow Donors: The Impact of HLA Matching Including HLA-DPB1 Allele in a Multivariable Risk Model
3428 - Survey of Serum Aspergillus Antigen in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia or Allogeneic Hematopoietic Stem Cell Transplantation: Role in Predicting Invasive Aspergillosis and in Modifying the Therapeutic Strategy
4324 - Optimizing the Outcomes of Allogeneic Hematopoietic Stem Cell (HSC) Transplantation for Hematological Malignancies: The Perfect Combination of Conditioning Regimen, Disease Stage and Type of HSC Donor
4477 - First Results of a Prospective Study on Erythropoietin Biosimilar (Epoetin zeta) Use in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies

Lejeune, J.

451 - Is Arsenic Trioxide (ATO) Required in the Treatment of Standard Risk Newly Diagnosed APL? Analysis of a Randomized Trial (APL 2006) By the French Belgian Swiss APL Group
492 - The Gain of the Short Arm of Chromosome 2 (2p+) Induces XPO1 Overexpression and Drug Resistance in Chronic Lymphocytic Leukemia
2892 - A Phase I-II Study of the Efficacy and Safety of Lenalidomide (LEN) Combined to Azacitidine (AZA) in Higher Risk MDS and AML with Del 5q - a Study By the Groupe Francophone Des Myelodysplasies (GFM)
2900 - A Phase II Add-on Study of Vorinostat (VOR) in Higher Risk Myelodysplastic Syndrome with Failure of Hypomethylating Agents (HMA): The GFM Azavor Study
3042 - Can Assessment of Patient Monoclonal Immunoglobulins By Heavy/Light Analysis be Used to Assign Patient Responses Analogous to IMWG Response Criteria?
4393 - Impact of NK Cell Reconstitution and Recipient HLA-C Typing on Clinical Outcome after Reduced Intensity Cord Blood Transplant: Results of a Prospective Phase II Multicentric Trial on Behalf of Societe Francaise De Greffe De Moelle Osseuse Et Therapie Cellulaire (SFGM-TC) and Eurocord

Lejniece, S.

2780 - Treatment and Outcome Analysis of 2,904 Pateints from the EUTOS Population Based Registry

Lejniece, S.

3034 - Analysis of Final Data from the Multinational, Non-Interventional, Observational Emmos Study (NCT01241396) in Patients (Pts) with Multiple Myeloma (MM) in Real-World Clinical Practice

Lekhakula, A.

1471 - Validation of German High-Grade Non-Hodgkin's Lymphoma (DSHNHL) Prognostic Model and the Impact of Treatment on Secondary Central Nervous System (CNS) Relapse in Diffuse Large B-Cell Lymphoma (DLBCL) in a Developing Country: Report from the Nationwide Multi-Institutional Registry of Thai Lymphoma Study Group (TLSG)
2676 - Clinical Characteristics and Outcomes of Limited-Stage Primary Extranodal Versus Nodal Diffuse Large B-Cell Lymphoma (DLBCL) in Thailand: A Nationwide Multi-Institutional Registry of 920 Cases in Thailand
2712 - Consolidation Radiotherapy Improved Survival in Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL): A Nationwide Multi-Institutional Registry of 816 Cases in Thailand
3326 - Mantle Cell Lymphoma, Rare Lymphoma Entity: A Result of Lymphoma Registry in Thailand

Lekieffre, M.

2774 - Very Long-Term Follow-up (> 80 months) of Imatinib (IM) First-Line for Chronic Phase (CP) CML Patients

Leleu, X.

191 - Evaluation of Minimal Residual Disease (MRD) By Next Generation Sequencing (NGS) Is Highly Predictive of Progression Free Survival in the IFM/DFCI 2009 Trial
1755 - MYC Regulation Via the LIN28B/Let-7 Axis in Multiple Myeloma
1770 - Circulating Exosomal microRNAs Are Prognostic Markers in Multiple Myeloma
1831 - Salvage Therapy Post Pomalidomide-Based Regimen in Relapsed/Refractory Myeloma
2086 - Assessment of Multiple Myeloma Patient Preferences on Treatment Choices: An International Discrete Choice Study
2096 - Generation of a Large Observational Pan-European Data Platform for Treatment and Outcome Patterns in Patients with Waldenstrom's Macroglobulinemia
3028 - Carfilzomib Weekly Plus Melphalan and Prednisone in Newly Diagnosed Elderly Multiple Myeloma (IFM 2012-03)
4201 - Outcomes after Initial Relapse of Multiple Myeloma: An International Myeloma Working Group Study
4245 - Time to Spare Newly Diagnosed Non Transplant Eligible Myeloma (eNDMM) from Thalidomide

Leleu, X.

2085 - Health-Related Quality of Life in Lenalidomide and Bortezomib Treated Patients with Relapsed/Refractory Multiple Myeloma
3042 - Can Assessment of Patient Monoclonal Immunoglobulins By Heavy/Light Analysis be Used to Assign Patient Responses Analogous to IMWG Response Criteria?

Lemal, R.

2948 - Central Nervous System Involvement in Chronic Lymphocytic Leukemia: Diagnosis and Treatment in a Retrospective Cohort of Thirty Patients
3222 - RIC Allogeneic Stem Cell Transplantation for High Risk CLL Followed By Preemptive MRD-Based Immunointervention - Intermediate Results from the Phase II ICLL03 Ricac-Pmm Trial (FILO & SFGM-TC French intergroup)
4170 - First Line Chronic Lymphocytic Leukemia Immunochemotherapy for the Elderly Patients over 79 Years Is Feasible, and Achieves Good Results : A Filo Retrospective Study

Lemarchand, P.

3122 - Impact of Pre-Transplant Diffusion Lung Capacity for Nitric Oxide (DLNO) and of Dlno/Pre-Transplant Diffusion Lung Capacity for Carbon Monoxide (DLNO/DLCO) Ratio on Pulmonary Outcomes in Adults Receiving Allogeneic Stem Cell Transplantation for Haematological Diseases

Lemasle, E.

129 - Recurrent Mutations of the Exportin 1 Gene (XPO1) in Primary Mediastinal B-Cell Lymphoma: A Lysa Study
218 - Clofarabine-Based Consolidation Improves Relapse-Free Survival of Younger Adults with Non-Favorable Acute Myeloid Leukemia (AML) in First Remission: Results of the Randomized ALFA-0702/Clara Study (NCT 00932412)

Lemech, C.

507 - Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results of a Phase 1/2 Study (GEN503)

Lemes, A.

608 - The Complete Mutatome and Clonal Architecture of Del(5q)

Lemieux, B.

3961 - Long-Term Outcomes, Secondary Malignancies, and Stem Cell Collection Following Bendamustine in Patients with Previously Treated Indolent Non-Hodgkin Lymphoma

Lemieux, C.

3171 - Safety and Efficacy of Autologous Hematopoietic Cell Transplantation for Elderly Patients with Lymphoma: Chemosensitive Disease Rather Than Age or Co-Morbidity Index Predicts Outcome

Lemieux, S.

802 - Mutational and Transcriptomic Landscape of AML with Core-Binding Factor Rearrangements
1859 - The Novel Leukemia Stem Cell Marker GPR56 Discriminates Leukemic Subclones with Divergent Stem Cell Properties in Human Acute Myeloid Leukemia
3855 - Transcriptome Analysis Reveals That G Protein-Coupled Receptors Are Potential Diagnostic Markers or Therapeutic Targets in Acute Myeloid Leukemia

Lemmens, H.

2969 - RPL5 Is a Candidate Tumor Suppressor on 1p22.1 in Multiple Myeloma of Which the Expression Is Linked to Bortezomib Response

Lemoli, R. M.

1019 - The Induction of Inhibitory Pathways in Dendritic Cells May Hamper the Efficient Activation of Anti-Leukemia T Cells within Chemotherapy-Induced Immunogenic Cell Death
1191 - Upregulation of Indoleamine 2,3-Dioxygenase Enzymes in Leukemic Mesenchymal Stromal Cells (MSCs) Can Influence MSC/Acute Myeloid Leukemia Cell Cross Talk
1375 - A Novel Synthetic Lethal Approach Targeting SIRT6 in Acute Myeloid Leukemia
2029 - High Predictive Value of Pre Transplant Minimal Residual Disease Assessment By Combining WT1 Expression and Flow Cytometry in Acute Myeloid Leukemia
2033 - Natural Killer (NK) Alloreactivity Seems Not to Play a Role in Preventing Leukemia Relapse in Unmanipulated Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide
2394 - The Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) Regulates the Function and Migration of Leukemic Blasts through CD63/PI3K/AKT/P21 Axis
2601 - High Prognostic Value of a 3-Genes Molecular Score in Non-High Risk Acute Promyelocytic Leukemia Treated with AIDA 2000 Protocol: A Retrospective Study from a Regional Register
3684 - P2X7 Receptor Activation By ATP As Target of Novel Therapies in Acute Myeloid Leukemia

Lemonne, N.

2174 - Effects of Poloxamer 188 on Red Blood Cells Membrane Properties in Sickle Cell Disease

Lemonnier, F.

129 - Recurrent Mutations of the Exportin 1 Gene (XPO1) in Primary Mediastinal B-Cell Lymphoma: A Lysa Study

Lemonnier, F.

3161 - Bronchiolitis Obliterans Occurring after Allogenic Hematopoietic Stem Cell Transplant: Comparison of Outcome Between Patients Equipped or Not with Home Spirometry Monitoring

Lemons, R. S.

4463 - Reduction in Inpatient Central Line Associated Blood Stream Infection Post Implementation of Bundled Care Measures in Patients with Benign and Malignant Hematological Conditions in a Single Pediatric Institution

Lemos, F.

4471 - Febrile Neutropenia Outcome in Hemato-Oncological Patients after the Implementation of an Adapted Therapeutic Protocol at a University Hospital in Uruguay

Lemos, M. M.

3935 - Results of the Mantle Cell Lymphoma Subset from a Phase 2a Study of Copanlisib, a Novel PI3K Inhibitor, in Patients with Indolent and Aggressive Lymphoma

Lenain, P.

134 - Combination of Dasatinib and Peg-Interferon Alpha 2b in Chronic Phase Chronic Myeloid Leukemia (CP-CML) First Line: Preliminary Results of a Phase II Trial, from the French Intergroup of CML (Fi-LMC)
393 - Bortezomib, Thalidomide and Dexamethasone (VTD) Is Superior to Bortezomib, Cyclophosphamide and Dexamethasone (VCD) Prior to Autologous Stem Cell Transplantation for Patients with De Novo Multiple Myeloma. Results of the Prospective IFM 2013-04 Trial
1578 - Pegylated Interferon-Alpha 2a in Combination with Nilotinib As First-Line Therapy in Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (Nilopeg trial). Four-Year Follow-up Results
3028 - Carfilzomib Weekly Plus Melphalan and Prednisone in Newly Diagnosed Elderly Multiple Myeloma (IFM 2012-03)
4039 - Ponatinib for Chronic Phase (CP) CML Failing Two or More Tyrosine Kinase Inhibitors (TKI) or Harboring a T315I Mutation in the Real Life: Pearl Observational Study

Lendvai, N.

509 - A Dose Finding Phase II Trial of Isatuximab (SAR650984, Anti-CD38 mAb) As a Single Agent in Relapsed/Refractory Multiple Myeloma
728 - Phase 2 Study of Carfilzomib (CFZ) with or without Filanesib (FIL) in Patients with Advanced Multiple Myeloma (MM)
1975 - Continuous Treatment with Lenalidomide Plus Low-Dose Dexamethasone (Ld) Versus Ld Induction Followed By Autologous Stem Cell Transplant (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Pooled Analysis of Two Randomized Clinical Trials
1996 - Autologous Hematopoietic Stem Cell Transplantation Overcomes Primary Refractory Disease in Multiple Myeloma Patients Treated with Novel Agents
3057 - The Long PD-1 Receptor Binding Kinetics of Nivolumab May Increase Efficacy of Subsequent Therapy in Relapsed and Refractory Multiple Myeloma Patients
3178 - Induction with Bortezomib and Dexamethasone (BD) Followed By Risk Adapted High Dose Melphalan and Autologous Stem Cell Transplantation and BD Consolidation in Patients with AL Amyloidosis: A Phase II Feasibility Study
4257 - Biomarkers of Cardiotoxicity Among Multiple Myeloma Patients Subsequently Treated with Proteasome Inhibitor Therapy
4265 - Incidence and Management of Proteasome Inhibitor-Related Cardiotoxicity in Multiple Myeloma Patients at Memorial Sloan Kettering Cancer Center

Leng, S.

1993 - A Comparison of the Outcomes of Early Versus Delayed Autologous Stem Cell Transplantation for Multiple Myeloma in the Era of Novel Therapies
4226 - A Phase II Study of Panobinostat with Lenalidomide and Weekly Dexamethasone in Myeloma

Lengauer, C.

568 - Blu-285, a Potent and Selective Inhibitor for Hematologic Malignancies with KIT Exon 17 Mutations

Lengerke, C.

858 - Treatment of Corticosteroid-Refractory Graft-Versus-Host Disease with Ruxolitinib in 95 Patients
2459 - Development of Hras-Induced Zebrafish Leukemia Models

Lengfelder, E.

1382 - Different Impact of Expression Levels of IGFBP2 and IGFBP7 on Survival and Relapse Rate in Acute Promyelocytic Leukemia

Lengliné, E.

456 - How to Treat Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Patients : Results on 86 Patients of the French BPDCN Network

Lengner, C.

714 - MSI2 Is Required for Maintaining the Activated Myelodysplastic Syndrome Stem Cell

Lenhard, D.

1459 - Influence of Different Components of the Tumor Microenvironment on Human Patient-Derived Lymphoma Cell Engraftment in Immmunodeficient Mice
2538 - Establishment and Characterization of a Panel of Patient-Derived Acute Leukemia Mouse Models As Emerging Platform for Translational Research

Lenhart, G.

4521 - Development of an Algorithm to Identify Patients with Multiple Myeloma Using Administrative Claims Data

Lenhoff, S.

4403 - Allogeneic Hematopoietic Cell Transplantation (HCT) for Advanced Mycosis Fungoides and Sezary Syndrome (MF/SS): Impact of Increasing the Use of Unrelated Donors (UD) - the EBMT Lymphoma Working Party Experience

Lenihan, D. J.

1841 - Six-Minute Walk Test As a Measure of Functional Change after Chemotherapy in Cardiac AL Amyloidosis
4250 - Serial Echocardiographic Assessment of Patients (Pts) with Relapsed Multiple Myeloma (RMM) Receiving Carfilzomib and Dexamethasone (Kd) Vs Bortezomib and Dexamethasone (Vd): A Substudy of the Phase 3 Endeavor Trial (NCT01568866)

Lenis, M.

1701 - Iron Chelation Is Associated with Improved Survival Adjusting for Disease and Patient Related Characteristics in Low/Int-1 Risk MDS at the Time of First Transfusion Dependence: A MDS-CAN Study

Lenive, O.

371 - Spatiotemporal Analysis of Intraclonal Heterogeneity in Multiple Myeloma: Unravelling the Impact of Treatment and the Propagating Capacity of Subclones Using Whole Exome Sequencing

Lennartsson, A.

2839 - Mutations in Histone Modulators Are Associated with Prolonged Survival during Azacitidine Therapy

Lennon, Á.

2276 - Platelet-Derived Beta Thromboglobulin: A Potential Novel Activator of Coagulation Factor X

Lennon, K. M.

1863 - Tracking Normal and Chronic Myeloid Leukemia Progenitor Cell Cycle Kinetics in a Defined Niche Using Live Time Lapse Confocal Imaging with Fucci2BL a Novel Lentiviral Bicistronic Reporter

Lennon, P.

1388 - Clinical Utility of High-Throughput and Complimentary Genomic Tumor Profiling in Hematologic Malignancies

Lenowitz, S.

3356 - Safety and Efficacy of Rapid (one hour) Single Intravenous Dose Low Molecular Weight Iron Dextran for Treatment of Oral Iron Intolerant Maternal Iron Deficient Anemia

Lens, T. G.

3910 - Systematic Analysis of Cell-of-Origin, Sequencing and Genomic Imbalances Identifies a Distinct Subset of Rituximab Treated Diffuse Large B-Cell Lymphoma with an Inferior Survival

Lenting, P. J.

3516 - Mechanisms and Therapeutic Modulation of the Bleeding Tendency in Genetically-Engineered Von Willebrand Disease Type 2B Mice

Lentz, S. R.

2304 - Successful Use of rFVIII, Turoctocog Alfa, during Orthopedic and Nonorthopedic Surgery in Patients with Severe Hemophilia A

Lentzsch, S.

188 - Results of Phase I Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients with AL Amyloidosis
3003 - IKZF1 Mutation Mediate Resistance to IMiDs in Human Hematopoietic Stem Cells
3009 - Mechanism Study of Matrix Metalloproteinase 13 Effects on Osteoclast Activation and Lytic Bone Lesions in Multiple Myeloma
3041 - Updated Results of a Phase 2 Study of Bendamustine in Combination with Dexamethasone (Ben/Dex) in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis
3075 - Interferon-Gamma Signaling in the Pathogenesis of Idiopathic Pneumonia Syndrome Following Allogeneic Bone Marrow Transplantation

Lentzsch, S.

508 - Open-Label, Multicenter, Phase 1b Study of Daratumumab in Combination with Pomalidomide and Dexamethasone in Patients with at Least 2 Lines of Prior Therapy and Relapsed or Relapsed and Refractory Multiple Myeloma
593 - Disruption of the mTOR-eIF4F Axis By Selectively Targeting PI3Kdelta and Proteasome Potently Inhibits Cap Dependent Translation of c-Myc in Aggressive Lymphomas
1975 - Continuous Treatment with Lenalidomide Plus Low-Dose Dexamethasone (Ld) Versus Ld Induction Followed By Autologous Stem Cell Transplant (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Pooled Analysis of Two Randomized Clinical Trials
2105 - Changes in Expert Recommendations and Global Practice Patterns from 2012-2015: Results from an Annually Updated Online Decision Aid for Multiple Myeloma (MM)

Lenz, G.

2025 - Allogeneic Stem Cell Transplantation (SCT) for Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) in Elderly Patients (Older than 60 Years)

Lenze, D.

3875 - Identification of Blut, a Novel Long-Noncoding RNA Differentially Expressed in Burkitt Lymphoma

Leo, E.

1573 - Aurora Kinase a: A New Component of Imatinib Resistance in Chronic Myeloid Leukemia

Leo, P.

1644 - Rare and Common Germline Variants Contribute to Occurrence of Myelodysplastic Syndrome

Leon, N.

1695 - Efficacy of Azacitidine (AZA) in Autoimmune and Inflammatory Disorders (AID) Associated with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Leonard, A.

988 - Early Initiation of Inhaled Corticosteroids Does Not Decrease Acute Chest Syndrome Morbidity in Pediatric Patients with Sickle Cell Disease

Léonard, A.

3018 - The Src Inhibitor AZD0530 Prevents the Development of Osteolytic Bone Disease in Multiple Myeloma

Leonard, E. J.

341 - First Multicenter, Randomized Phase 3 Study in Patients (Pts) with Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL): Alisertib (MLN8237) Versus Investigator's Choice (Lumiere trial; NCT01482962)

Leonard, J.

1329 - Dual Targeting of Ph+ ALL with Dasatinib and ABT-199 (Venetoclax)
2592 - Mutations Modifying Risk in NPM1+ AML

Leonard, J. P.

334 - Interfollicular CD10 Expression and Follicular PD1 Tumor-Infiltrating Lymphocytes As Biologic Risk Factors in Patients with Previously Untreated Follicular Lymphoma Receiving Rituximab-Based Biologic Therapy: An Alliance Correlative Science Study (CALGB 50901, 50402, 50701, 50803, 50401)
337 - Bortezomib Maintenance (BM) Versus Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): CALGB (Alliance)50403
341 - First Multicenter, Randomized Phase 3 Study in Patients (Pts) with Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL): Alisertib (MLN8237) Versus Investigator's Choice (Lumiere trial; NCT01482962)
471 - Phase I Study of Rituximab, Lenalidomide, and Ibrutinib in Previously Untreated Follicular Lymphoma (Alliance 051103)
518 - Pre-Transplant R-Bendamustine Induces High Rates of Minimial Residual Disease in MCL Patients: Updated Results of S1106: US Intergroup Study of a Randomized Phase II Trial of R-HCVAD Vs. R-Bendamustine Followed By Autologous Stem Cell Transplants for Patients with Mantle Cell Lymphoma
519 - Post Transplant Outcome of a Multicenter Phase II Study of Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT
578 - Initial Results of US Intergroup Trial of Response-Adapted Chemotherapy or Chemotherapy/Radiation Therapy Based on PET for Non-Bulky Stage I and II Hodgkin Lymphoma (HL) (CALGB/Alliance 50604)
811 - Randomized Phase 2 Open-Label Study of R-CHOP ± Bortezomib in Patients (Pts) with Untreated Non-Germinal Center B-Cell-like (Non-GCB) Subtype Diffuse Large Cell Lymphoma (DLBCL): Results from the Pyramid Trial (NCT00931918)
2636 - Outcomes in Adolescents and Young Adults (AYA) with Hodgkin Lymphoma (HL) Treated on US Cooperative Group Protocols: An Adult Intergroup (E2496) and Children's Oncology Group (COG AHOD0031) Comparative Analysis
2741 - Phase II Trial of Ofatumumab (OFA) in Previously Untreated Follicular Non-Hodgkin Lymphoma (NHL): CALGB 50901 (Alliance)
3961 - Long-Term Outcomes, Secondary Malignancies, and Stem Cell Collection Following Bendamustine in Patients with Previously Treated Indolent Non-Hodgkin Lymphoma
4527 - Clinical Impact of Internet-Based Tools to Help Guide Therapeutic Decisions for Mantle Cell Lymphoma (MCL)

Leonardi, A.

2288 - Safety & Efficacy of Human Plasma Derived Plasminogen Ophthalmic Drops for Treatment of Ligneous Conjunctivitis: Report of Phase 2/3 Clinical Trial

Leonardi, A.

868 - Cancer-Selective Targeting of the NF-κB Survival Pathway in Multiple Myeloma with the GADD45β/MKK7 Inhibitor, DTP3

Leonardi, G.

2871 - Association of Azacitidine and Lenalidomide (Combined vs Sequential Treatment) in High-Risk Myelodysplastic Syndromes. Final Results of a Randomized Phase II Multicenter Study

Leoncini, P. P.

2851 - Microrna-150 Regulates STAT5b Levels in Juvenile Myelomonocytic Leukemia (JMML)

Leone, E.

3019 - Growth Inhibition and Synergistic Induction of Apoptosis By Synthetic Mir-125b-5p Mimics and Myc-Targeting Agents in Human Myeloma Cell Lines
3025 - Pharmacokinetics and Biodistribution of Locked Nucleic Acid (LNA)-Mir-221 Inhibitor: A New Promising Anti-Myeloma Agent

Leone, G.

66 - Feasibililty of Azacitidine As Bridge to Allogeneic Stem Cell Transplantation in Patients with Higher-Risk MDS or Low-Blast Count AML: Results of the BMT-AZA Multicenter Prospective Study
1953 - Gut Microbiome Changes after Stem Cell Transplantation
4134 - MiR-181b in Chronic Lymphocytic Leukemia B Cells Is Regulated By Cellular Interaction with CD4+ T Cells and Increases the CTL Toxicity Versus the Leukemic Clone

Leonetti Crescenzi, S.

2821 - Application of the International Prognostic Score of Thrombosis for Essential Thrombocytemia(ET) (IPSET-Thrombosis) in a Cohort of ET Patients: Experience from Gruppo Laziale for Myeloproliferative Ph Negative Neoplasms

Leonetti-Crescenzi, S.

2815 - The Platelet COUNT at Diagnosis of Essential Thrombocythemia Is a Prognostic Factor for Thrombosis-Free Survival: Retrospective Analysis on 1201 Patients

Leong, J. W.

101 - Human Cytokine-Induced Memory-like NK Cells Exhibit in Vivo Anti-Leukemia Activity in Xenografted NSG Mice and in Patients with Acute Myeloid Leukemia (AML)

Leong-Poi, H.

2254 - Natural Killer Cells Contribute to Pathophysiology of Placenta Leading to Miscarriage in Fetal and Neonatal Alloimmune Thrombocytopenia

Leonhardt, H.

1274 - Tyrosin Kinase Inhibition Restores the Membrane Localization of FLT3-ITD

Leoni, J.

2306 - A Comparison of Von Willebrand Factor Indexes in Heartmate II Compared to Heartware Left Ventricular Assist Devices

Leoni, P.

1693 - Use of Lenalidomide in DEL(5q) MDS. a National AIFA (Agenzia Italiana del Farmaco) Registry Study

Leoni, P.

2120 - Quality of Life in Elderly Patients with Acute Myeloid Leukemia Undergoing Induction Chemotherapy
2792 - Long-Term Outcome to First-Line Imatinib according to 2013 European LeukemiaNet Response Criteria: a GIMEMA CML WP Analysis

Leotta, M.

916 - Selective Activation of the Non-Classical Estrogen Receptor Gper Elicits Potent Anti-Tumor Activity in Multiple Myeloma

Leotta, S.

4305 - Results and Cost Effectiveness of "on-Demand" Plerixafor Added to Chemotherapy and Granulocyte Colony-Stimulating Factor for Peripheral Blood Stem Cell Mobilization in Multiple Myeloma

Lepatan, L. M.

2298 - Efficacy and Safety of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Treated Patients with Hemophilia B Undergoing Major Orthopedic Surgeries

Lepeu, G.

3028 - Carfilzomib Weekly Plus Melphalan and Prednisone in Newly Diagnosed Elderly Multiple Myeloma (IFM 2012-03)

Lepist, I.

4099 - The JAK1/2 Inhibitor Momelotinib Does Not Inhibit Thiamine Uptake in Vitro

Lepore, J.

295 - Brca1 Deficiency Causes Bone Marrow Failure and Spontaneous Hematologic Malignancies in Mice

Lepore, N.

3384 - Analysis of Hemodynamic Changes and Bold Signals of Sickle Cell Disease Patients during Desaturation

Leporrier, M.

3917 - [¹⁸F]-Fludarabine Positron Emission Tomography in Diffuse Large B-Cell Lymphoma (DLBCL) Patients: Results of a Phase I Study

Leppä, S.

3199 - Factors Affecting Early Immune Recovery after Autologous Transplantation and Its Clinical Significance - a Prospective Analysis of Patients with Non-Hodgkin Lymphoma

Lepretre, S.

2492 - Pharmacokinetic and Pharmacodynamic Characterization of Graspa Versus Native L-Asparaginase in Combination with Cooprall Chemotherapy in a Phase 3 Randomized Trial for the Treatment of Patients with Relapsed Acute Lymphoblastic Leukemia (NCT01518517)
2948 - Central Nervous System Involvement in Chronic Lymphocytic Leukemia: Diagnosis and Treatment in a Retrospective Cohort of Thirty Patients
3723 - Updated Clinical Activity of Graspa Versus Native l-Asparaginase in Combination with Cooprall Regimen in Phase 3 Randomized Trial in Patients with Relapsed Acute Lymphoblastic Leukemia (NCT01518517)
3734 - Evaluation of the Impact of the Presence of Neutralizing L-Asparaginase Antibodies on the Efficacy and Safety of Graspa in Phase 3 Randomized Trial Versus Native L-Asparaginase in Patients with Relapsed Acute Lymphoblastic Leukemia (NCT01518517)
4170 - First Line Chronic Lymphocytic Leukemia Immunochemotherapy for the Elderly Patients over 79 Years Is Feasible, and Achieves Good Results : A Filo Retrospective Study

Leprêtre, S.

492 - The Gain of the Short Arm of Chromosome 2 (2p+) Induces XPO1 Overexpression and Drug Resistance in Chronic Lymphocytic Leukemia

Lerchenmueller, C.

3930 - Temsirolimus in Combination with Bendamustine and Rituximab for the Treatment of Relapsed Mantle Cell and Follicular Lymphoma: Report on an Ongoing Phase I/II Trial

Lerman, A.

3046 - Cardiotoxicity Risk with Bortezomib Versus Lenalidomide for Treatment of Multiple Myeloma: A Propensity-Matched Study of 1,128 Patients

Leroux, F.

456 - How to Treat Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Patients : Results on 86 Patients of the French BPDCN Network
3812 - Biological Description of 109 Cases of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) from the French Network of BPDCN

Leroy, E.

606 - Whole Exome Sequencing Identifies Novel MPL and JAK2 Mutations in Triple Negative Myeloproliferative Neoplasms

Leroy, K.

129 - Recurrent Mutations of the Exportin 1 Gene (XPO1) in Primary Mediastinal B-Cell Lymphoma: A Lysa Study
1472 - Integrative Analysis of Diffuse Large B Cell Lymphoma Mutational Landscape: A Lysa Study

LeRoy, M.

1145 - Effect of Lower Hematocrits on Buffy Coat Collection during Extracorporeal Photopheresis in Patients with Graft-Versus-Host Disease

Lersch, F.

374 - Safety of Treatment (Tx) with Pomalidomide (POM) and Low-Dose Dexamethasone (LoDEX) in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI), Including Those on Dialysis

Lertkiatmongkol, P.

1041 - Structural Basis for PECAM-1 Homophilic Binding

Lertkiatmongkol, P.

3450 - Species-Specific Roles for a2,3- and a2,6-Linked Sialic Acid Residues in PECAM-1-Mediated Homophilic Interactions

Lertkiatmongkol, P.

2340 - Involvement of the EGF Domain in the Formation of the Human Platelet Alloantigen, HPA-1a

Leseve, J. F.

2662 - Multicentric Analyses of the CD148, CD180, and CD200 Combination for the Diagnosis of Mature B-Cell Neoplasm Using Flow Cytometry

Lesh, M. B.

3266 - Radiologist-Performed Musculoskeletal Ultrasound (MSKUS) for Evaluation of Joint and Soft Tissue Pain Episodes in Patients with Bleeding Disorders

Leshchenko, V. V.

1253 - SOX11 Cooperates with CCND1 in Mantle Cell Lymphoma Pathogenesis
1851 - Patient-Specific Mutation-Derived Tumor Antigens As Targets for Cancer Immunotherapy in Multiple Myeloma
4226 - A Phase II Study of Panobinostat with Lenalidomide and Weekly Dexamethasone in Myeloma

Lesho, P.

506 - A Phase II Study of Anti PD-1 Antibody Pembrolizumab, Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Leslie, C. S.

440 - IKZF2, a Novel Target of MSI2 RNA-Binding Protein Plays an Oncogenic Role in Myeloid Leukemia
714 - MSI2 Is Required for Maintaining the Activated Myelodysplastic Syndrome Stem Cell
2994 - Global 3' UTR Sequencing in Multiple Myeloma (MM)
4110 - RBM15-Mediated RNA Splicing Fine-Tunes Epigenetic Program through Interaction with SF3B1

Lesmana, H.

3349 - Alu-Element Insertion in Pklr Gene As a Novel Cause of Severe Hereditary Nonspherocytic Hemolytic Anemia

Lesniewski-Kmak, K.

3943 - The Prognostic Role of Interim PET after First Chemotherapy Cycle and PET Sequential Evaluation of Response to ABVD in Hodgkin Lymphoma Patients - the Polish Lymphoma Research Group (PLRG) Observational Study

Lesokhin, A. M.

583 - Nivolumab in Patients (Pts) with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Clinical Outcomes from Extended Follow-up of a Phase 1 Study (CA209-039)
1785 - Presence of PD-1 Expressing T Cells Predicts for Inferior Overall Survival in Newly Diagnosed Multiple Myeloma
1966 - T Cell Exhaustion/Senescence in Relapsed Multiple Myeloma after Autologous Stem Cell Transplantation
1975 - Continuous Treatment with Lenalidomide Plus Low-Dose Dexamethasone (Ld) Versus Ld Induction Followed By Autologous Stem Cell Transplant (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Pooled Analysis of Two Randomized Clinical Trials
1996 - Autologous Hematopoietic Stem Cell Transplantation Overcomes Primary Refractory Disease in Multiple Myeloma Patients Treated with Novel Agents
3057 - The Long PD-1 Receptor Binding Kinetics of Nivolumab May Increase Efficacy of Subsequent Therapy in Relapsed and Refractory Multiple Myeloma Patients
4257 - Biomarkers of Cardiotoxicity Among Multiple Myeloma Patients Subsequently Treated with Proteasome Inhibitor Therapy

Lessi, F.

2710 - Rituximab-Bendamustine Cytarabine (R-BAC) As Frontline Therapy in Mantle Cell Lymphoma: A Single-Center Experience
3757 - Bloodstream Infections Caused By Klebsiella Pneumoniae in Onco-Hematological Patients: Incidence and Clinical Impact of Carbapenem Resistance in a Multicentre Prospective Survey

Lestang, E.

3218 - Allogeneic Stem Cell Transplantation for Primary or Secondary Myelofibrosis: A Retrospective Intent-to-Treat Analysis and Impact of Mutational Status and JAK1/2 Inhibitor Ruxolitinib Prescription in Patients Who Cannot Proceed to Transplantation

Lesty, C.

492 - The Gain of the Short Arm of Chromosome 2 (2p+) Induces XPO1 Overexpression and Drug Resistance in Chronic Lymphocytic Leukemia
1464 - Auto-Immune Origin of B Cells from HCV-Associated Lymphoma

Letai, A.

327 - A Phase 1b Study of Venetoclax (ABT-199/GDC-0199) in Combination with Decitabine or Azacitidine in Treatment-Naive Patients with Acute Myelogenous Leukemia Who Are ≥ to 65 Years and Not Eligible for Standard Induction Therapy
490 - Ibrutinib Therapy Increases BCL-2 Dependence and Enhances Sensitivity to Venetoclax in CLL
797 - The MDM2 Inhibitor NVP-CGM097 Is Highly Active in a Randomized Preclinical Trial of B-Cell Acute Lymphoblastic Leukemia Patient Derived Xenografts

Letendre, C.

4319 - Influence of Prophylactic Antibiotics Aiming at Gut Decontamination on Gastrointestinal Graft-Versus-Host Disease and Overall Survival Following Allogeneic Haematopoietic Stem Cell Transplantation

Letestu, R.

2927 - Splicing Factor 3B Subunit 1 (SF3B1) Mutations Impact FOXP1 Splicing in Chronic Lymphocytic Leukemia (CLL) Cells but Conserve the Balance Between Newly Described and Classical Splicing Variants of ZAP-70

Lethen, J.

4235 - Relationship of Carfilzomib Dosing and Duration of Therapy (DOT) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM)

Leto, F.

2133 - Earlier Antenatal Diagnosis of Hemoglobinopathies By Coelocentesis

Letsch, A.

2891 - Application of a Short Tandem Repeat Based PCR Assay for Chronological Monitoring of Myelodysplastic Syndrome (MDS) Patients with Deletion of Chromosome 5q Following Lenalidomide Treatment

Lettre, G.

638 - Crispr-Cas9 Saturating Mutagenesis Reveals an Achilles Heel in the BCL11A Erythroid Enhancer for Fetal Hemoglobin Induction (by Genome Editing)
3370 - Prospective Evaluation of Fetal Haemoglobin Induction in Maternal Erythrocytes: A Preliminary Analysis of a Cohort of 345 Parturients

Letzer, J. P.

3027 - An Expanded Treatment Protocol of Panobinostat Plus Bortezomib and Dexamethasone in Patients with Previously Treated Myeloma

Leu, H.

567 - RNA Splicing Modulation Impairs Acute Myeloid Leukemia Stem Cell Maintenance

Leuchtner, N.

3005 - Interfering with Arginine Metabolism As a New Treatment Strategy for Multiple Myeloma

Leung, A. W. K.

1169 - The Tetraspanin CD9 Regulates Engraftment and Mobilization of Human CD34+ Hematopoietic Stem/Progenitor Cells and Modulates VLA-4 Activity

Leung, A. Y.

1217 - A Retrospective Multicenter Study to Evaluate the Efficacy of Rabbit Antithymocyte Globulin (rATG) Immunosuppressive Therapy As First-Line Treatment of Aplastic Anemia
1400 - Whole Exome Sequencing of FLT3-ITD Sorafenib-Resistant Acute Myeloid Leukaemia

Leung, C.

3779 - Decreasing Early Deaths in Acute Promyelocytic Leukemia (APL) By Using a Simplified Treatment Algorithm and Establishing a Network with Academic and Community Centers in USA

Leung, E. K.

1055 - Simultaneous Assay of Agonist-Induced Endogenous and Non-Radioactive Isotopic Serotonin Secretion from Small Numbers of Human Platelets By Mass Spectrometry

Leung, I. W.

1798 - Tuning T Cell Affinity Improves Efficacy and Safety of Anti-CD38 × Anti-CD3 Bispecific Antibodies in Monkeys - a Potential Therapy for Multiple Myeloma

Leung, J.

2168 - Quantitative MRI of Hemodynamic Compromise in Children with Sickle Cell Disease: New Insights into Pathophysiology
3397 - Transfusion Therapy and Hydroxyurea Improves Cerebrovascular Reserve and Perfusion in Children with Sickle Cell Anemia: An MRI Study

Leung, J.

3614 - The North American Shwachman-Diamond Syndrome Registry: Genetically Undefined Shwachman-Diamond Syndrome

Leung, K. T.

995 - Gene Expressional Profile of Neonatal Neutrophils in Response to Bacterial Lipopolysaccharide (LPS) and Possible Mechanism of Transcription Factor NR4A2 on the Immune Signal Cascade
1169 - The Tetraspanin CD9 Regulates Engraftment and Mobilization of Human CD34+ Hematopoietic Stem/Progenitor Cells and Modulates VLA-4 Activity
2371 - RGS1 and RGS13 Regulate SDF-1-Mediated Responses and Homing in Human Cord Blood CD34+ Hematopoietic Stem/Progenitor Cells

Leung, K.

415 - Identification of the Genetic Mechanism Responsible for Racially-Dimorphic Expression of the Thrombin-Receptor Regulator, Pctp

Leung, N.

1050 - Novel Genetic Variants in Complement-Mediated Thrombotic Microangiopath
1774 - In Patients with Light-Chain (AL) Amyloidosis Myocardial Contraction Fraction (MCF) Is a Simple, but Powerful Prognostic Measure That Can be Calculated from a Standard Echocardiogram (ECHO)
3044 - The Impact of Induction Regimen Choice on Transplant Outcome and Survival in Newly Diagnosed Multiple Myeloma in the Era of Novel Agents
3177 - Impact of Bone Marrow Plasmacytosis on Outcome in Patients with AL Amyloidosis Following Autologous Stem Cell Transplant
3292 - N-Terminal Fragment of the Type-B Natriuretic Peptide (NT-proBNP) Is a Prognostic Factor for Overall Survival in Newly Diagnosed Patients with Multiple Myeloma (MM)
3317 - AL Amyloidosis and Patient Reported Quality of Life
4176 - Occurrence and Prognostic Significance of Cytogenetic Evolution in Patients with Multiple Myeloma
4197 - Presentation and Outcomes of Localized Amyloidosis: The Mayo Clinic Experience

Leung, R.

419 - Dynamin 2 (DNM2) and PACSIN2 Regulate Megakaryocyte Demarcation Membrane System Formation and Platelet Production in Concert

Leung, S.

1966 - T Cell Exhaustion/Senescence in Relapsed Multiple Myeloma after Autologous Stem Cell Transplantation

Leung, T. Y.

995 - Gene Expressional Profile of Neonatal Neutrophils in Response to Bacterial Lipopolysaccharide (LPS) and Possible Mechanism of Transcription Factor NR4A2 on the Immune Signal Cascade
1169 - The Tetraspanin CD9 Regulates Engraftment and Mobilization of Human CD34+ Hematopoietic Stem/Progenitor Cells and Modulates VLA-4 Activity
2371 - RGS1 and RGS13 Regulate SDF-1-Mediated Responses and Homing in Human Cord Blood CD34+ Hematopoietic Stem/Progenitor Cells

Leung, T. F.

2371 - RGS1 and RGS13 Regulate SDF-1-Mediated Responses and Homing in Human Cord Blood CD34+ Hematopoietic Stem/Progenitor Cells

Leung, W.

624 - Reduction in CMV and Adenovirus Viremia after Haploidentical Donor Transplantation Utilizing CD45RA Depletion and NK Cell Infusion

Leutenegger, E.

952 - Treatment of Chemotherapy-Induced Anemia Using Epoetin Alfa Biosimilar for Patients with Lymphoma and Myeloma: The Synergy Study
3363 - Epoetin Alfa Biosimilar Treatment for Chemotherapy-Induced Anemia in Current Oncology and Hematology Practice: An Iron Supplementation Subanalysis of the Synergy Study

Leuva, H.

3609 - Persistent Elevation of Plasma Thrombopoietin Levels in Severe Aplastic Anemia, Even with Hematologic Recovery

Levander, F.

2472 - Aberrant Activation of the PI3K/mTOR Pathway Promotes Resistance to Sorafenib in AML

Levato, L.

498 - Is the International Prognostic INDEX for CLL (CLL-IPI) Useful to Predict Time to First Treatment of Patients with EARLY Disease? Results of a Prospective Multicenter Analysis

Levato, L.

1570 - Bone Marrow (BM) Microenviroment Factors As Early Markers of Response in Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Treated with Nilotinib
2792 - Long-Term Outcome to First-Line Imatinib according to 2013 European LeukemiaNet Response Criteria: a GIMEMA CML WP Analysis
2930 - A Comprehensive Progression Risk Score to Predict Treatment Free Survival for Early Stage Chronic Lymphocytic Leukemia Patients
4046 - Prospective Metabolic and Cardiovascular Assessment in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Nilotinib 300 Mg Bid Frontline in the Gimema 0811 Trial
4049 - High BCR-ABL/GUS^IS Levels at Diagnosis Are Associated with Unfavorable Responses to Standard Dose Imatinib

Levent, A.

2417 - Mechanism of Action of PLX-R18, a Placental-Derived Cellular Therapy for the Treatment of Radiation-Induced Bone Marrow Failure

Leveque-El Mouttie, L.

34 - Hematopoeitic Stem Cells and Their Progenitors Critically Require Autophagy to Promote Early Engraftment Following Allogeneic Stem Cell Transplantation

Leverson, J.

327 - A Phase 1b Study of Venetoclax (ABT-199/GDC-0199) in Combination with Decitabine or Azacitidine in Treatment-Naive Patients with Acute Myelogenous Leukemia Who Are ≥ to 65 Years and Not Eligible for Standard Induction Therapy
328 - Mechanisms of Acquired Resistance to Venetoclax in Preclinical AML Models
673 - BCL-2 Inhibition By ABT-199 (Venetoclax/GDC-0199) and p53 Activation By RG7388 (Idasanutlin) Reciprocally Overcome Leukemia Apoptosis Resistance to Either Strategy Alone: Efficacy and Mechanisms
2544 - Concomitantly Targeting BCL-2 with Venetoclax (ABT-199/GDC-0199) and MAPK Signaling with Cobimetinib (GDC-0973) in Acute Myeloid Leukemia Models
3038 - Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase 1b Results
4219 - Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) Monotherapy for Relapsed/Refractory Multiple Myeloma: Phase 1 Preliminary Results

Leveson-Gower, D. B.

4284 - Increased Activity in the T Cell Effector Phase and Enhanced T Cell Repertoire Target-Tissue Stability Distinguish Alloreactivity Across Major Versus Minor Histocompatibility Barriers

Levesque, J. P.

512 - Mobilization of CD8⁺ Central Memory T-Cells with Enhanced Reconstitution Potential in Mice By a Combination of G-CSF and GMI-1271-Mediated E-Selectin Blockade

Levi, H.

3084 - Prevention of Acute GvHD Following Negative Functional Selection of Allogeneic T-Cells Using Fas Ligand Exposure of the Graft: Preliminary Results for Launching a Clinical Study

Levi, I.

4034 - The Effect of Adherence-Encouraging Interventions on Adherence to Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia (TAKE-IT): A Pre-Post Intervention Pilot Study

Levi, S.

406 - Peroxiredoxin-2: A Novel Factor Involved in Iron Homeostasis

Levie, S. E.

3146 - Donor-Derived B Cells Produce Potent AML-Specific Antibodies That Recognize Novel Tumor-Specific Antigens and Mediate Graft-Versus-Leukemia Immunity

Levin, A.

3168 - Day 100 Absolute Lymphocyte Count (ALC) Predicts Risk of Serious Infections in Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation (HCT)

Levin, M. D.

2914 - Chronic Lymphocytic Leukemia (CLL) Cells Are Susceptible to γδ-T Cell Mediated Killing, Provided CLL-Derived γδ-T Cell Dysfunction Can be Reversed

Levin, W. J.

2364 - A Platform for the Scalable Derivation of Genetically-Enhanced T and NK Lymphocytes from Naive Human Induced Pluripotent Stem Cells for Cancer Immunotherapy

Levin, W. J.

1884 - Ex Vivo Modulation of Donor Cells Results in Enhanced Survival and Reduced Gvhd Mortality
3237 - Human Induced Pluripotent Stem Cells Incorporating Safe Harbor Loci Integrated Inducible Suicide Systems for Use in the Application of Cellular Therapeutics
4500 - Economic Burden of Infections Following Allogeneic Hematopoietic Cell Transplant for Hematologic Malignancies

Levina, O.

1742 - A Phase 2 Study of Ofatumumab in Combination with a Pan-AKT Inhibitor (Afuresertib) in Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL)

Levine, B. L.

183 - Sustained Remissions Following Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas
681 - Durable Remissions in Children with Relapsed/Refractory ALL Treated with T Cells Engineered with a CD19-Targeted Chimeric Antigen Receptor (CTL019)
683 - Efficacy and Safety of Humanized Chimeric Antigen Receptor (CAR)-Modified T Cells Targeting CD19 in Children with Relapsed/ Refractory ALL
3100 - Successful Translation of Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Cell Processing Technology from Academia to Industry
3769 - Efficient Trafficking of Chimeric Antigen Receptor (CAR)-Modified T Cells to CSF and Induction of Durable CNS Remissions in Children with CNS/Combined Relapsed/Refractory ALL

Levine, J. D.

643 - MUC-1 Regulates MiR34a Expression in Acute Myeloid Leukemia Cells Resulting in an Accumulation of Granulocytic Myeloid-Derived Suppressor Cells
2473 - MUC1 Inhibition Overcomes Chemotherapy Resistance in Acute Myeloid Leukemia
2549 - DC/Aml Fusion Cell Vaccination Administered to AML Patients Who Achieve a Complete Remission Potently Expands Leukemia Reactive T Cells and Is Associated with Durable Remissions
3659 - Immunomodulatory Effect of MUC1-C in Acute Myeloid Leukemia
4218 - Blockade of PD-1 in Combination with Dendritic Cell/Myeloma Fusion Cell Vaccination Following Autologous Stem Cell Transplantation Is Well Tolerated, Induces Anti-Tumor Immunity and May Lead to Eradication of Measureable Disease

Levine, J. E.

619 - A Multicenter Phase II Trial of Unrelated Donor Reduced Intensity Bone Marrow Transplantation for Children with Severe Sickle Cell Disease (SCURT): Results of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0601) Study
1907 - Phase 1 Study of Carfilzomib for the Prevention of Relapse and Graft-Versus-Host Disease in Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
3154 - Guidelines for the Standardization of Acute Graft-Versus-Host Disease Clinical Data Collection: An International Consensus Report

Levine, R. L.

88 - Genomic and Proteomic Analysis of Primary Chemoresistance and Induction Failure in Acute Myeloid Leukemia
217 - North American Leukemia‚ Intergroup Phase III Randomized Trial of Single Agent Clofarabine As Induction and Post-Remission Therapy‚ and Decitabine As Maintenance Therapy in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age ≥60 Years): A Trial of the ECOG-ACRIN Cancer Research Group (E2906)
306 - Divergent Dynamics of Epigenetic and Genetic Heterogeneity in Relapsed Acute Myeloid Leukemia
323 - Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 Trial
434 - A Chromatin Reader That Acts As a Key to Lock in and Coordinate Recruitment of Transcription Factors and a Novel Polycomb Complex to Bivalent Chromatin Thus Driving Formation of Germinal Centers and B-Cell Lymphomas
435 - Dose-Dependent Role of the Cohesin Complex in Normal and Malignant Hematopoiesis
449 - Diverse Mechanisms of Vemurafenib Resistance in BRAF-Mutant Hairy Cell Leukemia
601 - Lysine-Specific Histone Demethylase, LSD1, (KDM1A) As a Novel Therapeutic Target in Myeloproliferative Neoplasms
603 - Preclinical Efficacy of TGF-Beta Receptor I Kinase Inhibitor, Galunisertib, in Myelofibrosis
677 - Recurrent Mutations in CCND3 Confer Clinical Resistance to FLT3 Inhibitors
713 - BAP1 Loss Results in EZH2-Dependent Transformation in Myelodysplastic Syndromes
1181 - Prmt5 Negatively Regulates Erythropoiesis By Multiple Mechanisms, Including Controlling DNA Methyltransferase 3A Protein Levels
1247 - Integrative Analysis of the Mutational Landscape of Mouse and Human AML Identifies Functionally Relevant Leukemia Disease Alleles
1259 - PHF6 - Somatic Mutations and Their Role in Pathophysiology of MDS and AML
1422 - Integrated DNA/RNA Profiling for Somatic Alterations in Adult B-Cell ALL
1485 - High-Depth, Targeted, Next Generation Sequencing Identifies Novel Genetic Alterations in Cutaneous T-Cell Lymphoma
2447 - Next-Generation Sequencing of Matched Normal Blood Identifies Clonal Hematopoiesis in a Significant Subset of Solid Tumor Patients without Hematologic Malignancies
2522 - Response to Hypomethylating Agent Therapy in Acute Myeloid Leukemia Based upon Mutations in the DNA Methylation Pathway
2591 - A Clinical Measure of DNA Methylation Predicts Outcome in De Novo AML
2668 - Defining the Incidence and Clinical Impact of Genomic Alterations Across Different Histologic Types of Lymphoma Using a Clinically Validated Comprehensive Targeted Sequencing Assay
3443 - SH2B3/LNK Loss of Function Promotes Atherosclerosis and Thrombosis
4061 - Targeted Sequencing Reveals a Relationship Between Mutational Burden and Clinical Phenotype in MPNs
4075 - AUY922, a Heat Shock Protein 90 (Hsp90) Inhibitor, Demonstrates Activity in Patients with Myeloproliferative Neoplasms (MPNs)
- US Perspective
- Laboratory & Translational Hematology Careers

Levis, A.

2879 - Prognostic Impact of Rare Single Abnormalities in Myelodysplastic Syndromes
3934 - Khorana Score and Histotype Predict the Incidence of Early Venous Thromboembolism (VTE) in Non Hodgkin Lymphoma (NHL). a Pooled Data Analysis of Twelve Clinical Trials of Fondazione Italiana Linfomi (FIL)

Levis, M. J.

Levitas, A.

2793 - Development of Xpert® BCR-ABL Ultra, an Automated and Standardized Multiplex Assay with Required Performance Characteristics for BCR-ABL1 Quantitative Measurement on an International Reporting Scale

Levkovitz, H.

421 - Factor XI Deficiency Protects Against Atherogenesis

Levy, B.

1475 - Genomic and Targeted Mutational Analysis of T/NK-Cell Post-Transplant Lymphoproliferative Disorders Provides Insight into Disease Biology

Levy, E. R.

3089 - mRNA Transfection of NK Cells with Gain-of-Function CXCR4 As a Novel Method to Enhance the Homing of Adoptively Transferred NK Cells to the Bone Marrow for the Treatment of Hematological Malignancies

Levy, J.

4207 - A Second Generation, Multiple Myeloma-Specific, Targeted Sequencing Platform for Detecting Translocations, Copy Number Alterations, and Single Nucleotide Variants

Levy, M. Y.

1588 - Relationship of Line of Therapy to Efficacy for Ponatinib in 3rd-Line Versus 4th-Line Chronic-Phase Chronic Myeloid Leukemia (CML)

Levy, M. Y.

3027 - An Expanded Treatment Protocol of Panobinostat Plus Bortezomib and Dexamethasone in Patients with Previously Treated Myeloma
3794 - Phase I Trial of Targeted Alpha-Particle Immunotherapy with Actinium-225 (²²⁵Ac)-Lintuzumab (Anti-CD33) and Low-Dose Cytarabine (LDAC) in Older Patients with Untreated Acute Myeloid Leukemia (AML)

Levy, R.

1546 - Sézary Syndrome: Clinicopathological and Immunophenotypical Characteristics and Outcomes

Levy, R. B.

3611 - Novel Multi-Target Immunosuppressive Approach for Treatment of Severe Aplastic Anemia
4281 - Targeting the IL-2/CD25 and TL1A/TNFRSF25 Pathways: A New Approach to Markedly Expand Donor Tregs in Multiple Compartments Leads to in Situ Immune Regulation

Levy, R.

114 - Noninvasive Genotyping and Assessment of Treatment Response in Diffuse Large B Cell Lymphoma
820 - Intratumoral Injection of TLR4 Agonist (G100) Leads to Tumor Regression of A20 Lymphoma and Induces Abscopal Responses
1536 - Phase I/II Clinical Trial of CpG-Activated Whole Cell Vaccine in Mantle Cell Lymphoma (MCL): Results in Safety and Efficacy from Planned Interim Analysis
1539 - Regulatory T Cells Are Depleted in Low-Grade Lymphoma By the Combination of Local Low-Dose Radiation Followed By Intratumoral CpG-ODN
2228 - T Regulatory Cells Exhibit Surface Expression of FoxP3 Derived Peptides Presented within Class I MHC
2748 - Development of a Novel Virus-like Particle (VLP) Vaccine for Personalized B-Cell Lymphoma and Chronic Lymphocytic Leukemia Therapy

Levy, V.

2948 - Central Nervous System Involvement in Chronic Lymphocytic Leukemia: Diagnosis and Treatment in a Retrospective Cohort of Thirty Patients
4147 - Mechanisms of the BCR-Mediated CXCR4 Down-Regulation and Its Clinical Relevance in Chronic Lymphocytic Leukemia Progression

Lewalle, P.

4391 - Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Reduce Transplant Related Mortality and Improve Overall Survival in Haploidentical HSCT for Patients with AML and ALL, Using an Immunosuppressant-Free Transplant Regimen

Lewin, S. R.

4312 - The Frequency of Cytomegalovirus (CMV)-Specific CD8+ T Cells Distinguishes CMV Clinical Outcomes Following Hematopoietic Allogeneic Stem Cell Transplant: A Prospective Multicentre Cohort Study

Lewin-Koh, S. C.

2924 - Analytical Validation of Patient-Specific PCR-Based MRD Assessment for Use As a Primary Endpoint in CLL Clinical Trials

Lewis, C. A.

443 - Targeting MTHFD2 in Acute Myeloid Leukemia

Lewis, D. J.

1898 - A Retrospective Single Center Comparison of Cyclophosphamide Plus G-CSF Versus G-CSF Alone for Peripheral Blood Stem Cell (PBSC) Mobilisation Following First Line Therapy in Patients with Multiple Myeloma

Lewis, I. D.

1365 - Investigation of a Novel Cyclin-Dependent-Kinase (CDK) Inhibitor Cdki-73 As an Effective Treatment Option for MLL-AML
1644 - Rare and Common Germline Variants Contribute to Occurrence of Myelodysplastic Syndrome
3562 - RBC Alloimmunization Burden Is High in Regularly RBC-Transfused Myelodysplastic Syndrome (MDS) Patients: A Report from South Australian-MDS Registry

Lewis, I. D.

306 - Divergent Dynamics of Epigenetic and Genetic Heterogeneity in Relapsed Acute Myeloid Leukemia
815 - Early Treatment Intensification with R-ICE Chemotherapy Followed By Autologous Stem Cell Transplantation (ASCT) Using Zevalin-BEAM for Patients with Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) As Identified By Interim PET/CT Scan Performed after Four Cycles of R-CHOP-14: A Multicenter Phase II Study of the Australasian Leukaemia Lymphoma Study Group (ALLG)

Lewis, K. B.

3507 - Neither Factor VIII Nor the Putative F8B Protein Is Detectable in Human Peripheral Blood Mononuclear Cells

Lewis, M.

70 - Association of Hemoglobin S and C Traits with Kidney Disease in African Americans in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study

Lewis, P.

2085 - Health-Related Quality of Life in Lenalidomide and Bortezomib Treated Patients with Relapsed/Refractory Multiple Myeloma
2086 - Assessment of Multiple Myeloma Patient Preferences on Treatment Choices: An International Discrete Choice Study

Lewis, V. A.

741 - Copies of Donor Killer Immunoglobulin-like Receptor Genes and Motifs Titrate Natural Killer (NK) Cells' Functional Response to Epstein - Barr Virus Infections and Influence the Risk of Developing Post-Transplant Lymphoproliferative Disease (PTLD) after Allogeneic Hematopoietic Cell Transplantation

Ley, J. N.

1653 - Preclinical Activity of Splicing Modulators in U2AF1 Mutant MDS/AML

Ley, T. J.

1654 - Detection of Clonal Hematopoiesis in Cytopenic Patients Using Targeted Sequencing

Ley, T. J.

433 - Specific Patterns of DNA Remethylation in the Bone Marrow Cells of Dnmt3a Deficient Mice after Induced Expression of Wild Type Human DNMT3A
574 - Recurrent Somatic Genomic Alterations in Follicular NHL (FL) Revealed By Exome and Custom-Capture Next Generation Sequencing
610 - Dynamic Changes in the Clonal Structure of MDS and AML in Response to Epigenetic Therapy
686 - Non-Malignant Oligoclonal Hematopoiesis Commonly Follows Cytoreductive Chemotherapy in Adult De Novo AML Patients
689 - Dynamic Changes in Clonal Clearance with Decitabine Therapy in AML and MDS Patients
1254 - Loss-of-Function Mutations of MIR142 May Contribute to Leukemogenesis By Expanding the Pool of Myeloid-Biased HSCs
1862 - Reprogramming of Leukemic and Pre-Leukemic Cells from Primary Human De Novo Acute Myeloid Leukemia Samples into Induced Pluripotent Stem (iPS) Cells
2458 - DNMT3A R882H Can Cooperate with FLT3-ITD to Cause AML in Mice
3649 - Characterization of snoRNA Expression in Acute Myeloid Leukemia

Lezon-Geyda, K.

3337 - Molecular Characterization of 140 Patients in the Pyruvate Kinase Deficiency (PKD) Natural History Study (NHS): Report of 20 New Variants

Lhéritier, V.

1 - Addition of Rituximab Improves the Outcome of Adult Patients with CD20-Positive, Ph-Negative, B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL): Results of the Randomized Graall-R 2005 Study

Li, A. J.

358 - Restoration of the Bone Marrow Microenvironment Improves Hematopoietic Function in a Murine Model of Myelodysplastic Syndrome

Li, A. J.

3922 - Comprehensive Analyses of Genetic Features Identify Coordinate Signatures in Diffuse Large B-Cell Lymphoma

Li, A.

3471 - Therapeutic Plasma Exchange for the Treatment of Thrombotic Microangiopathy without Severe ADAMTS13 Deficiency: A Propensity Score-Matched Study

Li, B.

659 - Therapeutic Efficacy of Anfibatide in a Murine Model of Thrombotic Thrombocytopenic Purpura

Li, B.

2627 - De Novo Purine Biosynthesis in Drug Resistance and Tumor Relapse of Childhood ALL

Li, B.

410 - Dimethyl Fumarate Induces Fetal Hemoglobin in Sickle Cell Disease

Li, B.

2835 - A Novel Erythroid Regulator MLF1IP Promotes Proliferation in Mice By Regulating Cell Cycle
2874 - Colony-Forming Unit Cell (CFU-C) Assays in Myelodysplastic Syndrome
2876 - Impact of Megakaryocyte Morphology on Prognosis of Persons with Myelodysplastic Syndromes

Li, B.

2226 - The Characteristic of TCR Signaling Pathway in T Cell from Patients with Aplastic Anemia

Li, B.

241 - Clonal Tracking of the Geographic Distribution of Hematopoiesis in Nonhuman Primates Provides New Insights into HSPC Migration and Differentiation

LI, B.

783 - IL-8 and CXCR1 Remodel the Vascular Niche to Promote Hematopoietic Stem and Progenitor Cell Engraftment

Li, C.

234 - Pharmacological Inhibition of Hsp90 Destabilizes the Histone Methyltransferase Ezh2 in Alloreactive T Cells and Reduces Graft-Versus-Host Disease While Retaining Anti-Leukemic Effects in Mice

Li, C.

4480 - Neurocognitive, Psychosocial, and Quality of Life Outcomes in Adult Survivors of Childhood Non-Hodgkin Lymphoma in the St. Jude Lifetime (SJLIFE) Cohort

Li, C. K.

995 - Gene Expressional Profile of Neonatal Neutrophils in Response to Bacterial Lipopolysaccharide (LPS) and Possible Mechanism of Transcription Factor NR4A2 on the Immune Signal Cascade
1169 - The Tetraspanin CD9 Regulates Engraftment and Mobilization of Human CD34+ Hematopoietic Stem/Progenitor Cells and Modulates VLA-4 Activity
1576 - Switch to Subsequent Line of Treatment in Children and Adolescents with Chronic Myeloid Leukemia (CML) Treated with Imatinib: Experience of the International Registry for Chronic Myeloid Leukemia in Children and Adolescents (I-CML-Ped Study)
2371 - RGS1 and RGS13 Regulate SDF-1-Mediated Responses and Homing in Human Cord Blood CD34+ Hematopoietic Stem/Progenitor Cells

Li, C.

2082 - Cost Comparison of Hematopoietic Stem Cell Transplantation and Conventional Therapy for Patients with Thalassemia Major in China

Li, C.

640 - Genome Editing Recreates Hereditary Persistence of Fetal Hemoglobin in Primary Human Erythroblasts

Li, C.

1525 - Exposure-Response Analysis to Assist Selection of Dose and Treatment Duration for Polatuzumab Vedotin As a Single Agent or in Combination with Rituximab for the Treatment of B-Cell Lymphoma

Li, C.

896 - PDK1 Controls the Differentiation of Hematopoietic Stem Cells Via Modulating ROS Levels

Li, D.

3073 - Intermediate Filament (IF) Protein Vimentin Regulates T Cell Mediated Immune Response in Gvhd
3435 - Ibrutinib Treatment Modulates T Cell Activation and Polarization in Immune Response

Li, D.

4300 - Cancer Germline Antigen Specific CTL As Immunotherapy for Neuroblastoma

Li, D.

1870 - Impact of Erythropoietin Modulation Using Hyperbaric Oxygen on Umbilical Cord Blood CD34+ Cell Homing

Li, D.

2144 - Chronic Iron Overload Damage the Erythropoiesis in MDS Mouse By Increasing GDF11 and ROS Levels

Li, D.

1242 - Roles of Palmitoylation and the KIKK Membrane-Targeting Motif in Leukemogenesis By Oncogenic KRAS4A
2353 - IRF8 Regulates Cell Cycle of Hematopoietic Stem Cells

Li, F.

3470 - Functional Plasticity in CD4⁺CD25⁺CD127^- Treg Population in Primary Immune Thrombocytopenia

Li, G.

754 - Down-Regulation of TfR1 Increases Erythroid Precursor Enucleation and Hepatocyte Hepcidin Expression in ß-Thalassemic Mice
755 - Role of Pleckstrin 2 in Improved Erythropoiesis of Transferrin-Treated Beta-Thalassemic Mice
2846 - Characteristic Macrocytic Anemia, Ineffective Erythropoiesis, and Iron Overload in 5q- Mice and Effect of Exogenous Transferrin

Li, G. X.

2006 - CTLA-4 Polymorphisms and Haplotype Correlate with Survival and aGVHD after Allogeneic Stem Cell Transplantation from Related HLA-Haplotype-Mismatched Donor

Li, G.

3906 - ID3 Loss In Vivo Synergizes with MYC-Driven Oncogenesis in Burkitt Lymphoma

Li, H.

2702 - Initial Therapy for Mantle Cell Lymphoma with Abbreviated R-CHOP Followed By Y⁹⁰-Ibritumomab Tiuxetan: Ten Year Follow-up of the Phase 2 ECOG-ACRIN Study E1499

Li, H.

35 - The Use of Eicosanoids to Enhance Donor Cell Engraftment after in Utero Hematopoietic Cell Transplantation (IUHCT)
1871 - The Intravenous Route Optimizes Engraftment and Survival in the Murine Model of in Utero Hematopoietic Cell Transplantation (IUHCT)

Li, H.

1725 - Intratumoral Genetic Heterogeneity Provides Additional Prognostic Significance of the CLL Genomic Features
3879 - Different Prognostic Significance of a Panel Cytogenetic Aberrations Between Chronic Lymphocytic Leukemia and Other B-Cell Chronic Lymphoproliferative Disorders

Li, H. Q.

2759 - Biomarker Predictive Ibrutinib Response Using Profiled ABC-DLBCL Patient Derived Xenografts

Li, H.

2313 - Risk Factors Associated with Hospital-Acquired Venous Thromboembolism in the Pediatric Intensive Care Unit
3267 - Acute Care in the Emergency Department Differs before and after Transition for Adolescents and Young Adults with Sickle Cell Disease

Li, H.

2404 - Bone Marrow Failure and Developmental Delay Caused By Mutations in Poly(A)-Specific Ribonuclease
2416 - Copy Number Variants Underlying Inherited Bone Marrow Failure Syndromes
3621 - Molecular Analysis of Diamond Blackfan Anemia and Genotype-Phenotype Correlation: Experience from the Canadian Inherited Marrow Failure Registry

Li, H.

518 - Pre-Transplant R-Bendamustine Induces High Rates of Minimial Residual Disease in MCL Patients: Updated Results of S1106: US Intergroup Study of a Randomized Phase II Trial of R-HCVAD Vs. R-Bendamustine Followed By Autologous Stem Cell Transplants for Patients with Mantle Cell Lymphoma
1498 - Feasibility of Interim PET-Adapted Therapy in HIV-Positive Patients with Advanced Hodgkin Lymphoma (HL): Sub-Analysis of SWOG S0816 Phase 2 Trial
2678 - Genomic Alterations Important for the Prognosis in Patients with Follicular Lymphoma Treated on SWOG Study S0016
3803 - Report of the Relapsed/Refractory Cohort of SWOG S0919: A Phase 2 Study of Idarubicin and Cytarabine in Combination with Pravastatin for Acute Myelogenous Leukemia
3931 - A Phase I/II Trial of Vorinostat (SAHA) in Combination with Rituximab-CHOP in Patients with Newly Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL): SWOG S0806

Li, H.

1736 - Cirmtuzumab (UC-961), a First-in-Class Anti-ROR1 Monoclonal Antibody: Planned Interim Analysis of Initial Phase 1 Cohorts

Li, H.

4096 - Ruxolitinib Does Not Affect Bone Marrow Stromal Cell (BMSC) Clonogenicity and Growth but Interferes with JAK Signaling Under Inflammatory Conditions - Implications for Fibrosis in Myeloproliferative Diseases?

Li, H.

4413 - A Novel Recombinant Eklf-GATA1 Fusion Protein Reduces Erythrocytes Sickling in Human Erythroid Culture Model

Li, H.

2627 - De Novo Purine Biosynthesis in Drug Resistance and Tumor Relapse of Childhood ALL

Li, H.

4044 - Sokal Risk Score Is Superior to Hasford and EUTOS in Determining Survival Outcomes for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients

Li, H.

754 - Down-Regulation of TfR1 Increases Erythroid Precursor Enucleation and Hepatocyte Hepcidin Expression in ß-Thalassemic Mice
755 - Role of Pleckstrin 2 in Improved Erythropoiesis of Transferrin-Treated Beta-Thalassemic Mice

Li, H.

3480 - Lower Dosages of Intravenous Immunoglobulin (IVIg) in Treating Immune Thrombocytopenia with Long-Term Follow-up of Three Years

Li, J. S.

4236 - Lower Dose Lenalidomide and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma Who Are Aged 60 Years or over and/or at Risk of Myelosuppression: Final Analysis of the Revlite Trial and Matched Comparison to the MM009 and MM010 Trials

Li, J.

1364 - The Highly Potent Bromodomain (BRD) Inhibitor FV-281 Displays Preclinical Efficacy in Acute Myeloid Leukemia (AML)

Li, J.

3298 - Are There Differences in Treatment Patterns, Cost, and Quality Indicators By Site of Care for First Line Treatment for Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia (NHL/CLL)?

Li, J.

192 - A Prospective Phase II Study of Combination of Low Dose Lenalidomide and Dexamethasone for Patients with Newly Diagnosed POEMS Syndrome
1757 - A Paracrine Circuit Regulates Vascular Endothelial Growth Factor Production By Bone Marrow Plasma Cells in Patients with POEMS Syndrome
3870 - Evaluation of Clinicopathologic Characteristics and the BRAF V600E Mutation in Erdheim-Chester Disease Among Chinese Adults

Li, J. M.

1028 - Absence of Vasoactive Intestinal Peptide Signaling Significantly Enhances T Cell Survival Following MCMV Infection Via Increased Expression of Bcl-2 and Bcl-XL
1877 - Blocking VIP Signaling during Allogeneic Bone Marrow Transplantation Separates the Graft Versus Leukemia from Graft Versus Host Disease Activity of Donor CD8 T-Cells
3438 - T Cell Activation By Plasmacytoid Dendritic Cells Is Augmented By Inhibition of Vasoactive Intestinal Polypeptide Signaling: Implications for Cellular Immunotherapy

Li, J.

2745 - Ibrutinib Therapy in Rituximab-Refractory Patients with Waldenström's Macroglobulinemia: Initial Results from an International, Multicenter, Open-Label Phase 3 Substudy (iNNOVATE^TM)

Li, J.

379 - Distinct Patterns of Early Hematopoietic Reconstitution in Patients Receiving Notch Expanded Non HLA-Matched Off-the-Shelf Cord Blood Derived Hematopoietic Stem and Progenitor Cells

Li, J.

156 - HLA-Mismatched Microtransplantation Vs HLA-Matched Nonmyeloablative Transplantation for Acute Myeloid Leukemia in Intermediate-Risk: Comparable Survival but Avoids of Gvhd
220 - Tamibarotene Compared to All-Trans Retinoic Acid (ATRA) As Add-on to Arsenic Trioxide (ATO) in Subjects with Relapsed Acute Promyelocytic Leukemia (APL)
455 - Microtransplantation Improved Outcome in Elderly Acute Myeloid Leukemia Patients - Report from China Microtransplantation Cooperative Group
495 - Results from the International, Randomized Phase 3 Study of Ibrutinib Versus Chlorambucil in Patients 65 Years and Older with Treatment-Naïve CLL/SLL (RESONATE-2^TM)
1300 - Clinical Significance of Co-Existence of PHF6 and NOTCH1 mutations in Adult T-Cell Acute Lymphoblastic Leukemia
1318 - Additional Decitabine Did Not Improve Outcomes of Elder Acute Myeloid Leukemia Patients Based on Microtransplantation with Cytarabine and Anthracycline Chemotherapy
1473 - Prognostic Significance of Bone Marrow Infiltration Detected By PET-CT in Newly Diagnosed Diffuse Large B Cell Lymphoma
1617 - Clinical Significance of CSF3R, SRSF2 and SETBP1mutation in Chronic Neutrophilic Leukemia and Chronic Myelomonocytic Leukemia
3657 - Clinical Significance of WDR5 High Expression and Its Effect on Tumorigenesis in Adult Leukemia
3713 - Clinical Significance of High C-MYC and Low MYCBP2 Expression and Their Association with Ikaros Dysfunction in Adult Acute Lymphoblastic Leukemia
3895 - The Distinct Clinical Features and Prognosis of the CD10+MUM1+ and CD10-Bcl6-MUM1- Diffuse Large B-Cell Lymphoma
3918 - The Prognostic Value of Whole-Body Suvmax of Nodal and Extranodal Lesions Detected By 18F-FDG PET-CT in Patients with Extranodal NK/T-Cell Lymphoma
4148 - Differential Diagnosis of Lymphoid Enhancer-Binding Factor 1 Between Chronic Lymphocytic Leukemia and Other B-Cell Chronic Lymphoproliferative Disorders

Li, J.

159 - Distinct Roles of TET Proteins in the Regulation of Normal and Disordered Human Erythropoiesis
754 - Down-Regulation of TfR1 Increases Erythroid Precursor Enucleation and Hepatocyte Hepcidin Expression in ß-Thalassemic Mice

Li, J.

1035 - Activated, But Not Unactivated, αIIbβ3 Can Mediate Adhesion to Fibrinogen Lacking the γ Chain Dodecapeptide
1036 - Inverse Effects of EDTA on αIIbβ3-Mediated Adhesion to Immobilized Fibrinogen Versus the D98 Plasmin Fragment of Fibrinogen

Li, J.

888 - Neutrophil DREAM Is a Novel Regulator for Beta2 Integrin Function through NF-Kappab Signaling and Modulates Neutrophil Recruitment during Vascular Inflammation

Li, J.

235 - Platelet Surface PDI Controls the Ligand-Binding Function of Glycoprotein Ibalpha and Platelet-Neutrophil Interactions Under Thromboinflammatory Conditions
3383 - Co-Administration of Hydroxyurea and a Specific AKT2 Inhibitor Has Beneficial Effects on Acute Vaso-Occlusive Events and Survival in Sickle Cell Disease Mice

Li, J.

1585 - Age and Cost Are Associated with Patient Preference for Stopping Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia

Li, J.

2804 - Continued Treatment with Ruxolitinib Provides Additional Hematocrit Control and Spleen Volume Responses in Patients with PV Treated in the RESPONSE Study

Li, J.

1877 - Blocking VIP Signaling during Allogeneic Bone Marrow Transplantation Separates the Graft Versus Leukemia from Graft Versus Host Disease Activity of Donor CD8 T-Cells

Li, J.

3438 - T Cell Activation By Plasmacytoid Dendritic Cells Is Augmented By Inhibition of Vasoactive Intestinal Polypeptide Signaling: Implications for Cellular Immunotherapy

Li, J.

12 - Platelet GPIba Is Important for Thrombopoietin Production and Thrombopoietin-Induced Platelet Generation

Li, J.

220 - Tamibarotene Compared to All-Trans Retinoic Acid (ATRA) As Add-on to Arsenic Trioxide (ATO) in Subjects with Relapsed Acute Promyelocytic Leukemia (APL)

Li, K. L.

1365 - Investigation of a Novel Cyclin-Dependent-Kinase (CDK) Inhibitor Cdki-73 As an Effective Treatment Option for MLL-AML

Li, K.

995 - Gene Expressional Profile of Neonatal Neutrophils in Response to Bacterial Lipopolysaccharide (LPS) and Possible Mechanism of Transcription Factor NR4A2 on the Immune Signal Cascade
1169 - The Tetraspanin CD9 Regulates Engraftment and Mobilization of Human CD34+ Hematopoietic Stem/Progenitor Cells and Modulates VLA-4 Activity
2371 - RGS1 and RGS13 Regulate SDF-1-Mediated Responses and Homing in Human Cord Blood CD34+ Hematopoietic Stem/Progenitor Cells

Li, L.

283 - PD-1 Inhibits TCR Proximal Signaling By Sequestering SHP-2 Phosphatase and Facilitating Csk-Mediated Inhibitory Phosphorylation of Lck
3422 - Rap1-GTP Augments TGF-b-Mediated Signaling in T Lymphocytes Via a Mechanism Dependent on the b Chain of LFA-1 Integrin

Li, L.

312 - A Wilms Tumor 1 (WT1) Mutation Causes Myelodysplastic Syndrome in a Knock-in Mouse Model, and a Mixed Myelodysplastic/Myeloproliferative Neoplam in Double Knock-in Mice with WT1 and FLT3/ITD Mutations
790 - FLT3 Inhibition and Retinoid Signaling Overcome Stromal Protection to Target FLT3/ITD-Expressing Leukemia Stem Cells in the Bone Marrow Microenvironment
3668 - DOCK2 Regulates DNA Damage Response and Modulates the Sensitivity to Chemotherapeutic Agents in FLT3/ITD Leukemic Cells

Li, L.

2482 - Investigation of the Mechanism of Idelalisib Resistance in the Follicular Lymphoma WSU-Fsccl Cell Line
3697 - Combination of Idelalisib and ONO/GS-4059 in Lymphoma Cell Lines Sensitive and Resistant to BTK Inhibitors
3707 - Up-Regulation of the PI3K Signaling Pathway Mediates Resistance to Idelalisib

Li, L.

3278 - Beta-Thalassemia Treatment and Complications in Two Large US Insured Population Databases

Li, L.

929 - Infusion of Ex Vivo Expanded Allogeneic Cord Blood-Derived Natural Killer Cells in Combination with Autologous Stem Cell Transplantation for Multiple Myeloma: Results of a Phase I Study

Li, L.

405 - Fam210b Is Required for Optimal Cellular and Mitochondrial Iron Uptake during Erythroid Differentiation

Li, L.

3650 - Combined Loss of Tet1 and Tet2 Promotes B-Cell, but Not Myeloid Malignancies in Mice

Li, L.

51 - Knockdown (KD) of Mir-126 Expression Enhances Tyrosine Kinase Inhibitor (TKI)-Mediated Targeting of Chronic Myelogenous Leukemia (CML) Stem Cells
54 - Inhibition of CML Stem Cell Renewal By the Porcupine Inhibitor WNT974
792 - 8-Chloro-Adenosine Inhibits Molecular Poor-Risk Acute Myeloid Leukemia (AML) and Leukemic Stem Cells (LSC) Growth Via Novel RNA- and ATP-Directed Mechanisms: A Novel Therapeutic Approach for AML

Li, L.

1166 - Amino Acid Transporter X Is Required for Hematopoietic Stem Cell Maintenance through Regulating Specific Amino Acids Level
1860 - Chemoresistant Leukemia-Initiating Cell Expansion Is Inhibited By Targeting Oncogenic Self-Renewal
2377 - A Conserved Cis-Regulatory Retinoic Acid Responsive Element Is Essential for Maintenance of Primitive Hematopoietic Stem Cells through Regulation of Hoxb Cluster

Li, L.

3663 - Lmo2's Oncogenic Function in T-Cell Leukemia Requires Ldb1

Li, L. S.

3252 - Proxe: A Public Repository of Xenografts to Facilitate Studies of Biology and Expedite Preclinical Drug Development in Leukemia and Lymphoma
4001 - B and T-Cell Lymphoma Patient-Derived Xenografts Recapitulate Aspects of Disease Biology and Progression and Represent Novel Tools for Preclinical Drug Development

Li, M.

659 - Therapeutic Efficacy of Anfibatide in a Murine Model of Thrombotic Thrombocytopenic Purpura

Li, M.

814 - Brentuximab Vedotin with RCHOP As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL): Results from an Ongoing Phase 2 Study

Li, M.

1300 - Clinical Significance of Co-Existence of PHF6 and NOTCH1 mutations in Adult T-Cell Acute Lymphoblastic Leukemia

Li, M.

1011 - Increased Alternative Macrophage-2 (M2) Polarization with Trib1 Gene over Expression in Myeloma Patients with Progressive Disease and Jak2 Inhibitors Reduce M2 Polarization
1778 - Serum Levels of B-Cell Maturation Antigen Are Elevated in Waldenström's Macroglobulinemia Patients and Correlate with Disease Status and Conventional M-Protein and IgM Levels
1799 - Soluble Bcma in Myeloma Serum Binds Its Ligands BAFF and Prevents Normal Antibody Production in Multiple Myeloma Patients
2931 - Plasma B-Cell Maturation Antigen Levels Are Elevated and Correlate with Disease Activity in Patients with Chronic Lymphocytic Leukemia
2995 - Crosslinking of Fc Gamma-Rllb and Fc Epsilon-RI Binding Peptides Inhibits Osteoclast Formation in Multiple Myeloma through Inactivation of the ITAM Signaling Pathway

Li, M.

3243 - Characterization of Lentiviral Vector Derived Anti-Bcma CAR T Cells Reveals Key Parameters for Robust Manufacturing of Cell-Based Gene Therapies for Multiple Myeloma

Li, N.

1278 - Proteasome Inhibitor-Adapted Myeloma Cells That Lack Proteasome Gene Mutations Resist Highly Efficient Proteasome Inhibition and Show Proteomic Alterations That Suggest Complex Metabolic Changes

Li, N.

2090 - Nilotinib Vs Dasatinib As Second-Line Therapy in Patients with Philadelphia-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP) Who Are Resistant or Intolerant to Imatinib: A Cost-Effectiveness Analysis (CEA) Based on Real-World Data

Li, P.

1184 - Podocalyxin Negatively Regulates Stress Myelopoiesis, Directly Binds Rap-1A and Modulates Its G-CSF-Induced Activity
3595 - Utilizing Exosomes As Innovative Microrna Biomarkers and Targeted Drug-Delivery Vehicles in Acute Myeloid Leukemia

Li, P. C.

3864 - Monoamine Oxidase a (MAO A) Is Expressed Selectively in Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Li, P.

1287 - Gli1 Inhibitor GANT61 Exhibits Antitumor Efficacy in T-Cell Lymphoma Cells through Down-Regulation of p-STAT3 and SOCS3 Pathways

Li, P.

2664 - Aberrant Expression of IL-22 Receptor 1 and IL-22 Stimulation Increase the Activation of STAT3 and ERK1/2 in ABC-DLBCL Cells

LI, P.

4125 - Stimulation of the B-Cell Receptor (BCR) Induces Successive Activation of STAT3 and Nuclear Factor-Kappa-B in CLL Cells
4143 - P300 Acetylates STAT3 and Increases Its Constitutive Transcriptional Activity in CLL Cells

Li Pira, G.

195 - Children with Acute Leukemia Given Hematopoietic Stem Cell Transplantation (HSCT) from an HLA-Compatible Sibling, or an Unrelated Donor (UD) or an HLA-Haploidentical Relative after Alpha/Beta T-Cell Depletion Have a Comparable Outcome
1931 - Clinical Outcome after Adoptive Infusion of BPX-501 Cells (donor T cells transduced with iC9 suicide gene) in Children Given Alpha/Beta T-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (haplo-HSCT): Preliminary Results of a Phase I-II Trial
3093 - Immune Reconstitution after Adoptive Infusion of BPX501 Cells (donor T cells transduced with iC9 suicide gene) in Children Given Alpha/Beta T-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (haplo-HSCT): Preliminary Phenotypic and Functional Results of a Phase I-II Trial
4299 - BPX-501 Cells (donor T cells transduced with iC9 suicide gene) Are Able to Clear Life-Threatening Viral Infections in Children with Primary Immune Deficiencies Given Alpha/Beta T-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (haplo-HSCT)

Li, P.

35 - The Use of Eicosanoids to Enhance Donor Cell Engraftment after in Utero Hematopoietic Cell Transplantation (IUHCT)

Li, Q.

1943 - Effect of Transfusion of the Third Party Umbilical Cord Blood on Haplo-Identical Hematopoietic Stem Cell Transplantation

Li, Q.

556 - Identification of BCL6 As a Therapeutic Target in RAS-Driven Acute Lymphoblastic Leukemia

Li, Q.

2451 - Oncogenic Nras Grants Apoptosis Resistance to Hematopoietic Stem Cells

Li, Q. Z.

1029 - Circadian Clock Protein CRY Controls B-Cell Intrinsic Tolerance

Li, R.

- Best of ASH in Hemostasis and Thrombosis

Li, R.

605 - TGFb1 Antagonist Inhibits Fibrosis in a Murine Model of Myelofibrosis
751 - Rap-536 (Murine ACE-536/Luspatercept) Inhibits Smad2/3 Signaling and Promotes Erythroid Differentiation By Restoring GATA-1 Function in Murine b-Thalassemia

Li, R.

1607 - Survival and Prognosis of Chinese Patients with Post-Polycythemia Vera Myelofibrosis
3599 - Cell Autonomous Defects of Mesenchymal Stem Progenitor Cells of Patients with CMML Contribute to Impaired Hematopoietic Supportive Activity

Li, R.

841 - Leukemia-Associated Cohesin Mutants Dominantly Enforce Stem Cell Programs and Impair Human Hematopoietic Progenitor Differentiation

Li, R.

4105 - A Germline Mutation in ERBB3 Predisposes to Inherited Erythroid Myelodysplasia/Erythroleukemia

Li, R.

3550 - Screening for Occult Malignancy Following First Unprovoked VTE: A Single Centre Experience

Li, R.

503 - Defining Primary Marrow Microenvironment-Induced Synthetic Lethality and Resistance for 2,684 Approved Drugs Across Molecularly Distinct Forms of Multiple Myeloma

Li, S.

1458 - Predictive Value of Interim ¹⁸f-FDG PET-CT Scans on Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Study

Li, S.

1441 - Differences in Outcome of Patients with Syncytial Variant Hodgkin Lymphoma (HL) Compared with Typical Nodular Sclerosis HL
3909 - MYC/BCL2 Double Hit Lymphoma: What Really Matters

Li, S.

306 - Divergent Dynamics of Epigenetic and Genetic Heterogeneity in Relapsed Acute Myeloid Leukemia

Li, S.

1240 - Mircrorna-550 Functions As a Critical Tumor Suppressor in Acute Myeloid Leukemia
3632 - Uncover TET1 Targets in MLL-Rearranged Leukemia
3667 - Overexpression and Knockout of Mir-126 Both Promote Leukemogenesis through Targeting Distinct Gene Signaling
3784 - Targeted Treatment of FLT3-Overexpressing Acute Myeloid Leukemia with MiR-150 Nanoparticles Guided By Conjugated FLT3 Ligand Peptides

Li, S.

3698 - Exploring Relationships of Exposure, Pharmacodynamic Changes and Gene Expression to Clinical Outcome in Adults with Acute Lymphoblastic Leukemia Receiving Inotuzumab Ozogamicin

Li, S.

593 - Disruption of the mTOR-eIF4F Axis By Selectively Targeting PI3Kdelta and Proteasome Potently Inhibits Cap Dependent Translation of c-Myc in Aggressive Lymphomas
3003 - IKZF1 Mutation Mediate Resistance to IMiDs in Human Hematopoietic Stem Cells
3009 - Mechanism Study of Matrix Metalloproteinase 13 Effects on Osteoclast Activation and Lytic Bone Lesions in Multiple Myeloma

Li, S.

864 - Hematopoietic Cell Transplantation with or without Sorafenib Maintenance for Patients with FLT3-ITD Acute Myeloid Leukemia in CR1
1930 - Phase I Multicenter Trial of Brentuximab Vedotin for Steroid Refractory Acute Graft-Vs.-Host Disease (GVHD)

Li, S.

38 - Rate of Bleeding-Rated Episodes (BREs) in Elderly Patients with Primary Immune Thrombocytopenia (ITP): A Population-Based Retrospective Cohort Study Using Medicare 20% Sample Data

Li, S.

2906 - Comprehensive Bulk and Single Cell Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia

Li, S.

2441 - Up-Regulation of Flt3 Is a Passive Event in Hoxa9/Meis1-Induced Acute Myeloid Leukemia

Li, T. N.

3918 - The Prognostic Value of Whole-Body Suvmax of Nodal and Extranodal Lesions Detected By 18F-FDG PET-CT in Patients with Extranodal NK/T-Cell Lymphoma

Li, T.

264 - 4SCAR19 Chimeric Antigen Receptor-Modified T Cells As a Breakthrough Therapy for Highly Chemotherapy-Resistant Late-Stage B Cell Lymphoma Patients with Bulky Tumor Mass

Li, W.

4505 - Interim Results of a Multi-Center Observational Study of Current Treatment Patterns for Patients with Severe Aplastic Anemia (SAA), Very Severe Aplastic Anemia (VSAA) and Transfusion-Dependent Non-Severe Aplastic Anemia (TD-NSAA) in China

Li, W.

2232 - Cadherin-6 Forms a Functional Adhesion Complex with Alpha-Catenin and Beta-Catenin in Platelets and Is Required for Platelet Aggregation and Thrombus Formation

Li, W.

1301 - Nilotinib Combined with Multi-Agents Chemotherapy for Adult Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of a Prospective Study from a Single Center

Li, W.

965 - Vessel Geometry Interacts with Red Blood Cell Stiffness to Promote Endothelial Dysfunction in Sickle Cell Disease

Li, W.

2450 - Myc-Directed Suppression of Autophagy Provides Therapeutic Vulnerabilities Targeting Amino Acid Homeostasis

Li, W.

1802 - Metabolomic, Proteomic and Genomic Profiling Identifies Biomarakers of Sensitivity to Glutaminase Inhibitor CB-839 in Multiple Myeloma

Li, W.

3590 - Thyroid Hormone Receptor Beta and NCOA4 Regulate Terminal Erythrocyte Differentiation

Li, W.

1330 - The JAK Inhibitor Ruxolitinib Is Effective in Treating T Cell Acute Lymphoblastic Leukemia with Gain of Function Mutations in IL-7R Alpha

Li, X.

3349 - Alu-Element Insertion in Pklr Gene As a Novel Cause of Severe Hereditary Nonspherocytic Hemolytic Anemia

Li, X.

1651 - DHX9 Mutations Are Identified As a Novel Recurrent Event in Patients with Myelodysplastic Syndromes and Closely Related to Bone Marrow Failure
1660 - EZH2-Mediated Activation of Serine Biosynthetic Pathway Is Critical for Resistance of Clonal Cells to Stress-Related Apoptosis in Low-Grade Myelodysplastic Syndrome
1689 - A Primary Study of the Gene Mutations in Predicting Treatment Response to Decitabine in Patients with MDS
2857 - Activation of Notch-Hes Signaling Pathway Impairs Osteogenic Differentiation and Hematopoietic Stem Cell-Supporting Capacitiy of Mesenchymal Stromal Cells Derived from Myelodysplastic Syndromes Patients

Li, X. M.

2323 - A Randomized, Double Blind, Placebo-Controlled, Cross-over Study to Evaluate the Haemostatic Effects of Three Commonly Used Traditional Herbal Medicines, (Curcuma Longa, Angelicae Sinensis and Panax Ginseng) and Their Interactions with Aspirin

Li, X.

3691 - Molecular Mechanism and Optimal Treatment Strategy in Acute Myeloid Leukemia with Resistance to Drugs and Radiation By NVP-LED225

Li, X.

4172 - Exposure-Response of Idelalisib Administered in Combination with Ofatumumab for the Treatment of Relapsed Chronic Lymphocytic Leukemia

Li, X.

37 - Effect of Romiplostim on Health-Related Quality of Life in Children with Immune Thrombocytopenia and Associated Burden in Their Parents: Results from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
2066 - Annual Patient and Caregiver Burden of Oncology Clinic Visits for Granulocyte-Colony Stimulating Factor (G-CSF) Therapy in the United States (US)
3274 - Cost of Bleeding-Related Episodes (BREs) in Adult Patients with Primary Immune Thrombocytopenia (ITP): A Population-Based Retrospective Cohort Study of Administrative Claims Data for Commercial Payers in the United States
4461 - Cost per Treatment Success of Thrombopoietin Receptor Agonists Vs "Watch and Rescue" Strategy for Treating Adult Non-Splenectomized Patients with Chronic Immune Thrombocytopenia: A US Payer Perspective

Li, X.

381 - Inhibition of Both Activated p38 MAPK and mTOR C1 Potentiates the Effect of SR1 on Promotion of Hematopoietic Stem Cell Expansion Ex Vivo

Li, X.

1287 - Gli1 Inhibitor GANT61 Exhibits Antitumor Efficacy in T-Cell Lymphoma Cells through Down-Regulation of p-STAT3 and SOCS3 Pathways

Li, X.

1458 - Predictive Value of Interim ¹⁸f-FDG PET-CT Scans on Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Study
2690 - RCHOP-21 Vs. RCHOP-14 for the Treatment of Newly Diagnosed Diffuse Large B Cell Lymphoma: A Prospective Randomized Phase III Clinical Trial from Cswog

Li, X.

3956 - A Prospective, Self-Controlled and Randomized Study about the Optimal Timing of Leucovorin Rescue after High Dose Methotrexate Management

Li, Y.

494 - Safety and Efficacy of a Combination of Venetoclax (GDC-0199/ABT-199) and Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia - Results from a Phase 1b Study (GP28331)
829 - Updated Safety and Preliminary Efficacy Data from a Phase 1b Study Combining Venetoclax (GDC-0199, ABT-199) with Bendamustine/Rituximab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia

Li, Y.

220 - Tamibarotene Compared to All-Trans Retinoic Acid (ATRA) As Add-on to Arsenic Trioxide (ATO) in Subjects with Relapsed Acute Promyelocytic Leukemia (APL)

Li, Y.

2509 - Evaluation of the Pharmacokinetics of AG-221, a Potent Mutant IDH2 Inhibitor, in Patients with IDH2-Mutation Positive Advanced Hematologic Malignancies in a Phase 1/2 Trial
3036 - A Phase 1, Multicenter Study of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Patients with Proteasome Inhibitor Exposed and Lenalidomide-Refractory Myeloma (Trial MM-005)

Li, Y.

1301 - Nilotinib Combined with Multi-Agents Chemotherapy for Adult Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of a Prospective Study from a Single Center

Li, Y.

4202 - Role of PET/CT As a Measure of Minimal Residual Disease (MRD) Negativity Among Patients with Myeloma Post Autologous Stem Cell Transplant (ASCT)

Li, Y.

708 - Synergistic Co-Targeting of BTK and BCL2 in Mantle Cell Lymphoma

Li, Y.

2226 - The Characteristic of TCR Signaling Pathway in T Cell from Patients with Aplastic Anemia
4019 - The Long Non-Coding RNA NEAT1 Modulates Imatinib-Induced Apoptosis in CML Cells

Li, Y.

3257 - Risk of Febrile Neutropenia (FN) in Select Myelosuppressive Chemotherapy Regimens

Li, Y.

548 - Efficacy and Safety Results of Prolong-9FP Clinical Program of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Treated Patients with Hemophilia B

Li, Y.

3643 - TET2 Downregulation Leads to AML Cells Sensitive to Decitabine

Li, Y.

1546 - Sézary Syndrome: Clinicopathological and Immunophenotypical Characteristics and Outcomes

Li, Y.

947 - Hepcidin and Atoh8 mRNA Expression Are Decreased in Murine Models of Hemochromatosis However Hepcidin Expression Is Unaffected By Atoh8 Knockout
948 - Peroxisome Proliferator-Activated Receptor Alpha Contributes to Hepcidin up-Regulation in Mice during Fasting

Li, Y.

370 - Genomic Landscape and Its Prognostic Implications in Multiple Myeloma Using a Targeted Sequencing Approach
554 - A Crispr/Cas9 Drop-out Screen Identifies Genome-Wide Genetic Valnerubilities in Acute Myeloid Leukaemia

Li, Y.

528 - A Study of Predictors of Clinical Outcomes and Healthcare Utilization in Children with Sickle Cell Disease Undergoing Allogeneic Hematopoietic Cell Transplantation
530 - Racial Disparities in Pediatric Acute Myeloid Leukemia during Induction

Li, Y.

3221 - Minimal Residual Disease (MRD) By Either Flow Cytometry or Cytogenetics Prior to an Allogeneic Hematopoietic Cell Transplant (allo-HCT) Predicts Poor Acute Myeloid Leukemia (AML) Outcomes
3852 - A New Model to Predict Remission Status in Acute Myeloid Leukemia (AML) Patients Based on Day 14 Bone Marrow (D14 BM) Biopsy

Li, Y.

2854 - Increased Expression of Circulating Mir-22 in the Peripheral Blood of Patients with Myelodysplastic Syndromes Was Associated with Poorer Prognosis

Li, Y.

4249 - Scattome: A Single-Cell Analysis of Targeted Transcriptome Program to Predict Drug Sensitivity of Single Cells within Human Myeloma Tumors

Li, Y. C.

264 - 4SCAR19 Chimeric Antigen Receptor-Modified T Cells As a Breakthrough Therapy for Highly Chemotherapy-Resistant Late-Stage B Cell Lymphoma Patients with Bulky Tumor Mass

Li, Y.

565 - Efficient Termination of CD123-Redirected Chimeric Antigen Receptor T Cells for Acute Myeloid Leukemia to Mitigate Toxicity
798 - Potent Efficacy of Combined PI3K/mTOR and JAK or SRC/ABL Inhibition in Philadelphia Chromosome-like Acute Lymphoblastic Leukemia

Li, Y.

171 - Next Generation Sequencing Identifies a Novel Subset of Non-Down Syndrome Acute Megakaryoblastic Leukemia Characterized By Chimeric Transcripts Involving HOX Cluster Genes
693 - Expression of an Oncogenic ERG isoform Characterizes a Distinct Subtype of B-Progenitor Acute Lymphoblastic Leukemia
694 - Mixed Lineage Leukemia Rearrangements (MLL-R) Are Determinants of High Risk Disease in Homeobox A (HOXA)-deregulated T-Lineage Acute Lymphoblastic Leukemia: A Children's Oncology Group Study
2618 - High Frequency and Poor Outcome of Ph-like Acute Lymphoblastic Leukemia in Adults

Li, Y.

3853 - Epigenetic Modifying Drugs Inhibit MDS/AML Cell Growth through Selective Disruption of the Interactions Between Lineage-Determining Transcription Factors and DNA/Histone Modifiers

Li, Y.

3667 - Overexpression and Knockout of Mir-126 Both Promote Leukemogenesis through Targeting Distinct Gene Signaling

Li, Y.

2439 - CDKN2 Gene Deletion Impair Prognosis in Adult Ph+ Acute Lymphoblastic Leukemia Even in Tyrosine Kinase Inhibitors Era
4036 - Therapeutic Immune Monitoring of Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors: Focus on CD4⁺CD25⁺t Cells

Li, Y.

833 - Outcome of Ibrutinib Treatment by Baseline Genetic Features in Patients with Relapsed or Refractory CLL/SLL with del17p in the Resonate-17 Study

Li, Y.

3797 - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Patient-Derived Xenografts Are Faithful Genomic and Phenotypic Models of Primary Leukemia and Respond to the IL3 Receptor Targeting Agent SL-401 In Vivo

Li, Z.

3632 - Uncover TET1 Targets in MLL-Rearranged Leukemia
3667 - Overexpression and Knockout of Mir-126 Both Promote Leukemogenesis through Targeting Distinct Gene Signaling
3784 - Targeted Treatment of FLT3-Overexpressing Acute Myeloid Leukemia with MiR-150 Nanoparticles Guided By Conjugated FLT3 Ligand Peptides

Li, Z.

3854 - Identification of Genetic Hereditary Predisposition to Hematologic Malignancies By Clinical Next-Generation Sequencing

Li, Sr., Z.

1725 - Intratumoral Genetic Heterogeneity Provides Additional Prognostic Significance of the CLL Genomic Features
1784 - Clonal Evolution Paths Significantly Impact the Outcome of Myeloma
3879 - Different Prognostic Significance of a Panel Cytogenetic Aberrations Between Chronic Lymphocytic Leukemia and Other B-Cell Chronic Lymphoproliferative Disorders
4186 - Serum High Expression of Micorna-214 Is a Novel Predictor for Myeloma Bone Disease and Poor Prognosis

Li, Z.

1157 - Developmental Stage and Sex-Specific Role of IGF/IGF1R Signaling in Hematopoietic Stem and Progenitor Cells

Li, Z.

3650 - Combined Loss of Tet1 and Tet2 Promotes B-Cell, but Not Myeloid Malignancies in Mice

Li, Z.

1166 - Amino Acid Transporter X Is Required for Hematopoietic Stem Cell Maintenance through Regulating Specific Amino Acids Level
2377 - A Conserved Cis-Regulatory Retinoic Acid Responsive Element Is Essential for Maintenance of Primitive Hematopoietic Stem Cells through Regulation of Hoxb Cluster

Li, Z.

4234 - Insulin Growth Factor 1 Receptor (IGF-1R) Inhibitor, Linsitinib (OSI-906) in Combination with Bortezomib and Dexamethasone Demonstrates Favorable Safety Prolife and Clinical Activity in Patients with Relapsed/Refractory Multiple Myeloma

Li, Z.

1521 - Clinical Outcome of P-Gemox ( Pegaspargase, Gemcitabine, Oxaliplatin ) for the Patients with Newly Diagnosed Stage III/IV or Relapsed/Refractory Extranodal Natural Killer/T Cell Lymphoma
3936 - Longterm Outcome of Induction Chemotherapy of P-Gemox Regimen Followed By Extensive Involved-Field Radiotherapy(EIFRT) for Newly Diagnosed Stage I/II Extranodal Natural Killer/T-Cell Lymphoma---a Single Center Experience

Li, Z.

1326 - Targeting Rac-Gtpases Reverses Stroma-Induced Resistance to Notch and mTOR-Inhibition in Acute T-Cell Leukemia
1383 - The Novel FLT3-N676K Mutant Induces Acute Leukemia Independently of the Inv(16) Chimeric Gene CBFB-MYH11

Li, Z.

1839 - Appropriate Dose Adjustment of Dexamethasone Does Not Compromise Outcomes in Relapsed Refractory Multiple Myeloma

Li, Z.

145 - Targeting the Human Notch 2-BCR Axis: A Driver of B-Cell Hyper-Responsiveness in Active Chronic Graft-Versus Host Disease (cGVHD)
1857 - A Phase I-II Study of the Combination of Bendamustine and Pomalidomide with Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma.

Li, Z.

74 - Blvrb Mutation Induces Thrombocytosis Via Redox Dysregulation in the Heme Degradation Pathway

Liakos, C.

4188 - Characterization of a PERK Kinase Inhibitor with Anti-Myeloma Activity

Lian, L.

418 - Platelet Pitp-Alpha Promotes Thrombin Generation and the Dissemination of Tumor Metastasis, but Has Minimal Effect on Vascular Plug Formation

Liang, D. C.

171 - Next Generation Sequencing Identifies a Novel Subset of Non-Down Syndrome Acute Megakaryoblastic Leukemia Characterized By Chimeric Transcripts Involving HOX Cluster Genes
3726 - Outcomes Following Discontinuation of E. coli-asparaginase upon Severe Allergic Reactions in Children with Acute Lymphoblastic Leukemia
4120 - Clonal Evolution of Gene Mutations Involving DNA Methylation in the Progression of CMML to Secondary AML

Liang, H. P.

216 - Coagulation Factor V Mediates Inhibition of Tissue Factor Signaling By Activated Protein C

Liang, H.

425 - Genetic Absence of Thrombin Receptor Par4 Overcomes the Obligate Requirement of EPCR in Mouse Placenta

Liang, H.

285 - Blocking Specific CD44 Splicing Variant Isoform Inhibits the Differentiation of Th-2 Cells through Interfering with IL-4/IL-4R Signaling Pathway

Liang, J.

1394 - Exome Sequencing Identifies Highly Recurrent Somatic GATA2 and CEBPA Mutations in Acute Erythroid Leukemia

Liang, J. H.

1473 - Prognostic Significance of Bone Marrow Infiltration Detected By PET-CT in Newly Diagnosed Diffuse Large B Cell Lymphoma
3895 - The Distinct Clinical Features and Prognosis of the CD10+MUM1+ and CD10-Bcl6-MUM1- Diffuse Large B-Cell Lymphoma
3918 - The Prognostic Value of Whole-Body Suvmax of Nodal and Extranodal Lesions Detected By 18F-FDG PET-CT in Patients with Extranodal NK/T-Cell Lymphoma

Liang, R.

756 - Loss of Foxo3 Reduces Erythroblast Apoptosis and Enhances RBC Production in Beta-Thalassemic Mice

Liang, R.

3945 - A Phase II Study of MESA Chemotherapy for Newly Diagnosed, Relapsed or Refractory Extranodal Natural Killer (NK)/T-Cell Lymphoma, Nasal Type: A Multicenter Trial of Northern-West of China

Liang, W.

3121 - Defibrotide for the Treatment of Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome with/without Multi-Organ Dysfunction Following Chemotherapy: Results from an Ongoing Expanded Access Program

Liang, W.

722 - Identification of Initiating Trunk Mutations and Distinct Molecular Subtypes: An Interim Analysis of the Mmrf Commpass Study
2973 - In-Depth Molecular Profiling of Multiple Myeloma in African Americans

Liang, X.

4099 - The JAK1/2 Inhibitor Momelotinib Does Not Inhibit Thiamine Uptake in Vitro

Liang, Y.

141 - Integrative Genome-Wide Analysis of RNA Binding and Splicing Reveals Complex Loss and Gain of Function Alterations By SRSF2 P95 Mutations in Myelodysplasia

Liang, Y.

4466 - Comparative Cost Analysis of Therapy in Sickle Cell Anemia: Supportive Care Vs. Bone Marrow Transplant

Liang, Y. M.

4505 - Interim Results of a Multi-Center Observational Study of Current Treatment Patterns for Patients with Severe Aplastic Anemia (SAA), Very Severe Aplastic Anemia (VSAA) and Transfusion-Dependent Non-Severe Aplastic Anemia (TD-NSAA) in China

Liang, Y.

699 - The Role of PIM1 in the Ibrutinib-Resistant ABC Subtype of Diffuse Large B-Cell Lymphoma
2642 - Mutation Impact of Targeted Genes in Diffuse Large B-Cell Lymphoma Patients Treated with Ibrutinib

Liang, Z. Y.

3870 - Evaluation of Clinicopathologic Characteristics and the BRAF V600E Mutation in Erdheim-Chester Disease Among Chinese Adults

Liao, C.

3990 - Selective MEK Inhibition with AZD-6244 (selumetinib) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A University of Chicago Phase II Consortium Trial

Liao, J.

2082 - Cost Comparison of Hematopoietic Stem Cell Transplantation and Conventional Therapy for Patients with Thalassemia Major in China

Liao, W.

1238 - Restoration of CCAAT Enhancer Binding Protein Alpha P42 Overcomes Myeloid Differentiation Block and All-Trans Retinoic Acid Resistance in Human Acute Promyelocytic Leukemia NB4-R1 Cells

Liao, W.

1247 - Integrative Analysis of the Mutational Landscape of Mouse and Human AML Identifies Functionally Relevant Leukemia Disease Alleles

Liaw, P. C.

2336 - Biological Rational for the Use of Heparin in Septic Shock: Translational Data from the Halo Pilot RCT

Libao, B.

3990 - Selective MEK Inhibition with AZD-6244 (selumetinib) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A University of Chicago Phase II Consortium Trial

Libby, III, E. N.

1540 - Preliminary Results from a Phase 1/2, Open-Label, Dose-Escalation Clinical Trial of IMO-8400 in Patients with Relapsed or Refractory Waldenstrom's Macroglobulinemia

Liberati, A. M.

1760 - Minimal Residual Disease Detection By Multiparametric Flow Cytometry in Newly Diagnosed Multiple Myeloma Patients: A Preliminary Analysis of the EMN02/HO95 MM Study
2735 - The Combination of Weekly Infusion of Rituximab and Bortezomib Is Effective in Relapsed or Refractory Indolent and Mantle Cell Lymphoma: Long-Term Results of Phase II BRIL06 Study of the Fondazione Italiana Linfomi (FIL)
2946 - Fludarabine, Cyclophosphamide, Ofatumumab (FC-O2) As Front-Line Treatment for Young and Fit Patients with Chronic Lymphocytic Leukemia (CLL): Preliminary Results of the Prospective Phase 2 LLC0911 Gimema Study
3946 - Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice, the Lenamant Study

Liberati, A. M.

91 - Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Results on Efficacy, Safety and Quality of Life of an International, Multicenter Prospective, Randomized, Trial
392 - Autologous Transplantation Versus Cyclophosphamide-Lenalidomide-Prednisone Followed By Lenalidomide-Prednisone Versus Lenalidomide Maintenance in Multiple Myeloma: Long-Term Results of a Phase III Trial
581 - Remarkable Clinical Efficacy, Stem Cell Mobilization Activity and Good Toxicity Profile of the Novel Begev Regimen (Bendamustine, Gemcitabine And Vinorelbine) Used As Salvage Therapy Prior to Autologous Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma
1828 - Weekly Carfilzomib, Cyclophosphamide and Dexamethasone (wCCyd) in Elderly Newly Diagnosed Multiple Myeloma Patients: Results of a Phase 2 Study
2799 - Safety and Efficacy of Ruxolitinib in an 1869-Patient Cohort of JUMP: An Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis
4071 - Clinical and Biological Features in Patients with Ph-Negative Chronic Myeloproliferative Neoplasm Showing Different Molecular Pattern. Comparative Study in 596 Patients of the Registro Italiano Trombocitemie (RIT)

Libernays, E.

3415 - Pain Experiences in Children with Sickle Cell Disease in the Era of Hydroxyurea

Libster, D.

3954 - Favorable Outcome of Primary Mediastinal Large B-Cell Lymphoma Patients Treated with Sequential R-CHOP/R- ICE Regimen Omitting Radiation

Licht, C.

2252 - Eculizumab Prevents Thrombotic Microangiopathy: Long-Term Follow-up Study of Patients with Atypical Hemolytic Uremic Syndrome

Licht, J. D.

437 - Allele-Specific Crispr Targeting Reveals Epigenetic and Phenotypic Effects of a MMSET Gain of Function Mutation Found in Relapsed Acute Lymphoblastic Leukemia
3251 - High Throughput Screening Identifies Potential Inhibitors of WHSC1/MMSET, a Histone Methyltransferase Oncoprotein in Multiple Myeloma and Acute Lymphocytic Leukemia

Lichtenberg, J.

2383 - Comparison of Expression and Epigenetic Profiles in Human and Mouse Erythropoiesis and Megakaryopoiesis Using a Systems Biology Model

Lichtenegger, F. S.

3677 - Identifying Immune Resistance Mechanisms to CD33/CD3 BiTE® Antibody Construct (AMG 330) Mediated Cytotoxicity
3805 - Next-Generation Dendritic Cell Vaccination in Postremission Therapy of AML: Results of a Clinical Phase I Trial

Lichtenstein, E.

586 - The Combination of Brentuximab Vedotin (Bv) and Bendamustine (B) Demonstrates Marked Activity in Heavily Treated Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) and Anaplastic Large T-Cell Lymphoma (ALCL): Results of an International Multi Center Phase I/II Experience
1280 - Translational Focus on Targeting HDAC6 with Ricolinostat Confirms Potent Activity in Preclinical Models of Lymphoma and a Favorable Toxicity Profile in Patients with Relapsed or Refractory Lymphoma
1282 - Targeting Epigenetic Operations with HDAC Inhibitor and Hypomethylating Drugs in Combination Exhibit Synergy in Preclinical and Clinical Experiences in Drug Resistant T-Cell Lymphoma (TCL): A Translational Focus on Doublet Development

Lichtenstein, R.

586 - The Combination of Brentuximab Vedotin (Bv) and Bendamustine (B) Demonstrates Marked Activity in Heavily Treated Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) and Anaplastic Large T-Cell Lymphoma (ALCL): Results of an International Multi Center Phase I/II Experience
1282 - Targeting Epigenetic Operations with HDAC Inhibitor and Hypomethylating Drugs in Combination Exhibit Synergy in Preclinical and Clinical Experiences in Drug Resistant T-Cell Lymphoma (TCL): A Translational Focus on Doublet Development

Lichtensztajn, D. Y.

1323 - Predictors of Early Death and Survival Among Children, Adolescents and Young Adults with Acute Myeloid Leukemia in California, 1988-2011: A Population-Based Study

Lichtensztejn, D.

177 - Disruption of Direct 3-Dimensional (3D) Telomere-TRF2 (Telomere Related Factor 2) Interaction Is a Hallmark of Primary Hodgkin (H) and Reed-Sternberg (RS) Cells

Lichter, P.

2436 - Progressive Epigenetic Programming during B Cell Maturation Is Reflected in a Continuum of Epigenetic Disease Phenotypes in Chronic Lymphocytic Leukemia

Lichy, D.

3399 - Altered Oxygenation, Vascular and Ischemic Pain Responses in Adults with Sickle Cell Anemia

Lico, A.

3876 - Phenotypic Heterogeneity of Chronic Lymphoproliferative Disorder of NK Cells

Liddy, C.

42 - Content, Utilization and Impact of a Hematology e-Consultation Service

Lidke, D.

4092 - A Recombinant Antibody to Siglec-8 Shows Selective ADCC Activity Against Mast Cells from Systemic Mastocytosis Patients

Lidonnici, M. R.

3069 - Intrinsic Molecular Features of Human Hematopoietic Stem Cells from Different Sources Define Their Specific Functional Properties

Lieber, M. R.

166 - Exposure to Inflammatory Immune Responses As Driver of Clonal Evolution in Childhood Acute Lymphoblastic Leukemia

Lieberman, L. D.

3569 - Post-Transfusion Fevers and Post-Reaction Culture Practices at a Large Academic Hospital Transfusion Service: Quality of Information and Calculated Bacterial Contamination Event Rates

Lieberman, S.

3072 - RIG-I-Induced Type I IFNs Promote Regeneration of the Intestinal Stem Cell Compartment during Acute Tissue Damage

Liebich, A.

224 - Characteristics and Prognosis of AML Patients with or without a History of Clonal Hematopoiesis
2836 - Patient Derived Xenotransplantation Model of Atypical Chronic Myeloid Leukemia (aCML)

Liede, A.

4501 - Utilization Patterns of Bone-Targeting Agents Among Patients with Multiple Myeloma: Analysis of Real-World Data

Liedtke, M.

3803 - Report of the Relapsed/Refractory Cohort of SWOG S0919: A Phase 2 Study of Idarubicin and Cytarabine in Combination with Pravastatin for Acute Myelogenous Leukemia

Liem, R. I.

1109 - Risk Factors for Neonatal Thrombosis in the Neonatal Intensive Care Unit -a Case Control Study
3417 - Opioid Prescription Practices at Discharge and 30-Day Returns in Children with Sickle Cell Disease and Pain
- Understanding Promotion and Tenure

Lienhart, A.

2298 - Efficacy and Safety of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Treated Patients with Hemophilia B Undergoing Major Orthopedic Surgeries

Lierman, E.

2837 - MPL p.S204P Is a Recurrent Mutation in Essential Thrombocythemia

Lieschke, G. J.

1180 - Zbtb11, an Evolutionarily Conserved Pu.1-Regulated Transcriptional Repressor of TP53, Is Required for Neutrophil Development

Liesner, R.

3520 - Long-Term Efficacy of rFVIIIFc Prophylaxis in Pediatric, Adolescent, and Adult Subjects with Target Joints and Severe Hemophilia A

Liesveld, J. L.

685 - Distinct Properties of Leukemia Stem Cells in Primary Refractory Acute Myeloid Leukemia
4266 - A Role for IL1RAP in Acute Myelogenous Leukemia Stem Cells Following Treatment and Progression

Lieuw, K.

3672 - Cbl^Y371H Transgene Combined with Hematopoietic Deletion of the Endogenous c-Cbl Gene Results in GM-CSF Hypersensitivity and Leukocytosis

Lievonen, J.

3006 - Stratification of Multiple Myeloma Patients Based on Ex Vivo Drug Sensitivity and Identification of New Treatments for Patients with High-Risk Relapsed/Refractory Disease

Light, D. R.

410 - Dimethyl Fumarate Induces Fetal Hemoglobin in Sickle Cell Disease
2271 - Prolonged Half-Life and Improved Recovery of Recombinant Factor IX-XTEN Fusion Proteins in Hemophilia B Mouse Model

Lightbourn, C. O.

4281 - Targeting the IL-2/CD25 and TL1A/TNFRSF25 Pathways: A New Approach to Markedly Expand Donor Tregs in Multiple Compartments Leads to in Situ Immune Regulation

Lignelli, A.

981 - Enhanced MRI Evaluation of Children with Sickle Cell Following Hematopoietic Stem Cell Transplantation

Ligocki, C. D.

4464 - A Systematic Review of Ultrasound Imaging As a Tool for Evaluating Hemophilic Arthropathy in Children and Adults

Ligon, A. H.

176 - PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome

Ligthart, P.

660 - IgG Alloantibodies Against RBC Induced By Pregnancy or Transfusion Have Unique Glycosylation Patterns Which Correlate with Clinical Outcome of Hemolytic Disease of the Fetus or Newborn

Liguori, R.

860 - A Multicenter Phase I/Ib Study of Ipilimumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation

Liles, D.

722 - Identification of Initiating Trunk Mutations and Distinct Molecular Subtypes: An Interim Analysis of the Mmrf Commpass Study
1046 - Plasma Exchange Taper for Acquired TTP Is Protective Against Recurrence at Both 30 Days and 6 Months: A Retrospective Study from 2 Academic Medical Centers

Lill, M.

- Bundled Case Rates in Bone Marrow Transplant
- Panel Discussion

Lilley, G.

3243 - Characterization of Lentiviral Vector Derived Anti-Bcma CAR T Cells Reveals Key Parameters for Robust Manufacturing of Cell-Based Gene Therapies for Multiple Myeloma

Lillis, J.

3577 - The Histone Methyltransferase Setd8 Is Essential for Mammalian Erythropoiesis

Lilljebjörn, H.

3830 - Comprehensive Prospective Next Generation Sequencing of Acute Myeloid Leukemia

Lillo, R.

921 - A New Multiple Single-Nucleotide Polymorphisms Based Predictive Model for Grades III to IV and Extensive Graft Versus Host Disease after Identical HLA-Allogeneic Stem-Cell

Lim, D.

3474 - Can Immature Platelet Fraction (IPF) be Used to Assess Bleeding Risk in Pediatric Immune Thrombocytopenia (ITP) and to Differentiate ITP from Bone Marrow Failure/Aplastic Anemia? A Retrospective Analysis

Lim, E. L.

687 - Comprehensive Sequence Analysis of Relapse and Refractory Pediatric Acute Myeloid Leukemia Identifies miRNA and mRNA Transcripts Associated with Treatment Resistance - a Report from the COG/NCI-Target AML Initiative

Lim, H. Y.

4468 - Ten Years of Cerebral Venous Thrombosis (CVT) in Melbourne, Australia: Male Gender and Presence of Myeloproliferative Neoplasm Is Associated with Thrombotic Recurrence in Unprovoked Events

Lim, J. Y.

1769 - Impact of Lenalidomide Plus Low-Dose Dexamethasone Treatment on Immune Cell Populations of the Patients with Refractory/Relapsed Multiple Myeloma
1941 - Granulocytic and Monocytic Myeloid-Derived Suppressor Cells May Have Different Role on Allogeneic Stem Cell Transplant Outcomes

Lim, J.

2061 - Characteristics and Treatment Patterns of Patients with Deep Vein Thrombosis and/or Pulmonary Embolism in the US Hospital Setting

Lim, J. Y.

171 - Next Generation Sequencing Identifies a Novel Subset of Non-Down Syndrome Acute Megakaryoblastic Leukemia Characterized By Chimeric Transcripts Involving HOX Cluster Genes

Lim, K. P. H.

4072 - Inflammatory Plasma Proteins Predict Disease Severity and Response to Therapy in Patients with LCH

Lim, K. H.

1610 - B Cell Immune Profiles in Essential Thrombocythemia with Calr Mutations: Clinical and Molecular Correlates

Lim, K. H.

1643 - Heterozygous Hotspot SF3B1 Mutations Found in Myelodysplastic Syndromes Downregulate Genes Involved in Differentiation of Erythroid Cells

Lim, M. S.

465 - NPM-ALK Mediated Tyrosine Phosphorylation of ATP Citrate Lyase Regulates Lipid Metabolism and Promotes Oncogenesis of Anaplastic Large Cell Lymphoma
697 - N-Glycoproteomic Landscape of Human Lymphoid Cancers Reveals Novel Biomarkers and Potential Therapeutic Targets
1550 - Comparative Phosphoproteomics Study Between Obinutuzumab (GA101) Vs. Rituximab (RTX) Against RTX Sensitive/Resistant Burkitt Lymphoma (BL): Differentially Phosphorylated B Cell Receptor, Fc-Gamma Receptor, Phagocytosis and Natural Killer Cell-Mediated Cytotoxicity Signaling Pathway Proteins

Lim, M.

3801 - Safety, Pharmacokinetics, and Efficacy of BP-100-1.01 (Liposomal Grb-2 Antisense Oligonucleotide) in Patients with Refractory or Relapsed Acute Myeloid Leukemia (AML), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), and Myelodysplastic Syndrome (MDS)

Lim, S. H.

3739 - Phase 2 Study of Epigenetic Priming Using Decitabine Followed By Cytarabine As an Induction Regimen in Older Patients with Newly Diagnosed Acute Myeloid Leukemia

Lim, S. T.

256 - Safety and Efficacy of Abexinostat, a Pan-Histone Deacetylase (HDAC) Inhibitor, in Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Results of an Ongoing Phase 2 Study

Lim, S. N.

2535 - A Prospective Randomized Comparison of Idarubicin and High-Dose Daunorubicin in the Induction Chemotherapy for Acute Myeloid Leukemia
4379 - Allogeneic Hematopoietic Cell Transplantation for Acute Myelogenous Leukemia in Remission - a Prospective Comparison of Three Different Donor Groups; Matched Sibling, Matched Unrelated, and Haploidentical Family Donors

Limal, N.

3460 - A Multicenter, Case-Control Study Evaluating the Characteristics and Outcome of ITP Patients Refractory to, Rituximab, Splenectomy and Both TPO Receptor Agonists
3483 - Portal or Splenic Vein Thrombosis after Splenectomy for Immune Cytopenia: A Retrospective Cohort Study

Limaye, A.

2094 - A Patient-Reported Outcome Measure for Symptoms and Symptom Burden of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Limperger, V.

2316 - Comparison of Rethrombosis-Free Survival in Children Versus Adults Suffering from Antithrombin-, Protein C- and Protein S-Deficiency: An Observational Multicenter Cohort Study

Limsakun, T.

3524 - Rviii-Singlechain Pharmacokinetics and Safety in Children Less Than 12 Years of Age

Lin, A.

3103 - Vinorelbine-Cyclophosphamide Compared to Cyclophosphamide in Peripheral Blood Stem Cell Mobilization for Multiple Myeloma

Lin, A.

51 - Knockdown (KD) of Mir-126 Expression Enhances Tyrosine Kinase Inhibitor (TKI)-Mediated Targeting of Chronic Myelogenous Leukemia (CML) Stem Cells
3857 - Proteomics Profiling of Leukemia Derived Exosomes: A Potential Role in Leukemic Transformation

Lin, A.

3743 - Combination of Dasatinib with Conventional Chemotherapy Is Associated with a High Response Rate in High Risk Acute Myeloid Leukemia (AML)

Lin, A. P.

463 - A Phosphodiesterase 4B-Mediated Interplay Between Tumor Cells and the Microenvironment Regulates Angiogenesis in B Cell Lymphoma

Lin, A.

1290 - Effects of Obesity on the Efficacy and Toxicity of Induction Chemotherapy in Adult Acute Lymphoblastic Leukemia (ALL)
1994 - Outcomes of Pharmacokinetically (PK) Directed Busulfan in Combination with Thiotepa & Cyclophosphamide (TBC) Conditioning with HDT-ASCT in Patients with Primary & Secondary CNS Lymphoma

Lin, C. P.

1551 - Alisertib, an Aurora a Kinase Inhibitor, Induces Synthetic Lethality and Overcomes Chemoresistance in Myc-Overexpressing Lymphoma Cells

Lin, C. P.

663 - Embigin Regulates HSPC Homing and Quiescence and Acts As a Cell Surface Marker for a Niche Factor-Enriched Subset of Osteolineage Cells
664 - Distinct Bone Marrow Blood Vessels Differentially Regulate Normal and Malignant Hematopoietic Stem and Progenitor Cells

Lin, C. Y.

838 - Discovery and Characterization of Promoter and Super-Enhancer-Associated Dependencies through E2F and BET Bromodomains in Multiple Myeloma

Lin, C. S.

1610 - B Cell Immune Profiles in Essential Thrombocythemia with Calr Mutations: Clinical and Molecular Correlates

Lin, C.

1593 - Safety and Efficacy of Nilotinib (NIL) in Patients (Pts) with Chronic Phase (CP) or Accelerated Phase (AP) Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) with Resistance or Intolerance to Imatinib Mesylate (IM): Results from the Multicenter, Observational NOVEL Study in Taiwan

Lin, C. H.

810 - Oncogenic Role for the Lck/ZAP70/PLCG2 Signaling Pathway in Pre-B-ALL Pathogenesis

Lin, D.

2440 - Down-Regulation of Mir-26b and Its Inhibition on the Growth of T Cell Acute Lymphoblastic Leukemia

Lin, D. C.

1029 - Circadian Clock Protein CRY Controls B-Cell Intrinsic Tolerance

Lin, D.

1301 - Nilotinib Combined with Multi-Agents Chemotherapy for Adult Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of a Prospective Study from a Single Center
2519 - Clinical and Laboratory Studies of 23 Patients with Acute Myeloid Leukemia Harboring t (7; 11) (p15; p15) Translocation

Lin, F. P.

4050 - Rapid Achievement of MR^4.5after Switching from Imatinib (IM) to Nilotinib (NIL) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Preliminary Results from ENESTgoal

Lin, F. C.

1903 - Decision-Tree Algorithm Optimize Hematopoietic Progenitor Cell-Based Prediction in Peripheral Blood Stem Cell Mobilization
3490 - At Equal Doses FIXFc (Alprolix) Is Not Significanly Better in a Saphenous Vein Bleeding Model Than Recombinant FIX (BeneFix) Seven Days Post-Infusion

Lin, H.

1265 - Binding of Released Bim to Mcl-1 Is Responsible for Resistance to ABT-199 Which Can be Overcome By Combination with Daunorubicin or Cytarabine in Acute Myeloid Leukemia Cells
2469 - Inhibition of CHK1 Enhances Cell Death Induced By the Bcl-2-Selective Inhibitor ABT-199 in Acute Myeloid Leukemia Cells

Lin, H.

1567 - Identification and Characterization of New Microrna Biomarkers and Target Genes in Drug-Insensitive CD34+ CML Stem/Progenitor Cells Using Global Comparative RNA-Seq Analyses

Lin, H.

3010 - RNA Polymerase I Inhibition with CX-5461 As a Novel Strategy to Target MYC in Multiple Myeloma

Lin, H.

4072 - Inflammatory Plasma Proteins Predict Disease Severity and Response to Therapy in Patients with LCH

Lin, H.

2718 - Treatment Outcome and Prognostic Model for Stage IE/IIE Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Retrospective Study in a Cohort of 305 Patients with Long Term Follow-up

Lin, H. C.

1610 - B Cell Immune Profiles in Essential Thrombocythemia with Calr Mutations: Clinical and Molecular Correlates

Lin, H. K.

2094 - A Patient-Reported Outcome Measure for Symptoms and Symptom Burden of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Lin, J.

876 - Economic Burden of Adverse Events Among Patients with Chronic Myelogenous Leukemia Treated with BCR-ABL1 Tyrosine Kinase Inhibitors
1126 - Is Adherence to the American College of Chest Physicians Recommended Anticoagulation Treatment Duration Associated with Different Outcomes Among Patients with Venous Thromboembolism?
2073 - Hospitalizations and Mortality Associated with dsDNA Viral Infections Among Hematopoietic Cell Transplant Recipients

Lin, J. S.

1903 - Decision-Tree Algorithm Optimize Hematopoietic Progenitor Cell-Based Prediction in Peripheral Blood Stem Cell Mobilization

Lin, J.

727 - Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study (NCT01564537)

Lin, J.

285 - Blocking Specific CD44 Splicing Variant Isoform Inhibits the Differentiation of Th-2 Cells through Interfering with IL-4/IL-4R Signaling Pathway
1431 - Apurinic/Apyrimidinic Endonuclease 1 Induced Genomic Instability Causes T-Cell Acute Lymphoblastic Leukemia in Zebrafish
2420 - Nuclease Activity Is Associated with Genomic Instability As Well As Survival in Myeloma; Underlying Mechanisms and Significance
3626 - Functional and Genomic Signatures of Homologous Recombination (HR) Predict for Clinical Outcome in Multiple Myeloma (MM)

Lin, J.

1458 - Predictive Value of Interim ¹⁸f-FDG PET-CT Scans on Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Study

Lin, J.

1610 - B Cell Immune Profiles in Essential Thrombocythemia with Calr Mutations: Clinical and Molecular Correlates

Lin, J.

2329 - Reversal of Heparin-Induced Anticoagulation By Andexanet Alfa, a Universal Antidote for Factor Xa Inhibitors

Lin, J.

3274 - Cost of Bleeding-Related Episodes (BREs) in Adult Patients with Primary Immune Thrombocytopenia (ITP): A Population-Based Retrospective Cohort Study of Administrative Claims Data for Commercial Payers in the United States
4461 - Cost per Treatment Success of Thrombopoietin Receptor Agonists Vs "Watch and Rescue" Strategy for Treating Adult Non-Splenectomized Patients with Chronic Immune Thrombocytopenia: A US Payer Perspective

Lin, K.

2440 - Down-Regulation of Mir-26b and Its Inhibition on the Growth of T Cell Acute Lymphoblastic Leukemia

Lin, K. Y.

4482 - Heart Failure Related Hospitalizations Are Associated with Increased Morbidity and Mortality in Pediatric Oncology Patients

Lin, M. T.

3726 - Outcomes Following Discontinuation of E. coli-asparaginase upon Severe Allergic Reactions in Children with Acute Lymphoblastic Leukemia

Lin, P.

1418 - Early T-Cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) Is a High-Risk Subtype in Adults
3909 - MYC/BCL2 Double Hit Lymphoma: What Really Matters

Lin, P. C.

3726 - Outcomes Following Discontinuation of E. coli-asparaginase upon Severe Allergic Reactions in Children with Acute Lymphoblastic Leukemia

Lin, P. Y.

851 - Expression of MyD88/CD40 Drives In Vivo Activation and Proliferation of Chimeric Antigen Receptor-Modified T Cells That Can be Effectively Regulated By Inducible Caspase-9

Lin, R.

3125 - Cytokine Gene Polymorphisms and Epstein-Barr Virus Infection after Allogeneic Hematopoietic Stem Cell Transplantation

Lin, S.

2454 - Lymphoid Lineage Preference of MLL-AF4 Is Revealed in a Species-Specific Model

Lin, S. F.

1593 - Safety and Efficacy of Nilotinib (NIL) in Patients (Pts) with Chronic Phase (CP) or Accelerated Phase (AP) Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) with Resistance or Intolerance to Imatinib Mesylate (IM): Results from the Multicenter, Observational NOVEL Study in Taiwan

Lin, S.

292 - Factor IX Expressed in Lettuce Chloroplasts Induces Oral Tolerance in Hemophilia B Mice

Lin, T. L.

1399 - Hyperbaric Oxygen Increases Sensitivity to Chemotherapy in Acute Leukemia
1870 - Impact of Erythropoietin Modulation Using Hyperbaric Oxygen on Umbilical Cord Blood CD34+ Cell Homing
1909 - Final Results of the First-in-Human Clinical Study Incorporating Hyperbaric Oxygen into Umbilical Cord Blood Transplantation
2510 - CPX-351 ((Cytarabine:Daunorubicin) Liposome Injection, (Vyxeos)) Does Not Prolong Qtcf Intervals, Requires No Dose Adjustment for Impaired Renal Function and Induces High Rates of Complete Remission in Acute Myeloid Leukemia
4333 - Impact of Hyperbaric Oxygen Treatment on Time to Transfusion Independency Post-UCB Transplant

Lin, T.

2490 - Survival Trends in Adult T-Acute Lymphoblastic Leukemia / Lymphoma (ALL), a Comparative Analysis of 92 Patients By Year of Diagnosis
2683 - Treatment Patterns and Outcomes of DLBCL after Failure of Front-Line Immunochemotherapy
3730 - Prognostic Correlates and Outcomes of Relapsed T-Cell Acute Lymphoblastic Leukemia/Lymphoma: An Analysis of 41 Consecutive Patients
3992 - Incidence and Outcomes of Treatment Refractory Diffuse Large B-Cell Lymphoma in the Immunochemotherapy Era

Lin, T.

100 - CD4 CAR T Cells Mediate CD8-like Cytotoxic Anti-Leukemic Effects Resulting in Leukemic Clearance and Are Less Susceptible to Attenuation By Endogenous TCR Activation Than CD8 CAR T Cells

Lin, T.

1458 - Predictive Value of Interim ¹⁸f-FDG PET-CT Scans on Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Study
2690 - RCHOP-21 Vs. RCHOP-14 for the Treatment of Newly Diagnosed Diffuse Large B Cell Lymphoma: A Prospective Randomized Phase III Clinical Trial from Cswog
3956 - A Prospective, Self-Controlled and Randomized Study about the Optimal Timing of Leucovorin Rescue after High Dose Methotrexate Management

Lin, T. H.

4083 - Clinical Relevance of Molecular Markers in Taiwan Chinese Patients with Primary Myelofibrosis: Endogenous Erythroid Colony Growth Is the Most Important Predictor of Outcomes
4120 - Clonal Evolution of Gene Mutations Involving DNA Methylation in the Progression of CMML to Secondary AML

Lin, T. L.

4083 - Clinical Relevance of Molecular Markers in Taiwan Chinese Patients with Primary Myelofibrosis: Endogenous Erythroid Colony Growth Is the Most Important Predictor of Outcomes

Lin, X.

2690 - RCHOP-21 Vs. RCHOP-14 for the Treatment of Newly Diagnosed Diffuse Large B Cell Lymphoma: A Prospective Randomized Phase III Clinical Trial from Cswog

Lin, X.

3956 - A Prospective, Self-Controlled and Randomized Study about the Optimal Timing of Leucovorin Rescue after High Dose Methotrexate Management

Lin, X.

3183 - Autologous Stem Cell Transplantation in First Complete Remission May Not Extend Progression Free Survival in Patients with ALK-Negative Peripheral T Cell Lymphoma

Lin, X.

3418 - Semi-Automatic Enrichment with High Resolution/Selected Reaction Monitoring (HR/SRM) Scan for the Detection of Urinary Hepcidin in Patients with Sickle Cell Disease

Lin, X.

3643 - TET2 Downregulation Leads to AML Cells Sensitive to Decitabine

Lin, Y.

834 - PD-1 Blockade with Pembrolizumab (MK-3475) in Relapsed/Refractory CLL Including Richter Transformation: An Early Efficacy Report from a Phase 2 Trial (MC1485)
1774 - In Patients with Light-Chain (AL) Amyloidosis Myocardial Contraction Fraction (MCF) Is a Simple, but Powerful Prognostic Measure That Can be Calculated from a Standard Echocardiogram (ECHO)
3039 - Anti-Tumor Phagocytic Cell Activation in Multiple Myeloma By the IAP Antagonist LCL161: Results of a Phase II Clinical Trial
3050 - Randomized Phase 2 Trial of Two Different Doses of Ixazomib in Patients with Relapsed Multiple Myeloma Not Refractory to Bortezomib
3292 - N-Terminal Fragment of the Type-B Natriuretic Peptide (NT-proBNP) Is a Prognostic Factor for Overall Survival in Newly Diagnosed Patients with Multiple Myeloma (MM)
3317 - AL Amyloidosis and Patient Reported Quality of Life
3992 - Incidence and Outcomes of Treatment Refractory Diffuse Large B-Cell Lymphoma in the Immunochemotherapy Era
4197 - Presentation and Outcomes of Localized Amyloidosis: The Mayo Clinic Experience

Lin, Y.

118 - A Novel Bispecific CD38 Antibody Eradicates Multiple Myeloma in a Mouse Model Following Yttrium-90-DOTA Capture

Lin, Y.

1141 - Safety of Lumbar Punctures in Adult Oncology Patients with Thrombocytopenia
3569 - Post-Transfusion Fevers and Post-Reaction Culture Practices at a Large Academic Hospital Transfusion Service: Quality of Information and Calculated Bacterial Contamination Event Rates

Lin, Z.

1202 - Rapamycin Is Highly Effective in a Mouse Model of Immune-Mediated Bone Marrow Failure By Mechanisms Distinct from Cyclosporine

Linares, J.

1559 - Mechanistic and Pharmacodynamic Studies of Adct-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies

Linares Latorre, M. D.

2896 - A Score Based on IPSS-R, Ferritin and EPO Levels Predicts Erythroid Response to ESAs and Survival in Lower Risk Anemic MDS Patients with High Probability of Response to ESAs: Spresas Sub-Analysis from the GESMD

Linch, D.

2689 - R-CHOP in Primary Mediastinal B-Cell Lymphoma (PMBL): Results from the UK NCRI R-CHOP 14 v 21 Trial

Linch, D. C.

1516 - Outcome of Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: Subgroup Analysis from the UK NCRI R-CHOP 14 Vs 21 Trial

Lind, E. F.

1374 - Defining the Immune Microenvironment in Patients with Acute Myeloid Leukemia

Lindahl, T. L.

2255 - Flow Cytometry-Based Platelet Function Testing Is Predictive of Symptom Burden in a Cohort of Bleeders

Lindberg, A. P.

2268 - Discovery and Characterization of a Highly Specific Antibody Inhibitor of Factor XIIa, and the Subsequent Generation of a Factor XIIa/Plasma Kallikrein Bispecific Antibody

Lindberg, E. H.

139 - Different Mutant Splicing Factors Cause Distinct Missplicing Events and Give Rise to Different Clinical Phenotypes in Myelodysplastic Syndromes

Lindberg, G.

2839 - Mutations in Histone Modulators Are Associated with Prolonged Survival during Azacitidine Therapy

Lindblad, O.

2472 - Aberrant Activation of the PI3K/mTOR Pathway Promotes Resistance to Sorafenib in AML

Lindeman, R.

710 - An Integrative Genomics Approach Uncovers the Basis of Resistance to AZA Therapy in MDS and CMML

Lindemann, H. W.

27 - Bortezomib Induction and Maintenance in Patients with Newly Diagnosed Multiple Myeloma: Long-Term Follow-up of the HOVON-65/GMMG-HD4 Trial
1581 - Major Route Additional Chromosomal Aberrations (ACA) Precede Increase of Blasts in CML: An Analysis of the German CML-Studies III and IIIA
3187 - Impact of Severe Infections during Induction Therapy on Dosage, Response and Survival in Newly Diagnosed Multiple Myeloma - a Subgroup Analysis from the Randomized Phase III Trial GMMG-HD4
4233 - Clinical Risk Factors for Peripheral Neuropathy in Patients Treated with Subcutaneous or Intravenous Bortezomib for Newly Diagnosed Multiple Myeloma

Lindemann, M.

4288 - The Functional Distance Between Mismatched HLA-DPB1 Increases Risks of Relapse and Mortality after Unrelated Donor Hematopoietic Cell Transplantation for AML, ALL and MDS: A Refinement of the T Cell Epitope Group Algorithm for Permissive Mismatches

Lindemans, C. A.

3072 - RIG-I-Induced Type I IFNs Promote Regeneration of the Intestinal Stem Cell Compartment during Acute Tissue Damage

Linder, L.

4463 - Reduction in Inpatient Central Line Associated Blood Stream Infection Post Implementation of Bundled Care Measures in Patients with Benign and Malignant Hematological Conditions in a Single Pediatric Institution

Linder, M. K.

1879 - P-Glycoprotein Modulation Facilitates the Selective Inhibition of Oxidative Phosphorylation in Alloreactive T Cells to Prevent Graft-Versus-Host Disease after Hematopoietic Stem Cell Transplant

Linder, S.

703 - VLX1570, a First in Class Dub Inhibitor, Modulates BCR Signaling and CXCR4 Expression and Demonstrates Significant In Vivo Antitumor Activity in a Murine Model of Human Waldenstrom Macroglobulinemia
1557 - Identification of USP14 and UCHL5 As Druggable Oncotargets in Ibrutinib-Resistant Mantle Cell Lymphoma

Lindhout, T.

2287 - Effect of Five Therapeutic Strategies on the Coagulation Defect Induced By the Thrombomodulin C.1611C>a Mutation

Lindner, R.

1261 - Effective Treatment of Human CML By RNAi In Vivo in a Xenotransplantation Mouse Model

Lindoerfer, D.

2780 - Treatment and Outcome Analysis of 2,904 Pateints from the EUTOS Population Based Registry

Lindquist, S.

2548 - Inactivating Heat Shock Factor 1 (HSF1) in Acute Myeloid Leukemia By Pharmacological Inhibition of eIF4a: A Promising Therapeutic Approach

Lindqvist, E. K.

4252 - No Risk of Arterial or Venous Thrombosis in Monoclonal Gammopathy of Undetermined Significance: Results from a Population-Based Study

Lindsey, M.

977 - Placenta Growth Factor Links the IL-13 Response and the Leukotriene Pathway to Augment Airway Hyper-Responsiveness

Lindsley, R. C.

356 - Cooperating Effect of Rps14, Csnk1a1 and miRNA145/miRNA146a Haploinsufficiency in the Activation of the Innate Immune System in Del(5q) MDS

Lindstrom, V.

1918 - Diagnosis of Sinusoidal Obstruction Syndrome/ Veno-Occlusive Disease of the Liver: Problems of Interpretation

Lineburg, K. E.

34 - Hematopoeitic Stem Cells and Their Progenitors Critically Require Autophagy to Promote Early Engraftment Following Allogeneic Stem Cell Transplantation

Linesch, J.

2931 - Plasma B-Cell Maturation Antigen Levels Are Elevated and Correlate with Disease Activity in Patients with Chronic Lymphocytic Leukemia

Linet, M. S.

562 - Emerging Risks of AML/MDS and Other Myeloid Neoplasms Following Chemotherapy for First Primary Malignancy, 2000-2012
2806 - Incidence and Patient Survival of Myeloproliferative Neoplasms (MPNs) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPNs) in the United States: A Population-Based View of the Modern Diagnostic Era

Ling, L. E.

3472 - M281: A Therapeutic Anti-FcRn Blocking Antibody for Rapid Clearance of IgG and IgG Autoantibodies in Immune Cytopenias and Other Auto/Allo-Immune Disease

Ling, L.

744 - The Abundance of Certain Bacteria in the Intestinal Flora Is Associated with Relapse after Allogeneic Hematopoietic Stem Cell Transplantation

Ling, M.

239 - N-Acetylcysteine Treatment in Two Patients with Relapsed Thrombotic Thrombocytopenic Purpura Increased ADAMTS13 Activity, Free Thiol Concentration in Plasma, and Inhibited Platelet Activation
3451 - ADAMTS13 Synergizes with HDL in Preventing Von Willebrand Factor Self-Association Under Shear Stress

Lingjærde, O. C.

110 - Discovery of Recurrent Mutations Associated with Chemo-Immunotherapy Relapse in Diffuse Large B-Cell Lymphoma

Lingjing, C.

3900 - Expression of B and T Lymphocyte Attenuator (BTLA) Correlates with CNS Metastasis and Adverse Prognosis in Activated B-Cell Lymphoma and Acute Lymphoblastic Leukemia

Lingo, J. D.

2990 - Differential ICAM3 Gene Expression Correlates with Susceptibility to Natural Killer Cell-Mediated Lysis in Multiple Myeloma

Lingohr-Smith, M.

876 - Economic Burden of Adverse Events Among Patients with Chronic Myelogenous Leukemia Treated with BCR-ABL1 Tyrosine Kinase Inhibitors
1126 - Is Adherence to the American College of Chest Physicians Recommended Anticoagulation Treatment Duration Associated with Different Outcomes Among Patients with Venous Thromboembolism?
2073 - Hospitalizations and Mortality Associated with dsDNA Viral Infections Among Hematopoietic Cell Transplant Recipients

Linhartova, J.

3727 - MRD Monitoring Using Minor-BCR-ABL1 Genomic Breakpoint in Childhood ALL Identifies a Subgroup with Distinct Biology and a Very Poor Prognosis

Link, B. K.

131 - Study of the Subclonal Mutations in Primary Diffuse Large B-Cell Lymphoma
342 - Risk-Adapted Therapy in Adults with Burkitt Lymphoma: Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R
1456 - Natural History of Central Nervous System Relapse in Diffuse Large B Cell Lymphoma in the Immunochemotherapy Era
1501 - Event-Free Survival at 12 Months and Subsequent Overall Survival in Patients with Peripheral T-Cell Lymphoma
2681 - Mutations Targeting the ErbB Pathway and MSC in Peripheral T-Cell Lymphoma
2683 - Treatment Patterns and Outcomes of DLBCL after Failure of Front-Line Immunochemotherapy
2744 - Activity of Idelalisib in High-Risk Follicular Lymphoma with Early Relapse Following Front Line Immunochemotherapy
3922 - Comprehensive Analyses of Genetic Features Identify Coordinate Signatures in Diffuse Large B-Cell Lymphoma
3992 - Incidence and Outcomes of Treatment Refractory Diffuse Large B-Cell Lymphoma in the Immunochemotherapy Era

Link, D. C.

686 - Non-Malignant Oligoclonal Hematopoiesis Commonly Follows Cytoreductive Chemotherapy in Adult De Novo AML Patients
689 - Dynamic Changes in Clonal Clearance with Decitabine Therapy in AML and MDS Patients
2401 - Targeting Bone Marrow Mesenchymal Stromal Cells Using Cre-Recombinase Transgenes

Link, D. C.

610 - Dynamic Changes in the Clonal Structure of MDS and AML in Response to Epigenetic Therapy
666 - Loss of TGF-β Signaling in Bone Marrow Mesenchymal Progenitors Promotes Adipocyte over Osteoblast Differentiation but Does Not Disrupt the HSC Niche
1254 - Loss-of-Function Mutations of MIR142 May Contribute to Leukemogenesis By Expanding the Pool of Myeloid-Biased HSCs
3649 - Characterization of snoRNA Expression in Acute Myeloid Leukemia

Link, E.

4236 - Lower Dose Lenalidomide and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma Who Are Aged 60 Years or over and/or at Risk of Myelosuppression: Final Analysis of the Revlite Trial and Matched Comparison to the MM009 and MM010 Trials

Link, H.

222 - Randomized Comparison of Intermediate-Dose Cytarabine Plus Mitoxantrone (IMA) Versus Standard-Dose Cytarabine Plus Daunorubicin (DA) for Induction Therapy in AML Patients >60 Years. Results from the SAL 60+ Trial

Link, K. A.

4417 - Innovative Hematopoietic Gene-Therapy Concepts for Hereditary Pulmonary Alveolar Proteinosis Utilizing Hematopoietic Stem Cell Derived Macrophages

Linkesch, W.

4022 - Single-Cell Immune Signatures in Patients with Chronic Phase Chronic Myeloid Leukemia (CML) Treated with Nilotinib: An ENEST1st Sub Study

Linkins, L. A.

1120 - Bleeding in Patients Receiving Low-Molecular-Weight Heparin for Cancer-Associated Thrombosis

Linkins, L. A.

428 - Outcomes of Low-Molecular-Weight Heparintreatment for Venous Thromboembolism in Patients with Primary and Metastatic Brain Tumors
1119 - Management of Cancer-Associated Upper Extremity Deep Vein Thrombosis with and without Venous Catheters at a Tertiary Care Center
3468 - Rivaroxaban for Treatment of Suspected or Confirmed Heparin-Induced Thrombocytopenia Study

Linn, Y. C.

3184 - Impact of Post-Remission Consolidation Modalities in the Clinical Outcomes of Acute Myeloid Leukemia Patients in First Remission - Is There a Role for Autologous Hematopoietic Stem Cell Transplant?

Linn, Y. C.

2323 - A Randomized, Double Blind, Placebo-Controlled, Cross-over Study to Evaluate the Haemostatic Effects of Three Commonly Used Traditional Herbal Medicines, (Curcuma Longa, Angelicae Sinensis and Panax Ginseng) and Their Interactions with Aspirin

Linton, K.

1499 - Improved Survival in Peripheral T-Cell Lymphoma (PTCL) Following Complete Response to First-Line Chemotherapy: 10 Year Experience at the Royal Marsden and the Christie Hospitals 2002-2012

Lionel, A.

2886 - Are Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Occurring during the Course of Lymphoma (Ly) Always Therapy Related?

Liossi, C.

993 - Prevention of Morbidity in Sickle Cell Disease (POMS 2): A Pilot Study of Nocturnal Respiratory Support Shows That Auto-Adjusting Positive Airways Pressure Is Safe and Is Preferred to Oxygen Therapy

Lioure, B.

456 - How to Treat Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Patients : Results on 86 Patients of the French BPDCN Network
1908 - CloB2A2 Reduced-Intensity Conditioning (RIC) Regimen Prior to Allogeneic Stem Cell Transplantation Provides Significant Better Survival Compared to FB2A2 RIC Regimen in Adults with Acute Myeloid Leukemia (AML): A Study on Behalf of the SFGM-TC
1985 - Autologous Hematopoietic Stem Cell Transplantation (AHSCT) in Severe Auto-Immune Disease Adult Patients: Analysis of Outcomes from the French Society for Bone Marrow Transplantation and Cellular Therapy (SFGMT-TC) in Light of the European Society for Blood and Marrow Transplantation (EBMT) Activity
3736 - Addition of Lomustine (CCNU) to Induction and Post-Remission Chemotherapy for Fit Elderly AML Patients without Unfavorable Cytogenetics: Results of the Lamsa-2007 Goelams Trial
3787 - Safety and Long-Term Efficacy of Maintenance Therapy with Alternating Azacytidine (AZA) and Lenalidomide (Len) Cycles in Elderly (≥ 60) Fit Patients (Pts) with Poor Prognosis AML in First Complete Remission (CR) After LIA Induction. A Phase II Multicentric GOELAMS Trial
4367 - Allogeneic Hematopoietic Stem Cell Transplantation Offers Similar Outcome after Myeloablative and Sequential Conditioning Regimen in Patients with Primary Refractory or Relapsed Acute Myeloid Leukemia: A Study from the Societe Francaise De Greffe De Moelle Et De Therapie Cellulaire (SFGM-TC)

Liozon, E.

1695 - Efficacy of Azacitidine (AZA) in Autoimmune and Inflammatory Disorders (AID) Associated with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Lipe, B. C.

1399 - Hyperbaric Oxygen Increases Sensitivity to Chemotherapy in Acute Leukemia
1870 - Impact of Erythropoietin Modulation Using Hyperbaric Oxygen on Umbilical Cord Blood CD34+ Cell Homing
4227 - Phase 1/1b Pharmacokinetic (PK) and Safety Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) with Severe Renal Impairment or End-Stage Renal Disease (ESRD) Requiring Hemodialysis

Lipka, D. B.

1655 - 5-Azacytidine Reduces Leukemic Burden in a Xenograft Model of Juvenile Myelomonocytic Leukemia
2436 - Progressive Epigenetic Programming during B Cell Maturation Is Reflected in a Continuum of Epigenetic Disease Phenotypes in Chronic Lymphocytic Leukemia

Lipka, D. B.

4060 - Efficacy, Safety, and Confirmation of the Recommended Phase 2 Starting Dose of the Combination of Ruxolitinib (RUX) and Panobinostat (PAN) in Patients (Pts) with Myelofibrosis (MF)

Lipkin, C.

3280 - Incidence of Hepatic Veno-Occlusive Disease (VOD) in Premier Healthcare Database
4452 - Hospital Cost Associated with Veno-Occlusive Disease (VOD) in Patients with Hematopoietic Stem Cell Transplant (HSCT)

Lipkin, S. M.

2976 - Exome Sequencing in Myeloma Pedigrees Implicates RAS1 and NOTCH Signaling Are Involved in Inherited Myeloma Risk

Lipp, S.

117 - Target Expression, Preclinical Activity and Mechanism of Action of EM801: A Novel First-in-Class Bcma T-Cell Bispecific Antibody for the Treatment of Multiple Myeloma

Lippert, L.

16 - Beclin-1 Phosphorylation By BCR-ABL Is Crucial for CML Leukemogenesis By Suppression of Autophagy

Lipson, D.

1422 - Integrated DNA/RNA Profiling for Somatic Alterations in Adult B-Cell ALL
2651 - Predictive and Prognostic Significance of Comprehensive Genomic Profiling in Patients with Diffuse Large B-Cell Lymphoma
3898 - Comprehensive Genomic Profiling (CGP) of Angioimmunoblastic T-Cell Lymphoma (AITL) to Prospectively Inform Diagnosis and Clinical Management

Lipstein, M.

593 - Disruption of the mTOR-eIF4F Axis By Selectively Targeting PI3Kdelta and Proteasome Potently Inhibits Cap Dependent Translation of c-Myc in Aggressive Lymphomas

Lipton, J. H.

344 - Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Final Results from ENESTxtnd Study
1568 - Whole Exome Sequencing Reveals That DNMT3A and ASXL1 Mutation Are Involved in the Development of Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid Leukemia Patients without ABL1 Tyrosine Kinase Domain Mutation
1917 - Incidence and Risk Factors for Nontuberculous Mycobacteria Infection after Allogeneic Hematopoietic Cell Transplantation
1921 - Incidence and Risk Factors for Vzv Infection after Allogeneic Hematopoietic Cell Transplantation in 1,045 Patients: Younger Age Less Than or Equal to 45, Occurrence of Cgvhd By NIH Consensus Criteria, and No T-Cell Depletion
1945 - Risk Factor Analysis for the Development of Large Granular Lymphocytosis after Allogeneic Hematopoietic Cell Transplantation: Randomized Stratification and Propensity Score Analysis
1948 - Prolonged Duration of Systemic Immunosuppression after Allogeneic Hematopoietic Cell Transplantation Associates with the Use of Peripheral Blood Stem Cells, Severe Grade of Chronic Gvhd, Progressive Type Onset of Chronic Gvhd, Grade 2-4 Acute Gvhd and Older Age, but Not with T-Cell Depletion or Conditioning Regimen
2416 - Copy Number Variants Underlying Inherited Bone Marrow Failure Syndromes
3621 - Molecular Analysis of Diamond Blackfan Anemia and Genotype-Phenotype Correlation: Experience from the Canadian Inherited Marrow Failure Registry
4026 - Propensity Score Matching Analysis Demonstrates the Use of Statin Enhances Chance of Achieving MR4.5 in Chronic Myeloid Leukemia Patients in Chronic Phase Following Imatinib Therapy Regardless of Other Clinical Features Including Age of the Patients
4029 - Treatment-Free Remission (TFR) Eligibility in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Residual Disease on Long-Term Imatinib (IM) Who Switched to Second-Line Nilotinib (NIL)
4041 - Predictors of Response Duration and Survival with Second-Line Bosutinib Therapy in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML) Resistant or Intolerant to Prior Imatinib

Lipton, J. H.

2020 - Extramedullary Disease at Diagnosis of Acute Myeloid Leukemia Does Not Influence Outcome of Patients Undergoing Allogeneic Hematopoietic Cell Transplant in First Complete Remission
2596 - Whole Exome Sequencing Reveals the Landscape of Clonal Evolution from MDS to AML Progression
3126 - Propensity Score Matching Analysis Comparing Azathioprine Plus Prednisone Vs Prednisone Alone Regimens As First-Line Treatment in Chronic Graft-Versus-Host Disease
3139 - Donor Type, Chronic Gvhd Subtype , and the Severity of Chronic Gvhd at the Time of Initiation of Chronic Gvhd Treatment Affect Failure-Free Survival in the Patients with Chronic Gvhd
3201 - Analysis of Impact of Comorbidities Constituting the HCT-CI Score on the Outcome of Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia
3289 - Predictors of the Trajectory of Neurocognitive Functioning in the First Six Months after Allogeneic Hematopoietic Stem Cell Transplantation

Lipton, J. M.

160 - Pomalidomide Transcriptionally Reprograms Adult Erythroid Progenitors Independently of Ikaros Proteasomal Degradation
3605 - Transcriptome Analysis of Erythroid Cells Cultured from Diamond Blackfan Anemia Patients with Ribosomal and GATA1 Mutations Reveals Dysregulation of Inflammatory Response Genes

Lira, S. M.

4308 - Autologous Hematopoietic Progenitor Cell Infusion Adverse Event Associated with Apheresis Product Granulocyte Content

Lira, S.

4072 - Inflammatory Plasma Proteins Predict Disease Severity and Response to Therapy in Patients with LCH

Lisanti, M.

1430 - Metabolic Reprogramming of Bone Marrow Stromal Cells By Leukemic Extracellular Vesicles in Acute Lymphoblastic Leukemia (ALL)

Lisby, S.

507 - Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results of a Phase 1/2 Study (GEN503)

Lisenko, K.

1506 - Minimal Renal Toxicity after Rituximab DHAP with a Modified Cisplatin Application Scheme in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma
1900 - A Single Center Comparison Between Two Different Apheresis Systems for Peripheral Blood Stem Cell Collections

Lishner, M.

1124 - Clopidogrel Treatment Is Associated with a Decrease in Cancer Incidence

Lisi, V.

553 - LMO2 Regulates DNA Replication in Hematopoietic Cells

Lisina, E.

936 - Thrombotic Complications Are Associated with Phlebotomy Therapy in Patients with Chuvash Polycythemia

Lissandre, S.

3787 - Safety and Long-Term Efficacy of Maintenance Therapy with Alternating Azacytidine (AZA) and Lenalidomide (Len) Cycles in Elderly (≥ 60) Fit Patients (Pts) with Poor Prognosis AML in First Complete Remission (CR) After LIA Induction. A Phase II Multicentric GOELAMS Trial

Lissitchkov, T.

547 - Personalized Prophylaxis with Human-Cl Recombinant FVIII in HA Patients
551 - A Subcutaneously Administered Investigational RNAi Therapeutic (ALN-AT3) Targeting Antithrombin for Treatment of Hemophilia: Interim Weekly and Monthly Dosing Results in Patients with Hemophilia A or B
1096 - Long-Term Use of Coagulation Factor IX (Recombinant) Albumin Fusion Protein (rIX-FP) in Previously Treated Patients with Hemophilia B in the Prolong-9FP Program

List, A. F.

Liston, A.

1025 - Excessive Anti-Viral CD8 T Cell Activation Inverts the IL-2 Consumptive Hierarchy Triggering Regulatory T Cell Collapse in Mouse Model for Hemophagocytic Lymphohistiocytosis

Litchev, B.

2040 - Adeno-Associated Virus 8 (AAV8) Vector Genome Biodistribution into Body Fluids Following Single Intravenous Administration of BAX 335 Gene Therapy for Hemophilia B

Little, J. A.

3379 - Point-of-Care Screening for Sickle Cell Disease By a Mobile Micro-Electrophoresis Platform

Little, J. A.

3267 - Acute Care in the Emergency Department Differs before and after Transition for Adolescents and Young Adults with Sickle Cell Disease

Little, R. F.

342 - Risk-Adapted Therapy in Adults with Burkitt Lymphoma: Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R
472 - Phase I Study of Dose-Adjusted-Teddi-R with Ibrutinib in Untreated and Relapsed/Refractory Primary CNS Lymphoma
2691 - Veliparib (ABT-888), Bendamustine, and Rituximab (VBR) Is Well Tolerated and Efficacious in Patients with Lymphoma: Final Analysis of a Phase 1b Clinical Trial of VB and a Cohort Expansion of Vbr in Patients with B-Cell Lymphoma

Little-Ihrig, L.

2184 - Elevated Plasma Thrombospondin-1 (TSP1) Levels Are Correlated with Oxidative Stress and Worse Cognitive Function in Sickle Cell Disease

Littman, E. R.

744 - The Abundance of Certain Bacteria in the Intestinal Flora Is Associated with Relapse after Allogeneic Hematopoietic Stem Cell Transplantation

Litvin, R.

4075 - AUY922, a Heat Shock Protein 90 (Hsp90) Inhibitor, Demonstrates Activity in Patients with Myeloproliferative Neoplasms (MPNs)

Litvinov, R. I.

2244 - Membrane Remodeling By Pathogenic Antibodies Underlies Monocyte Activation in Heparin-Induced Thrombocytopenia
3444 - The Platelet Integrin alphaIIbbeta3 Differentially Interacts with Fibrin and Fibrinogen

Litzow, M. R.

217 - North American Leukemia‚ Intergroup Phase III Randomized Trial of Single Agent Clofarabine As Induction and Post-Remission Therapy‚ and Decitabine As Maintenance Therapy in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age ≥60 Years): A Trial of the ECOG-ACRIN Cancer Research Group (E2906)
321 - Antileukemic Activity and Tolerability of ASP2215 80mg and Greater in FLT3 Mutation-Positive Subjects with Relapsed or Refractory Acute Myeloid Leukemia: Results from a Phase 1/2, Open-Label, Dose-Escalation/Dose-Response Study
389 - A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients with Hematological Malignancies
736 - Fludarabine Busulfan Compared to Fludarabine Melphalan Is Associated with Increased Relapse Risk in Reduced Intensity Conditioning Transplant Despite Pharmacokinetic Dosing
795 - in Philadelphia-Chromosome-Negative Acute Lymphoblastic Leukemia, Late Relapses Are Not Uncommon, Occur Mostly in Patients at Standard Risk and Have a Relatively Favorable Outcome. Results of the International ALL Trial: MRC Ukallxii/ECOG E2993
861 - Treatment with Anti-CD19 BiTE^® Blinatumomab in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (r/r ALL) Post-Allogeneic Hematopoietic Stem Cell Transplantation
908 - Additional Analyses of a Randomized Phase II Study of Azacitidine Combined with Lenalidomide or with Vorinostat Vs. Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML): North American Intergroup Study SWOG S1117
1013 - Incidence and Outcomes of Neutropenia in Patients with Celiac Disease- a Consecutive Analysis of 1729 Patients
1138 - North American Cooperative Group Members' Patterns of Blood Products Transfusion for Patients with Acute Leukemia
1308 - Tipifarnib As Maintenance Therapy in Acute Myeloid Leukemia (AML) Improves Survival in a Subgroup of Patients with High Risk Disease. Results of the Phase III Intergroup Trial E2902
1315 - Very Poor Long-Term Survival, Also in Contemporary Studies, of Patients with AML Who Relapse after Achieving a First Complete Remission: The ECOG-ACRIN Cancer Research Group Experience
1401 - Clinical Outcome of Therapy-Related Acute Myeloid Leukemia Is Strongly Related to Cytogenetic Analysis
1422 - Integrated DNA/RNA Profiling for Somatic Alterations in Adult B-Cell ALL
1913 - Early CMV Infection Detected By Quantitative Nucleic Acid Testing (QNAT) Is Associated with Lower Risk of Relapse after Reduced Intensity, but Not Myeloablative, Hematopoietic Cell Transplantation in Acute Myeloid Leukemia
1923 - Early T-Lymphocyte Chimerism Kinetics Is Influenced By Conditioning Regimen in Reduced Intensity Allogeneic Stem Cell Transplantation
2490 - Survival Trends in Adult T-Acute Lymphoblastic Leukemia / Lymphoma (ALL), a Comparative Analysis of 92 Patients By Year of Diagnosis
2563 - Randomized Phase II Trial of Timed Sequential Cytosine Arabinoside with and without the CHK1 Inhibitor MK-8876 in Adults with Relapsed and Refractory Acute Myelogenous Leukemia
2591 - A Clinical Measure of DNA Methylation Predicts Outcome in De Novo AML
2875 - Survival Trends in Primary Myelodysplastic Syndromes: A Comparative Analysis of 1000 Patients By Year of Diagnosis and Treatment
2882 - ASXL1 Mutations in Myelodysplastic Syndromes with 1% or More Ring Sideroblasts: Prevalence, Clinical Correlates and Prognostic Relevance
3154 - Guidelines for the Standardization of Acute Graft-Versus-Host Disease Clinical Data Collection: An International Consensus Report
3210 - Prognostic Impact of Peripheral Blood Count Recovery and Cytogenetic Remission Prior to Reduced Intensity Allogeneic Transplantation in Patients with Acute Myelogenous Leukemia and Myelodysplastic Syndromes
3730 - Prognostic Correlates and Outcomes of Relapsed T-Cell Acute Lymphoblastic Leukemia/Lymphoma: An Analysis of 41 Consecutive Patients
3747 - Disparity in the Overall Survival Improvement over Time and the Effect Time-to-Treatment on the Outcome of Acute Promyelocytic Leukemia: A US National Cancer Data Base Study from 1998-2011
3808 - A Phase II of Combination Daunorubicin and Cytarabine (Ara-c) and Nilotinib (TAsigna) (DATA) in Patients Newly Diagnosed with Acute Myeloid Leukemia and KIT Expression: Interim Results
4062 - Momelotinib Therapy for Myelofibrosis: Impact on Long-Term Survival and Genotype Correlations
4370 - The Role of Spleen Directed Therapy and Predictors of Outcomes with Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Primary Myelofibrosis and Splenomegaly
4455 - Patterns of Venous Thromboembolism Prophylaxis during Inpatient Treatment of Acute Leukemia: Results of a North American Web-Based Survey

Liu, A.

4247 - Which Should be Pursued, Cumulative Dose or Dose Intensity: A Real-World Effectiveness Analysis of Bortezomib-Based First Line Treatment for Untreated Multiple Myeloma Patients

Liu, A.

735 - A Phase I Trial of Total Marrow and Lymphoid Irradiation (TMLI)-Based Transplant Conditioning in Patients (Pts) with Relapsed/Refractory Acute Leukemia

Liu, B.

3613 - High Frequency of Circulating CD8⁺ Memory Stem T Cells in Acquired Aplastic Anemia

Liu, B.

896 - PDK1 Controls the Differentiation of Hematopoietic Stem Cells Via Modulating ROS Levels

Liu, B.

3513 - Characterization of a High-Affinity Fully Human IgG2 Antibody Against Tissue Factor Pathway Inhibitor As a Bypass Agent for the Treatment of Hemophilia

Liu, B.

1301 - Nilotinib Combined with Multi-Agents Chemotherapy for Adult Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of a Prospective Study from a Single Center
2519 - Clinical and Laboratory Studies of 23 Patients with Acute Myeloid Leukemia Harboring t (7; 11) (p15; p15) Translocation

Liu, B.

3499 - Recombinant FVIII and FVIIa Added to Flowing Hemophiliac Blood Co-Localize with Platelet Aggregates Adherent to a Collagen Surface, Promoting Local Fibrin Deposition in Wake-like Patterns Around the Aggregates

Liu, C.

1145 - Effect of Lower Hematocrits on Buffy Coat Collection during Extracorporeal Photopheresis in Patients with Graft-Versus-Host Disease

Liu, C.

1222 - Histone Deacetylase Inhibitors Induce microRNAs Targeting BTK in Acute Myeloid Leukemia

Liu, C.

148 - NLRP6 in Host Target Tissues Exacerbates Graft-Versus-Host Disease
149 - ATG5 Dependent Autophagy Uncouples T Cell Functions and Modulates Experimental Graft-Versus-Host Disease
229 - Donor T Cells Intrinsic Responses to Damps Regulated By Siglec-G-CD24 Axis Mitigate Gvhd but Maintain GVL in Experimental BMT Model
3072 - RIG-I-Induced Type I IFNs Promote Regeneration of the Intestinal Stem Cell Compartment during Acute Tissue Damage
3076 - Targeting Host Complement C3a/C5a Receptors to Control of Acute Graft-Versus-Host Disease in Mice

Liu, C.

2527 - A Therapeutic TCR Mimic Monoclonal Antibody for Intracellular PRAME Protein in Leukemias

Liu, C.

250 - Genetic Risk Factors for the Development of Osteonecrosis in Children Under Age 10 Treated for Acute Lymphoblastic Leukemia
3714 - Genome-Wide Association Study Identifies PNPLA3 I148M Variant Associated with Elevated Transaminase Levels after Induction Therapy in Pediatric ALL Patients

Liu, C. H.

2171 - Plasma FGF23 Is a Biomarker for Left Ventricular Hypertrophy and Mortality in Adults with Sickle Cell Anemia Chronic Kidney Disease

Liu, C. L.

114 - Noninvasive Genotyping and Assessment of Treatment Response in Diffuse Large B Cell Lymphoma

Liu, C. Y.

1903 - Decision-Tree Algorithm Optimize Hematopoietic Progenitor Cell-Based Prediction in Peripheral Blood Stem Cell Mobilization

Liu, D. H.

1943 - Effect of Transfusion of the Third Party Umbilical Cord Blood on Haplo-Identical Hematopoietic Stem Cell Transplantation
1964 - Similar Incidence of Severe Acute Gvhd and Less Extensive Chronic Gvhd in PBSCT from Unmanipulated Haploidentical Donor Compared with That from Matched Sibling Donor for Patients with Hematologic Malignancies
4365 - Haploidentical Unmanipulated G-CSF-Primed Peripheral Blood Stem Cell Transplantation for Patients with High-Risk Hematologic Malignancies

Liu, D.

1394 - Exome Sequencing Identifies Highly Recurrent Somatic GATA2 and CEBPA Mutations in Acute Erythroid Leukemia

Liu, D.

3795 - Lead-in Stage Results of a Pivotal Trial of SL-401, an Interleukin-3 Receptor (IL-3R) Targeting Biologic, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or Acute Myeloid Leukemia (AML)

Liu, D. Y.

3217 - Impact of Cytogenetic and Molecular Markers on Disease-Free Survival of Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia
3224 - Improved Outcomes of Haploidentical Blood and Marrow Transplantation in Hematologic Malignancies: A Single Center Study of 514 Cases

Liu, D.

313 - Ibrutinib Inhibits Both B-Cell Receptor and Toll-like Receptor Signaling in Chronic Lymphocytic Leukemia
2223 - Insights into Clonal Relationships of Putative Adaptive Natural Killer Cells (NK) in Humans, Via Mapping of Somatic Piga Mutations in Patients with Paroxysmal Nocturna Hemoglobinuria (PNH)

Liu, D.

3324 - Patient Choice and Lack of Medicare Coverage for HCT Are the Major Reasons Why Transplant Eligible Myelofibrosis Patients Do Not Undergo Transplant

Liu, E.

185 - Chimeric T Cells for Therapy of CD30+ Hodgkin and Non-Hodgkin Lymphomas

Liu, E.

929 - Infusion of Ex Vivo Expanded Allogeneic Cord Blood-Derived Natural Killer Cells in Combination with Autologous Stem Cell Transplantation for Multiple Myeloma: Results of a Phase I Study
1709 - The CXCR4/STAT3/IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia (CLL) and Can be Modulated By Lenalidomide
1737 - Ibrutinib Can Modulate the T Cell Response in Chronic Lymphocytic Leukemia By Reducing PD1/PDL1 Interactions
3091 - Cord Blood Derived Natural Killer Cells Engineered with a Chimeric Antigen Receptor Targeting CD19 and Expressing IL-15 Have Long Term Persistence and Exert Potent Anti-Leukemia Activity

Liu, F.

1181 - Prmt5 Negatively Regulates Erythropoiesis By Multiple Mechanisms, Including Controlling DNA Methyltransferase 3A Protein Levels

Liu, F.

4505 - Interim Results of a Multi-Center Observational Study of Current Treatment Patterns for Patients with Severe Aplastic Anemia (SAA), Very Severe Aplastic Anemia (VSAA) and Transfusion-Dependent Non-Severe Aplastic Anemia (TD-NSAA) in China

Liu, G.

3806 - AGS62P1, a Novel Anti-FLT3 Antibody Drug Conjugate, Employing Site Specific Conjugation, Demonstrates Preclinical Anti-Tumor Efficacy in AML Tumor and Patient Derived Xenografts

Liu, G.

2114 - Evaluation of Institutional Non-Core Chemotherapy Regimens Approved for the Treatment of Leukemia and Multiple Myeloma

Liu, G.

1255 - B-Lymphoid Transcription Factors Restrict Glycolytic Energy Supply for Oncogenic Signaling

Liu, H.

3145 - Alterations of Intestinal Microbiota Correlate with the Emergence of Acute Graft-Versus-Host Disease in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Liu, H.

1572 - USP47 Is a New Target in Chronic Myelogenous Leukemia
3497 - Thrombomodulin Gene Mutations Associated with Thromboembolic Diseases
3505 - The Association Between SERPINC1 C.883G>a and VT in the Chinese Population
3533 - Novel Association of a F11 Variant with Venous Thromboembolism in a Chinese Han Population

Liu, H.

185 - Chimeric T Cells for Therapy of CD30+ Hodgkin and Non-Hodgkin Lymphomas
186 - Immunotherapy for Lymphoma Using T Cells Targeting Multiple Tumor Associated Antigens

Liu, H.

1920 - Comparative Effectiveness of Fludarabine and Busulfan Versus Fludarabine and 400 cGy Total Body Irradiation Reduced Intensity Conditioning Regimens for Allogeneic Hematopoietic Cell Transplantation for AML/MDS
1987 - Daily Weight-Based Busulfan with Cyclophosphamide and Etoposide (Bu/Cy/VP) Produces Comparable Outcomes to 4-Times-Daily Busulfan Dosing for Lymphoma Patients Undergoing Autologous Stem Cell Transplantation (ASCT)
3327 - Response Adapted Induction Therapy for Multiple Myeloma
4221 - A Phase I Study of Ixazomib in Combination with Panobinostat and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
4494 - Association of Socioeconomic Status (SES) with Outcomes of Autologous Hematopoietic Cell Transplantation (ASCT) for Lymphoma

Liu, H.

1394 - Exome Sequencing Identifies Highly Recurrent Somatic GATA2 and CEBPA Mutations in Acute Erythroid Leukemia

Liu, H.

974 - Sustained Elevation of Adenosine-ADORA2B Signaling Promotes Chronic Pain through Neuro-Immune Interaction in Sickle Cell Disease
2134 - Metabolomic Profiling Identifies Hypoxia-Induced Imbalanced Lands' Cycle Promotes Sickling and Disease Progression

Liu, H. X.

3217 - Impact of Cytogenetic and Molecular Markers on Disease-Free Survival of Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia
3224 - Improved Outcomes of Haploidentical Blood and Marrow Transplantation in Hematologic Malignancies: A Single Center Study of 514 Cases

Liu, H.

2518 - Efficacy of Single-Agent Decitabine in Relapsed and Primary Refractory (rel/ref) Acute Myeloid Leukemia (AML)
3777 - Dose-Escalation Study of Azacitidine Followed By High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in High-Risk Acute Myeloid Leukemia (AML)

Liu, H.

919 - IL-2 Induces Selective Activation of Helios-Positive Regulatory T Cells and CD56^bright NK Cells in Vitro and in Patients with Chronic Gvhd Receiving Low-Dose IL-2 Therapy
2357 - Maturation and Phenotypic Diversity of Human CD4⁺ Regulatory T Cells in Umbilical Cord Blood and Peripheral Blood from Healthy Donors

Liu, H. C.

3726 - Outcomes Following Discontinuation of E. coli-asparaginase upon Severe Allergic Reactions in Children with Acute Lymphoblastic Leukemia

Liu, H.

341 - First Multicenter, Randomized Phase 3 Study in Patients (Pts) with Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL): Alisertib (MLN8237) Versus Investigator's Choice (Lumiere trial; NCT01482962)

Liu, H.

1310 - Longitudinal Pharmacokinetic/Pharmacodynamic Profile of AG-120, a Potent Inhibitor of the IDH1 Mutant Protein, in a Phase 1 Study of IDH1-Mutant Advanced Hematologic Malignancies

Liu, H.

2082 - Cost Comparison of Hematopoietic Stem Cell Transplantation and Conventional Therapy for Patients with Thalassemia Major in China

Liu, J. J.

2741 - Phase II Trial of Ofatumumab (OFA) in Previously Untreated Follicular Non-Hodgkin Lymphoma (NHL): CALGB 50901 (Alliance)

Liu, J.

3178 - Induction with Bortezomib and Dexamethasone (BD) Followed By Risk Adapted High Dose Melphalan and Autologous Stem Cell Transplantation and BD Consolidation in Patients with AL Amyloidosis: A Phase II Feasibility Study

Liu, J.

3697 - Combination of Idelalisib and ONO/GS-4059 in Lymphoma Cell Lines Sensitive and Resistant to BTK Inhibitors
3707 - Up-Regulation of the PI3K Signaling Pathway Mediates Resistance to Idelalisib

Liu, J.

3678 - Varying Responses of PML-Rara with Different Genetic Mutations to Arsenic Trioxide

Liu, J.

3492 - Recombinant FVIIIFc-VWF-XTEN Demonstrates Significant Bioavailability Following Subcutaneous Administration in Hemophilia A Mice

Liu, J.

2279 - Evaluation of Enhanced in Vitro Plasma Stability of a Novel Long Acting Recombinant FVIIIFc-VWF-XTEN Fusion Protein

Liu, J. H.

1903 - Decision-Tree Algorithm Optimize Hematopoietic Progenitor Cell-Based Prediction in Peripheral Blood Stem Cell Mobilization

Liu, J.

3505 - The Association Between SERPINC1 C.883G>a and VT in the Chinese Population

Liu, J. (.

1935 - A Phase I/II Trial of Intravenous Azacitidine for Acute Gvhd Prophylaxis in Patients Undergoing Matched Unrelated Stem Cell Transplantation: Phase I Results

Liu, J.

2874 - Colony-Forming Unit Cell (CFU-C) Assays in Myelodysplastic Syndrome

Liu, J.

4118 - Systematic Drug Repositioning By Integrating Transcriptome and Historical Clinical Data, Identification of Digoxin As a Novel Drug Reposition Candidate for High-Risk Myelodysplastic Syndromes

Liu, J.

1430 - Metabolic Reprogramming of Bone Marrow Stromal Cells By Leukemic Extracellular Vesicles in Acute Lymphoblastic Leukemia (ALL)

Liu, J. M.

160 - Pomalidomide Transcriptionally Reprograms Adult Erythroid Progenitors Independently of Ikaros Proteasomal Degradation
298 - Premature Senescence in Hematopoietic Stem and Progenitor Cells in Ribosomopathy-Associated Bone Marrow Failure Syndromes

Liu, J. O.

503 - Defining Primary Marrow Microenvironment-Induced Synthetic Lethality and Resistance for 2,684 Approved Drugs Across Molecularly Distinct Forms of Multiple Myeloma

Liu, K.

1301 - Nilotinib Combined with Multi-Agents Chemotherapy for Adult Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of a Prospective Study from a Single Center

Liu, K.

2006 - CTLA-4 Polymorphisms and Haplotype Correlate with Survival and aGVHD after Allogeneic Stem Cell Transplantation from Related HLA-Haplotype-Mismatched Donor

Liu, K.

2180 - Evaluation of Purified Poloxamer-188 (vepoloxamer) on Sickle Red Blood Cell (RBC) Membrane Function Properties

Liu, K.

3037 - Immunomodulatory Effects and Adaptive Immune Response to Daratumumab in Multiple Myeloma
4254 - Understanding the Dose Regimen for Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma (MM) after Prior Proteasome Inhibitors (PIs) and Immunomodulatory Drugs (IMiDs): A Quantitative Pharmacologic Perspective

Liu, L.

2480 - Suppression of Cdc37 Induces Bortezomib Resistance through Autophagy Activation and Plasma Cell Immaturation in Multiple Myeloma

Liu, L.

455 - Microtransplantation Improved Outcome in Elderly Acute Myeloid Leukemia Patients - Report from China Microtransplantation Cooperative Group

Liu, L.

3387 - Delta-Aminolevulinate Preferentially Induces Gamma-Globin Expression in Erythroid Cells through Activation of NRF2 Stress Response

Liu, L.

381 - Inhibition of Both Activated p38 MAPK and mTOR C1 Potentiates the Effect of SR1 on Promotion of Hematopoietic Stem Cell Expansion Ex Vivo

Liu, L.

2451 - Oncogenic Nras Grants Apoptosis Resistance to Hematopoietic Stem Cells

Liu, L.

1081 - Recombinant FIX/X-Bp from the Japanese Habu Snake Is a Universal Ligand for Purification of Highly Carboxylated Factor IX Variants and Factor X
2271 - Prolonged Half-Life and Improved Recovery of Recombinant Factor IX-XTEN Fusion Proteins in Hemophilia B Mouse Model
2280 - Identification of Active Coagulation Factor IX Variants with Insertion or Fusion of Unstructured Polypeptide Xten

Liu, M.

3234 - Clonal Analysis of Human Bone Marrow CD34+ Cells Edited By BCL11A-Targeting Zinc Finger Nucleases Reveals Clinically Relevant Levels of Fetal Globin Expression in Edited Erythroid Progeny

Liu, M. Q.

1943 - Effect of Transfusion of the Third Party Umbilical Cord Blood on Haplo-Identical Hematopoietic Stem Cell Transplantation

Liu, P. P.

2373 - Development of Multi-Lineage Hematopoiesis in Two Novel Zebrafish runx1 mutants

Liu, P.

2718 - Treatment Outcome and Prognostic Model for Stage IE/IIE Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Retrospective Study in a Cohort of 305 Patients with Long Term Follow-up

Liu, P.

1225 - High Resolution Mapping of Active RNA Polymerases Identifies KIT As a Target of BET Inhibitors in t(8;21) AML

Liu, P.

1242 - Roles of Palmitoylation and the KIKK Membrane-Targeting Motif in Leukemogenesis By Oncogenic KRAS4A
2353 - IRF8 Regulates Cell Cycle of Hematopoietic Stem Cells

Liu, P. P.

1167 - The Roles of RUNX1 in Human Hematopoiesis and Megakaryopoiesis Revealed By Genome-Targeted Human iPSCs and an Improved Hematopoietic Differentiation Model
3662 - CHD7 Deficiency Inhibits CBFB-MYH11-Induced Leukemogenesis
3666 - The Multimerization Domain of Cbfß-SMMHC Is Required for Leukemogenesis
3667 - Overexpression and Knockout of Mir-126 Both Promote Leukemogenesis through Targeting Distinct Gene Signaling

Liu, Q.

61 - Combined Donor and Recipient Non-HLA Genotypes Show Evidence of Genome Wide Association with Transplant Related Mortality (TRM) after HLA-Matched Unrelated Donor Blood and Marrow Transplantation (URD-BMT) (DISCOVeRY-BMT study)
2621 - Evidence for Heterogeneous Genetic Associations with Acute Lymphoblastic Leukemia (ALL) By Cytogenetics and Sex in High-Risk Patients Treated with Matched Unrelated Donor Allogeneic Blood or Marrow Transplant (URD-BMT)

Liu, Q.

397 - Genome-Wide Association Study of Overall and Progression-Free Survival after HLA-Matched Unrelated Donor Blood and Marrow Transplantation (DISCOVeRY-BMT study)

Liu, Q.

1003 - Whim Syndrome Caused By a 5 Base Pair Deletion in the C-Terminus of Chemokine Receptor CXCR4
3066 - CXCR4 Gene Dosage Is Critical for HSC Engraftment

Liu, Q.

1302 - Comparison of the Efficacy of the First and Second-Generation Tyrosine Kinase Inhibitors in the First-Line Treatment of Ph-Positive Acute Lymphoblastic Leukemia
2439 - CDKN2 Gene Deletion Impair Prognosis in Adult Ph+ Acute Lymphoblastic Leukemia Even in Tyrosine Kinase Inhibitors Era
3647 - APP Gene Involves in the Regulation of Cell Apoptosis in AML1-ETO-Positive Leukemia Via SCF/c-Kit Signaling Pathway

Liu, Q.

62 - Stem-Cell Transplantation in Adults with Philadelphia-Negative High-Risk Acute Lymphoblastic Leukemia in First Complete Remission: A Prospective Multicenter Trial Comparing Haploidentical Donors with Identical Sibling Donors
855 - Mesenchymal Stem Cell As a Salvage Treatment for Patients with Refractory Bronchiolitis Obliterans Syndrome after Allogenetic Hematopoietic Stem Cell Transplantation
2026 - A Comparison of Lamivudine and Entecavir for the Prophylaxis of Hepatitis B Virus Reactivation in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation: A Single Institutional Experience
3125 - Cytokine Gene Polymorphisms and Epstein-Barr Virus Infection after Allogeneic Hematopoietic Stem Cell Transplantation
4352 - Intrathecal Rituximab for EBV-Associated Post-Transplant Lymphoproliferative Disorder with Central Nervous System Involvement Unresponsive to Intravenous Rituximab-Based Treatments: A Prospective Study

Liu, R.

3774 - Chimeric Antigen Receptor 4SCAR19-Modified T Cells in Acute Lymphoid Leukemia: a Phase II Multi-Center Clinical Trial in China

Liu, S.

895 - Hypoxic Stress-Induced Serotonergic Stimulation Controls Hematopoietic Stem Cell Production Via the Hypothalamic-Pituitary-Interrenal Axis and Glucocorticoid Signaling

Liu, S.

1177 - Regulation of Hematopoietic Stem Cell Function By the Histone H2A Deubiquitinase Usp16

Liu, S.

3643 - TET2 Downregulation Leads to AML Cells Sensitive to Decitabine

Liu, S. H.

4162 - Targeting the CXCR4 - CXCL12 Pathway Using an Anti-CXCR4 IgG1 Antibody (PF-06747143) in Chronic Lymphocytic Leukemia

Liu, S. H.

1362 - Targeting Acute Myeloid Leukemia with a New CXCR4 Antagonist IgG1 Antibody (PF-06747143)in NOD/SCID Mice

Liu, S.

446 - NT5C2 As a Major Contributor to Thiopurine Resistance at ALL Relapse Via Multiple Mechanisms

Liu, S.

3808 - A Phase II of Combination Daunorubicin and Cytarabine (Ara-c) and Nilotinib (TAsigna) (DATA) in Patients Newly Diagnosed with Acute Myeloid Leukemia and KIT Expression: Interim Results

Liu, S.

4019 - The Long Non-Coding RNA NEAT1 Modulates Imatinib-Induced Apoptosis in CML Cells

Liu, S.

61 - Combined Donor and Recipient Non-HLA Genotypes Show Evidence of Genome Wide Association with Transplant Related Mortality (TRM) after HLA-Matched Unrelated Donor Blood and Marrow Transplantation (URD-BMT) (DISCOVeRY-BMT study)

Liu, S.

397 - Genome-Wide Association Study of Overall and Progression-Free Survival after HLA-Matched Unrelated Donor Blood and Marrow Transplantation (DISCOVeRY-BMT study)
2621 - Evidence for Heterogeneous Genetic Associations with Acute Lymphoblastic Leukemia (ALL) By Cytogenetics and Sex in High-Risk Patients Treated with Matched Unrelated Donor Allogeneic Blood or Marrow Transplant (URD-BMT)

Liu, T. Y.

3424 - Generation of BCR-ABL Reactive CD4+ T Helper Cells By Reprograming and Redifferentiation

LIU, T.

156 - HLA-Mismatched Microtransplantation Vs HLA-Matched Nonmyeloablative Transplantation for Acute Myeloid Leukemia in Intermediate-Risk: Comparable Survival but Avoids of Gvhd
455 - Microtransplantation Improved Outcome in Elderly Acute Myeloid Leukemia Patients - Report from China Microtransplantation Cooperative Group

Liu, T.

4118 - Systematic Drug Repositioning By Integrating Transcriptome and Historical Clinical Data, Identification of Digoxin As a Novel Drug Reposition Candidate for High-Risk Myelodysplastic Syndromes

Liu, T.

182 - A Phase 1 Study of Denintuzumab Mafodotin (SGN-CD19A) in Relapsed/Refactory B-Lineage Non-Hodgkin Lymphoma

Liu, T.

220 - Tamibarotene Compared to All-Trans Retinoic Acid (ATRA) As Add-on to Arsenic Trioxide (ATO) in Subjects with Relapsed Acute Promyelocytic Leukemia (APL)
264 - 4SCAR19 Chimeric Antigen Receptor-Modified T Cells As a Breakthrough Therapy for Highly Chemotherapy-Resistant Late-Stage B Cell Lymphoma Patients with Bulky Tumor Mass

Liu, T.

3774 - Chimeric Antigen Receptor 4SCAR19-Modified T Cells in Acute Lymphoid Leukemia: a Phase II Multi-Center Clinical Trial in China
4240 - Continuous Treatment with Lenalidomide and Low-Dose Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma in Asia: Subanalysis of the First Trial

LIU, T.

2540 - Comparison of Outcome and Prognosis of 248 Elderly Patients with Acute Myeloid Leukemia Treated with Standard-Dose or Low-Intensity Induction Therapy

Liu, T.

862 - Pre-Emptive Donor Lymphocyte Infusion with CD19-Directed, CAR-Modified T Cells Infused after Allogeneic Hematopoietic Cell Transplantation for Patients with Advanced CD19⁺ Malignancies

Liu, T.

3956 - A Prospective, Self-Controlled and Randomized Study about the Optimal Timing of Leucovorin Rescue after High Dose Methotrexate Management

Liu, T.

2279 - Evaluation of Enhanced in Vitro Plasma Stability of a Novel Long Acting Recombinant FVIIIFc-VWF-XTEN Fusion Protein
3492 - Recombinant FVIIIFc-VWF-XTEN Demonstrates Significant Bioavailability Following Subcutaneous Administration in Hemophilia A Mice

Liu, T.

4060 - Efficacy, Safety, and Confirmation of the Recommended Phase 2 Starting Dose of the Combination of Ruxolitinib (RUX) and Panobinostat (PAN) in Patients (Pts) with Myelofibrosis (MF)

Liu, T.

2452 - Characterization of Hematopoiesis in Tp53 R172H Mutant Mice

Liu, W.

569 - A Novel STAT3 Inhibitor Has Potent Activity in Preclinical Models of Acute Myeloid Leukemia That Incorporate the Stromal Environment

Liu, W.

877 - Cognitive, Behavior and Academic Problems in Adolescent Survivors of Childhood Acute Lymphoblastic Leukemia (ALL): A Report from the Childhood Cancer Survivor Study
3255 - Association Between Acute Leukoencephalopathy and Long-Term Neurobehavioral and Brain Imaging Outcomes in Survivors of Childhood Acute Lymphoblastic Leukemia Treated with Chemotherapy Only

Liu, W.

3426 - Human Transcription Factor KLF3 Maintains T Lymphocyte Quiescent Phenotype Via Inhibiting SHP-1 Expression

Liu, W.

1725 - Intratumoral Genetic Heterogeneity Provides Additional Prognostic Significance of the CLL Genomic Features
3879 - Different Prognostic Significance of a Panel Cytogenetic Aberrations Between Chronic Lymphocytic Leukemia and Other B-Cell Chronic Lymphoproliferative Disorders

Liu, W.

4003 - Preclinical Evaluation of the Oral Proteasome Inhibitor Ixazomib in Diffuse Large B-Cell Lymphoma

Liu, W.

2170 - Blood Antioxidant Defenses and Sickle Cell Disease: Analyzing Cytochrome b Reductase 1 Protein Levels and Structure in Erythrocyte Membranes

Liu, W.

1398 - Mapping Microenvironment-Mediated Signaling Dependency of Targeted Inhibitors: A Mechanism-Based Approach of Selecting Effective Therapy Targeting Drug Resistant AML

Liu, X.

128 - Next Generation Sequencing Identifies a Distinct Transcriptional Profile, Including Isoform Dysregulation That Segue with Genomic Alterations in Waldenstrom's Macoglobulinemia
705 - HCK Is a Highly Relevant Target of Ibrutinib in MYD88 Mutated Waldenstrom's Macroglobulinemia and Diffuse Large B-Cell Lymphoma
1486 - The Clonal Architecture of CXCR4mutations in Waldenstrom's Macroglobulinemia Shows Highly Variable Subclonal Distribution, and Multiple Mutations within Individual Patients Indicative of Targeted Genomic Instability
1563 - Targeting Myddosome Self-Assembly in Waldenstrom's Macroglobulinemia
2665 - Whole Genome and Transcriptome Analysis of Waldenstrom's Cell Lines Show Preservation of Many Important Genomic Features of Primary Disease, and Identify a Non-L265P Mutation in MYD88
4004 - Targeting IRAK1/IRAK4 Signaling in Waldenstrom's Macroglobulinemia

Liu, X.

704 - The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Engraftment and Antitumor Responses Against Mantle Cell Lymphoma

Liu, X.

52 - A New AHI-1-DNM2-BCR-ABL Complex Regulates Leukemic Properties of Primitive CML Cells through Mediation of Cellular Endocytosis and ROS-Induced Autophagy
4012 - Identification of a New AHI-1-Mediated-PP2A-Beta-Catenin-BCR-ABL-JAK2 Complex Modulating Resistance of CML Stem/Progenitor Cells to Tyrosine Kinase Inhibitors

Liu, X.

4280 - Multiplex Cripsr/Cas9 Genome Editing to Generate Potent Universal CART and PD1-Deficient Cells Against Leukemia
4431 - Improved Anti-Leukemia Activities of Adoptively Transferred T Cells Expressing Bites

Liu, X.

1302 - Comparison of the Efficacy of the First and Second-Generation Tyrosine Kinase Inhibitors in the First-Line Treatment of Ph-Positive Acute Lymphoblastic Leukemia

Liu, X.

143 - Ubiquitin Editing of a Spliceosome Auxiliary Factor By TRAF6 Links Chronic TLR Signaling with Hematopoietic Defects and Myelodysplasia

Liu, X.

2378 - Polycomb Repressive Complex 1 Enhances HSC Self-Renewal through Repressing the Canonical Wnt Signaling Pathway

Liu, X.

1246 - Acid Ceramidase Inhibition Impairs Tumor Progression in a Rat Model of LGL Leukemia

Liu, X.

47 - Quantitative Proteomic and Transcriptomic Analysis Reveals Post-Transcriptional Regulation of Mitochondrial Biogenesis during Erythropoiesis

Liu, X. F.

1332 - Immunotoxin Activity Against B-Lineage Leukemia and Lymphoma Is Exposure Time Dependent: Implications for Trial Design

Liu, X.

2379 - Transcription Pausing Regulates Hematopoietic Stem Cell Emergence through Fine-Tuning of Signaling Pathways

Liu, Y.

3907 - Smoothened (SMO) Is an Adaptor Protein That Recruits TRAF6 and Phospholipase C Gamma 2 (PLCg2) to Enhance the Activation of NF-Kb Signaling Pathway

Liu, Y.

307 - Mutant p53 Drives the Development of Pre-Leukemic Hematopoietic Stem Cells through Modulating Epigenetic Regulators
442 - S6K1 Regulates Self-Renewal of Leukemia Initiating Cells and Normal Hematopoietic Stem Cells
2378 - Polycomb Repressive Complex 1 Enhances HSC Self-Renewal through Repressing the Canonical Wnt Signaling Pathway

Liu, Y.

229 - Donor T Cells Intrinsic Responses to Damps Regulated By Siglec-G-CD24 Axis Mitigate Gvhd but Maintain GVL in Experimental BMT Model

Liu, Y.

426 - Factor X Mutant Zebrafish Tolerate a Severe Hemostatic Defect in Early Development Yet Develop Lethal Hemorrhage in Adulthood

Liu, Y.

1970 - Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation Might Overcome the Adverse Effect of Minimal Residue Disease Pretransplant in Patients with Standard-Risk Acute Myeloid Leukemia

Liu, Y.

3592 - The NFkB System Regulates Flt3-Mediated Hematopoiesis

Liu, Y.

233 - Programming of Donor T Cells Using Allogeneic Delta-like Ligand 4-Positive Dendritic Cells to Reduce Gvhd but Retain GVL Activity
234 - Pharmacological Inhibition of Hsp90 Destabilizes the Histone Methyltransferase Ezh2 in Alloreactive T Cells and Reduces Graft-Versus-Host Disease While Retaining Anti-Leukemic Effects in Mice

Liu, Y.

691 - The Genomic Landscape of Childhood T-Lineage Acute Lymphoblastic Leukemia

Liu, Y.

264 - 4SCAR19 Chimeric Antigen Receptor-Modified T Cells As a Breakthrough Therapy for Highly Chemotherapy-Resistant Late-Stage B Cell Lymphoma Patients with Bulky Tumor Mass

Liu, Y.

1513 - Phase II Study of Chidamide, a New Subtype-Selective Oral Histone Deacetylase Inhibitor, in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma

Liu, Y.

SCI-28 - Educating the Innate Immune System

Liu, Y.

655 - Altered Heme-Mediated Modulation of Dendritic Cell Function in Sickle Cell Alloimmunization

Liu, Y.

1301 - Nilotinib Combined with Multi-Agents Chemotherapy for Adult Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of a Prospective Study from a Single Center

Liu, Z.

2271 - Prolonged Half-Life and Improved Recovery of Recombinant Factor IX-XTEN Fusion Proteins in Hemophilia B Mouse Model

Liu, Z.

1572 - USP47 Is a New Target in Chronic Myelogenous Leukemia

Liu, Z. C.

1585 - Age and Cost Are Associated with Patient Preference for Stopping Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia

Liu, Z. J.

1171 - Mediator Kinase Inhibition Triggers a Phenotypic Switch from Neonatal to Adult-like Megakaryopoiesis

Liu, Z.

4125 - Stimulation of the B-Cell Receptor (BCR) Induces Successive Activation of STAT3 and Nuclear Factor-Kappa-B in CLL Cells
4143 - P300 Acetylates STAT3 and Increases Its Constitutive Transcriptional Activity in CLL Cells

LIU, Z.

156 - HLA-Mismatched Microtransplantation Vs HLA-Matched Nonmyeloablative Transplantation for Acute Myeloid Leukemia in Intermediate-Risk: Comparable Survival but Avoids of Gvhd
455 - Microtransplantation Improved Outcome in Elderly Acute Myeloid Leukemia Patients - Report from China Microtransplantation Cooperative Group

Liu, Z. G.

264 - 4SCAR19 Chimeric Antigen Receptor-Modified T Cells As a Breakthrough Therapy for Highly Chemotherapy-Resistant Late-Stage B Cell Lymphoma Patients with Bulky Tumor Mass

Liuksiala, T.

3646 - Identification of Novel Drug Targets in T-Cell Acute Lymphoblastic Leukemia

Livak, F.

53 - Role of the MSC-Derived Exosomal and Endogenous JAK2-SET/PP2A-Beta Catenin-Modulator Mir-300 in Leukemic Stem/Progenitor Proliferation and Survival in CML

Livak, K. J.

2906 - Comprehensive Bulk and Single Cell Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia

Livingston, E.

549 - The Effect of Prophylactic Recombinant Factor IX and Glycopegylated Factor IX to Normalize Articular Wound Healing Following Hemarthrosis Examined in Hemophilia B Mice

Livnat, T.

552 - Antithrombin Reduction Corrected Thrombin Generation in Samples from Hemophilia A and B Patients with Inhibitors

Ljubomir, B.

398 - A Predictive Model Using Telomere Length to Select Optimal Donors for Hematopoietic Stem Cell Transplant (HCT) for Acute Leukemia

Ljungman, P. T.

863 - Efficacy, Safety and Long Term Results of Prophylactic and Preemptive Donor Lymphocyte Infusion after Allogeneic Stem Cell Transplantation for Acute Leukemia: A Registry-Based Evaluation on 343 Patients By the Acute Leukemia Working Party of EBMT
3138 - Treatment of Chronic GvHD with Mesenchymal Stromal Cells Induces Durable Responses; A Phase II Study

Ljungqvist, M.

2309 - Post-Thrombotic Syndrome and Quality-of-Life after Venous Thromboembolism in Young and Middle-Aged Women

Ljungström, V.

4126 - EGR2 Mutations in Chronic Lymphocytic Leukemia: A New Bad Player

Ljungstrom, V.

365 - Genomic Disruption of the Histone Methyltransferase SETD2 in Chronic Lymphocytic Leukemia
1712 - ATM Mutations in Major Stereotyped CLL Subsets: Enrichment in Subset #2 is Associated with Unfavourable Outcome

Llamas, P.

2791 - Measurement of PTCH1 Expression at Diagnosis Is an Appropriate Tool for Tyrosine Kinase Inhibitors Selection in Chronic Myeloid Leukemia Patients in Chronic Phase

Llishi, A.

4388 - Allogeneic Hematopoietic Stem Cell Transplantation (HCT) for Acute Myeloid Leukemia (AML) Not in First Remission

Llobet, N.

4395 - Feasibility and Outcome of Allogeneic Hematopoietic Stem-Cell Transplantation in High-Risk AML: Real-Life Perspective from a Single Institution

Llop*, M.

1403 - Validation of a Next-Generation Sequencing Panel for AML Routine Diagnosis

Llorente, L.

2139 - Complement Genotype and Multiparametric Laboratory Analysis to Predict Response to Eculizumab and to Adjust Treatment in Patients with Paroxysmal Nocturnal Hemoglobinuria

Lo Coco, F.

459 - Inhibition of the Histone Demethylase LSD1 Combined with Caloric Restriction or IGF1/Insulin Inhibition Leads to Durable Responses in a Preclinical Model of Acute Myeloid Leukemia
2004 - Evolving Criteria of Donor Selection for Allogeneic Transplant in Acute Myeloid Leukemia
2821 - Application of the International Prognostic Score of Thrombosis for Essential Thrombocytemia(ET) (IPSET-Thrombosis) in a Cohort of ET Patients: Experience from Gruppo Laziale for Myeloproliferative Ph Negative Neoplasms
3230 - Variable Outcome of Allogeneic Stem Cell Transplant According to the Different Levels of Pre-Transplant Minimal Residual Disease, in Adult Patients with Acute Myeloid Leukemia

Lo Coco, L.

2339 - Cryopreserved Platelets: From in Vitro Thrombin Generation Potential to in Vivo Safety

Lo Iacono, M.

4412 - Hematopoietic Stem Cell Mobilization for Gene Therapy: The Combination of G-CSF+Plerixafor in Patients with Beta-Thalassemia Major Provides High Yields of CD34+ Cells with Primitive Signatures
4414 - The Sea Urchin sns5 Chromatin Insulator Improves the Likelihood of Lentiviral Vectors in Erythroid Milieu By Organizing an Independent Chromatin Domain at the Integration Site

Lo, M.

4458 - Frequency, Risk Factors and Mortality Effect of Venous Thromboembolism in Adult Patients with Central Nervous System Lymphoma

Lo, P.

1374 - Defining the Immune Microenvironment in Patients with Acute Myeloid Leukemia

Lo, R. W.

419 - Dynamin 2 (DNM2) and PACSIN2 Regulate Megakaryocyte Demarcation Membrane System Formation and Platelet Production in Concert

Lo, S.

3299 - Symptoms of Depression and Anxiety Assessed By the SF-36 Questionnaire in Patients with AL Amyloidosis

Lo, T. H.

2198 - Functional Studies on the C-Type Lectin Receptor CD302 Present on Dendritic Cells and Macrophages
3081 - Characterisation of Human CD83 Expression on Immune Cells and Their Targeting with CD83 Antibodies to Prevent Graft Versus Host Disease in Allogeneic Haematopoietic Cell Transplantation

Lo-Coco, F.

6 - The Multi-Kinase Inhibitor Midostaurin (M) Prolongs Survival Compared with Placebo (P) in Combination with Daunorubicin (D)/Cytarabine (C) Induction (ind), High-Dose C Consolidation (consol), and As Maintenance (maint) Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients (pts) Age 18-60 with FLT3 Mutations (muts): An International Prospective Randomized (rand) P-Controlled Double-Blind Trial (CALGB 10603/RATIFY [Alliance])

Loach, D.

3289 - Predictors of the Trajectory of Neurocognitive Functioning in the First Six Months after Allogeneic Hematopoietic Stem Cell Transplantation

Lobastov, K.

1132 - Blood Hypercoagulation Assessed with Thrombodynamics Test Predicts Postoperative Venous Thrombosis in Patients at High Risk
2332 - The Efficacy and Safety of Oral Rivaroxaban in Patients with Permanent Inferior Vena Cava Filter: A Pilot Case-Control Study

Lobato, J.

3888 - The NCCN-IPI Helps to Identify Very High-Risk Patients with DLBCL and Can be Improved By Other Independent Clinical Factors Including Bulky Disease and beta2-Microglobulin

Loberg, A.

977 - Placenta Growth Factor Links the IL-13 Response and the Leukotriene Pathway to Augment Airway Hyper-Responsiveness

Lobry, C.

4 - Therapeutic Targeting of Spliceosomal Mutant Myeloid Leukemias through Modulation of Splicing Catalysis

Locatelli, F.

153 - Outcomes of Cord Blood Transplantation from an HLA-Identical Sibling for Patients with Inherited or Acquired Bone Marrow Failure Disorders: A Report from Eurocord, Cord Blood Committee (CBC-CTIWP) and Severe Aplastic Anemia Working Party (SAAWP) of the European Group of Blood and Bone Marrow Transplantation (EBMT)

Locatelli, F.

171 - Next Generation Sequencing Identifies a Novel Subset of Non-Down Syndrome Acute Megakaryoblastic Leukemia Characterized By Chimeric Transcripts Involving HOX Cluster Genes
172 - Predictors of Early Death in Childhood Acute Promyelocytic Leukemia: Results of an International Retrospective Study
195 - Children with Acute Leukemia Given Hematopoietic Stem Cell Transplantation (HSCT) from an HLA-Compatible Sibling, or an Unrelated Donor (UD) or an HLA-Haploidentical Relative after Alpha/Beta T-Cell Depletion Have a Comparable Outcome
299 - Somatic Genetic and Epigenetic Architecture of Myelodysplastic Syndromes Arising from GATA2 Deficiency
541 - Hematopoietic Stem Cell Transplantation from HLA Identical Sibling Forsickle Cell Disease an International Survey on Behalf of Eurocord-Monacord, EBMT Paediatric Disease Working Party and CIBMTR
563 - Risk-Group Stratified and Minimal Residual Disease (MRD)-Guided Treatment with Extended ATRA and Reduced-Anthracycline Chemotherapy in Childhood Acute Promyelocytic Leukemia (APL): Results from ICC APL Study 01 (NCT01226303; EudraCT 2008-002311-40)
621 - Hematopoietic Stem Cell Transplantation for Hemophagocytic Lymphohistiocitosis : A National Retrospective Analysis of Data from the Italian Association of Pediatric Hematology Oncology (AIEOP)
1657 - The Integrated Immunological Signature of Refractory Cytopenia of Childhood (RCC)
1662 - Clonal Mutational Landscape of Childhood Myelodysplastic Syndromes
1929 - An Accelerated CD8+, but Not CD4+, T-Cell Reconstitution Associates with a More Favorable Outcome Following HLA-Haploidentical HSCT: Results from a Retrospective Study of the Cell Therapy and Immunobiology Working Party of the EBMT
1931 - Clinical Outcome after Adoptive Infusion of BPX-501 Cells (donor T cells transduced with iC9 suicide gene) in Children Given Alpha/Beta T-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (haplo-HSCT): Preliminary Results of a Phase I-II Trial
2598 - Prognostic Relevance of Recurrent Genetic Aberrations in Pediatric Acute Megakaryoblastic Leukemia
2622 - Clonal Evolution and Lack of BCR-ABL1 Mutations in Pediatric Ph+ ALL Patients Resistant/Refractory to Imatinib Treatment
2788 - Early Response Does Not Impact on the Long-Term Outcome of Children and Adolescents with Chronic Myeloid Leukemia Treated with High-Dose Imatinib. the Italian Experience
2851 - Microrna-150 Regulates STAT5b Levels in Juvenile Myelomonocytic Leukemia (JMML)
3093 - Immune Reconstitution after Adoptive Infusion of BPX501 Cells (donor T cells transduced with iC9 suicide gene) in Children Given Alpha/Beta T-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (haplo-HSCT): Preliminary Phenotypic and Functional Results of a Phase I-II Trial
3107 - Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome Following Hematopoietic Stem Cell Transplantation or Chemotherapy--Results from the Italian Therapeutic Use Protocol
3154 - Guidelines for the Standardization of Acute Graft-Versus-Host Disease Clinical Data Collection: An International Consensus Report
3845 - Clinical and Biological Characterization of Children with FLT3ITD Mutated Acute Myeloid Leukemia (AML): A Report from the AIEOP AML-2002 Study Group
4299 - BPX-501 Cells (donor T cells transduced with iC9 suicide gene) Are Able to Clear Life-Threatening Viral Infections in Children with Primary Immune Deficiencies Given Alpha/Beta T-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (haplo-HSCT)

Locatelli, S. L.

1495 - A Dose Escalation Study of RP6530, a Novel Dual PI3K Delta/Gamma Inhibitor, in Patients with Relapsed/Refractory Hematologic Malignancies
1561 - Synergistic Induction of Cell Death in Hodgkin Lymphoma Cells By the Novel PI3K Inhibitor RP6530 Combined with Brentuximab Vedotin (SGN-35) through Inhibition of Tumor Angiogenesis

Locatelli-Hoops, S. C.

1805 - E-Selectin Ligand Expression Increases with Progression of Myeloma and Induces Drug Resistance in a Murine Transplant Model, Which Is Overcome By the Glycomimetic E-Selectin Antagonist, GMI-1271

Lock, R. B.

1365 - Investigation of a Novel Cyclin-Dependent-Kinase (CDK) Inhibitor Cdki-73 As an Effective Treatment Option for MLL-AML
3759 - Evaluation of Patient-Derived Xenografts for Modeling Outcome of Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia
3766 - Efficacy of Focal Adhesion Kinase Inhibition in Combination with Dasatinib in BCR-ABL1 Acute Lymphoblastic Leukemia

Locke, F. L.

2730 - Phase 1 Biomarker Analysis of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)
2941 - Sequential Therapy with Ofatumumab, High Dose Methylprednisolone and Lenalidomide Is a Safe and Effective Regimen for the Treatment of Previously Treated and Untreated CLL/SLL: The Hilo Trial
3991 - Phase 1 Clinical Results of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)
4407 - Hypo-Albuminemia at Day+90 after Allogeneic Hematopoietic Cell Transplantation for Lymphoid Malignancies Independently Predicts for Inferior Overall Survival and Higher Non-Relapse Mortality

Locke, S. C.

2119 - Patient Experiences of Acute Myeloid Leukemia (AML): A Qualitative Study about Diagnosis, Illness Understanding, and Treatment Decision-Making
4496 - Symptom Burden, Quality of Life, and Distress in Acute Myeloid Leukemia Patients Receiving Induction Chemotherapy: Results of a Prospective Electronic Patient-Reported Outcomes Study

Lockhart, A. C.

3966 - An Open-Label, Phase 1 Study Evaluating the Safety and Pharmacokinetics of Pralatrexate in Relapsed/Refractory Advanced Solid Tumors or Advanced Lymphoma/Myeloma Patients with Mild, Moderate, and Severe Renal Impairment

Lockhart, E. L.

- Postpartum Hemorrhage: A Continuing Challenge

Lockmer, S.

1535 - Sequential Immune Cell Modulation in Nordic Follicular Lymphoma Patients in the SAKK 35/10 Randomized Trial with Rituximab and Lenalidomide

Lockwood, C.

2793 - Development of Xpert® BCR-ABL Ultra, an Automated and Standardized Multiplex Assay with Required Performance Characteristics for BCR-ABL1 Quantitative Measurement on an International Reporting Scale

Loden, M.

2918 - Assessment of p53 and ATM Functionality in Chronic Lymphocytic Leukemia By Multiplex Ligation-Dependent Probe Amplification

Lodish, H. F.

271 - Mitochondrial Protein Kinase A Regulates Heme Biosynthesis
405 - Fam210b Is Required for Optimal Cellular and Mitochondrial Iron Uptake during Erythroid Differentiation
3590 - Thyroid Hormone Receptor Beta and NCOA4 Regulate Terminal Erythrocyte Differentiation

Lodola, M.

3645 - GEP Analyses of Bone Marrow CD34+/Lin- Cells of Chronic Phase CML Patients at Diagnosis Identified Different Sets of Genes Associated to the Molecular Response after 3 and 6 Months of First-Line Nilotinib Treatment

Loeb, D.

312 - A Wilms Tumor 1 (WT1) Mutation Causes Myelodysplastic Syndrome in a Knock-in Mouse Model, and a Mixed Myelodysplastic/Myeloproliferative Neoplam in Double Knock-in Mice with WT1 and FLT3/ITD Mutations

Loeb, L. A.

478 - Emergence of Sub-Clonal Drug Resistance Mutations during CML Therapy

Loeff, F. C.

1435 - Loss of Pigh Expression Frequently Results in a GPI-Negative Subclone Lacking CD52 Membrane Expression, Conferring Alemtuzumab Resistance to B Cell Acute Lymphoblastic Leukemia
3134 - A Polyclonal Population of Piga Mutant CD52 and GPI Anchor Negative T Cells Can Give Early Immune Protection after Alemtuzumab-Based T Cell Depleted Allogeneic Stem Cell Transplantation

Loeffler, D.

2391 - Stem Cell-like Megakaryocyte Progenitors As Driving Forces of IFN-Induced Emergency Megakaryopooesis

Loeffler, M.

1509 - Obesity Is a Prognostic Factor in Elderly Female Patients with Aggressive B-Cell Lymphomas Treated with R- CHOP

Loeffler, M. W.

1027 - Interplay Between the Immune System and Colorectal Carcinoma - Towards Tumor-Specific Peptide-Based Vaccination for Any HLA-Type

Loeffler, P.

4443 - Does Adherence to Hydroxyurea Affect Emergency Department Observation Unit Utilization?

Loew, A.

683 - Efficacy and Safety of Humanized Chimeric Antigen Receptor (CAR)-Modified T Cells Targeting CD19 in Children with Relapsed/ Refractory ALL

Löfberg, C.

2912 - First-in-Class ROR1 Small Molecule Inhibitor (KAN0439834) Downregulated Wnt-Canonical and Non-Canonical Signaling Pathways and Induced Apoptosis of CLL Cells

Löffeld, P.

912 - Molecular Predictors of Outcome in Patients with MDS and AML Following MDS after Allogeneic Hematopoietic Stem Cell Transplantation

Loffler, D.

778 - Interleukin-1 Drives Precocious Myeloid Differentiation of Hematopoietic Stem Cells at the Expense of Self-Renewal

Löffler, M.

3922 - Comprehensive Analyses of Genetic Features Identify Coordinate Signatures in Diffuse Large B-Cell Lymphoma

Loftus, D.

398 - A Predictive Model Using Telomere Length to Select Optimal Donors for Hematopoietic Stem Cell Transplant (HCT) for Acute Leukemia

Logan, A. C.

503 - Defining Primary Marrow Microenvironment-Induced Synthetic Lethality and Resistance for 2,684 Approved Drugs Across Molecularly Distinct Forms of Multiple Myeloma
1420 - Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk Following Autologous Hematopoietic Cell Transplantation

Logan, A. C.

1337 - Panobinostat-Augmented Cytarabine and Daunorubicin (7+3) Induction for Older Patients with AML or High-Risk MDS Is Well Tolerated and Results in Favorable Clinical Outcomes: The Panda Trial
4340 - Molecular Remission One Year Following Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia Predicts Relapse-Free and Overall Survival: A Multi-Institutional Landmark Analysis
4350 - Multigene MRD Assessment Improves AML Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation

Logan, B.

193 - Outcome of Patients 65 Years and Older with Myelodysplastic Syndrome (MDS) Receiving Allogeneic Hematopoietic Stem Cell Transplantation Compared to Patients 55-64 Years of Age
270 - 5 Year Results of BMT CTN 0201: Unrelated Donor Bone Marrow Is Associated with Better Psychological Well-Being and Less Burdensome Chronic Gvhd Symptoms Than Peripheral Blood
619 - A Multicenter Phase II Trial of Unrelated Donor Reduced Intensity Bone Marrow Transplantation for Children with Severe Sickle Cell Disease (SCURT): Results of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0601) Study

Logan, E.

2549 - DC/Aml Fusion Cell Vaccination Administered to AML Patients Who Achieve a Complete Remission Potently Expands Leukemia Reactive T Cells and Is Associated with Durable Remissions
4218 - Blockade of PD-1 in Combination with Dendritic Cell/Myeloma Fusion Cell Vaccination Following Autologous Stem Cell Transplantation Is Well Tolerated, Induces Anti-Tumor Immunity and May Lead to Eradication of Measureable Disease

Loges, S.

1569 - BGB324 Inhibits BCR-ABL TKI-Resistant Chronic Myeloid Leukemia

Loghmani-khouzani, H.

648 - Homozygous Mutations in PHRF1 and PPARG in a Patient with Congenital Neutropenia and Profound Monocytosis: Understanding the Pathway Beyond Monocyte Versus Granulocyte Cell-Fate Choice

Loghmani-Khouzani, H.

1001 - Inhibition of the NAMPT-Triggered Deacetylation of HCLS1 Protein: A New Therapeutic Option in Chronic Myeloid Leukemia

Loglisci, G.

4038 - Event-Free Survival According to Age in Patients with Chronic Myeloid Leukemia Receiving Imatinib Frontline: The Younger, the Later, the Worse?

Logsdon, B.

3629 - Mini-Chromosome Maintenance (MCM) DNA Helicase Genes Influence Acute Myeloid Leukemia (AML) Replication and Response to Chemotherapy-Induced DNA Damage

Loh, M.

695 - Germline Genetic Variation in ETV6 and Predisposition to Childhood Acute Lymphoblastic Leukemia

Loh, M. L.

Loh, M. L.

84 - Characterization of Leukemias with ETV6-ABL1 Fusion

Loh, M. L.

556 - Identification of BCL6 As a Therapeutic Target in RAS-Driven Acute Lymphoblastic Leukemia

Loh, Y.

3184 - Impact of Post-Remission Consolidation Modalities in the Clinical Outcomes of Acute Myeloid Leukemia Patients in First Remission - Is There a Role for Autologous Hematopoietic Stem Cell Transplant?

Lohi, O.

3646 - Identification of Novel Drug Targets in T-Cell Acute Lymphoblastic Leukemia

Løhmann, D. J.

3745 - Effect of Age and Weight on Toxicity and Survival in Pediatric Acute Myeloid Leukemia

Lohneis, P.

576 - Modeling the CNS Tropism of Diffuse Large B-Cell Lymphomas in Vivo

Lohri, A.

3941 - Primary Progressive Disease in Hodgkin Lymphoma Patients: A Retrospective Analysis from the German Hodgkin Study Group

Loidolt, L.

3100 - Successful Translation of Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Cell Processing Technology from Academia to Industry

Loiseau, C.

3161 - Bronchiolitis Obliterans Occurring after Allogenic Hematopoietic Stem Cell Transplant: Comparison of Outcome Between Patients Equipped or Not with Home Spirometry Monitoring

Loiselle, C.

3800 - Anti-Leukemia Effect of FF-10501-01, a Novel Inosine 5'-Monophosphate Dehydrogenase Inhibitor, in Advanced Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS), Including Hypomethylating Agent (HMA) Failures

Loiselle, C.

1930 - Phase I Multicenter Trial of Brentuximab Vedotin for Steroid Refractory Acute Graft-Vs.-Host Disease (GVHD)

Loken, M. R.

560 - A Recurrent Immunophenotype at Diagnosis Independently Identifies High Risk Pediatric AML: A Report from the Children's Oncology Group Trial AAML0531
561 - Heirarchical Clustering of Immunophenotypic Cell Surface Antigen Expression Identifies Clinically Meaningful Cohorts in Childhood AML: A Report from the Children's Oncology Group Protocol AAML0531
799 - Treatment of 11q23/MLL+ AML with Gemtuzumab Ozogamicin: Results from the Randomized Phase III Children's Oncology Group Trial AAML0531
1377 - Recurrent Genetic Abnormalities Are Reflected in Phenotype at Diagnosis in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group Protocol AAML0531

Lokhorst, H.

29 - Clinical Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma
4174 - Genetic Mutational Panel Analyses of Extramedullary Relapses in Multiple Myeloma; No Gain of RAS Mutations

Lokhorst, H. M.

27 - Bortezomib Induction and Maintenance in Patients with Newly Diagnosed Multiple Myeloma: Long-Term Follow-up of the HOVON-65/GMMG-HD4 Trial
507 - Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results of a Phase 1/2 Study (GEN503)
1837 - Serum Proteomic Analysis of Multiple Myeloma Subjects Treated with Daratumumab Monotherapy
3037 - Immunomodulatory Effects and Adaptive Immune Response to Daratumumab in Multiple Myeloma
4222 - Target-Mediated Drug Disposition of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma after Prior Proteasome Inhibitors and Immunomodulatory Drugs: A Population Pharmacokinetic Analysis
4254 - Understanding the Dose Regimen for Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma (MM) after Prior Proteasome Inhibitors (PIs) and Immunomodulatory Drugs (IMiDs): A Quantitative Pharmacologic Perspective

Lollar, P.

1066 - Anti-C1 Domain Antibodies Are Pathogenic in a Murine Tail Snip Model Despite Low Inhibitor Titers
3491 - Frequency and Epitope Specificity of Anti-Factor VIII C1 Domain Antibodies in Acquired and Hereditary Hemophilia Inhibitor Patient Plasma

Lomaia, E.

4051 - Efficacy of Tyrosine Kinase Inhibitors in Third Line Therapy in Chronic Phase Chronic Myeloid Leukemia

Lombardo, K. A.

3896 - Comparative Analysis of Endemic and Sporadic Burkitt Lymphoma By RNA Sequencing

Lombardo, M.

1280 - Translational Focus on Targeting HDAC6 with Ricolinostat Confirms Potent Activity in Preclinical Models of Lymphoma and a Favorable Toxicity Profile in Patients with Relapsed or Refractory Lymphoma
3708 - Mechanisms of Acquired Drug Resistance to the Isoform Selective HDAC6 Inhibitor Ricolinostat Reveals Markedly Upregulated Elements of the BTK Pathway Revealing Rational Drug : Drug Combinations

Lomiento, M.

1356 - A New Entity of Acute Myeloid Leukemia Driven By Epigenetic and Somatic Dis-Regulation of Uncx, a Novel Homeobox Transcription Factor Gene

Lominska, C.

1909 - Final Results of the First-in-Human Clinical Study Incorporating Hyperbaric Oxygen into Umbilical Cord Blood Transplantation

London, N.

3356 - Safety and Efficacy of Rapid (one hour) Single Intravenous Dose Low Molecular Weight Iron Dextran for Treatment of Oral Iron Intolerant Maternal Iron Deficient Anemia

London, W. B.

260 - Gene Therapy Using a Self-Inactivating Lentiviral Vector Improves Clinical and Laboratory Manifestations of Wiskott-Aldrich Syndrome
2136 - The Phenotypic Spectrum of Pyruvate Kinase Deficiency (PKD) from the PKD Natural History Study (NHS): Description of Four Severity Groups By Anemia Status
3337 - Molecular Characterization of 140 Patients in the Pyruvate Kinase Deficiency (PKD) Natural History Study (NHS): Report of 20 New Variants

Londoño Joshi, A.

225 - High-Sensitivity Genomic Minimal Residual Disease Detection Reveals Multiclonal Hematopoiesis and Is Associated with Survival in Adult AML

Lone, A. M.

2225 - Pure Red Cell Aplasia - a New Manifestation of CTLA4 Mutation

Lone, Y. C.

106 - Identification of T Cell Epitope of ADAMTS13 in Thrombotic Thrombocytopenic Purpura Patients

Lonetree, C. L.

2045 - Megatal, Crispr/Cas9, and Talen T-Cell Receptor Gene Editing

Long, G. D.

1857 - A Phase I-II Study of the Combination of Bendamustine and Pomalidomide with Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma.

Long, H.

3252 - Proxe: A Public Repository of Xenografts to Facilitate Studies of Biology and Expedite Preclinical Drug Development in Leukemia and Lymphoma

Long, J. B.

1676 - Secondary Myeloid Neoplasms in Older Women with Breast Cancer after Radiotherapy: A Population-Based Study
3285 - Comparative Effectiveness of Azacitidine Versus Decitabine Among Older Adults Diagnosed with Higher-Risk Myelodysplastic Syndromes (HR-MDS)

Long, M.

2940 - Ibrutinib Treatment Reduces Both T-Regulatory Cells and B-Regulatory Cell Phenotype in Malignant B Cells in Chronic Lymphocytic Leukemia Patients

Long, S.

3239 - Human Factor VIII Expression and Normalization of Bleeding Following AAV Gene Therapy in a Double Knockout Mouse Model of Hemophilia

Long, S. R.

1539 - Regulatory T Cells Are Depleted in Low-Grade Lymphoma By the Combination of Local Low-Dose Radiation Followed By Intratumoral CpG-ODN

Long, W.

87 - Discovery and Functional Validation of Novel Pediatric Specific FLT3 Activating Mutations in Acute Myeloid Leukemia: Results from the COG/NCI Target Initiative
169 - Rearrangements in Nucleoporin Family of Genes in Childhood Acute Myeloid Leukemia: A Report from Children Oncology Group and NCI/COG Target AML Initiative
170 - Comprehensive Genomic and Transcript Profiling of CBL Gene in Childhood AML: A Report from Children's Oncology Group Studies AAML03P1, AAML0531 and COG/NCI Target AML Initiative
174 - CSF3R Mutations Represent a Novel Therapeutic Target in Pediatric AML with a High Degree of Overlap with CEBPA Mutations: a Report from COG AAML0531 and COG/NCI Target AML Initiative
1368 - TET2 Mutations Are Highly Associated with RUNX1-RUNX1T1 Translocations and NPMc+ in Childhood AML: a Report from Children's Oncology Group AAML03P1, AAML0531 and NCI/COG Target AML Initiative
2587 - ASXL1 and ASXL2 Mutations in Childhood AML Are Strongly Associated with t(8;21) but Do Not Independently Impact on Prognosis: A Report from the Children's Oncology Group and NCI/COG Target Initiative

Long, X.

569 - A Novel STAT3 Inhibitor Has Potent Activity in Preclinical Models of Acute Myeloid Leukemia That Incorporate the Stromal Environment

Longacre, M.

874 - Multiple Myeloma Patient Experience with Financial Toxicity: Findings from the Cancer Experience Registry

Longhini, A. L.

2860 - Knockdown of HCK Reduces Cell Death and Erythroid Differentiation in Human CD34⁺ Hematopoietic Progenitor Cells

Longmate, J.

3108 - Safety, Maximum Tolerated Dose and Immunogenicity of CMV-MVA-Triplex in Healthy Volunteers with or without Prior Immunity to CMV and Vaccinia

Longo, G.

2930 - A Comprehensive Progression Risk Score to Predict Treatment Free Survival for Early Stage Chronic Lymphocytic Leukemia Patients

Lonial, S.

Lonoce, A.

1356 - A New Entity of Acute Myeloid Leukemia Driven By Epigenetic and Somatic Dis-Regulation of Uncx, a Novel Homeobox Transcription Factor Gene

Loo, D.

1779 - Diagnosis of Amyloidosis Subtype By Laser-Capture Microdissection (LCM) and Tandem Mass Spectrometry (MS/MS) Proteomic Analysis

Loo, E. Y.

3864 - Monoamine Oxidase a (MAO A) Is Expressed Selectively in Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Loo, M.

2506 - Excellent Outcome in Pediatric AML with Response Guided Chemotherapy without Allogeneic HSCT in First Complete Remission: Results from Protocol DB-AML01

Look, A. T.

326 - Nuclear Export Inhibitor KPT-8602 Is Highly Active Against Leukemic Blasts and Leukemia-Initiating Cells in Patient-Derived Xenograft Models of AML

Lopes, M. R.

2847 - Methylation of HAI-2/SPINT2 in Bone Marrow Mesenchymal Stromal Cells of MDS and AML Patients Affects Hematopoietic Stem Cell Survival and Adhesion

Lopes, R. D.

- Anticoagulation in Patients with Renal Failure

Lopez, A.

2139 - Complement Genotype and Multiparametric Laboratory Analysis to Predict Response to Eculizumab and to Adjust Treatment in Patients with Paroxysmal Nocturnal Hemoglobinuria

López, A.

4231 - Assessment of Clinical Differences Between Starting Antimyeloma Treatment at Biological Relapse or at Clinical Relapse: Preliminary Results of an Observational Prospective Registry

López, A.

1333 - Post-Remission Treatment with Chemotherapy or Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) of High-Risk (HR) Philadelphia Chromosome-Negative (Ph-neg) Adult Acute Lymphoblastic Leukemia (ALL) According to Minimal Residual Disease (MRD). Preliminary Results of the Pethema ALL-HR-11 Trial

Lopez, C.

2460 - Attenuation of Apoptosis-Stimulating Protein of p53-2 (ASPP2) Promotes IL-3-Independent Growth and Enhances Cytogenetic Abnormalities after Gamma-Irradiation in Mouse Hematopoietic Cells - Mimicking Early Leukemogenesis of Therapy-Associated Human AML

Lopez Corral, L.

2007 - The Use of Busulphan As Compared to Melphalan in Combination with Fludarabine in the Reduced Intensity Conditioning Improves Overall Survival in Patients with Lymphoma

Lopez de la Guia, A.

2962 - Usefulness of Serum-Free-Light-Chains-Ratio (SFLCR) and Serum Heavy-Light-Chains-Ratio (SHLCR) in Multiple Myeloma in the Context of Three GEM/Pethema Clinical Trials

Lopez Fernandez, E.

1756 - Multiple Myeloma with Prior Precursor Disease Shows Better Outcome

Lopez, Sr., J.

496 - Results of the Safety Run-in Phase of CLL14 (BO25323): A Prospective, Open-Label, Multicenter Randomized Phase III Trial to Compare the Efficacy and Safety of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) with Obinutuzumab and Chlorambucil in Patients with Previously Untreated CLL and Coexisting Medical Conditions
582 - Evaluation of the Regimen Brentuximab Vedotin Plus ESHAP (BRESHAP) in Refractory or Relapsed Hodgkin Lymphoma Patients: Preliminary Results of a Phase I-II Trial from the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO)
1514 - Phase 2 Randomized Trial Comparing 6 Cycles of Standard RCHOP Chemotherapy Vs 6 Cycles of Brcap (bortezomib, rituximab, cyclophosphamide, adriamicine and prednisone) As First Line Treatment in Young Patients with Poor Prognosis Diffuse Large B-Cell Lymphoma (DLBCL): Interim Analysis

Lopez, J.

1354 - Targeting Transcriptional Dependency in Acute Myeloid Leukemia (AML) with a Covalent Inhibitor of Transcriptional Kinase CDK7

López Jiménez, J.

521 - Progression-Free Survival at 24 Months (PFS24) and Complete Response at 30 Months (CR30) from Autologous Stem Cell Transplantation (ASCT) Should be Used As Surrogates for OS in Follicular Lymphoma (FL) Patients

Lopez, J.

4363 - Pronostic Value of Pretransplant Echocardiography in Allogeneic Hematopoietic Cell Transplantation

Lopez, J. A.

3451 - ADAMTS13 Synergizes with HDL in Preventing Von Willebrand Factor Self-Association Under Shear Stress

Lopez, J. A.

972 - Evaluation of Cell Types and Morphologies in Sickle Cell Disease with an Imaging Flow Cytometer

Lopez, J. A.

239 - N-Acetylcysteine Treatment in Two Patients with Relapsed Thrombotic Thrombocytopenic Purpura Increased ADAMTS13 Activity, Free Thiol Concentration in Plasma, and Inhibited Platelet Activation
1044 - Effect of N-Acetyl-L-Cysteine on Cysteine Redox Status in Patients with Thrombotic Thrombocytopenic Purpura: Protein Disulfide Bound Cysteine As a Biomarker of Oxidative Stress

Lopez, L.

1003 - Whim Syndrome Caused By a 5 Base Pair Deletion in the C-Terminus of Chemokine Receptor CXCR4

López Longo, F. J.

2317 - Thromboelastometry Shows a Prothrombotic State in Systemic Lupus Erythematosus Related to Diminished Fibrinolysis and Microparticle-Derived Tissue Factor

López Lorenzo, J. L.

2786 - Safety and Efficacy of Bosutinib in Fourth Line Therapy of Chronic Myeloid Leukemia Patients

López, L.

3944 - Incidence, Risk Factors and Prognosis of Transformation in Follicular Lymphoma: a Multicentre Retrospective Analysis of 1763 Patients from the Geltamo Spanish Lymphoma Cooperative Group
3955 - Validation of the NCCN-IPI for Diffuse Large B-Cell Lymphoma (DLBCL) in a Nation-Wide Spanish Series of 1885 Patients. the Geltamo-IPI Project

Lopez, M. E.

2723 - Incidence, Treatment and Prognosis of Patients with Relapsed Burkitt Lymphoma/Leukemia Treated with Specific Chemotherapy or Immunochemotherapy in Spain

Lopez, O.

3871 - Prognostic Impact, Phenotypic and Molecular Characterization of Concordant and Discordant Bone Marrow Involvement in Patients with Diffuse Large b-Cell Lymphoma

López, P.

2654 - Addition of Absolute Lymphocytes/Monocytes Ratio Improves the Revised-International Prognostic Index (R-IPI) in Patients with Diffuse Large B Cell Lymphoma (DLBCL) Treated with R-CHOP

López, Sr., R.

4358 - Comparative Study of Post-Transplant Lymphoproliferative Disorders after Solid Organ Transplantation Versus Hematopoietic Stem Cell Transplantation

Lopez, R.

4356 - Immunoparesis Recovery As Predictor Marker of Progression after Autologous Stem Cell Transplantation in Multiple Myeloma

Lopez, R.

608 - The Complete Mutatome and Clonal Architecture of Del(5q)

Lopez-Anglada, L.

2962 - Usefulness of Serum-Free-Light-Chains-Ratio (SFLCR) and Serum Heavy-Light-Chains-Ratio (SHLCR) in Multiple Myeloma in the Context of Three GEM/Pethema Clinical Trials

Lopez-Ansoar, E.

2263 - Usefulness of Eltrombopag in Secondary ITP Patients in Clinical Practice

Lopez-Cadenas, F.

3871 - Prognostic Impact, Phenotypic and Molecular Characterization of Concordant and Discordant Bone Marrow Involvement in Patients with Diffuse Large b-Cell Lymphoma

Lopez-Corral, L.

2955 - Low-Dose Dexamethasone Does Not Abrogate the Immunomodulatory Effects of Lenalidomide and Both Reactivate the Impaired Immune System of High-Risk Smoldering Multiple Myeloma Patients
3142 - An International Multicenter Comparative Analysis of Tacrolimus Plus Sirolimus with or without Antithymocyte Globulin As Graft-Versus-Host Disease Prophylaxis in HLA-Mismatched Allogeneic Hematopoietic Cell Transplantation

Lopez-Godino, O.

3142 - An International Multicenter Comparative Analysis of Tacrolimus Plus Sirolimus with or without Antithymocyte Globulin As Graft-Versus-Host Disease Prophylaxis in HLA-Mismatched Allogeneic Hematopoietic Cell Transplantation

López-Guillermo, A.

521 - Progression-Free Survival at 24 Months (PFS24) and Complete Response at 30 Months (CR30) from Autologous Stem Cell Transplantation (ASCT) Should be Used As Surrogates for OS in Follicular Lymphoma (FL) Patients
582 - Evaluation of the Regimen Brentuximab Vedotin Plus ESHAP (BRESHAP) in Refractory or Relapsed Hodgkin Lymphoma Patients: Preliminary Results of a Phase I-II Trial from the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO)
3955 - Validation of the NCCN-IPI for Diffuse Large B-Cell Lymphoma (DLBCL) in a Nation-Wide Spanish Series of 1885 Patients. the Geltamo-IPI Project
4138 - Clinical Impact of Clonal and Subclonal TP53, SF3B1, BIRC3, and ATM Mutations in Chronic Lymphocytic Leukemia

Lopez-Guillermo, A.

1514 - Phase 2 Randomized Trial Comparing 6 Cycles of Standard RCHOP Chemotherapy Vs 6 Cycles of Brcap (bortezomib, rituximab, cyclophosphamide, adriamicine and prednisone) As First Line Treatment in Young Patients with Poor Prognosis Diffuse Large B-Cell Lymphoma (DLBCL): Interim Analysis
3902 - Gene Expression Profiling Signatures Allow the Identification of Unclassifiable Leukemic B-Cell Lymphoid Neoplasms

López-Guillermo‡, A.

3944 - Incidence, Risk Factors and Prognosis of Transformation in Follicular Lymphoma: a Multicentre Retrospective Analysis of 1763 Patients from the Geltamo Spanish Lymphoma Cooperative Group

López-Iglesias, A. A.

1801 - Mechanisms Underlying the Synergistic Interaction of Filanesib with Pomalidomide and Dexamethasone (FPD) in Multiple Myeloma
2923 - Prognostic Implications of PIM-2 Expression in Samples from Patients with Chronic Lymphocytic Leukemia and Impact in the Sensitivity to the Pan-PIM Kinase Inhibitor PIM447

Lopez-Jimenez, J.

3944 - Incidence, Risk Factors and Prognosis of Transformation in Follicular Lymphoma: a Multicentre Retrospective Analysis of 1763 Patients from the Geltamo Spanish Lymphoma Cooperative Group

López-López, E.

1237 - CNOT1 Microrna Single Nucleotide Polymorphism (SNP) Determines the Occurrence of Methotrexate Related Mucositis in Pediatric Acute Lymphoblastic Leukemia

López-Martín, J. A.

1494 - CC-122 Dosing on a Novel Intermittent Schedule Mitigates Neutropenia and Maintains Clinical Activity in Subjects with Relapsed or Refractory Diffuse Large B Cell Lymphoma
2704 - CC-122 Expands Activated and Memory CD4 and CD8 T Cells In Vivo and Induces T Cell Activation Ex Vivo in Subjects with Relapsed or Refractory Diffuse Large B Cell Lymphoma and Multiple Myeloma

López-Otín, C.

4138 - Clinical Impact of Clonal and Subclonal TP53, SF3B1, BIRC3, and ATM Mutations in Chronic Lymphocytic Leukemia

Lopez-Pardo, J.

2511 - Favorable Outcome of Older Patients with AML and a Favorable Genotype NPM1mut FLT3-ITD Treated with Intensive Chemotherapy: A Subgroup Analysis of Cetlam Protocol 2003 & 2012

Lopez-Pavia, M.

609 - An Analysis of Prognostic Markers and the Performance of Scoring Systems in 1837 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS)
2896 - A Score Based on IPSS-R, Ferritin and EPO Levels Predicts Erythroid Response to ESAs and Survival in Lower Risk Anemic MDS Patients with High Probability of Response to ESAs: Spresas Sub-Analysis from the GESMD

Lopez-Terrada, D.

1679 - A Targeted Next-Generation Sequencing Mutation Panel for Pediatric Acute Myeloid Leukemia and Myelodysplastic Syndrome (MDS) Detects Potential Additional Driver Mutations in Pediatric GATA2-MDS

Lorand-Metze, I.

4031 - Assessment of Cardiovascular Events in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors

Loren, A.

2543 - Outcome of Patients with Acute Myeloid Leukemia Treated with Salvage High-Dose Cytarabine Monotherapy
2591 - A Clinical Measure of DNA Methylation Predicts Outcome in De Novo AML
2929 - Utilization of Next Generation Sequencing Identifies Potentially Actionable Mutations with Prognostic Significance in Chronic Lymphocytic Leukemia
3183 - Autologous Stem Cell Transplantation in First Complete Remission May Not Extend Progression Free Survival in Patients with ALK-Negative Peripheral T Cell Lymphoma
4380 - Unrelated Donors Are Associated with Improved Relapse Free Survival Compared to Related Donors in Patients with Myelodysplastic Syndrome Undergoing Reduced Intensity Conditioned Allogeneic Stem-Cell Transplantation
- Fertility Issues in Patients with Hematologic Malignancies

Lorentino, F.

399 - HLA Disparities Impact on Outcomes after Unmanipulated Haploidentical Hematopoietic Stem Cells Transplantation (HaploSCT) in Acute Leukemia: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
4362 - Standardized Long-Term Follow-up after Allogeneic Stem Cell Transplantation: A Cross-Sectional 1-Year Evaluation in 260 Adults
4400 - Refined Disease Risk Index (DRI) and Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) Predict Survival after Haploidentical Stem Cell Transplantation: A Comparative Study with EBMT Risk Score in 220 Consecutive Patients

Lorenz, E.

1050 - Novel Genetic Variants in Complement-Mediated Thrombotic Microangiopath

Lorenz, M. R.

1020 - Hyperactive mTOR Pathway Promotes Lymphoproliferation and Abnormal Differentiation in Human Autoimmune Lymphoproliferative Syndrome

Lorenz, R. G.

1147 - Plasma Levels of Human Neutrophil Peptides and Complement Activation Markers in Patients with Acquired Autoimmune Thrombotic Thrombocytopenic Purpura
3572 - High Percentage of Evanescent Red Cell Antibodies in Patients with Sickle Cell Disease Highlights the Need for a National Antibody Database

Lorenzato, C.

3530 - Immune Tolerance Induction Treatment Is Cost-Effective in Adult Patients with Long-Standing High-Responding Inhibitors

Lorenzo V, F. R.

3332 - Tibetan Gain-of-Function Variant of Prolyl Hydroxylase 2 (EGLN1) and Selected SNPs of HIF-2-Alpha (EPAS1) Are Associated with Lower Hemoglobin Values in Tibetans

Lori, C.

722 - Identification of Initiating Trunk Mutations and Distinct Molecular Subtypes: An Interim Analysis of the Mmrf Commpass Study

Loriaux, M.

1329 - Dual Targeting of Ph+ ALL with Dasatinib and ABT-199 (Venetoclax)
1374 - Defining the Immune Microenvironment in Patients with Acute Myeloid Leukemia
2603 - p38MAPK Inhibition Blocks Inflammatory Signaling in Acute Myeloid Leukemia
3824 - CSF1R Inhibition Targets AML Cells By Depleting Supportive Microenvironmental Signal from CD14+ Monocytes
4439 - Colony Stimulating Factor 1 Receptor (CSF1R) As a Potential Novel Therapeutic Target in CLL

Lortholary, O.

1695 - Efficacy of Azacitidine (AZA) in Autoimmune and Inflammatory Disorders (AID) Associated with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Lorzadeh, A.

3637 - NOTCH1 Induces Differential Epigenomic Patterning and Genomic Organization in Fetal Liver- and Adult Bone Marrow-Derived Hematopoietic Progentiors

Loscertales, J.

2936 - Insights into the Management of Adverse Events in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Experience from the Phase 3 HELIOS Study of Ibrutinib Combined with Bendamustine/Rituximab
2938 - Improvement of Quality of Response with Ibrutinib Plus Bendamustine/Rituximab Vs Placebo Plus Bendamustine/Rituximab for Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Loschi, M.

1946 - Skin Immune Stimulation By Infections and Drug Toxicities during Induction and/or Consolidations Increases Incidence of Skin Acute Graft Versus Host Disease in Acute Myeloid Leukemia: A Study on Behalf of SFGM-TC and ALFA
4377 - Brentuximab Vedotin Followed By Allogeneic Stem-Cell Transplantation for Patients with CD30 Anaplastic or T Cell Non Hodgkin Lymphomas: A Study on Behalf of the SFGM-TC.

Losco, A.

2152 - Prospective, Multinational/Regional, Non-Interventional Study to Assess Treatment Practices in Anemia Patients Prone to Iron Overload: Results from the 3-Year Transfusional Hemosiderosis Registry (TORS)

Loscocco, F.

329 - Tosedostat Plus Low Dose Cytarabine Induces a High Rate of Responses That Can be Predicted By Genetic Profiling in Elderly AML
1675 - Prognostic Impact of TS, MTHFR and XRCC1 Genetic Variants in 113 Patients with Myelodysplastic Syndromes
1999 - Benda-BEAM High-Dose Therapy Prior to Auto-SCT Is Effective in Resistant/Relapsed DLBCL

Loscocco, G.

353 - Impact of Underlying Mutational Profile, and Changes during Treatment, in MPN Patients Treated with JAK Inhibitors

Losic, N.

4222 - Target-Mediated Drug Disposition of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma after Prior Proteasome Inhibitors and Immunomodulatory Drugs: A Population Pharmacokinetic Analysis

Loskog, A.

1534 - Third Generation CD19-CAR T Cells for Relapsed and Refractory Lymphoma and Leukemia Report from the Swedish Phase I/IIa Trial
4033 - Increased TACE (Tumor necrosis factor-alpha±-converting enzyme; ADAM17) Activity Associates with Decreased CD62L Expression, Increased Soluble CD62L Plasma Levels and Predicts Molecular Response to Nilotinib Therapy in Patients with Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP): Results from an ENEST1st Substudy

Lossos, I. S.

702 - Grb2 Directly Interacts with HGAL and Ameliorates Its Effects on B-Cell Receptor Signaling
3904 - FBXO10 Targets HGAL for Degradation

Lostaunau, G.

4231 - Assessment of Clinical Differences Between Starting Antimyeloma Treatment at Biological Relapse or at Clinical Relapse: Preliminary Results of an Observational Prospective Registry

Lotfi, K.

343 - Mature, Adaptive-like CD56^DIM NK Cells in Chronic Myeloid Leukemia Patients in Treatment Free Remission

Lothar, G.

1901 - Functional Characterization of a T Cell Stimulation Reagent for the Production of Therapeutic Chimeric Antigen Receptor T Cells

Lothe, P.

4466 - Comparative Cost Analysis of Therapy in Sickle Cell Anemia: Supportive Care Vs. Bone Marrow Transplant

Lothrop, C. D.

3487 - Complete Correction of Severe Canine Hemophilia B By Skeletal Muscle Directed AAV-Based FIX-Padua Gene Therapy in Inhibitor-Prone Dogs

Lou, J.

3449 - Force-Induced Cooperative Unfolding of Two Distinctive Domains in a Single Gpibalpha Molecule

Louache, F.

1362 - Targeting Acute Myeloid Leukemia with a New CXCR4 Antagonist IgG1 Antibody (PF-06747143)in NOD/SCID Mice

Loughran, Jr., T. P.

700 - Exome Sequencing of Aggressive Natural Killer Cell Leukemia and Drug Profiling Highlight Candidate Driver Pathways in Malignant Natural Killer Cells
1246 - Acid Ceramidase Inhibition Impairs Tumor Progression in a Rat Model of LGL Leukemia

Loughran, Jr., T. P.

1288 - FTY720 (Fingolimod) Targets the Sphingolipid Pathway and Induces Autophagy-Related Apoptosis in Human Natural Killer Large Granular Lymphocyte Leukemia

Louie, A. C.

2510 - CPX-351 ((Cytarabine:Daunorubicin) Liposome Injection, (Vyxeos)) Does Not Prolong Qtcf Intervals, Requires No Dose Adjustment for Impaired Renal Function and Induces High Rates of Complete Remission in Acute Myeloid Leukemia
4507 - CPX-351 Enables Administration of Consolidation Treatment in the Outpatient Setting and Increases the Time Spent out of the Hospital after Completion of AML Treatment Compared with 7+3

Louie, R. R.

3507 - Neither Factor VIII Nor the Putative F8B Protein Is Detectable in Human Peripheral Blood Mononuclear Cells

Louie, S.

3725 - Comparison of Vincristine Pharmacokinetics (PK) in Adolescent/Young Adult (AYA) Versus Younger Patients Defined By Tanner Stage during Treatment for Acute Lymphoblastic Leukemia (ALL)

Louis, C.

4425 - Safety of Multiple Doses of CAR T Cells

Louis, I.

4334 - Intrabone Infusion of Umbilical Cord Blood Stem Cells to Improve Hematopoietic Recovery after Allogeneic Umbilical Cord Blood Transplantation in Children

Louissaint, Jr., A.

3252 - Proxe: A Public Repository of Xenografts to Facilitate Studies of Biology and Expedite Preclinical Drug Development in Leukemia and Lymphoma
3925 - Pediatric-Type Nodal Follicular Lymphoma in Children and Adults Is Nearly Genetically Silent and Biologically Distinct from Typical Follicular Lymphoma
4001 - B and T-Cell Lymphoma Patient-Derived Xenografts Recapitulate Aspects of Disease Biology and Progression and Represent Novel Tools for Preclinical Drug Development

Loukogeorgakis, S.

35 - The Use of Eicosanoids to Enhance Donor Cell Engraftment after in Utero Hematopoietic Cell Transplantation (IUHCT)

Lourens, H. J.

1384 - Kinome Profiling Identifies Phospholipase C Gamma 1 (PLCγ1) As a Potential Target for t(8;21) AML

Lousada, I.

4525 - Health-Related Quality of Life in Patients with AL Amyloidosis: Qualitative Interviews with Physicians and Patients

Loussaief, L.

4010 - Development of an Anti-HTLV-1 Vaccine for the Treatment of Adult T-Cell Leukemia/Lymphoma

Loustau, V.

3483 - Portal or Splenic Vein Thrombosis after Splenectomy for Immune Cytopenia: A Retrospective Cohort Study

Loustaud-Ratti, V.

3938 - Anti-Lymphoma Activity of Interferon-Free Antiviral Treatment in Patients with Indolent B-Cell Lymphomas Associated with Hepatitis C Virus Infection

Louw, V.

2152 - Prospective, Multinational/Regional, Non-Interventional Study to Assess Treatment Practices in Anemia Patients Prone to Iron Overload: Results from the 3-Year Transfusional Hemosiderosis Registry (TORS)
3034 - Analysis of Final Data from the Multinational, Non-Interventional, Observational Emmos Study (NCT01241396) in Patients (Pts) with Multiple Myeloma (MM) in Real-World Clinical Practice

Louw, V. J.

344 - Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Final Results from ENESTxtnd Study

Louzada, M. L.

1116 - Updates on the Risk of Dalteparin Thromboprophylaxis Failure in Hospitalized Acutely Ill Medical Patients with Cancer (ARTIC STUDY)
1121 - Comparing the Efficacy of Aspirin or Low Molecular Weight Heparin or Vitamin K Antagonists in the Risk of Thromboembolic Events in Patients with Multiple Myeloma Treated with Lenalidomide-Based Therapy
2320 - Evaluating the Need for Anticoagulation Beyond 6 Months for Patients with Cancer-Associated Venous Thromboembolism (VTE): A Retrospect of Real Life (EXTEND study - updated results)
2321 - Thromboprophylaxis in Multiple Myeloma Patients Treated with Lenalidomide - a Systematic Review

Love, C.

558 - Recurrent Mutations in Focal Adhesion Genes Including the RhoA Signaling Axis Are a Defining Feature of Germinal Center (GC) Derived B Cell Lymphomas and Promote Aberrant Migration and Cellular Adhesion within the GC Niche
575 - Whole Exome Sequencing of Type 1 and Type 2 Enteropathy-Associated T Cell Lymphoma Reveals Genetic Basis of Eatl Oncogenesis
2639 - The Landscape of microRNA Expression in HIV and Non-HIV Associated Classical Hodgkin Lymphoma through Next Generation Sequencing
3636 - Whole Exome Sequencing Defines the Genetic Differences Between Pediatric and Adult Follicular Lymphoma
3906 - ID3 Loss In Vivo Synergizes with MYC-Driven Oncogenesis in Burkitt Lymphoma

Love, C.

361 - Exome-Wide Sequencing Reveals Oncogenic Mutations in Both Progressive and Non-Progressive MBL

Love, P.

3663 - Lmo2's Oncogenic Function in T-Cell Leukemia Requires Ldb1

Love, S.

1294 - Post Induction Minimal Residual Disease Levels Identifies a Group of High Risk Relapsed Childhood Acute Lymphoblastic Leukemia (rALL) with a Favorable Outcome Independent of Induction Therapy

Lovejoy, A. F.

114 - Noninvasive Genotyping and Assessment of Treatment Response in Diffuse Large B Cell Lymphoma
130 - Dynamic Noninvasive Genomic Monitoring for Outcome Prediction in Diffuse Large B-Cell Lymphoma

Loveless, S.

3614 - The North American Shwachman-Diamond Syndrome Registry: Genetically Undefined Shwachman-Diamond Syndrome

Lovera, D.

1375 - A Novel Synthetic Lethal Approach Targeting SIRT6 in Acute Myeloid Leukemia

Lovisa, F.

1413 - Prognostic Role of Minimal Residual Disease before and after Hematopoietic Stem Cell Transplantation in Childhood Acute Lymphoblastic Leukemia

Lovitch, S. B.

147 - Loss of Programmed Death Ligand-1 Expression on Donor T Cells Lessens Acute Graft-Versus-Host Disease Lethality

Low, E.

1840 - Carfilzomib, Cyclophosphamide and Dexamethasone Is Well Tolerated in Patients with Relapsed/Refractory Multiple Myeloma Who Have Received One Prior Regimen

Low, L.

522 - Double Expressing (MYC/BCL2) and Double-Hit Diffuse Large B-Cell Lymphomas Have Inferior Survival Following Autologous Stem Cell Transplantation

Lowder, J. N.

458 - Comparison of Efficacy and Safety Results in 103 Treatment-Naïve Acute Myeloid Leukemia (TN-AML) Patients Not Candidates for Intensive Chemotherapy Using 5-Day and 10-Day Regimens of Guadecitabine (SGI-110), a Novel Hypomethylating Agent (HMA)
1683 - Results of First in Human (FIH) Phase 1 Pharmacokinetic (PK) Guided Dose-Escalation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine in Subjects with Myelodysplastic Syndromes (MDS)

Lowe, C.

3806 - AGS62P1, a Novel Anti-FLT3 Antibody Drug Conjugate, Employing Site Specific Conjugation, Demonstrates Preclinical Anti-Tumor Efficacy in AML Tumor and Patient Derived Xenografts

Lowe, S.

1348 - Effects of CCL2/CCR2 Blockade in Acute Myeloid Leukemia

Lowell, C. A.

3716 - Targeted Activation of B Cell Autoimmunity Checkpoints in Acute Lymphoblastic Leukemia

Lowenberg, B.

306 - Divergent Dynamics of Epigenetic and Genetic Heterogeneity in Relapsed Acute Myeloid Leukemia
2547 - A Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Adults with Relapsed or Refractory Leukemia: Safety, Clinical Activity, Exposure and Target Inhibition

Lowsky, R.

3232 - Donor-Derived CIK Cell Infusion As Consolidative Therapy after Non-Myeloablative Allogeneic Transplant in Patients with Myeloid Neoplasms

Lozach, C.

1086 - Use of Power Doppler Ultrasound in Haemophilia Could Predict Early Relapse of Intra Articular Bleeding after Haemarthrosis: A Prospective Cohort of 27 Haemarthrosis Monitored By Articular Ultrasound

Lozano, E.

4192 - Long-Term Survivors after Stem Cell Transplantation in Multiple Myeloma: Bone Marrow Minimal Residual Disease, PET/CT and Immunological Status

Lozano, G.

- Biology of TP53 Loss and Mutation

Lozano, M. L.

3153 - Persistent Cytotoxic T Lymphocyte Expansions after Allogeneic Hematopoietic Stem Cell Transplantation: Kinetics, Clinical Impact and Absence of STAT3 Mutations

Lozano, S.

3223 - The EBMT Score Predicts Transplant Related Mortality and Overall Survival after Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes

Lozanski, G.

2953 - A Phase II Study of the Fc Engineered CD19 Antibody MOR208 in Combination with Lenalidomide for Patients with Chronic Lymphocytic Leukemia (CLL)

Lozanski, G.

2477 - BRAF^V600E Induces ABCB1/P-Glycoprotein Expression and Drug Resistance in B-Cells Via AP-1 Activation

Lozovatsky, L.

954 - Identification of a Novel SLC40A1 Arg88Ile Mutation in a Patient with Familial Iron Overload Treated By Phlebotomy

Lu, A.

851 - Expression of MyD88/CD40 Drives In Vivo Activation and Proliferation of Chimeric Antigen Receptor-Modified T Cells That Can be Effectively Regulated By Inducible Caspase-9
1886 - Inducible MyD88/CD40 Enhances Proliferation and Survival of PRAME-Specific TCR-Engineered T Cells and Increases Anti-Tumor Effects in Myeloma
4295 - Inducible MyD88/CD40 Allows Rimiducid-Dependent Activation to Control Proliferation and Survival of Chimeric Antigen Receptor-Modified T Cells

Lu, B.

1231 - ANP32A Dysregulation Contributes to Abnormal Megakaryopoiesis in Acute Megakaryoblastic Leukemia
2456 - ANP32A Dysregulation Involves Histone Modifications and Contributes to Myeloid Leukemia

Lu, B.

4445 - Hydroxyurea Use in Children with Sickle Cell Disease: Do Severely Affected Patients Use It and Does It Impact Hospitalization Outcomes?

Lu, C.

3075 - Interferon-Gamma Signaling in the Pathogenesis of Idiopathic Pneumonia Syndrome Following Allogeneic Bone Marrow Transplantation

Lu, C.

693 - Expression of an Oncogenic ERG isoform Characterizes a Distinct Subtype of B-Progenitor Acute Lymphoblastic Leukemia

Lu, D.

1525 - Exposure-Response Analysis to Assist Selection of Dose and Treatment Duration for Polatuzumab Vedotin As a Single Agent or in Combination with Rituximab for the Treatment of B-Cell Lymphoma

Lu, D. K.

3998 - Ibrutinib Enhances the Activity of Anti-CD20 Antibodies in an MCL Mouse Model: Effect of Drug at Clinically Relevant Concentrations on ADCC and ADCP

Lu, D. P.

3217 - Impact of Cytogenetic and Molecular Markers on Disease-Free Survival of Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia
3224 - Improved Outcomes of Haploidentical Blood and Marrow Transplantation in Hematologic Malignancies: A Single Center Study of 514 Cases
3774 - Chimeric Antigen Receptor 4SCAR19-Modified T Cells in Acute Lymphoid Leukemia: a Phase II Multi-Center Clinical Trial in China

Lu, G.

1135 - Pharmacokinetic and Pharmacodynamic (PKPD) Modeling to Determine the Andexanet Alfa Dose to Reverse the Anticoagulant Activity of Direct Fxa Inhibitors
2329 - Reversal of Heparin-Induced Anticoagulation By Andexanet Alfa, a Universal Antidote for Factor Xa Inhibitors

Lu, H.

820 - Intratumoral Injection of TLR4 Agonist (G100) Leads to Tumor Regression of A20 Lymphoma and Induces Abscopal Responses

Lu, J. J.

3319 - Use of an Electronic Medical Record (EMR) Database to Identify a Real-World Cohort of US Patients (Pts) with Myelodysplastic Syndromes (MDS)

Lu, J.

4240 - Continuous Treatment with Lenalidomide and Low-Dose Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma in Asia: Subanalysis of the First Trial
4247 - Which Should be Pursued, Cumulative Dose or Dose Intensity: A Real-World Effectiveness Analysis of Bortezomib-Based First Line Treatment for Untreated Multiple Myeloma Patients

Lu, J.

675 - BRD4 Proteolysis Targeting Chimera (PROTAC) Leads to Sustained Degradation of BRD4 with Broad Activity Against Acute Leukemias and Overcomes Stroma Mediated Resistance By Modulating Surface Expression of CXCR4
917 - Proteolytic Targeting Chimeric Molecules (PROTACs) Specific for Bromodomain-Containing Protein (BRD) 4 Are Active Against Pre-Clinical Models of Multiple Myeloma
2050 - BRD4 Degradation By Protacs Represents a More Effective Therapeutic Strategy Than BRD4 Inhibitors in DLBCL

Lu, K.

1287 - Gli1 Inhibitor GANT61 Exhibits Antitumor Efficacy in T-Cell Lymphoma Cells through Down-Regulation of p-STAT3 and SOCS3 Pathways

Lu, K.

1163 - Therapeutic Targeting of CD163 on Hematopoietic Progenitor Cells By Novel Monoclonal Antibody TBI 304H Demonstrates an Increase in Erythropoiesis in Humanized Mice

Lu, M. Y.

1217 - A Retrospective Multicenter Study to Evaluate the Efficacy of Rabbit Antithymocyte Globulin (rATG) Immunosuppressive Therapy As First-Line Treatment of Aplastic Anemia

Lu, M.

3900 - Expression of B and T Lymphocyte Attenuator (BTLA) Correlates with CNS Metastasis and Adverse Prognosis in Activated B-Cell Lymphoma and Acute Lymphoblastic Leukemia

Lu, P.

1185 - Leukemia Cell Infiltration Causes Defective Erythropoiesis Partially through MIP-1alpha

Lu, Q.

1081 - Recombinant FIX/X-Bp from the Japanese Habu Snake Is a Universal Ligand for Purification of Highly Carboxylated Factor IX Variants and Factor X

Lu, Q.

2439 - CDKN2 Gene Deletion Impair Prognosis in Adult Ph+ Acute Lymphoblastic Leukemia Even in Tyrosine Kinase Inhibitors Era
4036 - Therapeutic Immune Monitoring of Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors: Focus on CD4⁺CD25⁺t Cells

Lu, R.

241 - Clonal Tracking of the Geographic Distribution of Hematopoiesis in Nonhuman Primates Provides New Insights into HSPC Migration and Differentiation
1151 - The Impact of Aging of Hematopoietic Stem and Progenitor Cells (HSPCs) in Non-Human Primates As Interrogated By Genetic Barcode Clonal Tracking

Lu, R.

2430 - Epigenetic Reprogramming of Cis-Regulatory Sites By R882-Mutated DNMT3A Potentiates Aberrant Stem Cell Gene Program and Acute Leukemia Development

Lu, T. L.

99 - Allogeneic T-Cells Expressing an Anti-CD19 Chimeric Antigen Receptor Cause Remissions of B-Cell Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation without Causing Graft-Versus-Host Disease

Lu, T.

2664 - Aberrant Expression of IL-22 Receptor 1 and IL-22 Stimulation Increase the Activation of STAT3 and ERK1/2 in ABC-DLBCL Cells

Lu, T.

3895 - The Distinct Clinical Features and Prognosis of the CD10+MUM1+ and CD10-Bcl6-MUM1- Diffuse Large B-Cell Lymphoma

Lu, X.

1443 - IHC Analysis and Prognostic Factors in Post Transplant Lymphoproliferative Disorders after Solid Organ Transplantation: A Single Center Experience

Lu, X.

2226 - The Characteristic of TCR Signaling Pathway in T Cell from Patients with Aplastic Anemia

Lu, X.

1685 - Gene Mutations in MDS Associating with Peripheral Blood Count Abnormalities
2502 - Treatment-Related Mortality (TRM) in Children with Down Syndrome (DS) and B-Lymphoblastic Leukemia (B-ALL): An Interim Report from the Children's Oncology Group Trials AALL0932 and AALL1131

Lu, X.

702 - Grb2 Directly Interacts with HGAL and Ameliorates Its Effects on B-Cell Receptor Signaling

Lu, X.

1730 - RAS/RAF Pathway Mutations Define a Distinct Subset of Chronic Lymphocytic Leukemia

Lu, X. G.

3558 - Novel Additive Solution "Aayusol" Significantly Preserves Platelets in Lesion-Free State during Extended Storage

Lu, X.

1860 - Chemoresistant Leukemia-Initiating Cell Expansion Is Inhibited By Targeting Oncogenic Self-Renewal

Lu, X.

455 - Microtransplantation Improved Outcome in Elderly Acute Myeloid Leukemia Patients - Report from China Microtransplantation Cooperative Group

Lu, Y.

1467 - Inhibition of IL2-Inducible T-Cell Kinase (ITK)-Mediated Chemoresistance By Ibrutinib in T-Cell Lymphoproliferative Disorders

Lu, Y.

3217 - Impact of Cytogenetic and Molecular Markers on Disease-Free Survival of Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia
3224 - Improved Outcomes of Haploidentical Blood and Marrow Transplantation in Hematologic Malignancies: A Single Center Study of 514 Cases

Lu, Y.

4110 - RBM15-Mediated RNA Splicing Fine-Tunes Epigenetic Program through Interaction with SF3B1

Lu, Y.

157 - Conditional Knockout-First Gene Disruption of Dematin Causes Precipitous Loss of Erythrocyte Membrane Stability and Severe Hemolytic Anemia

Lu, Z.

2118 - Comparison of the 5 Year Medical Outcome and Quality of Life of Patients with Chronic Myeloid Leukemia Treated with Imatinib or Allogeneic Transplant

Lu, Z.

1378 - KBP-1 Supports Acute Myeloid Leukemia Development

Luan, J.

1175 - A Novel Regulatory Region of the p27 Locus Is Required for Normal Erythroid p27 Expression, and Produces a Long Noncoding RNA with No Detectable Function

Luan, Y.

256 - Safety and Efficacy of Abexinostat, a Pan-Histone Deacetylase (HDAC) Inhibitor, in Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Results of an Ongoing Phase 2 Study

Luaña, A.

2263 - Usefulness of Eltrombopag in Secondary ITP Patients in Clinical Practice

Luban, N. L.

3 - TCD with Transfusions Changing to Hydroxyurea (TWiTCH): Hydroxyurea Therapy As an Alternative to Transfusions for Primary Stroke Prevention in Children with Sickle Cell Anemia
2181 - Early Pathogenesis of Sickle Cell Anemia: Absolute Reticulocyte Counts Are Correlated with Increased Detection of CD36+ Reticulocytes during the First Two Years of Postnatal Life

Lubbers-Aalders, L.

2402 - Addition of the Vascular Niche Component to the Human Bone Marrow-like Scaffold Model

Lübbert, M.

299 - Somatic Genetic and Epigenetic Architecture of Myelodysplastic Syndromes Arising from GATA2 Deficiency
322 - Midostaurin in Combination with Intensive Induction and As Single Agent Maintenance Therapy after Consolidation Therapy with Allogeneic Hematopoietic Stem Cell Transplantation or High-Dose Cytarabine (NCT01477606)
609 - An Analysis of Prognostic Markers and the Performance of Scoring Systems in 1837 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS)
2432 - Combination Treatment of AML Cells with Dnmt and HDAC Inhibitors: Synergistic Target Gene Downregulation Associated with Gene Body Demethylation
3818 - Incidence and Prognostic Relevance of ASXL2 Mutations in Adult CBF-AML with t(8;21)(q22;q22): A Study of the German-Austrian AML Study Group (AMLSG)
3834 - Single Cell Genotyping of Inv(16) AML in CBL Mutated Clonal Hematopoiesis Characterizes Clonal Architecture and Evolution of Exome Sequencing-Identified Mutations in the Protein Tyrosine Phosphatase Ptprt and Other Genes

Lubetsky, A.

1096 - Long-Term Use of Coagulation Factor IX (Recombinant) Albumin Fusion Protein (rIX-FP) in Previously Treated Patients with Hemophilia B in the Prolong-9FP Program

Lubin, I.

2798 - Pathogenesis of Ponatinib Associated Vascular Disease in Chronic Myeloid Leukemia: An in Vitro Study

Lubking, A.

343 - Mature, Adaptive-like CD56^DIM NK Cells in Chronic Myeloid Leukemia Patients in Treatment Free Remission
477 - Safety and Efficacy of Addition of Pegylated Interferon alpha2b to Standard Dose Dasatinib in Newly Diagnosed Chronic Phase CML Patients
2812 - Limited Efficacy of Ponatinib in Myeloproliferative Neoplasms Associated with FGFR1 Fusion Genes

Luc, S.

638 - Crispr-Cas9 Saturating Mutagenesis Reveals an Achilles Heel in the BCL11A Erythroid Enhancer for Fetal Hemoglobin Induction (by Genome Editing)

Lucania, A.

3946 - Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice, the Lenamant Study

Lucarelli, B.

195 - Children with Acute Leukemia Given Hematopoietic Stem Cell Transplantation (HSCT) from an HLA-Compatible Sibling, or an Unrelated Donor (UD) or an HLA-Haploidentical Relative after Alpha/Beta T-Cell Depletion Have a Comparable Outcome
1931 - Clinical Outcome after Adoptive Infusion of BPX-501 Cells (donor T cells transduced with iC9 suicide gene) in Children Given Alpha/Beta T-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (haplo-HSCT): Preliminary Results of a Phase I-II Trial
3093 - Immune Reconstitution after Adoptive Infusion of BPX501 Cells (donor T cells transduced with iC9 suicide gene) in Children Given Alpha/Beta T-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (haplo-HSCT): Preliminary Phenotypic and Functional Results of a Phase I-II Trial
4299 - BPX-501 Cells (donor T cells transduced with iC9 suicide gene) Are Able to Clear Life-Threatening Viral Infections in Children with Primary Immune Deficiencies Given Alpha/Beta T-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (haplo-HSCT)

Lucarelli, G.

620 - Transplant Outcomes in High-Risk (Class 3) Patients with Thalassemia Treated with a Modified Protocol Are Equivalent to Low/Intermediate-Risk (Class 1/Class 2) Patients

Lucas, A. N.

342 - Risk-Adapted Therapy in Adults with Burkitt Lymphoma: Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R
472 - Phase I Study of Dose-Adjusted-Teddi-R with Ibrutinib in Untreated and Relapsed/Refractory Primary CNS Lymphoma

Lucas, C. M.

1396 - PP2A Inhibition By CIP2A or SETBP1 Leads to Elevated Levels of AKT S473 Which Can be Used As a Biomarker of Outcome in Acute Myeloid Leukaemia

Lucas, D.

898 - Muscarinic Receptor Type-1 Regulates Centrally Hematopoietic Stem Cell Mobilization By Granulocyte-Colony Stimulating Factor Via the Hypothalamic-Pituitary Axis

Lucas, D. M.

317 - Next Generation XPO1 Inhibitor Shows Improved Efficacy and In Vivo Tolerability in Hematologic Malignancies
1248 - NFkB p50 (Nfkb1) Contributes to Disease in the Eu-TCL1 Mouse Model of Chronic Lymphocytic Leukemia
2471 - In Vitro and In Vivo Anti-Leukemic Effects of KPT-9274, a Reported PAK4 Allosteric Modulator, in Acute Myeloid Leukemia: Promising Results Justifying Further Development in This Disease
2477 - BRAF^V600E Induces ABCB1/P-Glycoprotein Expression and Drug Resistance in B-Cells Via AP-1 Activation
2911 - The Aberrantly Expressed Long Noncoding RNA, TRERNA1, Predicts for Aggressive Disease in Chronic Lymphocytic Leukemia

Lucas, K.

4300 - Cancer Germline Antigen Specific CTL As Immunotherapy for Neuroblastoma

Lucchesi, A.

329 - Tosedostat Plus Low Dose Cytarabine Induces a High Rate of Responses That Can be Predicted By Genetic Profiling in Elderly AML

Lucchini, G.

4303 - The Best of Both? Megadose Stem Cells with CD34 Selection and T-Cell Addback Enables Engraftment from Mismatched Unrelated Donors Using Reduced Toxicity Conditioning in Primary Immunodeficiency
4404 - Allogeneic Stem Cell Transplantation for Refractory Acute Myeloid Leukemia in Pediatric Patients: The UK Experience

Luchetti, S.

1866 - Allogeneic Transplanst for ACUTE Myeloid Leukemia: Cut Off Levels of WT1 Expression in 207 Patients and Pre-Emptive Therapy of Relapse
4336 - Allogeneic STEM CELL Transplants for Patients with Myelofibrosis: Changes in the Transplant Platform and Improved the Outcome

Luchtman-Jones, L.

3 - TCD with Transfusions Changing to Hydroxyurea (TWiTCH): Hydroxyurea Therapy As an Alternative to Transfusions for Primary Stroke Prevention in Children with Sickle Cell Anemia

Luciani, L.

1181 - Prmt5 Negatively Regulates Erythropoiesis By Multiple Mechanisms, Including Controlling DNA Methyltransferase 3A Protein Levels

Luciani, M.

2564 - A Phase 1/2, Open-Label, Dose-Escalation Study of Midostaurin in Pediatric Patients (Pts) with Relapsed or Refractory (R/R) Acute Leukemia: Final Results of Study ITCC-024 (CPKC412A2114)

Luciani, M.

2775 - Imatinib Suspension and Validation (ISAV) Study: Results at 24 Months

Luciano, C.

1791 - Small RNA Deep Sequencing Highlights the Important Contribution of Mirnas in Regulating IRF4/c-Myc Axis in Myeloma Development

Luciano, F.

2958 - Implication of the Anti-Apoptotic Protein Bcl-B (BCL2L10) in the Pathogenesis of Multiple Myeloma

Luciano, L.

1570 - Bone Marrow (BM) Microenviroment Factors As Early Markers of Response in Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Treated with Nilotinib
1582 - Very Elderly Patients with Chronic Phase-Chronic Myeloid Leukemia on Imatinib: No Impact of Concomitant Drugs on Complete Cytogenetic Response

Luciano, L.

1598 - Long-Term Follow-up in Very Elderly Patients with Chronic Myeloid Leukemia Treated with Imatinib Frontline

Luck, J. V.

1038 - Vascular Remodeling Underlies Re-Bleeding in Hemophilic Arthropathy

Lucy, L. M.

3754 - The Safety and Tolerability of Azacitidine (AZA) Are Comparable in Patients with Acute Myeloid Leukemia (AML) or Higher-Risk Myelodysplastic Syndromes (MDS)

Luczak, M.

2986 - Comparative Proteomic Profiling of Refractory/Relapsed Multiple Myeloma Patient Plasma Cells Reveals Biomarkers and Pathways Involved in Bortezomib-Based-Therapy Resistance

Luden, J.

3 - TCD with Transfusions Changing to Hydroxyurea (TWiTCH): Hydroxyurea Therapy As an Alternative to Transfusions for Primary Stroke Prevention in Children with Sickle Cell Anemia

Luderer, M. J.

2978 - Tris DBA Palladium Overcomes Hypoxia Mediated Drug Resistance in Multiple Myeloma
2985 - Novel Method to Detect Minimal Residual Disease in Multiple Myeloma Predicts Recurrence Better Than CD138-Based Models
3694 - Integrin-Linked Kinase a Novel Therapeutic Target for Acute and Chronic Myeloid Leukemia
4436 - Tirapazamine As a Strategy to Overcome Hypoxia-Induced Drug Resistance in Multiple Myeloma

Ludin, A.

664 - Distinct Bone Marrow Blood Vessels Differentially Regulate Normal and Malignant Hematopoietic Stem and Progenitor Cells

Ludwig, H.

Luebbert, M.

224 - Characteristics and Prognosis of AML Patients with or without a History of Clonal Hematopoiesis
227 - Clinical Relevance of Minimal Residual Disease Monitoring in NPM1 Mutated AML: A Study of the AML Study Group (AMLSG)
858 - Treatment of Corticosteroid-Refractory Graft-Versus-Host Disease with Ruxolitinib in 95 Patients
2537 - Induction of Cancer Testis Antigen Expression in Circulating Acute Myeloid Leukemia Blasts Following Hypomethylating Agent Monotherapy
2538 - Establishment and Characterization of a Panel of Patient-Derived Acute Leukemia Mouse Models As Emerging Platform for Translational Research
2585 - Pharmacodynamic Monitoring of the Efficacy of a Targeted Therapy with Midostaurin By Plasma Inhibitor Activity (PIA) Analysis in FLT3-ITD Positive AML Patients within the AMLSG 16-10 Trial: A Study of the AML Study Group (AMLSG)
2586 - Molecular Characterization of Relapsed Core-Binding Factor (CBF) Acute Myeloid Leukemia (AML)
2879 - Prognostic Impact of Rare Single Abnormalities in Myelodysplastic Syndromes
2891 - Application of a Short Tandem Repeat Based PCR Assay for Chronological Monitoring of Myelodysplastic Syndrome (MDS) Patients with Deletion of Chromosome 5q Following Lenalidomide Treatment
3660 - Significance of the IL-3 Receptor Beta Chain (IL-3Rbc) for FLT3-ITD Dependent Oncogeneic Signaling in AML

Luedde, T.

15 - A Novel TNF-Alpha Antibody Based Therapeutic Approach to Target Leukemic Stem Cells in Bcr-Abl Disease

Luengo-Gil, G.

1648 - Downregulation of BAP1 in Chronic Myelomonocytic Leukemia: Correlated with a Post-Translational Reduction of BRCA1 Levels and Independent of Promoter Methylation

Luft, T.

856 - ATG and Statins Reduce Incidence of Severe Chronic Gvhd By Distinct Mechanisms Involving CXCL9 and Kynurenine Catabolism
1699 - Low Vitamin D Levels Are Associated with Inferior Survival Following Azacitidine Treatment in Patients with Myelodysplastic Syndrome
3083 - Cytokeratin (CK)-18 and CK18 Fragments As Sensitive and Specific Biomarkers of Acute Hepato-Intestinal Gvhd: Results of a Prospective Observational Study

Luger, S.

217 - North American Leukemia‚ Intergroup Phase III Randomized Trial of Single Agent Clofarabine As Induction and Post-Remission Therapy‚ and Decitabine As Maintenance Therapy in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age ≥60 Years): A Trial of the ECOG-ACRIN Cancer Research Group (E2906)
306 - Divergent Dynamics of Epigenetic and Genetic Heterogeneity in Relapsed Acute Myeloid Leukemia
693 - Expression of an Oncogenic ERG isoform Characterizes a Distinct Subtype of B-Progenitor Acute Lymphoblastic Leukemia
795 - in Philadelphia-Chromosome-Negative Acute Lymphoblastic Leukemia, Late Relapses Are Not Uncommon, Occur Mostly in Patients at Standard Risk and Have a Relatively Favorable Outcome. Results of the International ALL Trial: MRC Ukallxii/ECOG E2993
1138 - North American Cooperative Group Members' Patterns of Blood Products Transfusion for Patients with Acute Leukemia
1308 - Tipifarnib As Maintenance Therapy in Acute Myeloid Leukemia (AML) Improves Survival in a Subgroup of Patients with High Risk Disease. Results of the Phase III Intergroup Trial E2902
1315 - Very Poor Long-Term Survival, Also in Contemporary Studies, of Patients with AML Who Relapse after Achieving a First Complete Remission: The ECOG-ACRIN Cancer Research Group Experience
1422 - Integrated DNA/RNA Profiling for Somatic Alterations in Adult B-Cell ALL
2543 - Outcome of Patients with Acute Myeloid Leukemia Treated with Salvage High-Dose Cytarabine Monotherapy
2591 - A Clinical Measure of DNA Methylation Predicts Outcome in De Novo AML
2618 - High Frequency and Poor Outcome of Ph-like Acute Lymphoblastic Leukemia in Adults
4380 - Unrelated Donors Are Associated with Improved Relapse Free Survival Compared to Related Donors in Patients with Myelodysplastic Syndrome Undergoing Reduced Intensity Conditioned Allogeneic Stem-Cell Transplantation
4455 - Patterns of Venous Thromboembolism Prophylaxis during Inpatient Treatment of Acute Leukemia: Results of a North American Web-Based Survey

Lugtenburg, P. J.

339 - Bortezomib Maintenance Therapy after Induction with R-CHOP, ARA-C and Autologous Stem Cell Transplantation in Newly Diagnosed MCL Patients, Results of a Multicenter Phase II HOVON Study
1532 - Primary Results of the Health-Related Quality of Life Assessment from the Phase III Gadolin Study of Obinutuzumab Plus Bendamustine Compared with Bendamustine Alone in Patients with Rituximab-Refractory, Indolent Non-Hodgkin Lymphoma
2707 - Rituximab-Pecc Induction Followed By ⁹⁰y-Ibritumomab Tiuxetan Consolidation in Relapsed or Refractory DLBCL Patients Who Are Not Eligible for or Have Failed ASCT: Results from a Phase II HOVON Study

Lugthart, G.

1018 - CD69andCXCR6 Identify a Distinct Population of Human Bone Marrow and Spleen Resident NK Cells

Lui, C.

321 - Antileukemic Activity and Tolerability of ASP2215 80mg and Greater in FLT3 Mutation-Positive Subjects with Relapsed or Refractory Acute Myeloid Leukemia: Results from a Phase 1/2, Open-Label, Dose-Escalation/Dose-Response Study

Luider, J.

3189 - Bortezomib and High Dose Melphalan (Bor-HDM) Compared to HDM Conditioning for the Treatment of Transplant Eligible Multiple Myeloma: Report from a Single Center

Luijks, D.

2918 - Assessment of p53 and ATM Functionality in Chronic Lymphocytic Leukemia By Multiplex Ligation-Dependent Probe Amplification

Luisa, I.

3150 - Index of Bone Marrow Output and Imbalance of B-Lymphocyte Homeostasis before and after Transplantation Correlate Differently with Graft-Versus-Host Disease and Relapse

Luke, G. P.

1367 - FT-1101: A Structurally Distinct Pan-BET Bromodomain Inhibitor with Activity in Preclinical Models of Hematologic Malignancies

Luken, B. M.

1005 - Factor VII-Activating Protease Is a Regulator of Histone Cytotoxicity

Lukens, J.

3195 - Consolidative Radiation Therapy Following Autologous Transplantation in Relapsed or Refractory Hodgkin Lymphoma

Lukez, A.

860 - A Multicenter Phase I/Ib Study of Ipilimumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation

Lukina, E.

884 - Long-Term Hematologic Response to Eliglustat in Patients with Gaucher Disease Type 1: Results from a Phase 2 and Two Phase 3 Trials

Lukombo, I.

985 - Impact of Psychological Covariates on Experimental Pain Sensitivity in Children and Adolescents with SCD

Luks, A.

252 - Acute Leukemias of Ambiguous Lineage; Study on 247 Pediatric Patients

Lukyanchykov, P.

502 - Characterization of the Role of Regulatory T Cells (Tregs) in Inducing Progression of Multiple Myeloma

Lukyanov, S.

3532 - Safety and Efficacy of New Nonacog Alfa Drug (Innonafactor) in Prophylactic Treatment in Patients with Severe and Moderate Hemophilia B

Lulay, C.

263 - Tracking Genetically Engineered Lymphocytes Long-Term Reveals the Dynamics of T-Cell Immunological Memory

Lum, J.

3412 - The Effects of Glutamine Supplementation on Markers of Autophagy and Apoptosis in Peripheral Blood Mononuclear Cells from Patients with Sickle Cell Disease

Lum, L. G.

1902 - A Pilot Study of Peripheral Blood Hematopoietic Stem Cells Mobilization with the Combination of Bortezomib and G-CSF in Multiple Myeloma and Non-Hodgkin's Lymphoma Patients.
3228 - Encouraging Outcomes in African-American Patients with Use of Post-Transplant Cyclophosphamide after HLA Mismatched Hematopoietic Stem Cell Transplant

Lumbreras, E.

1648 - Downregulation of BAP1 in Chronic Myelomonocytic Leukemia: Correlated with a Post-Translational Reduction of BRCA1 Levels and Independent of Promoter Methylation
2890 - Could Chronic Gvhd Overcome the Poor Prognosis of Patients with MDS and TP53 Undergoing Allogeneic HSCT?

Luminari, S.

581 - Remarkable Clinical Efficacy, Stem Cell Mobilization Activity and Good Toxicity Profile of the Novel Begev Regimen (Bendamustine, Gemcitabine And Vinorelbine) Used As Salvage Therapy Prior to Autologous Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma
701 - Identification of a Novel Gene Expression Signature in Mantle Cell Lymphoma from the Fondazione Italiana Linfomi (FIL)-MCL-0208 Trial: A Focus on the B Cell Receptor Pathway
2686 - Pattern of Care in Indolent Non Follicular Lymphoma: A Report from NF10 Project, an International, Prospective, Observational Study Coordinated By the Fondazione Italiana Linfomi
3919 - Baseline Metabolic Tumour Volume Predicts Outcome in High Tumor Burden Follicular Lymphoma. A Pooled Analysis of Three Multicenter Studies
3934 - Khorana Score and Histotype Predict the Incidence of Early Venous Thromboembolism (VTE) in Non Hodgkin Lymphoma (NHL). a Pooled Data Analysis of Twelve Clinical Trials of Fondazione Italiana Linfomi (FIL)

Lunacsek, O.

3311 - Progression-Free Survival in Third-Line Treatment of Relapsed/ Refractory Multiple Myeloma Among Patients with Who Have Received Prior Bortezomib and Immunomodulatory Drugs

Lund, J.

3047 - The Rev II Trial: Lenalidomide and Dexamethasone As Second Line Treatment in Myeloma Followed By Extended Lenalidomid Vs Len/Dex

Lund, S. H.

1129 - Thromboembolism and Clinically Relevant Bleeding in Relation to Warfarin Anticoagulation Variability in Patients Monitored with Either Fiix-Prothrombin Time or Quick-Prothrombin Time. the Fiix-Trial
1134 - Gender Differences during Long-Term Warfarin Anticoagulation in Patients with Atrial Fibrillation Monitored with Fiix-Prothrombin Time or Prothrombin Time. the Fiix Trial
4252 - No Risk of Arterial or Venous Thrombosis in Monoclonal Gammopathy of Undetermined Significance: Results from a Population-Based Study

Lund, T. C.

388 - Impact of Frailty on Hematopoietic Cell on Early Transplant Outcomes in Older Recipients
782 - Adipogenic Chemokine Inhibition of Hematopoietic Cell Adherence and Transmigration, a Hurdle to Homing
2376 - A Mathematical Model of Hematopoietic Stem Cell Transplantation and Analysis of the Effect of Drug Treatments on Transplantation in Patients with Lymphoma

Lundan, T.

1977 - A Prospective Phase 2 Study to Assess Immunophenotypic Remission after Lenalidomide-Based Induction Followed By ASCT and Lenalidomide Maintenance in Patients with Newly Diagnosed Multiple Myeloma

Lundberg, A.

3376 - Gene Editing with Crispr-Cas9 for Treating Beta-Hemoglobinopathies

Lundberg, A. S.

2137 - Safety and Pharmacokinetics of the Complement Inhibitor TT30 in a Phase I Trial for Untreated PNH Patients

Lundby, M.

3798 - AML Patients in Minimal Residual Disease Vaccinated with a Novel Generation of Fast Dendritic Cells Expressing WT-1 and PRAME Mount Specific Immune Responses That Relate to Clinical Outcome

Lundin, E.

3748 - Reasons for Decreasing Early Mortality in Acute Myeloid Leukemia: An Epidemiological Study from the Swedish Acute Leukemia Registry

Lundin, J.

1734 - A Phase 2 Study of Alemtuzumab-Ofatumumab (A+O) Combination in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) - an Update
1745 - Real-World Results on Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Data from 97 Swedish Patients Treated in a Compassionate Use Program
4164 - In Vivo Effects of Lenalidomide on T Cell Proliferation and Immune Checkpoint Molecules in Patients with Advanced Stage CLL: Results from a Phase II Study

Lundin, K.

3137 - Targeting Integrin a4b7-Expressing T-Cells in Steroid Refractory Intestinal GvHD

Lundquist, P. A.

3372 - Deletional HPFH Vs. Delta Beta Thalassemia: Closing in on a Possible Hb F Silencer Location
3374 - Large Deletions Involving the Beta Globin Gene Complex: Genotype-Phenotype Correlation of 119 Cases

Lunghi, F.

4362 - Standardized Long-Term Follow-up after Allogeneic Stem Cell Transplantation: A Cross-Sectional 1-Year Evaluation in 260 Adults
4400 - Refined Disease Risk Index (DRI) and Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) Predict Survival after Haploidentical Stem Cell Transplantation: A Comparative Study with EBMT Risk Score in 220 Consecutive Patients

Luning Prak, E.

4289 - Mechanisms of B Cell Tolerance after in Utero Hematopoietic Cell Transplantation

Lunning, M. A.

377 - Combination Treatment of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib and Carfilzomib in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Initial Results from a Multicenter Phase 1/2b Study
1504 - Tolerability and Efficacy of Treatments in Elderly Patients with Hodgkin Lymphoma: A Report from the Nebraska Lymphoma Study Group
1538 - Ublituximab + TGR-1202 Demonstrates Activity and a Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL: Phase I Results
3482 - Use of Low Molecular Weight Heparin (LMWH) in Thrombocytopenic Patients with Hematologic Malignancy-Associated Venous Thromboembolism (VTE)

Luño, E.

2866 - RAEB-1 with Erythroid Hyperplasia and Erythroleukemia Share Clinico-Biological Features and Outcome: A Same Disease with Different Labels?
2894 - Myelodysplastic Syndromes (MDS) with Erythroid Hyperplasia: Enumerating Blasts from Non-Erythroid Cell Compartment Improves the Risk Stratification of MDS with Excess of Blasts

Luño, E.

608 - The Complete Mutatome and Clonal Architecture of Del(5q)
1672 - Disease-Attributable Mortality in the Myelodysplastic Syndromes (MDS): A Study from the Spanish MDS Cooperative Group (GESMD)
2896 - A Score Based on IPSS-R, Ferritin and EPO Levels Predicts Erythroid Response to ESAs and Survival in Lower Risk Anemic MDS Patients with High Probability of Response to ESAs: Spresas Sub-Analysis from the GESMD

Lunzer, M. M.

277 - Targeting Putative Mu Opioid/Chemokine Receptor Type 5 Heteromers Potently Attenuates Nociception in a Murine Model of Sickle Cell Disease

Luo, C.

2118 - Comparison of the 5 Year Medical Outcome and Quality of Life of Patients with Chronic Myeloid Leukemia Treated with Imatinib or Allogeneic Transplant

Luo, H. Y.

409 - A Candidate Trans-Acting Modulator of Fetal Hemoglobin Gene Expression in the Arab-Indian Haplotype of Sickle Cell Anemia

Luo, H. R.

1159 - Proteinase 3 Is Expressed in Stem Cells and Regulates Bone Marrow Hematopoiesis

Luo, J.

1091 - The Clinical Associations and Outcomes of Patients Admitted with Acquired Hemophilia; A Review of the 2012 National Inpatient Sample

Luo, J.

974 - Sustained Elevation of Adenosine-ADORA2B Signaling Promotes Chronic Pain through Neuro-Immune Interaction in Sickle Cell Disease

Luo, J.

4278 - Graft Versus Host Disease (GvHD) Is Attenuated By Administration of Pregnancy Specific Glycoproteins through Induction of Immune Tolerance

Luo, J.

3988 - A Phase I Trial of Brentuximab Vedotin in Combination with Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Luo, L.

832 - The BTK Inhibitor, Bgb-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed/ Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human Trial

Luo, M.

2387 - PRMT1-Mediated Methylation of DUSP4 Determines Megakaryocyte-Erythroid Lineage Choice By Regulating p38 Signaling

Luo, M.

450 - Crispr Sgrnas Genome-Wide Screen Identifies the Proteasome Regulatory Subunit PSMC6 As a Bortezomib Resistance Gene in Human Multiple Myeloma Cells

Luo, R. T.

2454 - Lymphoid Lineage Preference of MLL-AF4 Is Revealed in a Species-Specific Model

Luo, S.

879 - Statin Therapy Improves Multiple Myeloma (MM) Specific Surviva
2088 - Treatment-Related Weight Change and Overall Survival in United States Veterans with Follicular Lymphoma
4194 - Previous Agent Orange Exposure Is Correlated with Worse Outcome in Patients with Multiple Myeloma (MM)
4502 - Metformin Therapy and Survival in Multiple Myeloma Among US Veterans with Diabetes Mellitus

Luo, X.

1934 - Defining Successful Immune Reconstitution (IR) after Allogeneic Hematopoietic Cell Transplantation (HCT)

Luo, X.

1067 - The Impact of GPIba on the Efficacy of Platelet-Targeted FVIII Gene Therapy in Hemophilia a with Pre-Existing Anti-FVIII Immunity

Luo, X.

1071 - Immune Tolerance Developed in Platelet-Targeted FVIII Gene Therapy in Hemophilia Mice Is CD4⁺ T Cell-Mediated
4423 - Platelet-Targeted Gene Transfer Induces Immune Tolerance through Two Distinct Pathways

Luo, Y.

381 - Inhibition of Both Activated p38 MAPK and mTOR C1 Potentiates the Effect of SR1 on Promotion of Hematopoietic Stem Cell Expansion Ex Vivo

Luo, Y.

3130 - Excellent Therapeutic Results Achieved in Salvage Therapy for Steroid-Refractory Grades III-IV Acute Gvhd with Basiliximab and Etanercept : A Multicenter Prospective Study
3778 - First-in-Man CD123-Specific Chimeric Antigen Receptor-Modified T Cells for the Treatment of Refractory Acute Myeloid Leukemia

Lüoend, R.

2998 - A New Class of T-Cell Bispecific Antibodies for the Treatment of Multiple Myeloma, Binding to B Cell Maturation Antigen and CD3 and Showing Potent, Specific Antitumor Activity in Myeloma Cells and Long Duration of Action in Cynomolgus Monkeys

Lupo, P. J.

1312 - Poorer Relapse-Free Survival in Hispanic Children Diagnosed with Acute Myeloid Leukemia Compared with Non-Hispanics: A Texas Single Institution Experience
4059 - A Genome-Wide Assessment of Inherited Genetic Variants and the Risk of Langerhans Cell Histiocytosis

Lupo Stanghellini, M. T.

263 - Tracking Genetically Engineered Lymphocytes Long-Term Reveals the Dynamics of T-Cell Immunological Memory
743 - HLA Loss Leukemia Relapses after Partially-Incompatible Allogeneic HSCT As a Prototypical System to Investigate Natural Killer Cell Dynamics
3124 - Facing the Rising Tide of Multidrug Resistant Gram-Negative Pathogens in Allogeneic HSCT with Nanosphere's Verigene® System
4335 - Antifungal Prophylaxis with Posaconazole in Allogeneic Hematopoietic Stem Cell Transplantation Using Sirolimus for Prevention of Graft-Versus-Host Disease

Lupo-Stanghellini, M. T.

4362 - Standardized Long-Term Follow-up after Allogeneic Stem Cell Transplantation: A Cross-Sectional 1-Year Evaluation in 260 Adults
4400 - Refined Disease Risk Index (DRI) and Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) Predict Survival after Haploidentical Stem Cell Transplantation: A Comparative Study with EBMT Risk Score in 220 Consecutive Patients

Luppi, M.

613 - Ibrutinib Targets Nurse-like Cells Supporting an Immunosuppressive Phenotype in Chronic Lymphocytic Leukemia

Luptakova, K.

643 - MUC-1 Regulates MiR34a Expression in Acute Myeloid Leukemia Cells Resulting in an Accumulation of Granulocytic Myeloid-Derived Suppressor Cells
2473 - MUC1 Inhibition Overcomes Chemotherapy Resistance in Acute Myeloid Leukemia
2549 - DC/Aml Fusion Cell Vaccination Administered to AML Patients Who Achieve a Complete Remission Potently Expands Leukemia Reactive T Cells and Is Associated with Durable Remissions
2550 - A Phase 1 Study of Lenalidomide in Combination with Mitoxantrone, Etoposide, and Ara-C in Patients with Relapsed or Refractory Acute Myeloid Leukemia
3659 - Immunomodulatory Effect of MUC1-C in Acute Myeloid Leukemia
4218 - Blockade of PD-1 in Combination with Dendritic Cell/Myeloma Fusion Cell Vaccination Following Autologous Stem Cell Transplantation Is Well Tolerated, Induces Anti-Tumor Immunity and May Lead to Eradication of Measureable Disease

Lupu, C.

765 - Complement C5 Inhibition Blocks the Cytokine Storm and Consumptive Coagulopathy By Decreasing Lipopolysaccharide (LPS) Release in E. coli Sepsis

Lupu, F.

765 - Complement C5 Inhibition Blocks the Cytokine Storm and Consumptive Coagulopathy By Decreasing Lipopolysaccharide (LPS) Release in E. coli Sepsis
939 - Preclinical Evaluation of RA101495, a Potent Cyclic Peptide Inhibitor of C5 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria

Luque Paz, D.

2808 - Sequential Analysis By Next Generation Sequencing of 18 Genes in Polycythemia Vera and Essential Thrombocythemia Reveals a Association Between Mutational Status and Clinical Outcome after 3-Year Follow-up

Luquet, I.

90 - Immunophenotypic-Defined Stage of Leukemia Differentiation Arrest Identifies Oncogenic and Metabolic Signatures in AML
3736 - Addition of Lomustine (CCNU) to Induction and Post-Remission Chemotherapy for Fit Elderly AML Patients without Unfavorable Cytogenetics: Results of the Lamsa-2007 Goelams Trial
3787 - Safety and Long-Term Efficacy of Maintenance Therapy with Alternating Azacytidine (AZA) and Lenalidomide (Len) Cycles in Elderly (≥ 60) Fit Patients (Pts) with Poor Prognosis AML in First Complete Remission (CR) After LIA Induction. A Phase II Multicentric GOELAMS Trial

Lusina, D.

2568 - Correlation Between Bone Marrow Dysplasia and Genomic Profile in De Novo Acute Myeloid Leukemia (AML): A Study By the ALFA Group
3812 - Biological Description of 109 Cases of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) from the French Network of BPDCN

Lusina, D.

2881 - MDS with Isolated Trisomy 8. a Type of MDS Frequently Associated with Myeloproliferative Features? A Report from the GFM

Luskin, M. R.

2543 - Outcome of Patients with Acute Myeloid Leukemia Treated with Salvage High-Dose Cytarabine Monotherapy

Luskin, M. R.

2591 - A Clinical Measure of DNA Methylation Predicts Outcome in De Novo AML

Lussana, F.

4374 - Levels of Minimal Residual Disease Prior to Transplant Influence Outcome of Adult Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Lust, J. A.

1774 - In Patients with Light-Chain (AL) Amyloidosis Myocardial Contraction Fraction (MCF) Is a Simple, but Powerful Prognostic Measure That Can be Calculated from a Standard Echocardiogram (ECHO)
1830 - Necrobiotic Xanthogranuloma (NXG) Associated with Monoclonal Gammopathies (MG): Clinical Features and Treatment Outcomes
3177 - Impact of Bone Marrow Plasmacytosis on Outcome in Patients with AL Amyloidosis Following Autologous Stem Cell Transplant
3292 - N-Terminal Fragment of the Type-B Natriuretic Peptide (NT-proBNP) Is a Prognostic Factor for Overall Survival in Newly Diagnosed Patients with Multiple Myeloma (MM)
3317 - AL Amyloidosis and Patient Reported Quality of Life
4176 - Occurrence and Prognostic Significance of Cytogenetic Evolution in Patients with Multiple Myeloma
4197 - Presentation and Outcomes of Localized Amyloidosis: The Mayo Clinic Experience

Lustgarten, S.

1588 - Relationship of Line of Therapy to Efficacy for Ponatinib in 3rd-Line Versus 4th-Line Chronic-Phase Chronic Myeloid Leukemia (CML)
1591 - Real-World Ponatinib Prescribing Patterns and Outcomes in US Patients
4025 - Efficacy and Safety of Ponatinib in CP-CML Patients By Number of Prior Tyrosine Kinase Inhibitors: 4-Year Follow-up of the Phase 2 PACE Trial

Luten, M.

2707 - Rituximab-Pecc Induction Followed By ⁹⁰y-Ibritumomab Tiuxetan Consolidation in Relapsed or Refractory DLBCL Patients Who Are Not Eligible for or Have Failed ASCT: Results from a Phase II HOVON Study

Luthra, M.

1730 - RAS/RAF Pathway Mutations Define a Distinct Subset of Chronic Lymphocytic Leukemia

Luthra, R.

598 - Impact of the Type of BCR-ABL Fusion Transcripts on Response and Survival in Patients with Chronic Phase CML Treated with Four Frontline TKI Modalities
1392 - Mutation Analysis in 276 Cases of Newly Diagnosed Acute Myeloid Leukemia By Next Generation Sequencing: Association with Established Prognostic Variables and MRC Risk Groups
1703 - Mutation Analysis in 200 Cases of Newly Diagnosed Myelodysplastic Syndrome By Next Generation Sequencing: Association with Established Prognostic Variables and IPSS-R
1730 - RAS/RAF Pathway Mutations Define a Distinct Subset of Chronic Lymphocytic Leukemia
3756 - Qualitative and Quantitative Correlation of PML-Rara Fusion Transcript from Peripheral Blood and Bone Marrow Samples By Quantitative Real-Time PCR in Patients with Acute Promyelocytic Leukemia

Lutsey, P. L.

3551 - Race and Cancer-Associated Venous Thromboembolism in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study

Lutteropp, M.

789 - Expression of Novel Immune Checkpoint Molecules PVR and PVRL2 Confers a Negative Prognosis to Patients with Acute Myeloid Leukemia and Their Blockade Augments T-Cell Mediated Lysis of AML Cells Alone or in Combination with the BiTE^® Antibody Construct AMG 330

Luty, S. B.

1632 - A Blunted Response to the Anti-Inflammatory Cytokine IL-10 Contributes to Excessive TNF Production in Myeloproliferative Neoplasm

Lutynski, A.

3717 - Outcomes of Down-Syndrome Associated Acute Lymphoblastic Leukemia in Adults: A Single Center Retrospective Review

Lutz, L.

544 - French National Drepagreffe Trial: Cognitive Performances and Neuroimaging at Enrollment and after 12 Months on Transfusion Program or Transplantation (AP-HP: NCT 01340404)

Lutz, P.

541 - Hematopoietic Stem Cell Transplantation from HLA Identical Sibling Forsickle Cell Disease an International Survey on Behalf of Eurocord-Monacord, EBMT Paediatric Disease Working Party and CIBMTR
793 - t(12;21)/ETV6-RUNX1 Confers a Specific Pattern of In Vivo Sensitivity to Treatments in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL): Results of the Randomized Trials 58881 and 58951 of the EORTC Children Leukemia Group

Lutzko, C.

4417 - Innovative Hematopoietic Gene-Therapy Concepts for Hereditary Pulmonary Alveolar Proteinosis Utilizing Hematopoietic Stem Cell Derived Macrophages

Luu, B. W.

2292 - A Novel Biomarker for Inhibitor Risk Prediction—the HLA-II Bound and Unbound Components of FVIII Derived Peptides—Reveals a Protective Influence for N-Linked Glycosylation

Luxembourger, C.

1051 - Thrombosis in Immune Thrombocytopenia Patients with Antiphospholipid Antibodies: A Meta-Analysis

Luycx, O.

393 - Bortezomib, Thalidomide and Dexamethasone (VTD) Is Superior to Bortezomib, Cyclophosphamide and Dexamethasone (VCD) Prior to Autologous Stem Cell Transplantation for Patients with De Novo Multiple Myeloma. Results of the Prospective IFM 2013-04 Trial

Luyendyk, J. P.

1070 - Tumor Cell Thrombin/PAR-1 Signaling Drives Pancreatic Ductal Adenocarcinoma Growth and Dissemination

Luz, N. F.

975 - Heme Concentration As a Biomarker of Sickle Cell Disease Severity: Its Role in Steady-State and in Crisis Patients

Luzi, L.

459 - Inhibition of the Histone Demethylase LSD1 Combined with Caloric Restriction or IGF1/Insulin Inhibition Leads to Durable Responses in a Preclinical Model of Acute Myeloid Leukemia

Luzna, P.

3351 - Iron Chelation Reinforces DNA Damage Response and Leads to G2/M Checkpoint Activation and Autophagy in Myeloid Bone Marrow Cells of Preleukemia Mouse Model

Luznik, L.

1351 - Immune Modulation with Pomalidomide after Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML)
1666 - Stabilization of Myelodysplastic Syndromes (MDS) Following Hypomethylating Agent (HMAs) Failure Using the Immune Checkpoint Inhibitor Ipilimumab: A Phase I Trial
2002 - Nonmyeloablative (NMA), HLA-Mismatched Unrelated Donor (mMUD) BMT with High-Dose Posttransplantation Cyclophosphamide (PTCy) Has Outcomes Similar to Matched BMT
2031 - Using Haploidentical (haplo) Donors and High-Dose Post-Transplant Cyclophosphamide (PTCy) for Refractory Severe Aplastic Anemia (SAA)
3164 - Prospective Study of Peri-Transplant Use of Sorafenib As Remission Maintenance for FLT3-ITD Patients Undergoing Allogeneic Transplantation
3849 - Tracking Effector T Cell Dynamics and Immune Inhibitory Receptors in Patients with Acute Myeloid Leukemia (AML)

Luzy, S.

1086 - Use of Power Doppler Ultrasound in Haemophilia Could Predict Early Relapse of Intra Articular Bleeding after Haemarthrosis: A Prospective Cohort of 27 Haemarthrosis Monitored By Articular Ultrasound

Luzzatto, L.

2409 - Auto-Reactive Glycosyl-Phosphatidyl-Inositol (GPI) Specific T Cells Are Present in Most Patients with Idiopathic Aplastic Anemia (IAA)

Lv, R.

3879 - Different Prognostic Significance of a Panel Cytogenetic Aberrations Between Chronic Lymphocytic Leukemia and Other B-Cell Chronic Lymphoproliferative Disorders

Lv, X.

3426 - Human Transcription Factor KLF3 Maintains T Lymphocyte Quiescent Phenotype Via Inhibiting SHP-1 Expression

LY, I. D.

72 - Association Between Hyperhemolysis and Vascular Complications in Sickle Cell Disease Sub-Saharan African Patients

Lyde, Jr., R. B.

2266 - Towards the Care of Hemophilia a Patients Using Induced Pluripotent Stem Cell (iPSC)-Derived Megakaryocytes (iMks) Expressing Coagulation Factor (F) VIII
2352 - The Influence of FLI1 Expression Levels on Megakaryopoiesis: Studies Using iPSCs

Lyerly, S.

2556 - The Mitochondrial Metabolism Inhibitor Cpi-613 in Combination with High Dose Ara-C (HDAC) and Mitoxantrone Is Highly Active in Poor Risk Relapsed or Refractory Acute Myeloid Leukemia (AML)

Lykka, A.

3054 - Prospective Evaluation of Blood Pressure Monitoring and Baroreceptor Reflex Sensitivity (BRS) in Patients with AL Amyloidosis: Prognostic and Pathophysiologic Implications

Lyman, G. H.

427 - Dalteparin Thromboprophylaxis in Cancer Patients at High Risk for Venous Thromboembolism: A Randomized Trial
531 - Risk Factors, Mortality, and Costs of Adults with Acute Myeloid Leukemia (AML) Admitted to the Intensive Care Unit (ICU): A Longitudinal Cohort Study
2089 - Cost of Hospitalization in Patients with Cancer and Febrile Neutropenia and Impact of Comorbid Conditions

Lymboussaki, A.

2686 - Pattern of Care in Indolent Non Follicular Lymphoma: A Report from NF10 Project, an International, Prospective, Observational Study Coordinated By the Fondazione Italiana Linfomi

Lynch, Jr., J. W.

- Hematologic Malignancy (Myeloma, Lymphoma, CLL)

Lynch, J.

3061 - Targeting F2r/Beta-Catenin/JNK Signaling for Leukemia Stem Cell Eradication

Lynch, K.

710 - An Integrative Genomics Approach Uncovers the Basis of Resistance to AZA Therapy in MDS and CMML

Lynch, K.

2425 - Regulation of CD19 Exon 2 Inclusion in B-Lymphoid Cells By Splicing Factors and Epigenetic Marks

Lynch, M.

510 - Elotuzumab Plus Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: 2-Year Follow-up

Lyndal, H.

398 - A Predictive Model Using Telomere Length to Select Optimal Donors for Hematopoietic Stem Cell Transplant (HCT) for Acute Leukemia

Lynn, C.

1884 - Ex Vivo Modulation of Donor Cells Results in Enhanced Survival and Reduced Gvhd Mortality

Lyon, A.

4250 - Serial Echocardiographic Assessment of Patients (Pts) with Relapsed Multiple Myeloma (RMM) Receiving Carfilzomib and Dexamethasone (Kd) Vs Bortezomib and Dexamethasone (Vd): A Substudy of the Phase 3 Endeavor Trial (NCT01568866)

Lyon, M.

4443 - Does Adherence to Hydroxyurea Affect Emergency Department Observation Unit Utilization?

Lyons, H.

4217 - A Phase II Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVD-lite) for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma

Lyons, R. M.

373 - Weekly Carfilzomib with Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma: Updated Results from the Phase 1/2 Study Champion-1 (NCT01677858)
378 - Oprozomib, Pomalidomide, and Dexamethasone (OPomd) in Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): Initial Results of a Phase 1b Study (NCT01999335)
911 - A Randomized, Placebo-Controlled, Phase II Study of Pracinostat in Combination with Azacitidine (AZA) in Patients with Previously Untreated Myelodysplastic Syndrome (MDS)
4074 - Final Results of Anagrelide Controlled-Release (GALE-401) Safety, Efficacy and Pharmacokinetics in Subjects with Myeloproliferative Neoplasms (MPN)-Related Thrombocytosis

Lysaght, A.

1837 - Serum Proteomic Analysis of Multiple Myeloma Subjects Treated with Daratumumab Monotherapy

Lyssa, F.

398 - A Predictive Model Using Telomere Length to Select Optimal Donors for Hematopoietic Stem Cell Transplant (HCT) for Acute Leukemia

Lyszkiewicz, M.

287 - Regulation of Transcription Factors Foxp1, E2A and Egr-1 By microRNA-191 Constrains B Lymphocyte Development and Suppresses Development of Diffuse Large B Cell Lymphoma

Lyszkiewicz, M.

1026 - Complete Block of Early B Cell Differentiation in Mice Lacking the Endosomal Adaptor Protein p14

Author Index: L